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General practitioners (GPs) play a pivotal and increasing role in the care of people with 
dementia. However, GPs are challenged by the complexities of dementia care. A triangulated 
educational needs analysis conducted by the PREPARED project identified that GPs find the 
management of behavioural and psychological symptoms of dementia (BPSD) a particularly 
challenging aspect of dementia care. BPSD encompasses a wide range of non-cognitive 
symptoms such as anxiety and hallucinations that affect people with dementia. Although 
BPSD has been identified as a challenging area for GPs, an area in which they lack confidence, 
we do not have a good understanding of why this is a challenging area for GPs or the root 
causes of their lack of confidence. Furthermore, evidence suggests that current management 
of BPSD is sub-optimal. In BPSD non-pharmacological strategies are recommended first-line 
but uptake of these strategies is low. Despite their adverse effects, potentially harmful 
pharmacological treatments, such as antipsychotics, are frequently employed. Interventions 
are needed to improve the management of BPSD. It is apposite that these interventions 
should target GPs. However, interventions to date to improve the management of BPSD have 
either not targeted GPs or not effectively involved GPs in intervention development, a notable 
gap in the literature.  
Aim  
To enhance our understanding of the management of BPSD in general practice with a view 
to informing a theoretically-based, behaviour change intervention to improve the 




This was a mixed methods study underpinned by the UK Medical Research Council (MRC) 
guidance on the development of complex interventions in health care. Existing evidence on 
GPs’ knowledge of, attitudes towards and experiences with BPSD was systematically reviewed 
using a mixed methods approach and synthesised using meta-ethnography. Findings of this 
review were supplemented with new evidence from three studies. A descriptive interpretive 
qualitative study which explored GPs experiences of managing BPSD. The data collected from  
16 semi-structured interviews with a purposively selected sample of GPs were then 
thematically analysed. The second study was a cross-sectional descriptive study which 
assessed GPs’ knowledge of and attitudes towards pain in dementia, a key trigger for BPSD. 
In this study, a postal questionnaire was sent to a census sample of all GPs in Cork. The results 
were statistically analysed to explore associations between demographic data and responses. 
To further investigate the findings of the qualitative study a descriptive cross-sectional study 
was conducted that aimed to explore the knowledge and attitudes of GPs to the prescribing 
of antipsychotics in people with dementia. The study used an anonymous postal 
questionnaires that was sent to a census sample of all GPs based in Cork and Kerry. To develop 
the intervention, results from the systematic review, the qualitative and the two cross-
sectional studies were integrated, using the behavioural change theoretical approach 
outlined in the Behaviour Change Wheel (BCW). In addition, a modified eDelphi study was 
conducted with multidisciplinary experts on antipsychotic prescribing in dementia. The 






The over-arching finding from the systematic review was that a lack of practical, 
implementable non-pharmacological treatment strategies created a therapeutic void for 
GPs, which led to over-reliance on family caregivers and on psychotropic medications.  In 
the qualitative study some GPs described the challenges of managing BPSD as 
insurmountable and many struggled at an ethical level with the decision to prescribe 
potentially harmful psychotropic medication but felt they had little else to offer. Key 
challenges identified by GPs were; stretched resources, unrealistic expectations and a lack 
of implementable clinical guidelines. The cross-sectional descriptive study of GPs’ 
knowledge of and attitudes towards the management of pain identified aspects of GPs’ 
management of pain in dementia that could be improved upon and highlighted the 
importance of good relationships between GP and nursing home staff when managing 
dementia. The descriptive cross-sectional study of GPs’ attitudes towards antipsychotic 
prescribing in dementia found that the majority of GPs recommended non-pharmacological 
strategies first line when managing BPSD. The GPs reported that the main influencers of 
prescribing antipsychotics in BPSD were nursing staff and family.  Of note the majority of 
respondents did not routinely monitor antipsychotic prescribing in people with dementia 
Using the approach outlined in the Behaviour Change Wheel the findings of these four studies 
were used to select an aspect of GPs’ behaviour in the management of BPSD to target with 
an intervention:  ‘GPs to systematically monitor their prescribing of antipsychotic medication 
to people with dementia in nursing home settings’. To address this behaviour, a three-
component intervention was developed, consisting of: an interprofessional educational 
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session with GPs and nursing home staff; a repeat prescribing monitoring tool and the 
facilitation of a self-audit. 
 
Conclusion 
The research presented in this thesis adds depth to existing literature and advances our 
knowledge of the management of BPSD in general practice. Prior to this research it was 
known that GPs found BPSD challenging but the reasons for why GPs found BPSD to be 
challenging had not been explored. This research offers new insights into GPs’ perspectives 
on the management of BPSD. This new insight helps to explain apparent discrepancies 
between best practice recommendations in BPSD and real-life clinical practice. This deeper 
understanding of GPs’ management of BPSD informed the development of an intervention 
to improve an aspect of BPSD management that was identified as being sub-optimal. The 
intervention developed focuses on GP self-monitoring of their prescribing of antipsychotic 
medication to people with BPSD in nursing home settings. This intervention has the 









CHAPTER 1: THESIS OVERVIEW  
 
1.1 THESIS AIM AND OBJECTIVES 
The aim of this research is to develop an intervention to improve the management of BPSD 
in Irish general practice. Broadly, this involves gaining insights into GP’s current practice in 
BPSD and integrating these insights with behavioural theory to develop an evidence-based, 
theoretically-informed, behaviour change intervention to support and improve the 
management of BPSD in general practice. 
To achieve this aim, the objectives of this research were; 
(i) To systematically review and synthesise the qualitative and quantitative evidence 
on GPs’ knowledge of, attitudes towards and experiences with the management 
of BPSD. 
(ii) To explore the challenges GPs experience when managing BPSD 
(iii) To integrate the evidence gained from objectives (i) and (ii) with behavioural 
theory in order to inform the development of an intervention targeted at GPs. 
 
1.2 THESIS OUTLINE 
This thesis contains 9 chapters. 
In chapter 2, I will discuss dementia in terms of its prevalence and impact. I will explore the 
research context of general practice. I will examine how general practice is modelled 
internationally and then describe the structure of general practice in Ireland. I will outline 
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how the current model of general practice impacts on dementia care. Finally, I will discuss 
the wider research project that I have worked on for the past three years the PREPARED – 
(Primary Care Education, Pathways and Research of Dementia) project, how this PhD thesis 
fits within the context of PREPARED and why the focus of this PhD became the management 
of BPSD in general practice. 
Chapter 3 provides an overview of the literature on BPSD that has informed my work. I will 
discuss BPSD in terms of its prevalence, impact, evidence base for pharmacological and non-
pharmacological treatments. I will review interventions developed to date that have aimed 
to improve the management of BPSD in the community and in nursing home settings with a 
particular focus on the role played by GPs in these interventions.  
In chapter 4, I describe the philosophical approach underpinning this research and the 
methodological framework employed to address the thesis’ objectives.  
Chapters 5, 6, 7, 8, 9, 1O represent phases of the intervention design process outlined in the 
MRC framework. In chapter 5, the existing evidence on GPs’ knowledge of, attitudes 
towards and experiences with the management of BPSD is systematically reviewed and 
synthesised. This chapter is divided into two parts; part one is the published protocol for 
this systematic review and part two is the published systematic review. Chapter 6 is a 
qualitative study that explored the challenges GPs experience when managing BPSD. 
Chapter 7 describes a cross-sectional study that examined GPs’ knowledge of and attitudes 
towards the management of pain in dementia. Chapter 8 describes a cross-sectional study 
that assesses GPs’ knowledge of and attitudes towards the prescribing of antipsychotic 
medication in BPSD.  Chapter 9 describes an eDelphi consensus process used to decide 
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aspects of the clinical content of the intervention. In chapter 10, the process of developing a 
theory-based intervention for GPs managing BPSD is described.     
Chapter 11 provides an overall discussion of the research, including the main findings, 
limitations and implications for policy and practice.  
 
1.3 AUTHOR’S CONTRIBUTION TO INCLUDED STUDIES 
I was the lead author of the research studies outlined in Chapters 5 to 10. This involved 
developing the protocol for each study, literature searching, collecting, managing and 
analysing the data and drafting each manuscript.  
With regards to the specific studies included as part of this thesis (chapters 5 -10). Professor 
Colin Bradley, Professor Alice Coffey, Professor John Browne and Dr Tony Foley provided 
advice on the design, conduct and write-up of the systematic review protocol described in 
part one of Chapter 5. They also participated in the abstract screening, data synthesis and 
provided editorial feedback for Chapter 5. Professor Colin Bradley, Professor John Browne 
and Dr Tony Foley provided advice on the design, conduct and write-up of the qualitative 
study described in chapter 6. Dr Tony Foley also contributed to the data analysis of the 
qualitative study.  Dr Tony Foley and Professor John Browne provided advice on the design, 
conduct and write-up of the cross-sectional descriptive study described in chapter 7.  Dr 
Tony Foley provided advice on the design, conduct and write up of the cross-sectional 
descriptive study described in Chapter 8 and the eDelphi study described in Chapter 9. 
Professor Colin Bradley, Professor John Browne and Dr Tony Foley provided advice on the 
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design, conduct and write-up of the intervention development study described in chapter 
10. 
The following people provided additional expertise. 
1. Mr Kieran Walsh, PhD Candidate, School of Pharmacy, UCC 
In the systematic review (chapter 5) Kieran provided feedback on the data analysis 
and synthesis, assisted with the completion of the CERQual assessment and provided 
editorial comments on the manuscript drafts. 
2. Dr Sheena Mc Hugh, Lecturer, School of Public Health, UCC 
In the qualitative study (chapter 6) Sheena provided methodological advice, coded a 
subset of the interviews and provided editorial comments on the manuscript drafts. 
3. Dr Maura Linehan, GP, Kinsale Medical Practice, Cork 
In the cross-sectional descriptive study (chapter 7) Maura contributed to the overall 
study concept. She assisted with the data collection and provided editorial 
comments on the manuscript drafts. 
4. Dr Jenny Mc Sharry, Lecturer, School of Psychology, NUIG, Galway 
Jenny has a particular expertise in intervention design and, thus, provided 
methodological advice for chapter 8. She also participated in the expert panel 
outlined in chapter 8 and provided editorial feedback on the chapter. 
5. Dr Naoihse Guerin, Medical Intern, Cork Teaching Hospitals 
Naoihse contributed to the eDelphi consensus study (outlined in Chapter 8). Naoihse 
assisted in the data collection process by sending out the Delphi rounds to 
participants and she assisted in collating the results.  
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1.4 AUTHOR’S PROFESSIONAL ROLE 
While conducting this research I also worked clinically as a GP. I worked 1.5 days a week as a 
GP for the first year of the PhD from November 2015- November 2016. In the second year of 
my PhD, November 2016 – November 2017 I worked as a GP for 1 day per week. For the 
first six months of the final year of my PhD I worked 0.5 days per week as a GP. For the final 
six months of my PhD I temporarily suspended all clinical work to allow for completion of 
my PhD. During these years I also worked on the wider research project – PREPARED. As 
part as my role in the PREPARED project I worked on the following projects: 
(i) The development of the online dementia resource for healthcare professionals – 
www.dementiapathways.ie. I was responsible for the design, content, 
implementation and evaluation of this resource. 
(ii) In collaboration with Dr Tony Foley, P.I of the PREPARED project, I developed 
BPSD and other dementia workshops for GPs that were rolled out nationally 
through peer-led, practice based educational workshops. Over 700 GPs have 
participated in these workshops. I delivered some of these workshops and I was 
also involved in training the GP facilitators who delivered these workshops. 
Finally, I contributed to the evaluation of these workshops. 
(iii) I was responsible for the development, delivery and evaluation of a new 12 week 
online continuous professional development (CPD) dementia course for GPs. 
(iv) I contributed the development of a 10 unit e-learning dementia programme for 
GPs in conjunction with the Irish College of General Practitioners (ICGP). I led on 
the development of the content for the unit on BPSD.  
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(v) I helped to design an interprofessional dementia workshop for primary care 
teams and contributed to the evaluation of the pilot phase of these workshops. 
(vi) In association with the ICGP and the Irish Primary Care Research Network (iPCRN) 
I contributed to the development of dementia audit tools for use by GPs.  
 
1.5 AIM AND OBJECTIVES MAPPED TO THESIS CHAPTERS 
The following schematic (Figure 1) gives an overview of the thesis aim and objectives and 
how these objectives are mapped to the relevant chapters. 
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CHAPTER 2: THE RESEARCH CONTEXT  
This research is focused on the management of dementia in primary care with a particular 
focus on the role of GPs. There are multiple health care professionals involved in the care of 
a person with dementia. In the community setting public health nurses, occupational 
therapists, speech and language therapists, physiotherapists and other members of the 
primary care team have significant roles to play in the care of a person with dementia.1 In 
Ireland the availability, and the existence, of these primary care teams can vary significantly 
from one primary care area to the next. 2 In the nursing home setting, nurses 3 and health 
care assistants 4 play a central role in the care of people with dementia. While all these 
healthcare professionals play important roles at different times in the progression of the 
illness, the GP is the constant health care professional throughout the journey of people 
with dementia and their families 5-7 In this research I focus on the perspective and the role 
of the GP in the care of a person with dementia and, in particular, in the management of 
behavioural and psychological symptoms.  
In this chapter I will describe briefly the context for the research that follows. The chapter is 
divided into five main sections. In the first section, 2.1, I will give an overview of dementia, 
its prevalence and impact. I will discuss the development of national dementia strategies 
internationally with a particular focus on the Irish national dementia strategy. In section 2.2 
I will describe international models of general practice. In section 2.3 I will focus on the 
organisational and economic structure of general practice In Ireland. In section 2.4. I will 
examine the impact of the structure and function of general practice on dementia care. In 
the final section, 2.5, I will explain the wider research project on which I have worked for the 
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past three years (the PREPARED - Primary Care Education, Pathways and Research of 
Dementia project) and how this PhD thesis fits within the context of PREPARED. 
2.1 DEMENTIA  
Dementia is a disorder that is characterised by a decline in cognition involving one or more 
cognitive domains (learning and memory, language, executive function, complex attention, 
perceptual-motor, social cognition). The deficits must represent a decline from previous level 
of function and be severe enough to interfere with daily function and independence. 
Dementia was renamed ‘major neurocognitive disorder’ in the new Diagnostic and Statistical 
Manual of Mental Disorders, Fifth Edition (DSM-5), published in 2013. 8 However, the term 
dementia is still used as an acceptable alternative and will be used throughout this thesis. 
There are a number of sub-types of dementia; Alzheimer’s disease, vascular dementia, mixed 
dementia types and Lewy body dementia. The listed sub-types account for approximately 90% 
of all dementias. 9 
2.1.1 Prevalence of dementia 
As the world’s population ages, the number of people living with dementia grows. 10 It is 
estimated that there are currently 47 million people living with dementia worldwide and 
this figure is predicted to triple by 2050. 11  However, age is not the only risk factor for 
dementia. There are other modifiable risk factors for dementia such as diabetes and 
hypertension. 12 Estimates suggest that the combinations of these ‘modifiable’ risk factors 
means that up to 30% of dementia cases may be ‘preventable’. 12 There is recent evidence 
that the incidence of dementia is falling across successive generations in higher-income 
countries. 13-15 Therefore, in higher income countries the estimates of future dementia 
prevalence may not be at the level predicted from previous projections. The Cognitive 
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Functional Ageing Study was conducted over an interval of two decades at multiple sites in 
the UK and reported a 20% drop in dementia incidence. 15 That study found a far smaller 
increase than would have been expected from extrapolation of earlier estimates of 
dementia prevalence. The authors concluded that a reduction in age-specific incidence of 
dementia means that the numbers of people estimated to develop dementia in any one 
year in the UK has remained relatively stable. 15 Whereas, in lower income countries 
evidence suggests that previous estimates may have underestimated the burden of 
dementia. 16 
There are a number of potential explanations for this reduction in age-specific incidence of 
dementia in higher-income countries including improvements in the management of 
modifiable risk factors and improvements in “protective” factors such as education. 
Education has been transformed in higher-income countries over the past number of 
decades with resulting improvements in cognition.13  The impact of improvements in 
vascular risk reduction on the incidence of dementia is complex. The IMPACT-BAM study 
conducted in the UK identified that, although age-specific dementia is declining in the UK, 
the actual number of people with dementia in the UK is likely to increase by 57% from 2016 
to 2040. 17 The authors concluded that the projected increases in the burden of dementia, 
despite the significant downward trend in age specific incidence of dementia, is largely a 
consequence of improvements in life expectancy. So vascular risk reduction is driving down 
age-specific dementia incidence but is also leading to increased life expectancy which 
results in larger numbers of people who are susceptible to dementia. Therefore, although 
the evidence suggests that the incidence of dementia is declining, the magnitude of the 
decline is less certain. 17  
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It is unclear how these different trends will impact on dementia prevalence in Ireland. 
Ireland is predicted to have the largest growth in the older population of all European 
countries in the coming decades. 18 The most recent figures available estimate that, in 2016, 
there were 55,000 people living with dementia in Ireland and this figure was predicted to 
rise to 147,000 by 2041 19 (see Figure 2). These estimates were developed by applying 
dementia prevalence rates to Irish census data. Of the 55,000 people living with dementia in 
Ireland it is estimated that 63% live at home in the community, 34% live in nursing homes 
while the remaining 3% of people with dementia reside in the acute hospital or psychiatric 
setting.20 The majority of people with dementia live either at home or in a nursing home, 
therefore, their first point of medical contact is their GP.  
 





2.1.2 Personal and societal impact of dementia 
Dementia is an incurable and largely untreatable disease. 10 However, many of the 
manifestations of dementia are now known to be manageable and although the underlying 
illness is not curable, the course of the disease might be modifiable with good dementia 
care. 10 For many decades dementia has been associated with negative stereotyping and 
stigma. 22 Public awareness campaigns, such as the Understand Together campaign 23 which 
was recently run in Ireland, improves societal and individual understanding of dementia. 24 
This increased public awareness is welcomed but dementia remains a devastating diagnosis 
for many people. A diagnosis that is filled with uncertainty and isolation.25 The majority of 
people with dementia live at home and are cared for by their families. The burden of caring 
for a person with dementia can be significant for a family. Caring for a person with dementia 
can impact on a carer’s physical and psychological health.26 Quantifying the personal and 
societal impact of dementia, or any illness, is challenging. One approach to measuring the 
personal impact of dementia is to use the Global Burden of Disease (GBD) estimates which 
expresses the impact of the disease in terms of associated disability and mortality. 5 A key 
metric used in the GBD estimates is the Disability Adjusted Life Year (DALY). This metric is a 
composite measure of disease burden calculated as the combined sum of Years Lived with 
Disability (YLD) and Years of Life Lost (YLL). The World Health Organisation (WHO) engaged 
in wide international consensus when developing the WHO GBD Report. In this report 
disability from dementia, as estimated by the DALY metric, was accorded a higher disability 
weight than that for any other condition, with the exception of severe developmental 
disorders. 5  
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2.1.3 Economic impact of dementia 
The annual global cost of dementia is estimated to be US$818 billion. 5 When compared to 
other illnesses dementia has a relatively high cost burden. A UK study conducted in 2012 
found the health and social care services cost burden of dementia (£10.9 billion) to be 
significantly higher than the cost burden of cancer (£4.5 billion), stroke (£2.7 billion) or heart 
disease (£2.5 billion).27 Around 85% of the costs associated with dementia are related to 
family and social care rather than medical care. 10 In Ireland, in 2010, the total annual cost of 
dementia was estimated to be €1.69 billion, with 47% attributable to informal care and 43% 
attributable to residential care. 20  
In summary, dementia is a subject of increasing concern internationally as a result of the 
increasing prevalence rates and its significant impact on the healthcare system, the people 
living with dementia and their families. 
2.1.4 National Dementia Strategies 
In response to the rising prevalence of dementia and its significant societal and economic 
impact, many countries have developed national dementia strategies. 28-30 These national 
dementia strategies broadly reflect the recommendations from the Kyoto Declaration which 
was published in 2004 by members of the Alzheimer’s Disease International. 31 The Kyoto 
Declaration was a consensus document that made 10 key recommendations to combat 
dementia. The recommendations have a strong focus on the provision of care in the 
community and highlights the important role of primary care. In 2006 the Paris Declaration 
was published by members of Alzheimer’s Europe. 32 The Paris Declaration built on the 
Kyoto Declaration and called upon the World Health Organisation and the European Union 
to recognise dementia as a major public health challenge and to promote the development 
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and implementation of national programmes to address dementia. Following these 
declarations national dementia strategies have been developed worldwide. 
2.1.4.1 The Irish National Dementia Strategy 
 Ireland’s first National Dementia Strategy was published in December 2014. 29 The Irish 
National Dementia Strategy identified six key priority areas for dementia care in Ireland: 
(i) Better awareness and understanding 
(ii) Timely diagnosis and intervention 
(iii) Integrated services and supports for people with dementia and their carers 
(iv) Training and education 
(v) Research and information systems 
(vi) Leadership 
Like many national dementia strategies, the Irish National Dementia Strategy highlights the 
central role of GPs in dementia care. The strategy particularly emphasises the central role of 
the GP in the key priority areas of timely diagnosis and integrated services and supports. 
Other areas of dementia care where GPs play an important role are also highlighted, namely 
palliative care and the management of behavioural and psychological symptoms of 
dementia. The Irish National Dementia Strategy acknowledges the pivotal role GPs play in 
the implementation of the key elements of the strategy. However, the strategy fails to 
acknowledge the current resource constraints in Irish general practice and fails to consider 





2.2 INTERNATIONAL MODELS OF GENERAL PRACTICE 
I will now focus on the context of my research area – general practice. I will first discuss the 
different models of general practice internationally. I will then outline the economic 
structure and function of general practice in Ireland and how this impacts on the provision 
of chronic disease management, nursing home care and dementia care.  
2.2.1 Healthcare funding and international approaches to allocation of 
funding to general practice 
Internationally healthcare is funded through multiple sources, usually through general tax 
revenue, statutory health insurance, private health insurance or a combination of these 
sources. 33 There is considerable variation in the amount of gross domestic product (GDP) 
that is dedicated to health across different countries. Analysis of the OECD data on health 
spending from 2016 shows that Ireland spends only 7.8% of its GDP on health, lagging 
significantly behind countries such as Germany (11.3% of GDP), France (11% of GDP), 
Canada (10.3% of GDP) and the UK (9.2% of GDP). 33 Within health services the approach to 
allocating money to general practice varies internationally but typically follows one of the 
following systems; capitation, payment-for-performance or fees-for-service. Capitation 
payments are related to the characteristics of the patient population registered in a 
practice, such as age of the patient, and are not linked to any measure of the quality of care 
provided. In several countries, including Sweden and New Zealand, the capitation payment 
system is combined with a ‘pay-for-performance’ model. 34 This approach attempts to link 
additional funding to GPs who reach certain targets. For example, in Ireland GPs receive 
payments for meeting childhood vaccination targets. The third model, the ‘fee-for-service’ 
model, is the predominant GP payment system in Australia 34 and the U.S.. This model 
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allows GPs to be reimbursed for providing a specific service. The capitation system is 
present to some extent in most countries and is often combined with the fee-for-service 
model. This combined system is the funding model for general practice in Ireland, Germany 
and France. The Netherlands recently changed their model of general practice funding to 
include all three payment models; capitation payments account for ~75% of spending, fees-
for-service represent about 15% and additional funding of 10% that is negotiated at 
individual GP level. 33  
There are pros and cons to each funding model. For example, the capitation model is 
criticised for its inflexibility and the fact that it does not incentivise GPs to treat time-
consuming patients. 35 The ‘pay-for performance’ model was introduced in England and 
Northern Ireland through the quality and outcomes framework (QOF). However, the system 
has been criticised by some as being reductive, acting as a barrier to the provision of 
patient-focused care. The ‘evidence’ on which the QOF is based has also been called into 
question. 36 The pay-for-performance model is highly dependent on the quality indicators 
that underpin it and generally fails to account for the most significant influence on health 
outcomes – the social determinants of health. 37 The third model, the fee-for-service model, 
has also been criticised for being costly, inefficient and for not promoting integrated care. 35 
Ultimately, there is no consensus on what approach to funding general practice is best but it 
is likely to be a combination of several approaches. The funding approach chosen has 
consequences for the demand for general practice, GPs’ workload and the GP’s role within 





2.3.2 The role of the GP internationally 
The role of the GP varies across countries. In general, GPs are patients’ first point of contact 
in the healthcare system providing ‘cradle to the grave’ care. In many countries, such as in 
Ireland, the UK, Australia and Canada, GPs have a gatekeeper role, controlling access to 
secondary care. 38 In other countries, such as Sweden and Germany, although GPs are often 
the natural first point of contact within the healthcare system, a GP referral is not required 
to access secondary care. There are pros and cons to GPs acting as a gatekeeper. 38 The 
presence of a GP gatekeeper can lead to lower use of health services and can protect 
against over treatment. However, the gatekeeping role is thought by some to negate the 
ethos of patient choice and empowerment. 38 It can also increase GPs’ workload. In many 
countries such as Ireland, New Zealand, France and the Netherlands, GPs are self-employed 
and function much like a small business. 33 However, in other countries, such as Sweden, 
GPs are salaried government employees. 33 The model of GP care where a GP fulfils these 
multiple functions of; gatekeeper for the healthcare system, advocate for the patient and 
owner of a small business, can create tensions for GPs who may struggle to maintain their 
primary advocacy role for their patient amidst these potentially conflicting roles. 
2.3.3 Changes to GP workload 
Internationally, the important role of primary care in delivering care to people living in the 
community with chronic diseases is being increasingly recognised. Modern day general 
practice in which the GP is a member of a multidisciplinary team and is supported by 
computerised medical records is aptly placed to deliver chronic disease management. 39 
Internationally, there has been a shift away from hospital-led specialist care to community-
led generalist care. However, this shift has also created tensions for GPs. Managing chronic 
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diseases in general practice is complex. 40 It often involves managing people with multiple 
comorbidities which results in more frequent attendances, 41 longer consultation times and 
typically requires input from multiple different health care professionals which can create 
challenges for GPs as the co-ordinators of care.42  As practice size increases and the number 
of GPs in full-time practice decreases, GPs can struggle to provide the continuity of care that 
is the hallmark of general practice and an important component of effective chronic disease 
management. Furthermore, poor integration of primary and secondary care services can 
negatively impact on a GP’s ability to effectively co-ordinate the care of a person with a 
chronic disease. Finally, this shift in the care provided in general practice requires a re-
direction of resources into primary care if it is to be successful.39,43 
I will now focus on general practice in Ireland. I will explore the changes that have occurred 
in general practice in Ireland over the past number of decades and how these changes have 
impacted upon the function and structure of general practice in Ireland. 
 
2.3 GENERAL PRACTICE IN IRELAND 
The changes in general practice workforce and patterns of work that have occurred in 
Ireland over the past few decades mirror changes that have occurred in general practice 
internationally. 44  Thirty years ago the typical Irish GP was a single handed practitioner, 
usually operating from his/her own home and permanently ‘on-call’. This traditional model 
has undergone significant transition over the past 30 years. A study published in 2015 
provides a picture of the changing face of general practice in Ireland by comparing data 
from equivalent national GP surveys conducted at four points in time – 1982, 1992, 2005 
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and 2015. 45 The 2015 survey found that 97% of GPs in Ireland now work in purpose-built or 
specially adapted premises. The overwhelming majority (99%) of GPs in Ireland are now part 
of an out-of-hours co-operative or rota.45 There has been a substantial decline in the 
traditional single handed practice (from 63% of GPs working in single handed practices in 
1982 to just 18% of GPs in 2015).45  The vast majority of GP practices (94%) are now 
computerised. Additionally, the percentage of GPs in full-time practice has fallen – from 97% 
of GPs in full-time practice in 1992 to 84% in 2015. 45 Despite these changes, satisfaction 
rates with general practice remain high. 46 However, GPs working in Ireland in 2015 reported 
higher stress and lower morale than was reported in any previous survey. The proportion of 
GPs reporting low morale tripled between 2005 and 2015. Similarly, the levels of self-
reported stress increased from 12% in 2005 to 58% in 2015. 45 The reasons for the low 
morale and high stress levels of GPs is multifactorial. The authors of the 2015 survey 
postulated that it could be a reflection of the low morale of the country over those years 
due to the economic collapse.45 However, it is likely that low morale is also related, at least 
in part, to the organisational and economic structure of general practice in Ireland. General 
practice in Ireland has transformed over the past thirty years but the economic structure of 
Irish general practice has not evolved in response to this transformation. I will now outline 
the economic structure of Irish general practice and the impact of government policies on 
the organisational structure of general practice. 
2.3.1 The economic structure of Irish general practice  
Healthcare in Ireland is a mix of private and public provision. The vast majority of GPs in 
Ireland are self-employed ‘independent contractors’ of the Irish Health Service Executive 
(HSE) for those patients eligible for state-funded care through the state-run General Medical 
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Service (GMS) scheme.45  In Ireland the main system for allocating money to general 
practice is predominantly through annual capitation payments. Ireland is unusual 
internationally in terms of the relatively high proportion of people that pay out-of-pocket 
charges to attend a GP. 47  These charges are paid in full at the point of contact without any 
subsidisation, insurance or other rebate. In Ireland ‘medical cards’, which allow free access 
to GP care and most medications, are strictly means-tested. 48 If a patient has a medical card 
then they must register with a specific GP. Only 37% of the Irish population qualify for state-
funded GP care in the form of ‘medical cards’. Medical cards can also sometimes be granted 
on medical grounds, such as advancing terminal illness. People who don’t qualify for a 
medical card may qualify for a ‘GP visit card’ which allows the person to attend their GP 
without charge but they must pay for all medication costs. In total approximately 43% of the 
Irish population are covered by either a medical card or a GP visit card. 
GPs in Ireland receive a capitation payment for their GMS patients based on the patient’s 
age and gender. 49 For example, for a male GMS patient aged 68 years of age who lives at 
home in the community, a GP would receive an annual capitation fee of €129.72 per annum 
regardless of the number of times the patient attended the GP. Whereas, for a male GMS 
patient aged 70 years of age a GP would receive a substantially higher annual capitation fee 
of €271.62 per annum. 50 GPs who provide care to nursing home residents under the GMS 
scheme receive an annual capitation on a scale of €121.29 - €434.15 per patient depending 
on the age of the patient. 50 Most GPs also provide care for private patients (i.e. the 57% of 
the population not eligible for state-funded care) on a scale of fees the GPs set themselves. 
For people that are not eligible for a medical card, the fee for attending a GP in Ireland is 
typically €50 - €60 per consultation. There is evidence that these costs do deter some 
people from attending their GP, 51 particularly people in the middle income range. 52 In 
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contrast to general practice fees, hospital treatment is either highly-subsidised by the 
government or covered by a patient’s private medical insurance, (about 43% of the Irish 
population has private medical insurance). 48  
2.3.2 The impact of government policy on the organisational structure of 
general practice in Ireland 
Funding of the Irish healthcare system has been historically hospital-centric.53 Culturally and 
economically the focus of the health care system has been on the provision of hospital care 
rather than on the provision of care in the community. While there was a 61% increase in 
GPs in Ireland between 1982 and 2015 the corresponding increase in public hospital 
consultants was 153%. 45 The health care focus on hospitals meant that successive 
governments have not invested in primary care in Ireland to the extent seen in other 
(similar) countries. In Ireland 4.5% of the overall health budget is expended on general 
practice, significantly lower than other European countries. 54 I will now outline how 
government policies have impacted on Irish general practice. 
2.3.2.1 The impact of austerity  
In response to the economic crisis Ireland faced in 2008 the government introduced a series 
of austerity measures. One such provision was a piece of legislation called the Financial 
Emergency Measures in the Public Interest (FEMPI) Act 2009. This FEMPI Act resulted in a 
series of reductions in the government payments to all public servants including GMS 
payments to GPs. 55 As a result of the implementation of FEMPI, capitation payments to GPs 
were reduced by about 30% over a four year period from 2009 to 2013. The economic 
situation in Ireland has since improved. Cuts to government payments to many public 
service workers under FEMPI have since been rolled back. However, roll back in cuts to 
41 
 
government payments to GPs has yet to occur. Of note, the capitation fee now paid to GPs 
attending nursing homes is ~30% less than it would have been before the introduction of 
FEMPI. Additionally, prior to 2009 all people over the age of 70 were automatically entitled 
to a medical card. However, in 2009 in a cost saving measure, the government removed this 
‘automatic’ entitlement and since then people over the age of 70 are eligible for a doctor’s 
visit card but they must satisfy a means test to receive a medical card. 56 This measure had a 
disproportionate effect on nursing home residents.57 With the loss of this automatic 
entitlement of patients over 70 years to a medical cards GPs also lost an annual capitation 
payment of €720 per nursing home resident they attended. As a result of the combined 
FEMPI cuts and the loss of the ‘top-up’ capitation payment for providing care to a nursing 
home resident many GPs report that they can no longer provide care to nursing homes. 58  
2.3.2.2 The GP Contract 
A further challenge facing general practice in Ireland is the current GP contract between the 
HSE and GPs. This contract is now four decades old. In keeping with the type of clinical care 
delivered by GPs at the time this contract was first developed, the focus of the current 
contract is on the delivery of acute medical care without any focus on chronic disease 
management. GPs in Ireland have long advocated for re-negotiation of their contract. In 
2015 a new cycle of care was introduced for people with diabetes whereby GPs are now 
paid a once-off registration fee of €30 per GMS patient with diabetes and enhanced 
capitation payments of €100 per patient with diabetes for conducting two reviews annually. 
There has yet to be any evaluation of the impact of the introduction of this ‘diabetes cycle 
of care’ on the quality of care provided to people with diabetes. However, recent Irish 
research that evaluated the primary care led diabetes structured care programme in the 
Midlands region did show that the programme led to some promising improvements in the 
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quality of diabetes care provided over time.59 There are currently no incentivisation 
schemes for the management of any other chronic disease in adults in Irish general practice 
but the introduction of the diabetes cycle of care is a promising precedent. 
2.3.2.3 Primary Care Teams 
In recognition of the need to increase Ireland’s healthcare focus on primary care, in 2001 
the Department of Health in Ireland launched a report named ‘Primary Care - A New 
Direction’. 60 This report signalled a substantial reform in the approach to health care in 
Ireland. It acknowledged the central role of primary care in the future development of the 
Irish health service and proposed an inter-disciplinary team based approach. The members 
of the team were to include GPs, nurses, physiotherapists, occupational therapists, social 
workers, home helps and the team would be further supported by a wider network of 
primary care professionals. However, the implementation of this strategy has been 
challenging. Ten years after the launch of the governments ‘New Direction’ plan, a national 
survey of GPs conducted by the Irish College of General Practitioners (ICGP) found that only 
58.4% of responding GPs were part of a Primary Care Team (PCT) and that of these GPs 
64.7% felt the PCT was poorly functioning. 2 The 2011 ICGP report identified a number of 
barriers to GPs engaging in PCT meetings. One such barrier was that GPs may be assigned to 
several different PCTs, as patients are assigned to teams based on their geographical 
location rather than on their general practice registration. The report also identified specific 
sources of frustration for the GP, such as the fact that in most instances residents in private 
nursing homes are not eligible for PCT care. The ICGP report made a number of 
recommendations on how GP involvement in PCTs could be improved. One 
recommendation was that resources be provided to support the implementation of PCTs. 
Another was that resources needed to move from secondary to primary care in order to 
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optimise chronic disease management. A subsequent 2016 survey of GPs and primary care 
professionals identified that adequate resources and GP participation were the most 
important elements of effective PCTs. 61 The majority of respondents to the 2016 survey 
reported that little or no progress had been made with the implementation of the 2001 
Primary Care Strategy.61 At the time of writing this thesis no steps have been taken to 
change the structure of PCTs in Ireland. The limited evidence available suggests that 
functioning PCTs, that meet regularly to provide an integrated care system, are a rare 
entity.62 
2.3.2.4 Sláintecare 
The Irish government (at the time of writing, 2018) is committed to rolling out free GP care 
at the point of contact to the entire population. Sláintecare is the name of the government’s 
plan to provide universal healthcare to all in Ireland.63 Sláintecare proposes a health reform 
plan that will be rolled out over the next ten years. The result will be a shift in the emphasis 
of the Irish health care system out of the hospitals and into the community. Over a five-year 
period all Irish citizens will be eligible for a Carta Sláinte (health card) that will enable them 
to access a wide range of health services (including general practice) that will be free at the 
point of contact. The aim of Sláintecare is to provide “a universal, single-tier health services 
where patients are treated on the basis of health need not ability to pay”.63 The Sláintecare 
Implementation Strategy was published on the 8th of August 2018 but has been criticised for 
not providing specific details on how the plan will be implemented and financed. 64  
2.3.2.5 The current manpower crisis in Irish General Practice 
Sláintecare represents a new vision for Irish healthcare. However, in order for this vision to 
become a reality significant investment into general practice is required to increase current 
capacity. 47  Currently there is an ageing cohort of GPs in Ireland with 14% of practising GPs 
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now over the age of 65.45  Over 660 GPs in Ireland (approximately 25% of all GPs in Ireland) 
are due to retire in next seven years.65 Rural Irish general practice will be particularly 
affected. In some rural counties up to 50% of GPs are due to retire in the next seven years.66 
Over 2,500 new GPs are required to meet existing and future demands within the next 7 
years. However, Ireland is failing to retain GP graduates, with one in five choosing to 
immigrate within a year of graduation.67 In a recent survey of Irish GP graduates conducted 
over 3 years from 2014 -2017, emigrating GPs reported that the decision to leave Irish 
general practice was primarily influenced by quality of life and financial considerations.67 Of 
the newly qualified GPs who decide to remain in Ireland the majority plan to only work part-
time and do not want senior partnership roles. 67 This combination of an ageing cohort of 
GPs and the high levels of GP graduates emigrating has led to a substantial recruitment crisis 
in Irish general practice. In 2015 the government introduced ‘free’ GP care for children 
under-6 at the point of contact. This led to a 28% increase in GP visits for this patient 
population.68 If Sláintecare is implemented, extending free GP visits to the entire Irish 
population, without the necessary investment in general practice to improve capacity, it is 
likely that the government’s plans for free GP care will result in long waiting times for GP 
appointments and put further strain on an already over-stretched service.  
2.3.2.5 The impact of these policies on dementia care 
Between 2015 and 2018 the number of people in Ireland with medical cards fell from 1.75 
million to just under 1.6 million but 30% are GP visit cards. 69 The number of people with 
‘full’ medical cards fell from 1.65 million to 1 million over this three year period. The Irish 
government is increasing the number of GP visit cards, which provide free access to the GP, 
but significantly reducing the number of ‘full’ medical cards. It is these “full” medical cards 
that fund medication costs and provide access to community health services such as public 
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health nurses and allied health care professionals. The deficits in primary care funding, the 
GP manpower crisis and the restrictions in access to medical cards impact to varying 
degrees on the public at large, but for the person with dementia they can have a particularly 
negative impact. People with dementia and their families need access to multi-disciplinary 
supports but, as outlined, functioning multi-disciplinary primary care teams are few and far 
between. Furthermore, even if such a functioning primary care team exists in the area, the 
person with dementia may not be able to access these supports as they have no automatic 
entitlement to a medical card. I will now examine in detail the impact of the current model 
of general practice on dementia care. 
 
2.4 THE IMPACT OF THE CURRENT MODEL OF GENERAL PRACTICE ON 
DEMENTIA CARE  
In dementia care the role of a GP is increasing, partly as a result of the rising prevalence but 
also as a result of national strategies that aim to move the care of people with dementia out 
of hospitals and into the community. General practice is the most appropriate place for 
chronic disease management and dementia is an example of one such chronic disease that 
is particularly suited to the continuity and holistic care that general practice can offer. 
However, increasing demand on GP practices in the context of reduced remuneration, 
limited access to multidisciplinary support and a substantial manpower crisis has meant that 
many GPs feel they are unable to provide structured chronic disease care, unless adequately 
resourced to do so. 43  Furthermore, dementia care poses a number of unique challenges for 
GPs who report finding many aspects of dementia care, such as diagnosis, post-diagnostic 
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support and the management of behavioural and psychological symptoms of dementia, 
particularly difficult. 
2.4.1 Dementia diagnosis 
GPs are, in many ways, uniquely placed to notice some of the early symptoms of dementia 
such as missed appointments, issues around drug adherence, and changes in personality or 
mood. Often in general practice it is a family member that presents with concerns rather 
than the individual with the emerging dementia.  However, the variable and insidious onset 
of dementia can make recognition of the illness problematic in primary care. 70 
Furthermore, research has identified a reluctance on the part of GPs to be directly involved 
in the diagnosis of dementia, with GPs reporting concerns about lack of resources and lack 
of confidence in making and disclosing a diagnosis of dementia.71  Other barriers to 
diagnosing dementia in general practice include lack of support for the patient and 
caregiver, time constraints, stigma and therapeutic nihilism. 72 However, the complexities of 
making a timely diagnosis of dementia in general practice need to be understood. The 
nuanced balancing judgements adopted by GPs when deciding on the timeliness of a 
dementia diagnosis should not be conflated with a GP’s lack of awareness of the importance 
of making diagnosis. It does not necessarily represent any specific training need, rather it 
highlights the need for a personalised approach to the diagnosis of dementia. 73  
In Ireland there is no financial incentive for GPs to make a diagnosis of dementia. In England 
GPs are financially incentivised for making a dementia diagnosis under the QOF programme. 
The scheme was criticised as being unethical 74 and described as “crossing a line”. 75 A 
recent evaluation of the scheme demonstrated that the incentive scheme appears to have 
closed the gap between recorded and expected prevalence of dementia in general practice. 
47 
 
76 The authors concluded that the findings support evidence that financial incentives can 
motivate improved performance in dementia care in general practice. 76 In line with existing 
NICE guidance, 77 the Irish national dementia strategy recommends that GPs refer for 
specialist confirmation of the diagnosis and for subtyping of the dementia. 29 However, GPs 
in Ireland can experience difficulties accessing secondary care services to investigate or 
confirm a diagnosis of dementia. Ideally, GPs would be able to refer to a memory clinic for 
confirmation of the diagnosis and subtyping. However, memory clinics are a variable and 
inconsistent entity in Ireland. A 2017 review found that there are large areas of the country 
without any access to a memory clinic. 78  Only two clinics have full access to PET and CSF 
biomarkers as part of diagnostic work-up.78 Furthermore, there is variability in terms of the 
compliment of allied healthcare professionals and services offered in the different memory 
clinics with no standardised approach. 78,79  
2.4.2 Post diagnostic support 
The Irish National Dementia Strategy also highlights the important role GPs play in the 
provision of post-diagnostic support to people with dementia. However, providing advice on 
local dementia services and supports is a particularly challenging aspect of dementia care 
for GPs. 80-83 This can be because of the limited availability of services and supports or 
because GPs are often unaware of the existences of these services. 72 The GP co-ordinates 
the care of the person with dementia in the community but can be constrained by the 
resource limitations of the healthcare system in which they operate. As outlined in section 
2.3.2.3 many GPs in Ireland do not function within a primary care team nor do they have 
access to multidisciplinary support from allied primary healthcare professionals. 2 This can 
result in difficulties accessing multidisciplinary supports in the community for people with 
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dementia. Additionally, people with dementia in Ireland are not automatically entitled to a 
medical card. This can further impede the provision of care as many services, such as access 
to a Public Health Nurse, are only available to people with medical cards. There can also be 
significant difficulties accessing community based services such as home help hours. These 
services are vital as they enable people to live at home for as long as possible, delaying 
transitions to long term care settings. Recent health planning estimates predict that 
Ireland’s need for home help will continue to increase with an expected increased need 
from 300,000 home help hours required in 2017 to 2,270,000 in 2022. 84 However, despite 
the increased need there has not been any substantial investment in home help hours. 
Indeed many caregivers are finding it increasingly difficult to access any home help. A report 
from 2016 indicated that fewer funds were being spent on home care than were spent in 
2008. 85 With these resource constraints GPs can find providing optimum care to people 
with dementia and their families to be challenging. Furthermore, it can create a two-tiered 
system where families that can afford to pay privately for services such as home help 
receive them but those that cannot afford to pay for them must go without. 
2.4.3 BPSD  
The management of behavioural and psychological symptoms of dementia (BPSD) is an 
aspect of dementia care that GPs consistently report they find challenging. 86-90 The 
assessment and management of behaviours such as aggression, wandering and symptoms 
such as depression and apathy can be time-intensive and would, ideally, involve support 
from a multidisciplinary team. The presence of BPSD can be particularly traumatic for 
families who may then present to their GP in crisis and disarray. 91 The Irish National 
Dementia Strategy highlighted the importance of appropriate management of BPSD and 
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emphasised that the current BPSD treatment model that focuses on pharmacological 
management rather than non-pharmacological management of BPSD needs to be 
addressed. 29  BPSD can affect a person with dementia at any stage of their illness but is 
typically associated with moderate to advanced stages of dementia 92 and with residence in 
a nursing home. 93 I will now examine the role of the GP in nursing home settings in Ireland.  
2.4.4 The role of the GP in the provision of nursing home care 
In the UK in the 1990’s the long-term care of older people moved from hospitals to nursing 
homes. 94 Consequently, the medical responsibility for these patients moved from hospital 
specialists to general practitioners. 95 A similar shift occurred in Ireland. One-third of people 
with dementia in Ireland now live in residential care, 20 which, in Ireland, means residing in a 
nursing home. In Ireland, nursing home care refers to care homes that provide all the day-
to-day care and medical needs of its residents. The nursing homes are staffed by nurses who 
are on-duty all day and all night.  This is really the only kind of care home environment on 
offer in Ireland. In this thesis, when reference is made to long-term care or nursing homes, 
this fully-staffed nursing-led nursing home is the model of care being referred to.  As is the 
case in many countries, 95,96 in Ireland GPs can choose to provide care to people residing in 
long term care settings, in addition to care they provide to their patients in the community. 
A recent survey of European geriatric medicine societies asked respondents to estimate the 
proportion of nursing home care delivered by various physician specialities. 97 The study 
found that in 17 of the 22 countries surveyed, over 70% of the medical care in nursing 
homes is delivered by GPs. In that study it was estimated that, in Ireland, GPs provide 75% 
of the medical care to nursing home residents. 97  
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In Ireland, nursing homes are comprised of a mixture of state-funded nursing homes and 
private nursing homes. Based on data obtained from personal correspondence with Nursing 
Home Ireland, the national representative organisation for the private and voluntary nursing 
home sector, there are currently 450 nursing homes in Ireland; 130 of these nursing homes 
are state run and the remaining 320 are private. GPs who attend large, state-run nursing 
homes may be supported by secondary care colleagues – old age psychiatrists or 
geriatricians who also provide care to the nursing homes. However, the majority of GPs 
providing care in nursing homes do not have any formal support from a hospital specialist. 
The nursing home commitment of a GP in Ireland varies considerably; some GPs have no 
nursing home commitment, some provide care to just a few nursing home residents and 
others provide care to large numbers of nursing home residents. There are advantages to a 
GP caring for a large number of nursing home residents. Research has demonstrated that 
the likelihood of a GP providing regular, structured visits to a nursing home increases with 
the number of residents in the care home registered with the GP. 95 However, a potential 
drawback is the loss of continuity of care when a new resident switches care from their life-
long GP to the GP who provides the majority of care in the nursing home. 96 In Ireland the 
exact proportion of GPs providing care to nursing homes and the extent of their nursing 
home commitment is unknown.  
Nursing homes in Ireland are regulated by HIQA (Health Information and Quality Authority). 
HIQA was established in 2007 and is responsible for developing standards and guidance, as 
well as inspecting and reviewing nursing homes. HIQA has improved standards of care being 
provided to nursing home residents but some would argue it has also placed an enormous 
administrative burden on nursing homes. 98 Some of this burden has been passed on to GPs. 
GPs report that minor illnesses that would have previously been managed by the nursing 
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home staff are now being referred to the GP 58 for fear of breaching a perceived HIQA 
regulation. 98 Although HIQA regulations do not advise on how these medical issues should 
be handled, the fear of an adverse report from the regulatory body has changed nursing 
home policy on the management of minor illness away from the nursing staff and toward 
the GP. The increased workload of attending nursing homes, in the context of the reduced 
remuneration to GPs providing this care, has led to a general dissatisfaction of GPs in Ireland 
providing care to nursing homes,98 echoing similar dissatisfaction reported by GPs in 
Australia 99 and the UK 100 and prompting calls by GPs in Ireland that the provision of nursing 
home care be explicitly dealt with in any new GP contract. 58  
 
2.5 THE PREPARED PROJECT 
The Irish National Dementia Strategy was developed with input from an expert advisory 
group. One of the key recommendations of the Irish National Dementia Strategy was the 
importance of training of health care professionals in dementia care.  In acknowledgement 
of the importance of upskilling primary care based health professionals in dementia care, Dr 
Tony Foley was awarded funding for the PREPARED (PRimary care Education, Pathways And 
Research in Dementia) project. PREPARED is one of the three implementation work-streams 
of the National Dementia Strategy. The aim of PREPARED is to develop, deliver and evaluate 
training and education interventions to GPs and primary care clinicians. PREPARED is a three 




2.5.1 GPs’ educational needs in dementia care  
To inform the development of PREPARED’s educational interventions it was important that 
the educational needs of GPs in Ireland were identified. Therefore, a triangulated 
educational needs analysis was conducted.87  (Published paper available in appendix 12). 
Semi-structured interviews were conducted with GPs (n=14), people with dementia (n=5) 
and family carers (n=12). The aim of these interviews was to get multiple perspectives on 
what GPs’ educational needs were in dementia care. In addition to asking GPs what their 
needs were, people living with dementia and their family caregivers were also asked about 
what their experience was with their GP- what they felt their GP did well and what they 
could have done better. The interviews were thematically analysed. 101 Five main themes on 
GPs’ educational needs in dementia care were developed. These themes were; (i) diagnosis 
(ii) disclosure (iii) BPSD (iv) signposting services and supports (v) counselling. The 
management of BPSD was a significant theme, particularly among GPs but also among 
carers. GPs described prescribing dilemmas in BPSD: 
‘When do you add in psychotropic medication, what type of medication, what 
dosages, for how long?’ (GP3) 
While carers spoke about the lack of guidance their GP was able to provide on the 
management of BPSD: 
‘…I had to develop a technique to try to snap him out of that, and I used to try 
reminiscing and that kind of thing and that worked, but I learnt all that myself 
through the internet, to be quite honest with you’  (FC1) 
BPSD emerged as a particularly challenging area for GPs, therefore, this specific topic 





Rising dementia prevalence combined with policy objectives of keeping people with 
dementia living in the community has resulted in GPs taking on an increasing role in 
dementia care. The Irish National Dementia Strategy, echoing dementia strategies 
internationally, advocates for community centred dementia care, yet current Irish 
healthcare policy does not have a community-centric approach to healthcare delivery. In the 
context of diminishing resources and economic structures that focus on the provision of 
acute care, GPs struggle to provide chronic disease management. The challenges of 
providing chronic disease management in general practice are particularly apparent when it 
comes to dementia care. Dementia is a complex, evolving illness that needs continuity of 
care and multidisciplinary input. As identified in the triangulated educational needs analysis 
conducted by the PREPARED project, GPs are challenged by the specific complexities of 
dementia care. In particular, they are challenged by the management of BPSD. The Irish 
National Dementia Strategy calls for integrated, multidisciplinary, community-led care for 
people with dementia. The strategy advocates for the up-skilling of all clinicians, including 
GPs who are encouraged in the strategy to take on an increasing amount of dementia care 
and to improve their current management of BPSD. In order for this recommendation to 
become a reality we need to understand the evidence for best practice in BPSD. We need to 
understand how these best practice recommendations compare with the reality of how care 




CHAPTER 3. A REVIEW OF THE BPSD LITERATURE 
 
3.1 INTRODUCTION 
This chapter provides an overview of the literature on BPSD that has informed my work. I 
begin by describing the problem of BPSD; its definition, prevalence and impact on people 
with dementia, their caregivers and the wider health system. I will then discuss best practice 
approaches to the assessment of BPSD. I will review the current evidence base for the 
management of BPSD, both non-pharmacological and pharmacological. Finally, I will review 
interventions developed to date that have aimed to improve the management of BPSD in 
primary care, with a particular focus on the role of GPs in these interventions. 
 
3.2 BPSD: WHAT’S IN A NAME? 
Cognitive impairment in dementia is often associated with behavioural and psychological 
symptoms. BPSD is an umbrella term that embraces a heterogeneous group of non-
cognitive symptoms and behaviours that occur in people with dementia. 91 Traditionally 
these symptoms and behaviours were discussed as single entities, such as depression, 
aggression and wandering. The term BPSD was first coined in 1996 by the International 
Psychiatric Association (IPA). 102 The term BPSD categorised these symptoms and behaviours 
into observed behaviours and or elicited psychological symptoms. 102 Observed behaviours 
are usually identified on the basis of observation of the patient, including physical 
aggression, screaming, restlessness, agitation, wandering, culturally inappropriate 
behaviours, sexual disinhibition, hoarding, cursing and shadowing. Psychological symptoms 
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are mainly assessed on the basis of interviews with patients and relatives; these symptoms 
include anxiety, depressive mood, hallucinations and delusions. This division has been 
criticised as being an over-simplification of these behaviours and symptoms that, in real 
clinical practice, tend to overlap and occur together in clusters rather than as isolated 
symptoms 91. Research to date has demonstrated significant association between the 
following pairs of symptoms and behaviours; anxiety/ depression, psychosis/ apathy, 
irritability/ persecution, wandering/ sleep problems. 103    
There are other terms used to describe these behaviours and symptoms. The term BPSD is 
challenged by some as being pejorative. Consequently, people may describe these 
behaviours and symptoms as ‘behaviours that challenge’, ‘responsive behaviours’ or ‘non-
cognitive symptoms’. For this thesis the term BPSD will be used in preference to these other 
terms. It was felt that these other terms do not fully encompass all the behaviours and 
symptoms covered by the term BPSD. Some of the symptoms of BPSD, such as apathy, may 
not necessarily ‘challenge’.  Likewise, ‘responsive behaviour’ may not cover all aspects of 
BPSD, since not all of the behaviours are necessarily ‘in response’ to a specific trigger. For 
example, delusions and hallucinations in a person living with dementia are not typically in 
response to an external trigger. The term ‘non-cognitive symptoms’ encompasses all 
symptoms that affect people living with dementia that are not related to cognition. 
However, it is a very broad term that could, in theory, include other non-memory dementia 
symptoms such as apraxia or agnosia. The term ‘non-cognitive neuropsychiatric symptoms’ 
is also used in the literature to describe these behaviours and symptoms 104 and is a 
comprehensive term. However, in view of the extensive use of the term BPSD, both in 
academic research and in clinical practice, the term BPSD will be used throughout this thesis 
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to describe the psychological symptoms and behaviours that affect people living with 
dementia.  
3.3 THE PREVALENCE OF BPSD 
The majority of people with dementia will experience BPSD at some time during their 
illness, particularly in the middle and later stages. 103 Estimates of prevalence vary 105,106 and 
the presence of BPSD can be influenced by several factors including dementia severity. 107  A 
cross-sectional study conducted in the United States in 2002 estimated the prevalence of 
BPSD in the population using data from the Cardiovascular Health study and found that 80% 
(n=233) of people with dementia exhibited at least one symptom of BPSD at some stage in 
their illness. 106 In 2009, a large population- based cohort study estimated the prevalence of 
twelve behavioural and psychological symptoms in the population of England and Wales. 103  
The prevalence of the symptoms were estimated in participants with dementia (n= 587) and 
those without dementia (n =2050). This data was supported by interviews (n =1782) with 
participants and their caregivers. Each symptom, apart from sleeping problems, was more 
common in the population with dementia. Apathy was the most prevalent symptom in 
people with dementia. The study concluded that BPSD affects nearly every person with 
dementia at some stage in the illness. 
 
3.4 THE IMPACT OF BPSD 
BPSD is one of the most complex, stressful and costly aspects of dementia care. 108 BPSD is 
associated with many of the negative outcomes of dementia; nursing home placements, 
caregiver stress and depression, and decreased quality of life for the person with dementia 
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and their caregiver.109 In this section I will outline the impact of BPSD on the person with 
dementia, their caregiver and the wider healthcare system. 
3.4.1 The impact of BPSD on the person living with dementia 
BPSD can negatively impact on a person with dementia’s quality of life.   A longitudinal study 
conducted in nine nursing homes in the Netherlands used two measurements, the Qualidem 
questionnaire and the neuropsychiatric inventory, to assess quality of life in 290 people with 
dementia. 110  The study found that the changes in the neuropsychiatric score consistently 
and negatively affected quality of life. 110 An earlier U.S. study examined the impact of BPSD 
in 62 people with Alzheimer’s disease and their caregivers. 111  Each person with dementia 
and their caregiver completed patient quality of life ratings. The study found that the 
presence of BPSD negatively correlated with the quality of life of a person with dementia. 
Furthermore, the presence of BPSD is associated with a myriad of negative health outcomes 
including; increased morbidity and mortality, 112 longer in-patient hospital stays 113 and early 
placement in a nursing homes. 114  
3.4.2 The impact of BPSD on family caregivers 
The negative impact of BPSD on the caregiver is well established. It is acknowledged that 
dementia care is different from other types of caregiving. Dementia caregivers spend more 
hours per week providing care than non-dementia caregivers. 115 They also report greater 
negative impacts in terms of employment complications, mental and physical health 
problems and family conflict. 115  BPSD is a major contributor to caregiver stress and 
depression in caregivers. 116  A recent systematic review and meta-analysis investigated the 
role of the individual symptoms of BPSD in relation to their impact on family care-giver well-
being and found that depressive symptoms were the most distressing for care-givers 
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followed by agitation/aggression and apathy. 117 BPSD is reported to be more stressful for 
caregivers than the cognitive or functional problems that occur as part of dementia. 118 119 
This may be related to the fact that cognitive symptoms generally tend to follow an 
expected steady decline, whereas BPSD can ebb and flow in a less predictable way. 
Additionally, BPSD can affect a person’s personality and so may contribute more 
dramatically to a caregivers’ sense of loss than the cognitive symptoms. 116 A recent 
systematic review and meta-ethnographic synthesis explored the challenges for family 
carers of managing BPSD. 120 The authors found that the sense that people with dementia 
“lose their identity” or become “dehumanised” was a key explanatory theme for the 
challenges of managing BPSD in a family setting. In the meta-ethnographic synthesis BPSD 
was described as “an invader” which “creeps up on people and steals them from 
themselves”. 120 Furthermore, caregivers generally understand that cognitive symptoms 
develop as part of dementia. However, they may not be aware that BPSD can also occur as 
part of the illness. Recent research found that family carers observed significant levels of 
agitated behaviour when caring for their loved ones with dementia, behaviour that they felt 
unprepared for as they were unaware that agitation could occur as part of dementia. 121 In 
this context it is, perhaps, unsurprising that caregivers can have a negative emotional 
response to BPSD. Research has found that BPSD is associated with more caregiver anger 
and resentment toward the person with dementia than the aspects of the illness associated 
with cognitive decline. 118  This can create a vicious cycle where caregiver stress impacts on 
their ability to effectively communicate with the person with dementia, exacerbating 
symptoms of BPSD, which in turn further increases caregiver stress. The negative impact of 
BPSD on a caregiver’s physical and mental health can mean that caregivers become “the 
forgotten patient” in dementia care. 122   Although the presence of BPSD is often a trigger 
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for nursing home placement, it is important to note that the impact of caring for a person 
with dementia does not necessarily stop with a nursing home placement. Ongoing, as yet 
unpublished research, on which I am collaborating on has explored the impact on the family 
caregiver of an admission of a person with dementia to a nursing home. Qualitative semi-
structured interviews were conducted with family caregivers in the period after admission 
to a nursing home. This research has found that caregivers can have conflicted emotions 
when a person with dementia is admitted to nursing home care. 123  Family caregivers 
described feeling guilty about the decision to admit a family member to a nursing home. 
Caregivers reported feeling like they have failed their loved one. They also described the 
practical and logistical challenges of visiting the nursing home regularly, as the nursing home 
can often be located quite a distance from the family home. 
3.4.3 The impact of BPSD on formal caregivers 
The impact of BPSD on formal carers in a nursing home setting can be substantial. The 
presence of BPSD was found to be significantly correlated with higher formal caregiver 
burden in a 2010 study conducted in Japan. 124 The behaviour that was the strongest 
predictor of formal caregiver burden was aggression. This finding is, perhaps, unsurprising 
as aggression, especially physical aggression, has the potential to harm not only the formal 
caregiver but also other residents. A meta-ethnography that explored the experience of 
hospital staff of caring for people with dementia, identified the challenges of providing 
optimal care in the context of organisational constraints. 125 It highlighted the benefits of 
adopting person-centred care approaches and identified the need for training of healthcare 
professionals. Education, particularly education that improves caregivers’ communicative 
behaviour, can provide formal caregivers with the skills to improve their interaction with 
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people experiencing BPSD, 126 thus lessening the burden caregivers experience managing 
BPSD. Therefore, education and training of formal caregivers’ needs to be appropriately 
resourced.   
3.4.4 The economic and social costs associated with BPSD 
In 2014, Connolly et al. used a cost of illness approach to provide an estimate of the social 
and economic costs of dementia in Ireland. 127 The total cost of dementia in Ireland was 
estimated to be €1.69 billion per annum. 48% of these costs were attributed to the 
opportunity cost of informal care typically provided by family and friends. 43% of the costs 
were attributable to residential care with only 9% of the total cost attributed to formal 
health and social care costs. 127 The specific impact of BPSD on the economic and social 
costs associated with providing dementia care in Ireland has yet to be determined. 
However, we know that the presence of BPSD results in increased rates of admission to long 
term care facilities 93 128 and longer in-patient hospital stays. 113 These are costly pathways 
of care for the health service.  
The costs of managing BPSD in the community are also substantial. The high opportunity 
costs of informal dementia care in the community are evident in the 2014 Connolly study. 
127 These opportunity costs refer to the cost associated with the loss of economic (labour) 
and leisure time valued by the carer. Studies from other healthcare settings have looked 
specifically at how the presence of BPSD impacts on the opportunity costs associated with 
managing BPSD in the community. An Israeli study used interviews with 71 community 
dwelling people with Alzheimer’s disease and their caregivers to explore the costs of BPSD 
within a prospective study that examined the overall cost of Alzheimer’s disease in Israel. 129 
The study found that 30% of the total annual cost of Alzheimer’s disease is invested in the 
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direct management of BPSD. Likewise, a U.S. study interviewed caregivers of 128 people 
with dementia and found that the existence of BPSD significantly increased the direct cost of 
care. 130  
3.5 CAUSES OF BPSD 
BPSD is not a diagnosis in itself but a collection of varied symptoms and behaviours. 91 BPSD 
is a consequence of the confluence of multiple, but sometimes modifiable, interacting 
factors internal and external to a person with dementia. BPSD is closely linked to the 
underlying brain disease causing cognitive symptoms and also results, in part, from a 
heightened vulnerability to the environment as cognitive ability declines. 104 As a result of 
the neurodegeneration associated with dementia, a person with dementia has an increased 
vulnerability to stressors which changes their ability to interact with others and the 
environment. BPSD can have many potential causes and triggers. The Unmet Needs Model 
postulates that BPSD results from unmet needs. 131 The model stems from the concept that 
a person with dementia may be unable to either identify their needs or communicate their 
needs verbally. As a result, they may react to situations with behaviour that is disturbing to 
others. Identifying what ‘need’ they are trying to communicate is the key to assessing and 
ultimately managing BPSD.   
A 2015 study examined unmet needs in 69 nursing home residents living in six nursing 
homes in the U.S. 131 The study identified, on average, three unmet needs per person.  The 
most prevalent needs identified were boredom/sensory deprivation, loneliness/need for 
social interaction and need for meaningful activity. 131 However, some behaviours and 
symptoms of BPSD may not be as a result of an ‘unmet need’. For some symptoms, such as 
psychosis, the disease itself may directly contribute to the development of the symptom by 
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disrupting brain circuitry involved in behaviour and emotion. 108 However, all attempts need 
to be made to ensure that a potentially reversible cause of the behaviour is not missed.  
3.6 ASSESSMENT OF BPSD 
An approach to assessing BPSD and identifying any underlying triggers is illustrated below 
(Figure 3).  I developed this suggested algorithm following a review of best practice 
recommendations in the assessment of BPSD. It was developed for use in educational 
workshops with GPs as part of the wider PREPARED project. 132,133 See appendix 12 for 
published paper on the development and evaluation of these workshops. 
The first step in the proactive management of BPSD is a careful clinical assessment of the 
patient in order to identify possible underlying reversible causes of the behaviour.108  BPSD 
is not a diagnosis in itself, 91 therefore, a thorough assessment is always necessary.  As 
outlined in Figure 3 below there are a number of potential causes of a change in behaviour 
such as pain, constipation, medication side effects or environmental changes. Assessing for 
these potential triggers requires at the very least a thorough history of the behaviour, 
medication review and a physical assessment.  Any acute or sub-acute change in behaviour 
should be considered to be a delirium until proven otherwise. People with dementia are at 
particularly high risk of developing a delirium 134 and a relatively benign insult, such as a 
single dose of a sleeping tablet, may be enough to precipitate a delirium. However, 
identifying delirium in the context of dementia is challenging. 135 This is particularly true of 
hypoactive delirium, which generally presents with lethargy and sedation and although it is 
the most common type of delirium it is underdiagnosed. 136 Underlying medical conditions 
such as an infection can be the cause of the change in behaviour of a person with dementia 
and need to be considered when assessing any person presenting with BPSD. Pain is a 
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particularly important trigger to consider as people with dementia have a significantly 
increased risk of pain, 137 with up to half of people with dementia estimated to be living with 
chronic pain. 138-140 Non-medical triggers of BPSD that need to be considered include 
caregiver factors such as how the caregiver interacts and communicates with the person 
with dementia and environmental factors such as inactivity and a lack of routine. 108 A 
thorough assessment of the potential triggers of BPSD often negates the need for a 
treatment plan. If the trigger is identified the management plan is the treatment of the 
trigger. Assessment is, in itself, the core component of management in BPSD. However, in 
some cases, despite a thorough assessment, a trigger may not be identified and further 
management strategies are required. 
Figure 3. Suggested approach to BPSD assessment  
 
Source: Jennings A, Foley T, Dementia Care in General Practice: Facilitator’s Workshop Guide. Primary Care Education, 
Pathways and Research of Dementia (PREPARED), University College Cork, 2016 
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3.7 N0N-PHARMACOLOGICAL MANAGEMENT OF BPSD 
Guidelines on the management of BPSD 141,142  recommend that non-pharmacological 
strategies be used first-line, unless the person with dementia poses a significant risk to 
themselves or others. The overall aim of non-pharmacological strategies in BPSD should be 
to provide an intervention that is personalised to the person with BPSD. 143 I will now 
discuss some of the non-pharmacological strategies that have been shown to be helpful in 
managing mild to moderate BPSD. 
3.7.1 The role of different non-pharmacological strategies in the 
management of BPSD 
Non-pharmacological interventions used in BPSD include the following; reminiscence 
therapy, 144 personalised music, 145 146 validation therapy, 147 personalised activities, 144 social 
interaction, personalised exercise interventions and person-centred care training for care 
staff.148 149 The evidence base for these different non-pharmacological strategies vary with 
the particular symptom being treated and with the severity of that symptom. The non-
pharmacological strategies that have the best evidence base for the management of 
agitation are personalised activities 144,149 and communication skills training for nursing 
home staff.  148 149,150 Music therapy has been shown to have some benefit in the 
management of agitation and anxiety. 144,148  However, hard evidence alone should perhaps 
not be the only arbiter of the usefulness of these interventions. Ultimately, these are 
relatively safe, low-risk, person-centred, respectful approaches that comply with a person’s 
human rights. For example, techniques such as validation therapy have little evidence to 
support their use. 147,150  However, validation therapy, which is intended to give a person an 
opportunity to resolve unfinished conflicts by encouraging and validating expression of 
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feeling, still remains one of the few ways of responding to high expressed emotion in the 
moment of agitation. The best evidence for the use of non-pharmacological treatments is 
predominantly for people with mild-to-moderate symptoms of agitation. 149 The use of 
these strategies may be impractical in people with severe agitation, which carries the 
greatest distress and risk. Furthermore, implementing many of these non-pharmacological 
strategies needs time and depends on the presence of a health care professional who is 
trained to deliver the intervention or to advise a family carer how to implement these 
interventions. However, both time and relevant expertise in non-pharmacological strategies 
are often in short supply in a primary care setting.  
3.7.2 The uptake of non-pharmacological strategies in primary care settings 
Although guidelines are in almost universal agreement that non-pharmacological strategies 
should be used first line, 141 effective non-pharmacologic strategies for BPSD have not been 
widely adopted in real-world clinical practice. 151 A 2011 survey by Buhagiar et al 152 looked 
at the knowledge and attitude of 109 GPs in Ireland towards BPSD. The study did not 
ascertain whether the GPs had a nursing home commitment in addition to their community 
practice. 92.5% of the GPs surveyed recognised and highly valued the role of non-
pharmacological management in BPSD. Despite this none of GPs surveyed used non-
pharmacological management strategies in their daily practice, with all GPs expressing a 
preference for pharmacological treatments. 152 The study did not explore the reasons for 
the discrepancy between the GPs’ awareness of the importance of non-pharmacological 
management strategies and their reluctance to recommend these strategies. The study 
authors postulated that the difficulty a GP may experience accessing advice from specialist 
services on non-pharmacological strategies could be a contributing factor. They also 
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suggested that GPs may lack confidence when recommending non-pharmacological 
strategies. Furthermore, the authors suggested that GPs may come under pressure from 
caregivers to prescribe medication.  Similarly, a survey of GPs in the UK in 2013 examined 
GPs’ perspectives on the challenges of reducing antipsychotics in people with dementia in 
long term care settings. 153 In this survey GPs reported that they did not find existing 
guidelines on the management of BPSD clinically useful and that non-pharmacological 
alternatives to antipsychotics provided in existing guidelines were not implementable given 
resource constraints.  Low staffing levels 154,155  and lack of appropriate resources 155 have 
also been identified as barriers to GPs recommending non-pharmacological strategies in 
nursing home settings, thereby resulting in an increased reliance on pharmacological 
management in BPSD. 
 
3.8 PHARMACOLOGICAL MANAGEMENT OF BPSD 
The medications used in the management of BPSD are psychotropic medications. 
Psychotropic medications include the following classes of drugs; antipsychotics, 
antidepressants, benzodiazepines, ‘Z’ drugs (including zopiclone and zolpidem), memantine, 
acetylcholinesterase inhibitors and anticonvulsants. I will now discuss the role of each of 
these classes of drugs in the management of BPSD.  
3.8.1 The role of antipsychotic medication in BPSD 
Antipsychotics are the most commonly prescribed medication in the management of BPSD. 
156 157 However, unless there is a significant risk of harm to either the person with dementia 
or others, antipsychotic medications are not recommended to treat BPSD. 141 The risks of 
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antipsychotics to people with dementia has been consistently shown to out-weigh the 
benefits. 158,159 Antipsychotics are frequently associated with adverse effects, including 
increased risk of falls and drowsiness, hip fractures, pneumonia, reduced motor function, 
parkinsonism, akathisia, tardive dyskinesia, social withdrawal, accelerated cognitive decline, 
QT prolongation and stroke. 160 Studies have shown an association between treatment with 
antipsychotic drugs and increased morbidity and mortality in people with dementia. 158 159 In 
April 2005, a meta-analysis of 17 double blind randomised controlled trials among people 
with dementia determined a 1.7 time increased risk of all-cause mortality associated with 
atypical antipsychotic use compared with placebo. 93 This led to the Food and Drug 
Administration (FDA) in the US giving a “black box warning”, the most serious warning the 
FDA issues, for use of antipsychotic medications in people with dementia. 93 
The definitive CATIE-AD study 160 was a placebo-controlled, double-blind, randomized clinical 
trial that compared three antipsychotics (quetiapine, risperidone, olanzapine) to each other 
and to placebo. This study followed 421 out-patients with Alzheimer’s disease and psychosis 
or agitated/ aggressive behaviour over a nine-month period. The study found that there 
were no significant differences among treatments with regard to the time to the 
discontinuation of treatment for any reason: olanzapine (median, 8.1 weeks), quetiapine 
(median, 5.3 weeks), risperidone (median, 7.4 weeks), and placebo (median,8.0 weeks) (P = 
0.52). However, those taking any of the three antipsychotic medications were more likely to 
discontinue use because of intolerable side effects than those taking placebo. The 
conclusion of the study was that the overall benefit of these medications is offset by 
intolerability to associated side effects. 
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Antipsychotics do have a role in certain situations in the management of BPSD. A Cochrane 
review concluded that certain antipsychotics do have a role when managing aggression or 
psychosis if the person with dementia is in severe distress or there is substantial risk to the 
person or others. 161 However, the role of antipsychotics in the management of BPSD is 
limited by its serious adverse effects and its minimal effectiveness. I will now present the 
evidence for a number of other psychotropic medications that are most commonly 
prescribed to people with BPSD namely antidepressants, hypnotics, memantine, 
cholinesterase inhibitors and anticonvulsants. 
3.8.2 The role of antidepressants in BPSD 
Studies have examined the role Selective Serotonin Re-uptake Inhibitors (SSRIs) can play in 
the management of two common aspects of BPSD; agitation and depression.  
3.8.2.1 The evidence for antidepressants in the management of agitation in dementia 
A Cochrane review in 2011 found some evidence to support the role for antidepressants in 
the treatment of agitation in dementia but commented on the dearth of studies in this area 
162. Subsequently in 2014 the Cit-AD trial, a large, well-powered 9 week multi-centred 
placebo-controlled double-blind randomised controlled trial (RCT), looked at the 
effectiveness of citalopram in managing agitation in people with dementia. 163 Cit-AD found 
that 40% of patients on citalopram had a moderate or marked improvement from baseline 
compared to 26% on placebo, a clinically meaningful reduction in agitation comparable to 
that seen with antipsychotics 163. However, the citalopram group did see worsening of 
cognition and QT interval prolongation. The authors of the Cit-AD study concluded that 
although citalopram does effectively reduce agitation in this patient group, the cognitive and 
cardiac adverse effects of citalopram may limit its practical application.  However, the dose 
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used in that RCT was 30 mg/day dose and the current prescribing information recommends 
a maximum daily dose of 20 mg of citalopram for patients over 60 years of age because of 
substantially higher exposures, decreased clearance, and prolonged cardiac repolarization 
potential. 164 The RCT did not have enough people in the 20mg group to assess the efficacy 
of that dose. Overall, it appears that in carefully selected patients there is evidence to 
support the role of citalopram to treat moderate agitation in dementia. However, prescribers 
should be aware of a possible risk of worsening of cognition and QT prolongation. 
3.8.2.2 The evidence for antidepressants in the management of depression in dementia 
A Cochrane review in 2002 looking at the use of antidepressants for the management of 
depression found that the evidence to support the use of antidepressants was weak, however, 
this analysis was based on a number of studies of small sample size and the authors 
commented on the paucity of research in this area 165. A meta-analysis in 2012 analysed five 
different studies that examined the effect of SSRIs on depression in people with dementia and 
found that current evidence does not support the efficacy of SSRI treatment for symptoms of 
comorbid depression in Alzheimer’s Disease. 166 The most recent and definitive trial in this 
area was the HTA-SADD trial conducted in 2011. This multi-centred, parallel-group, double-
blind, placebo-controlled, randomised trial found that when treating depression in people 
with dementia neither mirtazapine nor sertraline had a benefit over placebo. 167 This was the 
largest study to date of SSRI treatment for depression in dementia and had 13 and 39 week 
follow-up. This RCT found that neither sertraline nor mirtazapine reduced severity of clinically 
significant depression over 39 weeks compared with placebo in people with dementia. In 
addition, adverse events were more common with antidepressants than with placebo. The 
HAT-SADD study concluded that it is possible that depression in dementia might be different 
in terms of neurobiology than depression occurring in those without dementia and that is why 
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antidepressants are not effective. Based on current evidence antidepressants appear to be 
ineffective at managing depression in people with dementia, however, it should be noted that 
the vast majority of these trials focused on sertraline. Despite the lack of evidence for use of 
antidepressants in dementia with co-morbid depression, in real-world clinical practice, old age 
psychiatrists, GPs and geriatricians do use antidepressants to treat depression in people with 
dementia. Furthermore, in clinical practice it can be quite difficult to identify depression in a 
person with dementia 168 and likewise it can be difficult to assess response to medication.  
In summary, the lack of evidence for the use of antidepressants in dementia is disappointing 
but there are some positive results from studies that SSRIs could have a promising role to play 
in the management of mild to moderate agitation. 
 
3.8.3 The role of benzodiazepines & Z drugs in the management of BPSD 
Benzodiazepines are frequently prescribed to people with BPSD. 169 However, the AGS-Beers 
criteria includes benzodiazepines in the potentially inappropriate medications class and 
recommends avoiding their use in older adults, especially for the treatment of insomnia, 
agitation or delirium. 170 They are also included in the potentially inappropriate medications 
and classes to avoid in older adults, in particular those with cognitive impairment and 
dementia as they can worsen cognition.170 Similarly the STOPP/START tool advises that 
benzodiazepines should be withdrawn if prescribed long-term (>1 month) or if the person is 
at risk of falls. 171  A systematic review on the role of benzodiazepine in the management of 
BPSD found that available data, although limited, does not support the routine use of 
benzodiazepines for the treatment of BPSD. 172  Likewise, sedative hypnotics are not 
recommended in older people with insomnia. 173 Overall, due to their significant side effects 
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including falls, increased confusion, and drowsiness neither benzodiazepines nor hypnotics 
are recommended for use in patients with dementia. However, benzodiazepines may have a 
role in certain situations such as in an emergency crisis situation. Expert consensus 
recommendations has also outlined a potential use for benzodiazepines as short term use in 
a person with agitation while waiting for a SSRI to take effect. 174 
 
3.8.4 The role for memantine in the management of BPSD 
Previous studies and pooled analysis of studies did indicate that there was significant 
benefit for memantine versus placebo in treating agitation, delusions and hallucinations in 
people with dementia 175,176. However, the problem with these studies is that the trials were 
initially designed with the purpose of testing cognition so the populations recruited did not 
necessarily have problematic agitation or high levels of neuropsychiatric symptoms. A more 
recent trial published in 2012 177 specifically looked at the efficacy of memantine in treating 
agitation in people with dementia. This was a well-run randomised double-blind placebo-
controlled trial which ran in the UK over a 3 year period with 153 people with dementia. 
This trial found that memantine is no better than placebo in treating agitation in dementia. 
Similarly, the 2015 MAIN-AD trial was a randomized double-blind placebo-controlled 
withdrawal trial comparing memantine with antipsychotics for the treatment of 
neuropsychiatric symptoms in 199 people with dementia over 24 weeks. The trial found no 
benefits for memantine in the long-term treatment and prophylaxis of clinically significant 
neuropsychiatric symptoms. 178 The recent STOPPFrail (Screening Tool of Older Persons 
Prescriptions in Frail adults with limited life expectancy) consensus validation recommends 
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discontinuing and monitoring memantine in people with moderate to severe dementia, 
unless memantine has clearly improved BPSD. 179 
 
3.8.5 The role of cholinesterase Inhibitors in the management of BPSD 
Despite earlier studies that showed cholinesterase inhibitors have a modest benefit in BPSD, 
180,181 the definitive study (CALM-AD trial) found that donepezil was no more effective than 
placebo at managing agitation in people with Alzheimer’s disease. 182 In the CALM-AD trial 
272 people with Alzheimer’s disease who had clinically significant agitation were randomly 
assigned to receive 10mg of donepezil (n =128) or placebo (n=131) for 12 weeks. The primary 
outcome measure was a change in the score on the Cohen-Mansfield Agitation Inventory 
(CMAI). There was no significant difference between the effects of donepezil and those of 
placebo on the basis of change in the CMAI from baseline to 12 weeks. The study authors 
concluded that donepezil was no more effective than placebo in the management of agitation 
in people with Alzheimer’s disease. No large randomised controlled trials have been 
conducted in this area since the CALM-AD trial. Notable side effects of cholinesterase 
inhibitors include nausea and GI upset both of which could potentially contribute to BPSD. 
 
3.8.6 The role for anticonvulsants in the management of BPSD 
There is a paucity of well-conducted studies exploring the efficacy of anticonvulsants such as 
valproate, carbamazepine and gabapentin in BPSD. A Cochrane review in 2009 on the use of 
valproate in agitation concluded that valproate preparations are ineffective in treating 
agitation in people with dementia and noted that valproate therapy is associated with an 
unacceptable rate of adverse effects.183  The evidence base for carbamazepine is very small 
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and there are concerns regarding its tolerability. 184 Side effects of this class of medication 
include sedation, gait disturbance, hyponatreamia and cognitive impairment. 185 The elderly 
population, who often are multimorbid with associated polypharmacy, are particularly at risk 
of pharmacokinetic interactions and side effects from anticonvulsants. The use of 
anticonvulants in BPSD is limited by both their side effects and the minimal evidence to 
support their use. 186 At present anticonvulsants are not indicated in the most recently 
published NICE guideline as a treatment of BPSD. 141  
 
3.8.7 Summary of the evidence for pharmacological management of BPSD 
Antipsychotics are not recommended in the management BPSD unless there is a serious risk 
of harm to the patient or to others. 187 However, from the evidence outlined above, 
effective pharmacological alternatives remain scarce. 188 Of the pharmacological agents 
used to treat BPSD, antipsychotics still have the strongest evidence base, although their 
benefits are modest at best. 109 Reductions in antipsychotic prescribing could potentially 
result in a shift to the prescribing of even less efficacious and similarly toxic drugs (such as 
anticonvulsants and benzodiazepines). 7,104  Apart from the potential role for citalopram in 
mild-moderate agitation, 163 pharmacological alternatives to antipsychotics appear to have 
little effect beyond their ability to sedate.  
Overall, the lack of evidence for various pharmacological treatments of BPSD, including 
antipsychotics, is disappointing but perhaps unsurprising. If we accept that a significant 
proportion of the time there is an unmet physical, environmental, emotional or 
psychological need that is triggering BPSD then it is unsurprising that medication cannot 
reverse these needs. While there is a role for medication in managing some of the 
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symptoms and behaviours associated with BPSD, 189 prescribers need to be aware of the 
evidence for the pharmacological management options and be aware of the potential 
adverse effects of treating people with BPSD with these medications. Caution is needed to 
ensure appropriate prescribing of antipsychotic medications. However, criticising the 
prescribing of antipsychotics without providing health care professionals with any practical 
management alternatives is unlikely to improve the care provided to people with dementia. 
I will now examine the rates of prescribing of these medications to people with dementia in 
primary care in Ireland. 
 
3.9 CURRENT PRESCRIBING IN BPSD IN IRELAND 
There is a paucity of data on the rates of psychotropic prescribing to people with dementia 
living in the community or in nursing homes in Ireland. Available data is derived from 
analysis of studies conducted in secondary care. Although a systematic review published in 
2016 found that Ireland, Austria and Belgium had the highest rates of antipsychotic 
prescribing in nursing homes in Western Europe 190 this review included just one Irish study 
that was actually conducted in Northern Ireland and not the Republic of Ireland. 191 To 
examine this issue of prescribing rates I will first discuss the rates of psychotropic 
prescribing in dementia in Ireland. Since antipsychotics are the most commonly prescribed 
psychotropic medication in BPSD, 190 I will then specifically focus on the rates of 
antipsychotic prescribing in people with dementia in Ireland. 
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3.9.1 Rates of psychotropic prescribing in people with dementia in primary 
care in Ireland 
A retrospective cross-sectional study explored prescribing patterns in a well-defined cohort 
of people >70 years who were admitted to any of the six acute hospitals in Cork between 
2012 and 2013. 156 The study examined the difference in prescribing patterns between 
people with and without dementia, in particular the study examined prescribing of 
psychotropic medications. Of the 598 patients recruited 149 had dementia. Of these 149 
patients with dementia, only 53 patients had a known diagnosis of dementia before 
admission, the remainder were diagnosed after admission. The study found that people 
with dementia were significantly more likely to be prescribed at least one psychotropic 
medication and were more than three times more likely to experience psychotropic 
polypharmacy. Atypical antipsychotics, anti-depressants and anxiolytics were all significantly 
more likely to be prescribed to people with dementia, even after the authors controlled for 
age, sex and co-morbidity. 156 
3.9.2 Rates of antipsychotic prescribing in people with dementia in primary 
care in Ireland 
The retrospective cross-sectional study described above 156 also specifically examined the 
rates of antipsychotic prescribing in the patients admitted. The study found that 28% of 
people with a known diagnosis of dementia at admission (15/53) were prescribed an 
antipsychotic medication. People with dementia admitted from a nursing home were almost 
five times more likely to be prescribed an antipsychotic medication than people with 
dementia admitted from home. 156 This finding is likely to reflect the fact that nursing home 
residents are more likely to have more advanced dementia than those residing in the 
community 192 but is, nonetheless, concerning. Evidence to date has demonstrated that that 
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people with dementia living in nursing homes are at particularly high risk of inappropriate 
prescribing. 193  
Gallagher et al conducted an audit of antipsychotic prescribing in people with dementia 
attending all 35 publically funded hospitals in Ireland in 2013 and found that 29% (190/656) 
of people with dementia admitted to hospital were prescribed antipsychotic medications 
prior to admission. 194 People with dementia who were admitted from a nursing home were 
significantly more likely to have an existing prescription for an antipsychotic than those 
admitted from their own homes. Out of the 243 people with dementia admitted from a 
nursing home setting, 45% (110/243) had an existing prescription for an antipsychotic. Of 
the 409 people with dementia admitted from their own homes 19% (78/243) had an existing 
prescription for an antipsychotic. Using this study to provide data on the rates of prescribing 
in primary care in Ireland is not without its limitations. To be included in this study the 
person with dementia had to have been hospitalised for a minimum of five days. We know 
that, in itself, BPSD can be a cause for admission and can result in prolonged hospital 
stays.113 Therefore, this data may not be representative of antipsychotic prescribing in 
people with dementia and may, in fact, over-estimate the rates of antipsychotic prescribing 
to people with dementia in Irish primary care. However, when the 2013 Gallagher et al audit 
is compared with a very similar audit conducted in general hospitals in the UK there is 
further evidence that the rate of 29% people with dementia in Ireland being prescribed an 
antipsychotic 194 is high. Comparable findings from the National Dementia Audit in England 
and Wales found that in 2010 and 2012 respectively, 28.3% and 17.7% of inpatients with 
dementia were prescribed antipsychotic medication. 195 The dramatic fall in prescribing of 
antipsychotic medication in the UK between 2010 and 2012 is likely to be as a result of a 
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number of UK initiatives and calls to action including the 2009 Banerjee Report 196 and the 
2009 UK National Dementia Strategy. 28  (The impact of these interventions will be discussed 
in more detail in section 3.12). The Irish National Dementia strategy was published in 2014 
and is still in its implementation stage. Therefore, it is interesting to note that the Irish 
figure of 29% of people with dementia being prescribed an antipsychotic closely mirrors the 
UK figures from 2010. The UK reduction indicates that if the problem is addressed with 
appropriate strategies we could hope for a similar improvement in the prescribing rates in 
Ireland over the coming years. 
 
3.10 THE ROLE OF THE GP IN THE MANAGEMENT OF BPSD  
The GP plays a key role in the assessment and management of BPSD. In the community 
setting, the GP is the first point of contact for family caregivers. The GP has often known the 
person with dementia and the wider family for many years. This can be a real advantage 
when assessing for potential triggers of BPSD. In the nursing home setting a GP may find 
themselves at a disadvantage if they have not cared for the person prior to admission to the 
nursing home. In both settings the GP has a role in managing BPSD. In the community 
setting it generally falls to the GP to recommend non-pharmacological strategies. However, 
in the triangulated educational needs analysis conducted as part of the wider PREPARED 
project, carers consistently reported that GPs did not tend to do this well. 87 Furthermore, 
we know from the Buhagiar et al survey that GPs in Ireland do not feel comfortable advising 
on non-pharmacological strategies. 152 In a nursing home setting, although GPs do have a 
role in suggesting and discussing non-pharmacological strategies, the nursing staff are 
typically responsible for implementing them. GPs have a central role in prescribing 
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medications for BPSD in both settings. Typically prescribing rates of antipsychotic and other 
psychotropic medications are higher in nursing home settings than in community settings. 
194 A UK study in 2012 197 looked at the prevalence of anti-psychotic prescribing in dementia 
in 59 GP practices and found that 15.3% (161/1051) of people on the register were receiving 
low-dose anti-psychotics. This UK study examined whether the prescription originated in 
primary or secondary care and found that 43% (70/161) of prescriptions for anti-psychotics 
were initiated by the GP. Therefore, the majority of prescriptions for antipsychotics in 
people with dementia in the community originated from secondary care. The origin of 
prescriptions in nursing home settings is less clear. Given that the GP is often the sole 
physician providing care to a person with dementia in a nursing home setting it is likely that 
psychotropic medications used to manage BPSD in nursing home settings are prescribed by, 
or at least continued by, the GP. Despite their central role in the assessment and 
management of BPSD, internationally GPs consistently report that BPSD is an area of 
dementia that they find particularly challenging to manage. 87,88,90,198 
 
3.11 THE ROLE FOR INTERVENTIONS AIMED AT IMPROVING THE 
MANAGEMENT OF BPSD IN A PRIMARY CARE SETTING  
The high rates of potentially inappropriate prescribing of psychotropic medications in BPSD 
156,194 and the low uptake of non-pharmacological strategies 152 indicates a mismatch 
between best practice recommendations in BPSD 141 and current clinical practice in primary 
care in Ireland. Interventions are needed to address this discrepancy between 
recommended and actual care in order to improve the management of BPSD in primary 
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care. However, in order to develop these interventions we need a better understanding of 
why this mismatch exists. 
I will now describe some of the non-pharmacological interventions that have aimed to 
improve the management of BPSD in a primary care setting. I will first discuss community 
based interventions and then discuss interventions conducted in long term care settings. I 
will specifically focus on interventions that involved GPs.  
3.11.1 Community based interventions in BPSD and the role of the GP in the 
interventions 
In 2018 Trivedi et al published a systematic review of the effectiveness of non-
pharmacological interventions for BPSD among people with dementia living at home. 199 
Studies conducted in long-term care settings were excluded from the review. The review 
examined evidence from 48 randomised controlled trials and presented the findings in the 
form of a narrative synthesis. All the interventions targeted people living with dementia and 
family carers. Although not an exclusion criterion, no intervention included in the systematic 
review targeted health care professionals. The review found that family carer training and 
educational programmes for carers can improve outcomes in BPSD. It also established that 
community based nurses and occupational therapists can play an important role in the 
delivery of these interventions.  
Only one study in the Trivedi et al review involved GPs in the intervention. 200 That study 
was an RCT conducted in the U.S between 2002 and 2004 evaluating the effectiveness of a 
collaborative care model to improve the quality of care in people with Alzheimer’s disease 
(n=153) experiencing BPSD. 200 The intervention involved a nurse practitioner meeting the 
intervention patients and their caregiver regularly over a one year period.  If specific BPSD 
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symptoms were present then an appropriate non-pharmacological approach was 
recommended. If this approach failed then the person was referred to their GP for 
consideration of pharmacological treatment. The study found that the intervention resulted 
in significant improvements in behavioural symptoms and improvements in caregiver 
distress and depression. There was no significant difference in the use of psychotropic drugs 
between the intervention and control group, however, this study was conducted before the 
significant adverse effects of antipsychotics in dementia were known. Although no formal 
cost-effectiveness was conducted, the cost of the advanced nurse practitioner was 
estimated to be $1,000 per patient based on a case load of 75 patients per year. In the 
context of the economic impact of BPSD this cost is not prohibitive. 
3.11.2 Nursing home based interventions in BPSD and the role of the GP in 
the interventions 
A well-conducted systematic review published in 2014 by Thompson-Coon et al evaluated 
the effectiveness of interventions to reduce inappropriate prescribing of antipsychotics to 
people with dementia living in residential care settings. 201 All 22 intervention studies 
included in the review targeted health care professionals.  The most frequently used 
intervention component was educational (present in some form in 14 studies). Medication 
reviews were also used successfully as an intervention to improve antipsychotic prescribing 
in four studies included in the review. GPs were involved in the interventions as either the 
primary target 202,203 or one of several healthcare professionals targeted 204 with the 
intervention. In some studies it was unclear whether the physician targeted with the 
intervention was a GP or a secondary care doctor. 205-207  Several of the studies that targeted 
GPs used education in-reach approaches 203,206 which were delivered by up-skilled 
pharmacists. 203,207 For example, in one study conducted in Northern Ireland in 2010, 
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specially trained pharmacists visited the nursing home and reviewed the appropriateness of 
the GP’s prescribing of psychotropic medications and then worked with the GPs to improve 
the prescribing.203 This led to a significant fall in the proportion of residents taking 
inappropriate psychotropic medications. 203 Overall, the review found that, where the study 
design was robust, antipsychotic prescribing fell by between 12% and 20% as a result of the 
intervention implemented. This fall was regardless of what intervention was implemented - 
all interventions led to a fall in antipsychotic prescribing. However, the authors commented 
on the lack of detail provided for many of the interventions, making future replication 
difficult. Additionally, as a result of the heterogeneity of the included studies and the often 
poor quality of the included studies or of their reporting, the authors were unable to make 
any definitive recommendations for practice. Furthermore, the review highlighted the 
challenges of implementing best practice in appropriate prescribing in the context of time 
constraints, staffing levels, staff competence with non-pharmacological alternatives and 
pressure to prescribe. The authors’ recommended further qualitative work be conducted in 
this area.  
Since the Thompson-Coon systematic review was published in 2014 there have been 
additional studies that evaluated interventions for BPSD in long term care settings. In 2018 
Birkenhager-Gilesse et al published a systematic review and meta-analysis of the effect of 
multidisciplinary psychosocial interventions for BPSD on the psychotropic drug prescription 
rate in nursing homes. 208  The review also included two notable intervention studies 
involving GPs that were published after 2014. One study was a cluster RCT that involved 
healthcare professionals (including GPs) participating in five educational sessions where a 
step-wise approach to the assessment of a person with BPSD was outlined. 209 The 
intervention resulted in an improvement in BPSD, a significant reduction in antidepressant 
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use and a non-significant reduction in antipsychotics and sedatives. 209 The second notable 
intervention that involved GPs was the WHELD study. 210 The WHELD intervention focused 
on upskilling care home staff and GPs in the principles of person-centred care. 211  In the 
WHELD study 16 UK nursing homes received a training intervention in person-centred care 
for 9 months. Intervention care homes were also randomly assigned to antipsychotic 
review, to a social interaction intervention, and to an exercise intervention for 9 months. 
The GPs who provided care to nursing homes in the antipsychotic review intervention arm 
attended interactive educational sessions. 212 Antipsychotic review was found to 
significantly reduce antipsychotic prescribing. 210 Antipsychotic review combined with the 
social interaction intervention significantly reduced mortality when compared with the 
group receiving neither. The WHELD study also examined the impact of the different 
interventions arms on quality of life.212 The social interaction intervention resulted in 
improved health-related quality of life score. The social interaction combined with 
antipsychotic review intervention showed no deterioration in health-related quality of life. 
However, the intervention that just introduced an antipsychotic review without any 
complementary non-pharmacological intervention resulted in significant worsening in two 
quality of life scores.  The study authors’ concluded that in the current climate in the UK 
where there is more judicious prescribing of antipsychotic medication, further reductions in 
prescribing may not ultimately be beneficial to people with dementia, 210 unless they are 
provided in conjunction with evidence-based non-pharmacological interventions. 212 
‘However, it is important to note that as outlined in section 3.9 the current prescribing rates 
of antipsychotic medication to people with dementia in Ireland are not as judicious as the 
UK prescribing rates. 
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Overall, the Birkenhager-Gilesse et al meta-analysis found that educational interventions 
that targeted care staff were not more effective than care-as-usual. (Although, the 
description of what constituted ‘care-as-usual’ was poorly described in the majority of the 
studies included in the review.) The review authors argued that education typically only has 
a temporary impact. To be effective education has to be repeated and imbedded in daily 
practice. The review found that longer lasting interventions that involved a change of 
culture or process change were superior to care-as-usual interventions at lowering 
antipsychotic drug use. 208 The review also found that the involvement of the physician in 
the intervention was “indispensable for obtaining and maintaining a reduction in the use of 
antipsychotic drugs”. 208 
3.11.3 Summary of interventions in the community and in nursing homes to 
improve the management of BPSD 
Interventions to improve BPSD are poorly described making interpretation of the results and 
future replication of the studies difficult. 208 201 Why the particular intervention was chosen 
and how it was developed is rarely adequately reported. As a result of the limitations in 
study quality and the poor descriptions of the interventions, the exact components of an 
intervention that will improve the management of BPSD remains unclear. From the 
evidence available, there is a potential role for educational interventions in interventions in 
a nursing home setting. However, in order to be effective in the longer-term these 
educational interventions need to embedded in daily practice and be part of wider attempt 
to change the culture of the nursing home. 208  Unsurprisingly, in order to change 
prescribing behaviour the intervention needs to target the prescribing physician, 208 yet 
surprisingly GPs involvement in these intervention studies to date has been minimal. 
Despite the poor understanding of the challenges GPs experience managing BPSD, it 
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appears that none of the interventions targeting GPs actively sought to understand or 
address the challenges GPs experience managing BPSD. Furthermore, the studies did not 
appear to involve GPs in the development of the intervention. Finally, although the vast 
majority of people with dementia live at home in the community under the care of their GP, 
interventions involving GPs have focused on the nursing home setting. To my knowledge no 
study based in the community has targeted GPs and only one community-based study 
involved GPs in the implementation of the intervention. 200 
 
3.12 POLICY INTERVENTIONS TO IMPROVE THE APPROPRIATENESS OF 
PRESCRIBING TO PEOPLE WITH BPSD  
Over the past decade, regulatory bodies have issued drug safety warnings on the use of 
antipsychotics in people with BPSD in Canada,213 the U.S.214 and in many European 
countries.215-217 However, in Ireland, apart from the aforementioned National Dementia 
Strategy,29 there has been little or no national guidance or policy interventions in this area. 
Nor has any research captured temporal changes to the prescribing of antipsychotics in 
Ireland. It is important that we explore the impact of policy interventions in the area of 
prescribing in BPSD in other countries in order to ascertain what lessons can be learned, and 
potentially applied, to an Irish context. To date, virtually all of the different policy 
interventions introduced in various countries have focused on the appropriate prescribing of 
antipsychotics to people with BPSD. I will now summarise some of the policy interventions 
introduced in the UK and other countries over the past decade. As the UK has a very similar 
healthcare structure to Ireland I will focus initially on policy interventions introduced in the 
UK. I will then briefly describe policy intervention introduced in other countries. Finally I will 




3.12.1 Policy interventions to reduce inappropriate prescribing of 
antipsychotics in BPSD  
A number of policy interventions have been implemented in the UK since 2004.218 In 2004 
the UK Committee for the Safety of Medicines (CSM) warned all healthcare professionals 
that neither risperidone nor olanzapine should be used to treat BPSD because of the 
increased risk of stroke. 219 Data later emerged that demonstrated similar risks for other 
second-generation antipsychotics and first-generation antipsychotics.160  In March 2009 the 
Medicines Healthcare products Regulatory Agency (MHRA) released a drug safety update 
stating that risperidone was licensed for short term use (<6 weeks) to manage severe 
aggression in a person with dementia. 220 This was followed by a further warning on the risks 
of antipsychotics in people with dementia in June 2009.221 However, this 2009 warning was 
not disseminated as widely as the original 2004 warning had been. 222 Another important 
intervention that occurred at this time was the publication of the seminal Banerjee report in 
October 2009. 196 The report, which was commissioned by the Dept. of Health in the UK, 
drew some concerning conclusions, such as estimating that up to two-thirds of prescriptions 
of antipsychotics to people with dementia were unnecessary and potentially harmful. 196 
Also in November 2009, in response to the Banerjee report, the UK government pledged to 
reduce the use of antipsychotics in people with dementia. 223 This pledge was followed by 
the Prime Minister’s challenge in 2012 which was a challenge set by the then Prime Minister 
to deliver major improvements in dementia care and research by 2015. 224  
Similar warnings and policy recommendations on appropriate prescribing of antipsychotic 
medication in dementia have been introduced in several other countries including the US 
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and Canada. In 2005 in the US the FDA issued a black box warning on atypical antipsychotics 
that stated “treatment of behavioural disorders in elderly patients with dementia with 
atypical antipsychotic medications is associated with increased mortality”. 225 This warning 
was expanded to all antipsychotics in 2008. More recent initiatives include the launch of a 
national partnership programme to improve the quality of care for nursing home residents 
with dementia. 226 This programme was launched in 2012 by the Centres for Medicare and 
Medicaid Services (CMS)  and involved public reporting of antipsychotic use, comprehensive 
training for nursing home staff and a five-star quality rating system for nursing homes. 214  
3.12.2 The impact of policy interventions on prescribing rates  
The main measure used to evaluate the outcome of these policy interventions is the 
percentage of people with dementia, but without primary psychotic disorder, who are 
prescribed an antipsychotic medication, as this prescription is then presumed to be for 
BPSD. In the UK two large studies have evaluated the impact of policy efforts to reduce 
prescribing in BPSD. The first study by Donegan et al published in 2015 was a longitudinal 
retrospective cohort study which looked at prescribing in dementia in the UK over a 10 year 
period from 2005-2015. 227 The study found that there was a large reduction in prescriptions 
for antipsychotic medication in dementia from 22.1% in 2005 to 11.4% in 2015. However, 
most of this reduction resulted from a decrease in prescribing of first generation 
antipsychotics (22.1% in 2005 to 11.4% in 2015) with a smaller decrease in second 
generation (or atypical) antipsychotics (which only reduced from 13.6% in 2005 to 9.7% in 
2015). The study also found that prescribing of hypnotics reduced (14.3% in 2005 to 9.5% in 
2015) but the prescribing of antidepressants increased (28% in 2005 to 36.6% in 2015). The 
second study by Stocks et al examined the temporal changes in prescribing of antipsychotics 
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to people with dementia from 2001 to 2014 but differed slightly in its criteria as it looked 
only at long-term prescribing of antipsychotic medication (at least two prescriptions in 6 
months and 90 days apart) to people with dementia who did not have a diagnosis of 
psychosis. 218 The Stocks et al study found that although the long-term prescribing of first 
generation antipsychotics to people with dementia declined substantially between 2001 and 
2014 (decrease from 8.9% in 2001 to 1.4% in 2014), the frequency of prescribing of second-
generation antipsychotic drugs remained essentially the same in 2014 as 2001 (6.6% in 2001 
and 6.9% in 2014). The study noted that since 2013 the decreasing trend in second 
generation antipsychotic prescribing in people with dementia had plateaued and reported 
that this plateau had been largely the result of increasing prescribing of risperidone. 218 On a 
positive note the Stocks et al study did demonstrate the significant and sustained impact of 
the 2006 NICE guidelines 187 on the rates of antipsychotic prescribing, 218 indicating that the 
implementation of similar guidance in Ireland may have a similar positive impact on 
prescribing rates. 
Unlike the Donegan et al study, the Stocks et al study did not examine the prescribing of 
other psychotropic medication to people with dementia during this time. Examining the 
impact of policy interventions in antipsychotic medications on the prescribing of other 
psychotropic medications is critical if we are to fully understand the impact on prescribers’ 
behaviours. What does a fall in antipsychotic prescribing truly represent? As Kales & Maust 
point out in their commentary on the Stocks et al study “it is critical to understand whether 
a decline in antipsychotic use represents a true decrease in people with dementia receiving 
potentially inappropriate psychotropic medication, or whether measuring antipsychotic use 
has simply led providers to prescribe other medications”. 109 Importantly, the goal should be 
to reduce inappropriate antipsychotic prescribing while increasing the use of non-
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pharmacological strategies but it remains unknown if reductions in antipsychotic prescribing 
have any such impact on the uptake of non-pharmacological strategies. 109 
Overall, the studies demonstrate that clinicians respond to changes in policy 
recommendations and to changes in drug safety warnings. 218,227  However, the fact that the 
prescribing of second generation antipsychotics to people with dementia has remained 
essentially the same despite various policies and warnings, 218 demonstrates the magnitude 
of the problem of managing BPSD and the difficulties clinicians experience adhering to 
safety warnings in this area. Simply communicating to prescribers the dangers these 
medications pose to people with dementia will not eliminate prescriptions of antipsychotic 
medications. Increasing awareness of the dangers of antipsychotics without providing 
healthcare professionals with realistic alternative strategies is unlikely to fully address the 
problem.  
Evaluations of the impact of policy interventions in BPSD in other countries outside of the 
UK has shown similar trends in prescribing. In the US a time-series analysis estimated the 
effect of the various warnings on out-patient prescriptions for antipsychotics using national 
Veterans Affairs data from 1999 to 2007. 228 The study found that the FDA black-box 
warning was temporally associated with a significant acceleration in the decline in the use of 
atypical antipsychotics in BPSD. However, importantly the study found that the reductions in 
antipsychotic use were merely offset by increases in prescriptions of other psychotropic 
medication to people with dementia - such as a small but significant increase in 
anticonvulsant prescriptions. 228 There was no overall reduction in psychotropic use, which 
remained fairly constant throughout the study period at 40%. 228 Similarly, a Canadian study 
examined the changes over a ten year period (2004-2013) in the dispensing of 
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antipsychotics and other psychotropic medication among people with dementia living in 
long-term care facilities. 229 The study found that although prescriptions for atypical 
antipsychotics decreased over the ten years (decrease of 4%), these reductions were offset 
by the increases in prescriptions for anticonvulsants and sedating antidepressants.229 It 
seems, therefore, that when developing policy to promote the appropriate pharmacological 
management of BPSD we need to be careful that we do not find ourselves moving from a 
bad situation to a worse one. We need to be aware that one of the potential consequences 
of reducing prescriptions for antipsychotic medications is simply moving people from a 
potential harmful but minimally effective medication to a potentially harmful but ineffective 
medication.  
 
3.13 SUMMARY AND RESEARCH GAPS 
GPs play a central role the management of BPSD. However, BPSD is an aspect of dementia 
care that GPs find particularly challenging. There is a dearth of research examining GPs 
experiences of managing BPSD, therefore, the reasons why GPs find BPSD so challenging is 
unclear. Furthermore, the evidence suggests that current management of BPSD is sup-
optimal with high rates of psychotropic prescribing and low uptake of non-pharmacological 
strategies. There is a discrepancy between best practice recommendations in relation to the 
management of BPSD and clinical practice. However, the reason for this discrepancy is not 
clear from the literature. Interventions are required to improve the quality of care provided 
to people with BPSD in general practice. However, to date, interventions aiming to improve 
GPs’ management of BPSD are limited, particularly in the community setting. Interventions 
involving GPs in a nursing home setting are often poorly described, so when they are 
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successful it is not always clear why. There is little evidence that GPs were involved in the 
intervention development process, nor do the interventions explore GPs experiences of 
implementing the intervention. In designing the interventions the reasons why GPs find 
BPSD challenging were not explored. If we do not understand the reasons for the apparent 
discrepancy between best practice recommendations in BPSD and real-life clinical practice, 
we cannot design an effective intervention to address the problem. Interventions are 
required to improve the management of BPSD in general practice and, given the significant 
role GPs play in the management of BPSD, it is apposite that these interventions focus on 
GPs. However, to design an effective intervention we need to first have a clear 
understanding of GPs’ knowledge, attitudes and experiences of managing BPSD. We need to 
understand what GPs’ perspectives are on the barriers and enablers to implementing best 
practice recommendations for BPSD. We need to address this gap in the literature or we run 











CHAPTER 4: PHILOSOPHICAL AND METHODOLOGICAL APPROACH 
This chapter provides a description of the philosophical approach that underpins this 
research and the methodological framework employed to address the thesis aims and 
objectives. An overview of the methods used to address each phase of the research is 
provided here. Each individual chapter provides greater detail on the specific methods 
employed for each research phase.  
4.1 PHILOSOPHICAL ORIENTATION 
A pragmatic paradigm was adopted for this research. The research design and methodology 
was guided by the aims and objectives of the thesis. Both qualitative and quantitative 
methods were employed to address the different objectives of the thesis. This decision to 
include both qualitative and quantitative methods reflects the pragmatic paradigm that 
underpins this thesis. A major tenet of the concept of pragmatism is that quantitative and 
qualitative methods are compatible. 230 Pragmatism rejects the forced choice between 
qualitative and quantitative research methodologies, instead advocating that the choice of 
method should be informed by the research question. The epistemological differences 
between qualitative and quantitative approaches are acknowledged. However, these two 
form of inquiry are not seen as incommensurable. 231 Indeed, it was felt that, given the 
complexity of the research environment and the complexity of the research question, 
adopting a mixed methods approach to the thesis was appropriate. 
Creswell et al have outlined four designs for mixed methods research; exploratory, 
explanatory, triangulation and embedded designs. 232 The approach taken to this research 
was sequential with an exploratory design, in that each step of the research occurred 
sequentially, informing the next step but with a particular emphasis on the qualitative 
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component. This approach is graphically outlined in Figure 3.  Although mixed methods 
were used the core component was the qualitative research. The quantitative research 
functioned as a supplemental component which expanded on the core qualitative data. 233 
 
Figure 4. Illustration of the sequential exploratory design to mixed methods research as 





*Capitals indicate component is typically emphasised or prioritised in the design. Lower case 
indicates component is used in a supportive capacity.  
 
To further illustrate this approach I will explain how the different steps in the thesis were 
timed and the emphasis placed on each. The mixed methods systematic review was 
conducted first and is reported in Chapter 5. The systematic review findings were analysed 
and synthesised using a meta-ethnographic approach which is a recognised method of 
synthesising qualitative data.234 The next step, described in Chapter 6, was a qualitative 
study with GPs and explored their experiences of the challenges of managing BPSD. The 
methodological approach used was descriptive interpretative and the method of analysis 
was thematic analysis as outlined by Braun and Clarke.101 In the qualitative study a specific 
concern was raised by GPs on the challenges of identifying potential causes of BPSD, in 






particular pain. This led to the concept for a quantitative descriptive cross-sectional study of 
GPs’ knowledge of and attitudes towards pain management in dementia, which is reported 
in Chapter 7. A further questionnaire based survey that aimed to assess GPs’ attitudes to 
prescribing antipsychotics in BPSD is reported in Chapter 8. An eDelphi consensus study was 
employed to achieve consensus on some of the clinical components of the intervention is 
reported in Chapter 9.  The findings from these five studies were then used to inform the 
development of the intervention in Chapter 8. The intervention development process 
incorporated behaviour change theory and was facilitated by expert consensus meetings. 
Finally, the clinical content of the intervention was finalised with qualitative input from 
stakeholder experts in semi-structured interviews. 
Combining these two lines of inquiry (quantitative and qualitative) is not without its 
challenges. Philosophically, quantitative approaches are traditionally associated with a 
positivist epistemology while qualitative research approaches are traditionally associated 
with constructivist or interpretive epistemology. 235 A positivist epistemology assumes there 
is an absolute knowledge and an objective reality, with the researcher and the researched 
acting as independent entities. 235 On the other hand, an interpretative epistemology is tied 
to the ontological position of relativism – the view that reality is subjective and that truth is 
only knowable through our own conceptual frameworks which, of course, differ from 
person to person. 231  In this thesis the integrity of each research component was 
maintained. However, the ontological perspective that underpins the pragmatic approach 
adopted for this research is one of subtle realism. Subtle realism assumes that we can only 
know reality from our own perspective of it. The role of the researcher and the influence of 
the researcher on how the research is interpreted is, therefore, paramount.  
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My experience as a GP, who has worked extensively managing BPSD both in the community 
and in nursing home settings, undoubtedly influenced the topic under scrutiny. My own 
experiences adjusted the lens with which I conducted and analysed the research. I have 
worked in a variety of urban and rural general practices. The provision of nursing home care 
has always been a significant part of my workload as a GP. I have had significant exposure 
to, and experience with, providing medical care in large and small nursing homes, 
community hospitals and in residential care settings. I have witnessed the provision of what 
was, in my opinion, suboptimal care in nursing homes and I have also witnessed the 
provision of optimal care. In the community setting, I have worked within functioning, 
proactive primary care teams and I have worked without the support of a primary care 
team. Furthermore, I qualified as a GP during the economic crash and I have witnessed 
some of the changes in the funding of general practice that accompanied the economic 
crash. I have my own personal experiences of how dementia care is provided in nursing 
homes and in the community. Undoubtedly this has altered my own approach to clinical 
practice and to how I approached this research. The impact of my own professional 
experiences and background is acknowledged within the methods sections and occasionally 
in the limitation sections of the individual chapters that follow.  
 
4.2 METHODOLOGICAL FRAMEWORK 
The overall research design is a theory-based, predominantly qualitative, approach to the 
development of an intervention to improve the management of BPSD in general practice.  
The methodological approach chosen follows a structured, systematic and transparent 
approach to the design of an intervention that targets GPs’ management of BPSD.  
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The UK Medical Research Council (MRC) framework for developing complex interventions 
was the overarching framework for this thesis. (See Figure 4). The MRC framework proposes 
a phased approach to the development and evaluation of complex interventions.  
 
 
Figure 5. MRC Framework for the development and evaluation of complex interventions 
 
 
4.2.1 MRC phase 1: Intervention Development 
The first phase of the MRC framework for developing and evaluating a complex intervention 
focuses on the intervention development. The focus of this thesis is only on this first phase 
of the MRC framework. This thesis concentrates exclusively on this first part of the MRC 
framework and explores two of the sub-sections of this phase; identifying the evidence base 
and identifying or developing theory. 
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Identifying the evidence base 
As outlined in chapter 3 there is a paucity of research on the management of BPSD in 
general practice. Consequently, it was necessary to conduct research in this area to provide 
an evidence base that would inform the intervention development process.  
Existing evidence 
The existing evidence on GPs’ knowledge of, attitudes towards and experiences with BPSD 
was systematically reviewed. To ensure all relevant literature was included, a mixed 
methods approach was undertaken ensuring all relevant quantitative and qualitative studies 
were eligible for inclusion in the review. The methodological approach adopted is described 
in detail in chapter 5.  
New evidence 
The existing evidence identified from the mixed methods systematic review was 
supplemented with evidence generated from two new studies: 
(i) The first study was a qualitative study with GPs exploring the challenges they 
experience when managing BPSD and to explore how these challenges influence 
their management decisions in BPSD. This was a descriptive interpretative study 
and data analysis followed the principles of thematic analysis as outlined by 
Braun & Clarke. 101 Further information on the methodological approach 
employed is outline in chapter 6. 
(ii) The second study was a quantitative study that examined GPs’ knowledge of and 
attitudes towards the management of pain in dementia. Assessing and managing 
pain was identified in the qualitative study as a particularly challenging aspect of 
managing BPSD. Pain is a common trigger for BPSD, yet pain is underdiagnosed 
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and undertreated in people with dementia. This study was a cross-sectional 
descriptive study using questionnaires which were distributed to a 
representative sample of GPs in Ireland. Statistical analysis was completed using 
SPSS. A detailed description of the methodology used is available in chapter 7. 
(iii) The third study was also a descriptive cross-sectional study which assessed the 
attitudes of GPs to the prescribing of antipsychotics in BPSD. Statistical analysis 
was completed using SPSS. This study is reported in detail in chapter 8. 
 
Identifying theory and modelling process and outcomes 
The MRC guidance advocates for the use of theory to inform intervention design. The 
limited success of efforts to implement interventions has previously been attributed to a 
lack of an explicit rationale for the intervention chosen and the use of inappropriate 
methods to design interventions. 236 Theory can overcome these issues by providing an 
explicit statement of the structural and psychological processes that are hypothesised to 
influence behaviour, thus informing the design of practice change interventions and 
allowing structured investigation of implementation difficulties. 237 By adopting a theory-
based approach to the development of an intervention one targets the causal determinants 
of behaviour and behaviour change, thus developing a more effective intervention. 238 The 
Behaviour Change Wheel (BCW) developed by Michie et al describes a structured, 
reproducible approach to applying behavioural theory to intervention development. 239 (See 
Figure 6) 
In this thesis, the BCW was used to explicitly integrate behaviour theory with the evidence 
generated in chapters 5, 6, 7 and 8 to develop a complex intervention for BPSD targeted at 
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GPs. In chapter 10 there is a detailed description of how the BCW was used, within the 
overarching MRC framework, to design the intervention with input from an expert panel.  
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In the context of rising dementia prevalence the workload of General Practitioners (GPs) in 
dementia care is set to increase. However, there are many aspects of dementia care that 
GPs find challenging. Behavioural and psychological symptoms of dementia (BPSD) affect 
the majority of people with dementia and is an aspect of dementia care that GPs find 
particularly difficult to manage.  The aim of this mixed method systematic review is to 
undertake a synthesis of qualitative and quantitative studies on GP’s knowledge, attitudes 
and experiences of managing BPSD. 
Methods 
Seven electronic bibliographic databases will be searched from inception to present. All 
qualitative or quantitative studies that explore the knowledge, attitude or experiences of 
GPs towards the management of BPSD in community and/or residential settings will be 
eligible for inclusion. A meta-ethnography will be conducted to synthesise included studies. 
Primary outcome measures will include GPs’ experiences of managing BPSD, GPs’ 
knowledge of BPSD and their attitude to different approaches to the management of BPSD, 
in particular their attitude to non-pharmacological approaches. All included papers will be 
independently assessed for methodological validity by two reviewers using the following 
tools; the Joanna Briggs Institute checklist for qualitative research, the Effective Public 
Health Practice Project (EPHPP) tool for intervention studies and the National Institute of 
Health (NIH) quality assessment tool for observational and analytical cross-sectional studies. 
As there is no agreed quality assessment tool for descriptive cross-sectional studies an 
original tool will be developed. Two independent reviewers will apply the Confidence in the 
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Evidence from Reviews of Qualitative Research (CERQual) tool to the review findings. The 
results will be reported in line with the Enhancing Transparency in Reporting the Synthesis 
of Qualitative Research (ENTREQ) statement.  
Discussion 
This study will be the first systematic review that synthesises the existing literature of GPs’ 
knowledge, attitudes and experiences of managing BPSD in community and residential care. 
This review will improve our understanding of GPs’ perspectives on the management of 
BPSD and the results will be used to inform the development of an intervention to improve 
the management of BPSD in general practice. 
Systematic review registration  











General practitioners play a pivotal role in the care of a person with dementia and their 
families 6.  It is estimated that there are currently 47 million people living with dementia 
worldwide and this figure is predicted to triple by 2050 10. In the context of rising dementia 
prevalence 11 the dementia workload of general practitioners (GPs) is set to increase further. 
National dementia strategies have been developed internationally to respond to the 
challenge posed by increasing dementia prevalence and have emphasized the central role of 
GPs in successful implementation 28-30. GPs find many aspects of dementia care, such as 
diagnosis disclosure and co-ordinating support services, to be challenging 86. However, the 
one area that consistently emerges as a particularly challenging aspect of dementia care for 
GPs internationally is the management of behavioural and psychological symptoms of 
dementia (BPSD) 86-90. 
BPSD encompasses a wide range of symptoms and behaviours that affect people with 
dementia. BPSD includes behaviours such as aggression, wandering, sexual disinhibition, 
agitation and symptoms such as anxiety, depression and delusions. These symptoms and 
behaviours often overlap and occur together rather than occurring as isolated symptoms 91. 
The majority of people with dementia will experience BPSD 92. Estimates of BPSD prevalence 
vary 105,106 and we know the presence of BPSD can be influenced by several factors including 
dementia severity 107, however, some studies estimate that up to 80% of people with 
dementia experience at least one symptom of BPSD at some stage in their illness 106. The 
presence of BPSD results in increased rates of admission to long term care facilities 93 128 and 
longer in-patient hospital stays 113. The development of BPSD is also associated with a worse 
prognosis for the patient and a more rapid rate of illness progression 240. From a carer 
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perspective, BPSD is a major contributor to stress and depression, even more significant 
than cognitive decline 116.  For physicians, the assessment of BPSD is complex and effective 
treatment options are limited 104. Antipsychotics are associated with serious adverse effects 
including stroke 158-160 and are not recommended unless there is a serious risk to self or 
others 187, however, credible pharmacological alternatives remain scarce 188. There is 
agreement that in most cases non-pharmacological interventions should be used first line 
241, however, effective non-pharmacologic strategies for BPSD have not been translated into 
real-world clinical practice 151 and are not viewed by many GPs as being credible options 152.  
If GPs are to play the pivotal role described in the various national strategies then 
interventions will be needed to support GPs in their management of BPSD, however, we are 
unaware of any such interventions. An important first step in intervention design is to 
establish a thorough understanding of existing behaviour 239,242. To date no qualitative or 
quantitative synthesis has been performed on studies which focused on GPs’ perspectives 
on the management of BPSD in community and residential care settings. Primary 
quantitative studies performed to date, 80,152, have been conducted in different contexts 
and at different times in the evolution of the management of BPSD. Likewise qualitative 
studies in this area 153,243, were conducted in different healthcare systems and took different 
approaches to the evidence. Exploring these contextual differences will improve the depth 
of our overall understanding of the research question. In order to effectively address our 
research aim we will include both relevant quantitative and qualitative studies, as a review 
which “focuses exclusively on one form of evidence presents only half the picture and thus 
will have limited applicability” 244.   
104 
 
The aim of this mixed methods systematic review is to develop a synthesis of qualitative and 
quantitative studies on GPs’ knowledge, attitudes and experiences of managing BPSD in 
order to develop a conceptual understanding of the perspective of GPs on the management 
of BPSD. The results of this systematic review will subsequently inform the development of 
a future behavioural change intervention.  
 
5.1.3 METHODS 
This review protocol was developed using the Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses Protocol (PRISMA-P) 245 (available in Appendix 1, supplementary 
material 1). The systematic review was registered with the International Prospective 
Register of Systematic Reviews (PROSPERO) on the 11th of January 2017 and was last 
updated on the 25th of July 2017 (registration number 42017054916). 
Methodological framework 
This mixed methods systematic review will take an integrated approach to synthesis as 
described by Sandelowski et al. 244,246. The integrated approach involves assimilating study 
findings into each other as opposed to the segregated approach, which involves separate 
qualitative and quantitative syntheses (see Figure 7) 246,247.  The assimilation approach is 
particularly appropriate when findings are viewed as confirming each other or converging in 
the same direction 247. The integrated approach will involve transforming quantitative data, 
usually obtained from GPs’ responses to standardised questionnaires, into qualitative form 
so that it can be combined with data from qualitative studies and subjected to qualitative 
analysis. This approach has been used effectively in previous mixed method systematic 
reviews of similar research questions 120,248. Once the data is in qualitative form our 
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approach to qualitative synthesis will follow the seven step model of meta-ethnography as 
described by Noblit and Hare 234 (see Table 1). Meta-ethnography is explicit when describing 
the act of ‘translation’ where terms and concepts which have resonance are enveloped into 
‘high order constructs’ 249 and goes beyond merely describing or summarising the data 
allowing an original interpretation of the topic under review. 
 
Figure 7. The Integrated Approach to Mixed Method Systematic Review (adapted from the 

















Syntheses of qualitative data have been criticised as being mechanistic. Indeed there is the 
risk with meta-ethnography that the richness or integrity of the original work will be lost 250, 
a concern that by overly deconstructing the original qualitative work the researcher 
attempts to “sum up a poem” 251. However, when conducted rigorously, a synthesis of 
qualitative studies leads to a more substantive interpretation of the research phenomenon 
than is available from a single study 252.  Rather than attempting to totalise concepts, a 
synthesis of qualitative literature aims to offer fresh new insights into the phenomenon of 
interest 253. In order to achieve a deeper understanding of the shared meanings of the area 
under review, it is essential that rigour is applied to each stage of the review process.  In this 
review all efforts will be made to retain the content and context of the original studies 
throughout the data extraction and analysis. Each stage of the review process will involve at 
1. Getting started 
2. Deciding what is relevant to the initial interest 
3. Reading the studies 
4. Determining how the studies are related 
5. Translating the studies into one another 
6. Synthesising translations 







least two authors working independently. At every stage a third author, experienced in 
performing meta-ethnographic synthesis, will be available for consultation. 
We will report our results in line with the Enhancing Transparency in Reporting the 
Synthesis of Qualitative Research (ENTREQ) statement 254 and we will express our search 
strategy results using the Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) flow diagram 255. 
Eligibility Criteria 
Qualitative or quantitative studies that explore the knowledge, attitude or experiences of 
GPs towards the management of BPSD in nursing homes and/or in the community setting 
will be eligible for inclusion. All study designs will be included. Qualitative studies that focus 
more generally on GPs’ perspectives on dementia management will be included only if there 
is a specific reference to BPSD in the results. Quantitative studies that focus on the 
knowledge and attitude of GPs to other aspects of dementia care will only be included if 
there is a specific reference to BPSD in the results. Randomised control trials and other 
intervention studies will be included in the review if they identify the knowledge-base or 
attitude of GPs towards BPSD during the study. Opinion pieces and non-peer-reviewed 
articles will be excluded. Studies not written in the English language will be excluded. This is 
due to resource limitations which prevent employment of formal translation services. 
However, if eligible non-English language studies are identified, we will attempt to contact 
the study authors to see if there are any English translations available. A list of possibly 
relevant titles in other languages will be provided as an appendix. Studies that do not 
describe in detail the knowledge and attitudes of GPs in relation to BPSD will be excluded. 
Studies that report on the perspective of non-GP healthcare professionals to BPSD in 
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addition to GPs will be included so long as the views of GPs are represented or analysed 
separately. See table 2 for eligibility criteria.  
 
Table 2. Eligibility Criteria for studies in the systematic review 
Inclusion Criteria Exclusion Criteria 
- Studies that explore the knowledge, 
attitude or experiences of GPs in the 
management of BPSD in residential 
settings and/or in community setting. 
- Qualitative or quantitative study design 
- Studies must include GPs 
- Studies that do not describe in detail 
the knowledge and attitudes of General 
Practitioners in relation to BPSD 
- Non-English language studies 
- Studies reporting the perspective of 
non-GP healthcare professionals where 
the views of GPs are not represented or 
analysed separately 
- Studies reporting on GPs’ perspectives 
on managing another aspect of 
dementia without any reference to the 
management of BPSD  
- Opinion pieces and non-peer reviewed 
articles 
 
Information Sources & Search Strategy 
We will search the following seven electronic bibliographic databases from inception to 
present with no date limits; MEDLINE (Ovid) 1946- present, EMBASE (Elsevier), CINAHL, 
PsycINFO, Academic Search Complete, SocIndex, Social Science Full Text. The search 
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strategy has been developed using database-specific search terms with input from the 
review team and a health services librarian with expertise in systematic review searching. 
The MEDLINE search strategy is available in table 3. How these search terms will be 
combined with Boolean logic are available in Appendix 1, supplementary material 2. Other 
search methods utilised will include; hand-searching key journals and conference 
proceedings, forward citation searching of eligible studies and searching reference lists of 
included studies.  
Table 3. The Medline, Ovid search strategy 
 Primary Care Physicians Dementia BPSD 
MeSH Terms/ 
Subheadings 
Exp Primary Health Care/  
Exp General Practice 
Family Practice/  
Exp General Practitioners/ 
Exp Physicians, Family/ 







Exp Antipsychotic Agents/  
Exp Anxiety/ 
Exp Aggression/  
Exp Wandering behavior/ 
Exp Sleep Disorders/ 
Exp Apathy/ 
Exp Irritable Mood/ 
Exp Psychotic Disorders/ 
Exp Depression/ 
 



































(agitated or agitation).ti,ab 
(depressed or 
depression).ti,ab 




A flow diagram using PRISMA guidelines will be used to report the selection process and all 
results. The results of our search will be exported to Covidence (www.covidence.org). 
Duplicates will be identified and removed. Covidence will then be used to manage citations, 
and perform title and abstract screening.  
Study Selection 
At the first stage duplicates and clearly irrelevant studies (for example pre-clinical studies) 
will be removed. In the next stage abstract screening will be conducted.  To manage the 
workload that may result from a large number of citations four reviewers (AJ, TF, AC, CB) 
will form three paired teams; AJ and TF, AJ and AC, AJ and CB.  The search results will be 
randomly divided into three groups and assigned to a paired team. The two reviewers in 
each paired team will independently screen each study abstract and assess the study’s 
suitability for inclusion based on pre-determined inclusion and exclusion criteria. Conflicts 
will be resolved through discussion and where necessary a third reviewer, selected from a 
different paired team, will act as adjudicator. Subsequently all potentially eligible studies 
included in full-text screening will be assigned to a paired team for eligibility assessment. 
Any conflicts regarding the eligibility of a study at full-text screening will be resolved 
through discussion between the two members of the paired team. Where consensus is not 
reached through discussion a third reviewer, selected from a different paired team, will 
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adjudicate and make the final decision regarding inclusion. All studies that are excluded 
after full-text screening will be displayed, with their reason for exclusion, as an appendix in 
table form.  
Data extraction, analysis and synthesis 
We will follow the meta-ethnographic approach as described by Nobilt and Hare when 
extracting, analysing and synthesising the data. This stage of the review process maps to 
steps 3- 7 of the meta-ethnographic approach [see Table 1].  
Data Extraction 
The data extraction and analysis stage will involve four of the reviewers (AJ, TF, KW, CB). All 
four reviewers will independently read and re-read all the eligible studies in chronological 
order focusing initially on the content and context (step 3 of meta-ethnography approach).  
Data concerning participant characteristics, aims, setting and methods will be extracted 
independently by two reviewers (AJ, TF) and displayed in tabular form. Data extraction will 
be facilitated by the use of standardised data extraction tables. The data extraction forms 
will be pilot tested by the reviewers on the first two included studies to ensure consistency 
and reliability between reviewers. A third reviewer (KW) will oversee the data extraction 
process and will be available for consultation. If necessary we will contact the study authors 
to resolve any uncertainties. Table 4 shows data categories that will be extracted from all 
the included studies.  






4. Study Objectives 
5. Study Design 
6. Analysis 




Data analysis & synthesis 
The lead author (AJ) will open code all the included studies focusing specifically on the first 
and second order interpretations (Figure 8). First order interpretations refer to the 
participants’ views as they are reported in the results section of the study. In the qualitative 
studies the first order interpretations will focus on attitudes and experiences of GPs.  In the 
quantitative studies the first order interpretations will involve creating a text file that 
describes participants’ responses to questionnaire items. In the studies that include other 
healthcare professionals, the study findings, where possible, will be restricted to the views 
of GPs. Second order interpretations refer to the original study author’s interpretation of 
the participants’ views usually found in the discussion section. In the qualitative studies, 
author-derived themes, conclusions, interpretations, recommendations will form the basis 
of the second order interpretations. In the quantitative studies the second order 
interpretations will be derived from the results, recommendations and conclusions. The 
data will be extracted verbatim for all the included studies to ensure no valuable detail is 
lost. All efforts will be made to retain the context of the findings from both the qualitative 
and the quantitative studies during data extraction 256. At this point the data collected from 
quantitative and from qualitative studies will be no longer distinguishable in terms of study 





















We acknowledge that performing the second order interpretations can be challenging as the 
value of second order constructs lies to an extent in the richness and depth of the analysis 
performed by the original authors 257.  To ensure credibility and dependability of coding a 
second reviewer (KW) will code a random selection of studies. Conceptual groupings for 
each study will be created and illustrated with the development of conceptual mind maps. 
The two reviewers involved (AJ, KW) will meet regularly to discuss differences in 
interpretation of the studies. A third reviewer (CB) will oversee the data analysis process 
and will be available for consultation. Finally all four members of the data extraction and 
analysis team (AJ, KW, CB, TF) will meet to discuss the key concepts emerging from the 
analysis of the included studies. The software package NVivo version 11 will be used to 
facilitate data analysis and synthesis. 
 
 
The          The 




Second Order Interpretations   
(Primary study author’s 
interpretation of participants’ views) 
First Order Interpretations 
(Participants’ views or beliefs)  
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Step 4 of the meta-ethnographic approach involves determining how studies are related to 
each other. To facilitate this step a table will be developed to display the identified concepts 
and themes across all the studies. Relationships between the conceptual groups and themes 
will be organised and illustrated by the use of conceptual maps. Step 5 of the meta-
ethnography involves translating the studies into one another. To examine the contribution 
of each study to a key concept the review team will compare the themes and concepts from 
study 1 with study 2 and the synthesis of these two studies with study 3 and so on. This 
process will be conducted in chronological order starting with the earliest study 257. A 
chronological approach is appropriate as the included studies are likely to range over 
multiple decades, during which time significant changes in the management of BPSD 
occurred. Within the key concepts attention will be paid to deviant cases. Two authors (AJ, 
KW) will perform reciprocal and refutational analyses to summarise shared themes across 
the studies. We will attempt at all times to consider the influence of context to the study 
finding, however, we acknowledge that this may be difficult as previous meta-ethnographies 
have reported on the challenges of retaining the context of the primary studies when 
contextual information is often poorly reported 257. Step 6 will involve synthesising the 
translations in each key concept to iteratively develop third-order interpretations. A 
synthesis of first and second order interpretations, the third-order interpretations 
constructs a new model or theory about a problem. The synthesis team (all authors) will link 
the third-order interpretations into a ‘line of argument’ which will represent the overarching 
perspective of GPs towards BPSD. The final step in the meta-ethnography approach involves 




Assessment of confidence in the study findings 
Two independent reviewers (AJ, KW) will apply the Confidence in the Evidence from 
Reviews of Qualitative Research (CERQual) tool to the review findings (i.e. third order 
interpretations) as conducted in a recent meta-ethnography 3. The CERQual approach 
provides a transparent method of assessing the confidence of findings of systematic reviews 
of qualitative research 258. There are four key components to the CERQual approach; (i) 
methodological limitations of the qualitative studies contributing to a review finding, (ii) the 
relevance to the review question of the studies contributing to a review finding, (iii) the 
coherence of the review finding, and (iv) the adequacy of data supporting a review finding. 
Judgements relating to each CERQual component will be summarised in table form. Each 
review finding will be rated and given an assessment of confidence as high, moderate, low 
or very low. We will assign high confidence if it is highly likely, moderate confidence if it is 
likely, low confidence if it is possible and very low confidence if it is unclear if the review 
finding is a reasonable representation of the phenomenon of interest 258.   
 
Outcomes  
Primary outcome measures will include GPs’ experiences of managing BPSD, especially their 
confidence in this field. GPs’ knowledge of strategies to manage BPSD and their attitude to 
different approaches to the management of BPSD, in particular the role of non-
pharmacological approaches will also be included. Additionally we will seek to identify data 





All included papers will be independently assessed by two reviewers (AJ, JB) for 
methodological validity. Agreement on the quality assessment will be measured using 
Cohen’s Kappa and in consideration of previous literature in this area values greater or 
equal to 0.6 will be considered an acceptable level of agreement 259.  Disagreements will be 
resolved by discussion between the two reviewers. Given the large number of study designs 
that will potentially be included in the study a number of quality assessment tools will be 
required.  
The quality assessment tools that will be used to assess the quality of the quantitative 
studies have been agreed through consultation with the systematic review team. The 
Effective Public Health Practice Project (EPHPP) tool will be used for intervention studies 260. 
The National Institute of Health (NIH) quality assessment tool for observational and 
analytical cross-sectional studies will be used where appropriate 261.  Since there is no 
agreed quality assessment tool for assessing the quality of descriptive cross-sectional 
studies a new original tool will be developed by two of the reviewers (AJ, JB) that will be 
based on other original tools developed for a similar purpose 248,262. This new tool will also 
consider recommendations on how survey questionnaires should be designed 263.  
There are a number of quality appraisal tools available for assessing the quality of 
qualitative studies 264. However, it is recognised that critical appraisal instruments for 
qualitative research differ in the criteria they apply to a critical appraisal process 265. On 
examining potential quality assessment tools it is clear that many of the existing appraisal 
instruments for qualitative research use quite broad criteria that often reflects the quality of 
the reporting of the research rather than addressing the core quality issues inherent to 
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qualitative research; such as issues relating to the credibility, dependability, confirmability 
and transferability of the research. Qualitative studies may rate as “low quality” when 
assessed as a result of methodological flaws, a poorly designed quality assessment tool or 
simply because of lack of reporting; which can often be a consequence of meeting tight 
word count deadlines for journals. However, these studies may still generate novel concepts 
and insights 266. As Dixon-Woods observes some of the most important qualities of 
qualitative research can be the hardest to measure 267  Appraisal tools, generally,  focus on 
the methodological strength of the paper rather than its conceptual strength 268. However, a 
qualitative study that has clearly reported its methods may not generate rich interpretation 
of the phenomenon of interest. Likewise, a qualitative study that appears to have face 
validity and offers rich, insightful interpretations might not necessarily do well on quality 
assessment 257. This then leads to questions on whether the quality of qualitative can be 
legitimately judged, or indeed whether it should be judged at all 269.   
We have chosen to assess the quality of the qualitative studies. However, quality appraisal 
will not be used to exclude qualitative or quantitative studies that otherwise meet the 
inclusion criteria. The CERQual assessment requires an evaluation of the methodological 
limitations of each of the studies that supports each third order interpretation 258. 
Therefore, the quality assessment given to the studies will influence the confidence rating 
we can give to each review finding. A poor quality assessment will not, on its own, alter the 
confidence assessment but the results of quality assessment will be considered as part of a 
wider assessment of the confidence we have in our review findings which will be assessed 
using the CERQual assessment. 
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Following a process of consultation and discussion between the members of the review 
team the Joanna Briggs Institute Critical Appraisal Checklist for Qualitative Research was 
chosen as the quality assessment tool that will be used to assess the qualitative studies 270. 
This particular quality assessment tool was chosen as it was found to focus on the quality of 
the study design rather than just the reporting rigour. Additionally, this quality assessment 
tool is specifically designed for use in systematic reviews. 
5.1.4 DISCUSSION  
This study will be the first systematic review that synthesises the existing literature of GPs’ 
knowledge, attitudes and experiences of managing BPSD in community and residential care. 
This review will contribute to improved understanding of GPs’ perspectives on the 
management of BPSD. We know that BPSD is a challenging area of dementia care for GPs 
86,87, however, this mixed method synthesis of all the available quantitative and qualitative 
research in this field will offer fresh insights and interpretations into why this is a 
challenging area for GPs. The findings of this review can then be used to inform the 
development of interventions to improve the management of BPSD in primary care. We 
believe this review will expose gaps in the literature, gaps that should be the focus of future 
research. Additionally this review will be valuable to policy makers and health care providers 
who are attempting to implement national dementia strategies, as many of these strategies 
depend upon general practitioners taking on an increasing amount of dementia care. In 
order to effectively implement these strategies the current barriers and facilitators of 
managing this particularly challenging aspect of dementia in primary care need to be 
identified and addressed. The use of CERQual will provide policy-makers with a transparent 
method for assessing the confidence of the review findings. 
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Strengths and limitations 
This systematic review is being conducted as part of a wider national project which is one of 
the implementation work-streams of the Irish National Dementia Strategy 29. Due to time 
constraints associated with the wider project this review will not include a search of the 
grey literature. However, since our search of the electronic databases will be extensive we 
feel that the grey literature is unlikely to result in any additional eligible peer-reviewed 
study. 
Existing validated approaches for synthesising quantitative and qualitative data for mixed 
method systematic reviews will be followed 246,247, however we recognise that the potential 
heterogeneity of the evidence may make this synthesis challenging. The benefit of using a 
mixed methods approach here is that it will enable us to integrate the quantitative 
assessments of GP’s knowledge of and attitudes towards BPSD with a more qualitative 
understanding of GP’s experiences of BPSD. Combining these two sources of data into a 
systematic review will enhance the review’s utility and impact. The development of a new 
original tool to assess the quality of descriptive cross-sectional studies will be a strength of 
this review. The tool will be useful for researchers undertaking similar mixed methods 
systematic reviews. Finally, the application of the CERQual tool to our review findings will 
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To synthesise the existing published literature on GP’s knowledge, attitudes and experiences 
of managing behavioural and psychological symptoms of dementia (BPSD) with a view to 
informing future interventions.  
Methods  
We conducted a systematic review and synthesis of quantitative and qualitative studies that 
explored GPs’ experiences of managing BPSD (PROSPERO protocol registration 
CRD42017054916). 7 electronic databases were searched from inception to October 2017. 
Each stage of the review process involved at least two authors working independently. The 
meta-ethnographic approach was employed to synthesise the findings of the included 
studies while preserving the context of the primary data. The Confidence in the Evidence 
from Reviews of Qualitative research (CERQual) was used to assess the confidence in our 
individual review findings. 
Results  
Of the 1,638 articles identified, 76 full texts were reviewed and 11 were included. Three 
main concepts specific to GPs’ experiences of managing BPSD emerged; unmet primary care 
resource needs, justification of antipsychotic prescribing and the pivotal role of families. A 
‘line of argument’ was drawn which described how in the context of resource limitations a 
therapeutic void was created. This resulted in GPs being over reliant on antipsychotics and 
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family caregivers. These factors appeared to culminate in a reactive response to BPSD 
whereby behaviours and symptoms could escalate until a crisis point was reached. 
Conclusion 
This systematic review offers new insights into GPs’ perspectives on the management of 
























General practitioners (GPs) play a pivotal role in the care of people with dementia and their 
families 5-7. National strategies developed to address the increased prevalence of dementia 
11  have emphasized the role of GPs in successful implementation 28,29,271 but dementia care 
in the community can be challenging 72,272. In common with their hospital-based colleagues 
273  GPs find the management of the behavioural and psychological symptoms of dementia 
(BPSD) particularly difficult 87,88,90,198.  
BPSD encompasses behaviours such as aggression, wandering, sexual disinhibition, agitation 
and symptoms such as anxiety, depression and delusions. Most people with dementia will 
experience BPSD at some time during their illness 103. BPSD is associated with increased 
rates of admission to nursing homes 114, longer in-patient hospital stays 113 and is a major 
contributor to caregiver stress and depression 116. The assessment of BPSD is complex 108 
and effective treatment options are limited. Non-pharmacological interventions are 
recommended as the first line of treatment in most cases 187. Personalised non-
pharmacological interventions such as personalised music therapy 144,148 and formal 
caregiver training to enhance communication skills 148 may have a role in the management 
of BPSD, however, uptake of non-pharmacological strategies is low 151. Psychotropic 
medications such as antipsychotics, anxiolytics, hypnotics and antidepressants are 
frequently used to manage BPSD 156,157.  Antipsychotics are the most commonly prescribed 
psychotropic in BPSD 157, however, the benefits of antipsychotics in BPSD are modest at best 
160. Furthermore, in BPSD any benefits are usually offset by the significant adverse effects of 
antipsychotics in dementia, including increased risk of cerebrovascular events and increased 
mortality 158-160,196. However, based on current available evidence, pharmacological 
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alternatives to antipsychotics in BPSD are largely ineffective 177,178,182,274,275. Although there 
may be a role for citalopram in managing milder agitation 163, it too can result in significant 
side-effects including QT prolongation and worsening of cognitive impairment 164.  
There is a need for interventions designed to support GPs in their management of BPSD.  An 
important first step in intervention design is to establish a thorough understanding of the 
existing problem 239,242. The aim of this systematic review was to gain a deeper 
understanding of GPs’ knowledge, attitudes and experiences of managing BPSD. It will also 
inform the development of an intervention to assist GPs with the management of BPSD. 
 
5.2.3 METHODS 
We performed a systematic review of studies that used qualitative or quantitative methods 
to explore GPs’ experiences of managing BPSD. A mixed methods approach was employed 
to ensure all relevant literature was included 244. To synthesise the qualitative and 
quantitative results an integrated design was adopted 246. This involved transforming 
quantitative data obtained from GPs’ responses to standardised questionnaires into 
qualitative form so that it could be combined with data from qualitative studies and 
subjected to qualitative analysis. Once the data was in qualitative form, the synthesis was 
guided by the meta-ethnographic approach as described by Noblit and Hare 234. Meta-
ethnography goes beyond merely describing or summarising the literature: the aim is to use 
the source material to develop original interpretations by accounting for both the context of 
the research and the reported findings. Further detail on the methodological approach 
employed is available in the published protocol for this review. 276 
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Table 5 outlines the eligibility and exclusion criteria. We included all studies that explored 
the knowledge, attitude or experiences of GPs in the management of BPSD in the 
community and in nursing home settings. Studies that did not describe in detail the 
knowledge and attitudes of practising GPs in relation to BPSD were excluded. Studies that 
focused on GPs who sub-specialised in elderly care medicine and now work exclusively as 
specialist elderly care physicians in nursing home settings277 were excluded from this 
review.  It was considered that, as a result of their specialist training, the knowledge and 
attitudes of these specialist elderly care physicians towards BPSD would not be 
representative of GPs generally. 
Table 5. Inclusion and Exclusion Criteria 
Inclusion Criteria Exclusion Criteria 
- Studies that explore the knowledge, 
attitude or experiences of GPs in the 
management of BPSD in residential 
settings and/or in community 
setting. 
- Qualitative or quantitative study 
design 
- Studies must include GPs 
- Studies that do not describe in 
detail the knowledge and attitudes 
of General Practitioners in relation 
to BPSD 
- Non-English language studies 
- Studies reporting the perspective of 
non-GP healthcare professionals 
where the views of GPs are not 
represented or analysed separately 
- Studies reporting on GPs’ 
perspectives on managing another 
aspect of dementia without any 
reference to the management of 
BPSD  
- Opinion pieces and non-peer 
reviewed articles 
 
7 electronic bibliographic databases were searched from inception to present; MEDLINE 
(Ovid), EMBASE (Elsevier), CINAHL, PsychINFO, Academic Search Complete, SocIndex, Social 
Science Full Text. The initial search was conducted in June 2017 and repeated on 25th of 
October 2017. The search strategy was developed using database-specific search terms with 
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input from a health services librarian. The MEDLINE search strategy is available in Appendix 
1, supplementary file 2. Other search methods utilised included; hand-searching key 
journals and conference proceedings, citation searching of highly cited key papers and 
scanning reference lists of key papers.  
For the first stage of abstract screening duplicates and clearly irrelevant studies (for example 
pre-clinical studies) were removed by one reviewer (AJ).  In the next stage two independent 
reviewers from the screening team (AJ, TF, AC, CB) independently screened each study 
abstract. All eligible studies were then assessed by two independent reviewers. Any conflicts 
regarding the eligibility of a study were resolved through discussion between the paired 
teams. Where necessary, a third reviewer adjudicated and made the final decision regarding 
inclusion. All studies that were excluded after full-text screening are listed, with their reason 
for exclusion, in Appendix 1, supplementary material 3. 
Data concerning participant characteristics, aims, setting and methods was extracted 
independently by two reviewers (AJ, TF). Members of the review team independently read 
and re-read all the eligible studies in chronological order focusing initially on the content 
and context. The lead author (AJ) open coded all the included studies focusing specifically 
on the first-order interpretations (views of participants) and second-order interpretations 
(views of the authors). In the qualitative studies the first order interpretations focused on 
the attitudes and experiences of GPs as presented in the result sections of the studies. In 
the quantitative studies the first order interpretations were identified from participants’ 
responses to questionnaire items and a text file was created describing these responses.  
Second order interpretations were derived from the discussions and conclusions. At this 
point the data collected from quantitative and qualitative studies were no longer 
127 
 
distinguishable, enabling the synthesis of all the data in qualitative form. The software 
package NVivo 11 was used to facilitate data analysis and synthesis.  
To ensure credibility and dependability of coding a second reviewer (KW) also coded three 
studies 152,243,278. Conceptual groupings were created for each study and illustrated with 
conceptual mind maps. The two reviewers involved (AJ, KW) met regularly to discuss 
differences in interpretation of the studies. All four members of the analysis team (AJ, KW, 
CB, TF) met to discuss the key concepts emerging from the analysis of the included studies. 
To determine how the studies related to each other a table was iteratively developed that 
displayed the identified concepts and themes across all studies. This table is available in 
Appendix 1, supplementary material 4. To examine the contribution of each study to a key 
concept, the review team compared the themes and concepts from each individual study in 
chronological order. Attention was paid to deviant cases and to the influence of context on 
the study findings. The third-order interpretations were iteratively developed by the 
analysis team. Finally, the analysis team collectively linked the third-order interpretations 
into a ‘line of argument’ 234 which represents the overarching perspective of GPs towards 
BPSD.   
All included papers were independently assessed by two reviewers (AJ, JB) for 
methodological validity.  AJ was a co-author on one of the included studies 279, therefore, 
the quality assessment of that study was carried out by CB and JB. The Joanna Briggs 
Institute (JBI) Critical Appraisal Checklist for Qualitative Research was used to assess the 
quality of the included qualitative studies 270. Since there is no agreed quality assessment 
tool for assessing the quality of descriptive cross-sectional studies a new original tool was 
developed by two of the reviewers (AJ, JB). This tool was based on other original tools 
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developed for a similar purpose 248,262 and also considered recommendations on how survey 
questionnaires should be designed 263. This tool is available in Appendix 1, supplementary 
material 5. Judgements on the quality of the study were not used to exclude studies that 
otherwise meet the inclusion criteria.  
We report our results to conform with the Enhancing Transparency in Reporting the 
Synthesis of Qualitative Research (ENTREQ) statement 254  (Available in Appendix 1, 
supplementary material 5). We express our search strategy results using the Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram 255 
(Figure 9). Two independent reviewers (AJ, KW) applied the Confidence in the Evidence from 
Reviews of Qualitative Research (CERQual) tool to the review findings. The CERQual 
approach provides a transparent method of assessing the confidence of findings of 




The search returned 2,361 citations. 1,638 citations remained to be screened after 
duplicates were removed. 1,558 citations were removed from abstract screening (Appendix 
1, supplementary material 7) leaving 75 full-texts to be assessed for eligibility. Following full-
text review 10 eligible studies were included (see figure 9 and appendix 1, supplementary 
material 3). The final repeat search resulted in the inclusion of 1 additional full-text. 
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database searching  

























Additional records identified 
through other sources  
(n = 6) 
Records after duplicates removed  
(n = 1,638) 
1st round of title and abstract screening  
(n = 1,638) 
Records excluded † 
(n = 435) 
Records excluded † 
(n = 1,128) 
 
Full-text articles assessed for eligibility  
(n = 75) 
 
Studies included after full-text review  
(n=10) 
Duplicate removed 
(n = 723) 
2nd round of title & abstract screening 
with 2 independent reviewers 
(n = 1,203) 
  
Records excluded (n= 65) 
Does not look at 
knowledge/attitudes/ 
experiences of GPs in relation 
to BPSD = 24 
GP’s perspective on another 
aspect of dementia with no 
reference to BPSD =16 
Editorial, opinion piece, 
conference abstract= 13 
No English version available 
= 10 
Views of GPs are not 
represented separately = 2 
 
 
New studies included when search 
was re-done prior to final analysis 
(n=1) 
 
Studies included in the review 
(n = 11) 
† Reasons for the exclusion of records at the abstract screening stages are available in appendix 1, supplementary material 3 
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Characteristics of included studies 
Of the 11 included studies; 4 were qualitative, 6 were quantitative and 1 was mixed-
methods. The characteristics of the included studies are shown in Table 6. In total the views 
of 526 GPs from five different countries were represented. 
 
Quality Appraisal 
We judged the overall quality of the qualitative studies in the review to be high (Appendix 1, 
supplementary material 8, Table 1). The most common weakness was poor reflexivity: only 
one study  278 was found to have fully addressed this issue. Three of the descriptive cross-
sectional studies were rated as low quality (achieving only 3 out of 7 quality markers). These 
studies all reported on the same cohort 280-282. The overall quality of the other 4 descriptive 
cross-sectional studies ranged from moderate to high (Appendix 1, supplementary material 
8, Table 1). Common areas of weakness were, the lack of involvement of the target 
population in the instrument development 152,280-282 and the lack of clarity on whether the 
sample used in the study was likely to be representative of the study population 152,280-282. 
None of the descriptive cross-sectional studies provided a sample size justification, 
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Translation of included studies 
The analysis led to the identification of three key concepts (in bold and numbered below) 
which encompassed eight sub-themes (in bold below) reflecting GPs’ experiences of 
managing BPSD. Each sub-theme was supported by data from both qualitative and 
quantitative studies. The findings supporting first-order interpretations are indicated by 
italicised quotations and those supporting second-order interpretations by non-italicised 
quotations. 
1. Unmet Primary Care Needs 
GPs’ knowledge and self-efficacy 
Nearly all the included studies examined issues pertaining to GPs’ knowledge and self-
efficacy 152,153,155,243,278,279,281,283. In some studies BPSD was considered by GPs to be “very 
difficult to deal with” 279 and  “distressing” 284. GPs tended to be “critical of their perceived 
skills in the diagnosis and management of BPSD” 152. Specifically, in some studies GPs were 
critical of their knowledge of prescribing psychotropic medications 243,279 : “When do you 
add in  psychotropic medication, what type of medication, what dosages, for how long?” 279. 
GPs’ perceived lack of knowledge impacted upon their confidence prescribing these 
medications: “I do rely on psychiatry because I admit that I am not the most knowledgeable 
person about people with agitation and behavioral problems at home. I get a little nervous 
about anti-psychotic meds and I tend to send those people to psychiatry” 243. GPs also lacked 
confidence when differentiating BPSD from other potential causes of these behaviours and 
symptoms 152,243:  “I want a second opinion too in making sure my diagnosis is correct” 243. In 
addition to GPs’  lack of knowledge of and confidence in pharmacological management in 
BPSD, GPs were also found to lack knowledge on non-pharmacological interventions 278,281 
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and, at times, the confidence to recommend them 152 . However, in some of the studies 
participating GPs demonstrated a good knowledge of both non-pharmacological and 
pharmacological management options in BPSD 152,153,155. For example, in one study most GPs 
reported proactively reducing psychotropic medications and routinely recommending non-
pharmacological interventions prior to commencing medications 155, however, these GPs 
still felt they required “more training” 155 in BPSD.  
 
Lack of defined pathways of care 
Several studies identified the need for clearly defined pathways of care that would allow 
GPs to access advice from relevant experts in the area 152,153,243,279,284. The difficulty caused 
by long waiting lists was highlighted 152,243,284 : “there’s a weekly outreach clinic, but it can 
take several months to get in” 284.  Additionally, GPs identified difficulty accessing other 
relevant healthcare professionals: “dementia care it’s a team care, dietician, social work, 
psychiatry, psychologist, and pharmacist...I feel I don’t have this.” 243. GPs found identifying 
the relevant members of the primary care team to be a “struggle” 279. In some studies there 
was “confusion regarding [the GP’s] role”153 in BPSD. In many studies the GP emerged as an 
isolated figure when managing BPSD 152,153,243,284, expressing “frustration [at] being placed in 
a situation in which they felt compelled to provide care that they felt was beyond their 
realm of expertise” 243. The need for “improved communication and collaboration” 153  
between the different healthcare professionals was highlighted to avoid GPs feeling that 






The time required to assess and manage BPSD emerged as an issue in several studies 
243,280,284: “…it’s a lot more complicated than the intact 50-year-old hypertensive diabetic” 
243. Addressing the needs of family caregivers also required time 243,280,284: “I spend as much 
time asking how the caregiver’s doing as I do the patient” 284.  GPs sometimes described 
feeling overwhelmed with the workload that a person with dementia can generate; “I think 
we’re all drowning … we are all truly trying to keep our heads above water...These people do 
take a lot of time and energy”  243. As a result of the time-intensive nature of managing BPSD 
and in the context of inadequate “reimbursement” 243 some GPs considered managing 
people with dementia to be burdensome: “they cause chaos, and so they get referred or 
something happens” 243. The symptoms and behaviours were “neglected” 243 until an 
“emergency situation” 280 or “time of “crisis” 243.  
 
2. Justification of antipsychotic prescribing 
Antipsychotics to facilitate coping 
In 4 studies 153,155,278,283 the prescribing of antipsychotics was seen to enable carers, nursing 
home staff and the person with dementia to cope with BPSD: “he was weeping for his wife 
who has been dead for many years … on quetiapine… the uncontrollable weeping had 
stopped” 278. Although in some studies GPs were aware of the risks of antipsychotic 
prescribing in people with dementia, these risks were seen to relate to longevity of life 
whereas in BPSD “quality of life issues prevailed”153. In several studies GPs’ believed 
antipsychotics positively impacted on the quality of life of people with BPSD 155,278,283. This 
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contributed to their reluctance to discontinue antipsychotics 155,278,283.  Additionally, in two 
studies GPs expressed a concern that discontinuing the antipsychotic would lead to a 
“return of challenging behaviours” 155,283. 
 
Barriers to implementation of non-pharmacological strategies 
Several studies considered the challenges inherent to implementing non-pharmacological 
strategies in BPSD 152,153,280,283. A key finding in three of the studies that were conducted in 
nursing home settings related to the influence of nursing home staff on the implementation 
of non-pharmacological strategies 153,155,283.  Pressure from staff to prescribe medication 
153,155 influenced the GPs’ management decisions and acted as a barrier to recommending 
non-pharmacological strategies: ‘‘often it is pressure from nursing homes … for medication 
to calm a patient down that is trigger for prescribing” 153. One study found that in a nursing 
home setting “nursing staff have the largest influence on prescribing psychotropic 
medication” 155. However, this study also found that experienced GPs (in practice >20 years) 
were significantly less likely than more recently qualified GPs “to rate pressure to prescribe 
from aged care facility staff as a barrier” 155 to recommending non-pharmacological 
strategies.  
In a nursing home context, although a GP can recommend non-pharmacological strategies 
their implementation typically falls to nursing home staff not to the GP. Two of the studies 
reported that chronic understaffing of nursing homes 155,283 acted as a barrier to the GP 
recommending non-pharmacological strategy. An additional factor that hindered the 
implementation of non-pharmacological strategies in nursing home settings was the lack of 
shared perspectives 153,155,283 between GPs and nursing home staff. For example, one study 
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identified a “culture of blaming”, reporting that GP felt under pressure from nursing home 
staff to prescribe, while nursing home staff reported that it was the GPs that insisted on 
pharmacological treatment 153. A final barrier to the implementation of non-
pharmacological strategies was that, in the context of “healthcare budgets and resource 
constraints” 153, guidelines on non-pharmacological management strategies were perceived 
to be impractical 152 153. 
 
Traditional prescribing role 
In some studies 152,278,280,281 it was suggested that GPs were more comfortable with their 
role as prescribers of medications and less comfortable “with the more alien non-
pharmacological methods” 152. In several earlier studies GPs reported a preference for 
“medication as the primary intervention” 280 and were found to be “ wedded to a traditional 
medical model of care” 281. In more recent studies 152,278 the value of non-pharmacological 
management strategies was increasingly recognised. However, some participating GPs were 
still reluctant to reduce their prescribing 278. Although accepting the important role of non-
pharmacological management “this belief was not put into clinical practice” 152. A GP in one 
study felt that antipsychotics were sometimes the “easy option, because it’s something as 
doctors we do, we just prescribe medications” 278.  
 
3. Pivotal Role of Families 
Influence of family 
The critical role played by family members in the management of BPSD was highlighted by 
several studies that explored GPs’ experiences of managing BPSD in the community setting 
141 
 
243,279,280,284. GPs’ management of the person with BPSD was influenced by the family 
152,280,284 who “contributed to making treatment processes either more difficult or more 
straightforward” 284. The impact of pressure from families was discussed in 3 studies 
152,280,284. These studies described  “repeated phone calls” from family members 280 or a 
mismatch of expectations of the family and the capabilities of the GP: “resistant children … 
who promised they’d never put mom in a nursing home, but they don’t want to take her… so 
we try to hire someone, which is virtually impossible” 284. There was some evidence of GPs 
deflecting responsibility for the management of BPSD back to the family; “usually, the family 
deals with it [BPSD]” 243. However, the important role a GP plays in supporting carers was 
emphasised by GPs in several studies 243,279,284; “one of the big learnings I’ve had is … how 
important carer support is” 279. Studies that focused on the management of BPSD in nursing 
home settings found family members were less influential on prescribing 155. 
 
Community based supports for family caregivers 
GPs highlighted the importance of access to community supports for family caregivers 
243,279,284; “I think you live on this lifeline of getting this respite and that helps you to cope as 
a carer” 279. However, accessing these supports was challenging for GPs.  Supports 
sometimes weren’t there; “we don’t have much in the way of support groups ... we are in a 
no man’s land” 284; or the GP didn’t know how to access the supports; “I myself wouldn’t be 
able to provide the specifics of it” 279; or the GP felt that providing information on these 
supports was beyond their professional remit and capabilities; “since I’m not a licensed 




Impact of context on findings 
Some studies focused on a subset of a GP’s professional responsibility for people with 
dementia. Three of the studies focused on GPs who cared for people with dementia in a 
nursing home setting and excluded those managing dementia in the community 155,278,283.  
Four of the studies in the review focused on a singular aspect of the management of BPSD; 
antipsychotic prescribing 153,155,278,283 and were conducted by pharmacists or 
pharmacologists 155,278,283. The authors of the remaining eight studies were from other 
disciplines including psychiatry, nursing and general practice. They adopted a more holistic 
approach to discussing the assessment and management of BPSD.  Of note, only one study 
was authored by a GP 279. Five of the eleven studies included in this review were from the 
U.S. 243,280-282,284 from which the sub-theme on ‘time’ emerged. This may be influenced by 
factors specific to the healthcare system in the U.S.  
The studies spanned 22 years (1995 to 2017). Over this time there have been substantial 
changes to recommendations regarding the management of BPSD. Earlier studies described 
how antipsychotics “may be the best available option for physicians” 280. However, as the 
evidence for the harmful effects of using antipsychotic medications in people with dementia 
emerged 160,196 there has been a distinct shift. The use of antipsychotics became less 
acceptable: “antipsychotics should not be prescribed to reduce stress in carers…” 278. The 
studies in this review highlight the journey the management of BPSD has travelled over the 
past two decades - from ‘what is the right psychotropic to use?’; to ‘should we be using 
psychotropic medication?’; to ‘stop using psychotropic medication’. A parallel journey 





Six third –order interpretations were iteratively developed by synthesising the first and 
second order interpretations.  The third order interpretations and their associated CERQual 
confidence levels are shown in Table 7 and further expanded in appendix 1, supplementary 
material 9.  These third order interpretations were synthesised into a ‘line of argument’ 




















Table 7. Summary of CERQual Assessment 






Explanation of CERQual assessment 
Unmet primary care needs    
1. Managing BPSD was complex, resource intensive and 
sometimes unrewarding for the GP.  
243,284 Low confidence Substantial concerns regarding 
adequacy and minor concerns 
regarding methodological limitations 
and relevance. 
2. GPs lacked confidence when managing BPSD and wanted 
input from either secondary care or relevant members of 
the primary care team. However, the lack of clearly defined 
care pathways meant that GPs experienced difficulty 
accessing advice.  
152,153,243,279,284 High confidence Minor concerns regarding 
methodological limitations and 
adequacy. 
Justification of antipsychotic prescribing    
1. GPs were more comfortable prescribing medication than 




Moderate concerns regarding the 
adequacy of the data and 
methodological limitations. Minor 
concerns about the relevance of the 
studies. 
2. GPs found that antipsychotics enabled the person with 
dementia, the family caregiver, the nursing home staff and 
the GPs themselves to cope with BPSD.  
153,155,278,283 High confidence Minor concerns regarding 
methodological limitations, 
relevance and adequacy. 
 
3. GPs had a tendency to over-estimate the benefits of 
antipsychotic prescribing. Consequently, in the context of 
the challenges of implementing non-pharmacological 
alternatives, the risks associated with antipsychotics were 
tolerated.  
 
153,155,283 Low confidence Substantial concerns regarding 
adequacy and minor concerns 
regarding methodological 










Explanation of CERQual assessment 
Pivotal role of family    
1. The family of the person with dementia plays a crucial role 
in the management of BPSD. However, the needs of the 
carer could be intensive and challenging for the GP, 
particularly in the context of limited community supports for 
family caregivers.  
243,279,284 Moderate 
confidence 
Minor concerns about 
methodological limitations, 
relevance. Moderate concerns 
regarding data adequacy 
 
 
Table 8. Line of Argument 
Line of argument 
synthesis: 
GPs experience difficulties accessing supports for family caregivers and for themselves when managing 
BPSD. Under-resourcing, poorly defined roles and a lack of integrated care pathways may contribute to GPs’ 
feelings of isolation and low self-efficacy when managing BPSD. Low self-efficacy is further exacerbated 
by the lack of practical, implementable non-pharmacological treatment strategies which can lead to an 
over-reliance on both family care-givers and psychotropic medications to fill the therapeutic void created.  It 
appears that these conditions can culminate in a reactive response to the care of people with BPSD where 














This is first review to systematically review and synthesise the literature on GPs’ knowledge, 
attitudes and experiences of managing BPSD. A wide range of issues were identified 
including the knowledge and resource needs of GPs, the reliance on antipsychotic 
medications and the influential role of the family. These are areas that could be targeted to 
improve the management of this challenging aspect of dementia care.  
Comparison with previous research 
In this review GPs were found to have a low sense of self-efficacy when managing BPSD. A 
systematic review on the barriers to diagnosing and managing dementia in general practice 
identified that GPs’ limited knowledge about dementia can act as a barrier to the provision 
of optimum care to people with dementia 72. A previous quantitative study of GPs 
knowledge of and attitude towards dementia found that the vast majority of respondents 
lacked confidence in the management of BPSD, prompting the authors to recommend that 
future educational support should focus on BPSD 198.  While educational interventions are a 
reasonable and important focus 133, it is likely that GPs’ low sense of self-efficacy stems from 
more than a lack of knowledge of BPSD. GPs can find managing dementia stressful 285. The 
resource-intensive nature of managing BPSD coupled with the lack of clearly defined 
pathways of care will impact on a GPs sense of self-efficacy when managing such a complex 
clinical condition. Previous systematic reviews have identified that to effectively change 
GPs’ behaviour in dementia care education alone is not sufficient; education needs to be 
combined with service innovation ideally in the form of organisational incentives 286,287.  





efficacy, GPs also need to be supported by clear pathways of care and appropriate 
resourcing.  
Antipsychotics were considered to be justifiable in the context of need. They were perceived 
to improve the quality of life of people with BPSD and enabled everyone, including the GP, 
to cope with the constraints imposed by insufficient resources. A recent systematic review 
examined the influences of decision-making on antipsychotic prescribing in nursing home 
residents and found that to circumvent the problems of inadequate resourcing 
antipsychotics were ‘employed’ as cheap and effective staff members 3. In this current 
review the benefits of antipsychotics were often over-estimated and their potential harmful 
side-effects were sometimes overlooked because these side effects were perceived to relate 
to longevity of life rather than quality of life. Similarly, the systematic review on prescribing 
influences in nursing home residents found that inadequate knowledge of the risks and 
benefits of antipsychotic prescribing in dementia enabled inappropriate prescribing 3. 
However, the benefit of antipsychotics in BPSD is minimal 160 and many of the side effects, 
such as extrapyramidal symptoms and sedation, occur in the short term. GPs’ concern that 
discontinuation of antipsychotics will lead to a re-emergence of BPSD is also challenged by 
current evidence that suggests, for most people with Alzheimer’s type dementia, 
antipsychotic discontinuation has no detrimental effect on cognition or functional status 288. 
The care provided to the person with BPSD in the community hinged on the positive 
involvement of family care-givers. A recent mixed methods systematic review of the 
challenges BPSD creates for carers highlighted the importance of acknowledging the unmet 
psychological needs of carers 120. The reliance on family caregivers, in the context of 





further impact on carers’ unmet psychological needs. Discussions on non-pharmacological 
strategies to manage BPSD often focus on a nursing home setting. However, BPSD is not 
limited to nursing home settings. Recent research has found that family carers observed 
significant levels of agitated behaviour, behaviour that they felt unprepared for as they were 
unaware that agitation could occur as part of dementia 121. Carers value a proactive 
approach to dementia care from GPs 289.  Therefore, a more proactive initial discussion with 
family care-givers on BPSD, combined with regular screening questions as part of dementia 
reviews in general practice, could help to address how unprepared carers feel when faced 
with managing BPSD at home.   
Implications 
Our review highlights the complexity of managing BPSD and how, in the face of this 
complexity, the care provided to people with dementia is often reactive. This raises the 
question; what does proactive care look like and how can this be delivered by GPs? 
Particularly in the face of the challenges posed by resource limitations, low self-efficacy and 
uncertainty regarding roles and responsibilities. We acknowledge that in clinical practice 
pro-active management of BPSD can be complicated. Firstly, a prerequisite of any open, 
honest discussion on BPSD is that the person’s dementia has been diagnosed and fully 
disclosed. However, we know that the diagnostic rates of dementia, although improving 227, 
are low 290. Furthermore, although the majority of people with dementia wish to know the 
diagnosis 291 GPs can be reluctant to fully disclose it 87,292,293. Secondly, GPs may be reluctant 
to initiate a conversation about BPSD unless they feel comfortable giving practical advice to 
family caregivers on managing BPSD, something many GPs struggle with 87,294,295. A final 





unwillingness on the part of family-members, and sometimes the person with dementia, to 
confront the unpleasant realities of cognitive decline.  
This review identifies a number of potential targets for interventions to improve the 
management of BPSD in general practice. There is a clear need for interventions that 
address GPs’ reliance on psychotropic medications to manage BPSD and GPs’ reluctance to 
discontinue these medications. Other relevant areas to address include the lack of resources 
in the nursing home setting, the lack of clarity regarding roles and responsibilities of 
different healthcare professionals and the limited availability of community based supports 
for family caregivers. The challenge is how to implement effective interventions in the 
context of resource limitations, pressure to prescribe medications and a lack of clearly 
defined care pathways that interface appropriately with secondary care and allied health 
care professionals in the community. Existing interventions aimed at improving the 
management of dementia care in general practice have focused on educational initiatives 
133,286,287,296 . However, we know that educational interventions alone have limited effect 
when attempting to change GP practice in dementia care 286,287.To improve dementia care 
educational interventions in general practice should be combined with service innovations 
such as dementia case managers 287 and supported by resources like decision support 
software 297 . 
From the findings of this review inappropriate antipsychotic prescribing appears to be a 
relevant and worthwhile behaviour to target.  However, in addition to any educational 
component, an intervention aimed at improving appropriate prescribing of antipsychotics in 
dementia needs to be supported by practical resources that enable GPs to implement best 





potential for biannual, structured, multi-disciplinary medication reviews to improve 
appropriate prescribing of psychotropic medications in nursing home patients with 
dementia 298. Although psychotropic medication reviews may occur in nursing homes, if 
implemented they are often performed in an ad-hoc manner without adequate resources 
and usually without multi-disciplinary input.  
Medication reviews can reduce inappropriate antipsychotic prescribing in dementia 210. 
However, to effectively improve the quality of life of a person with dementia, strategies that 
aim to reduce antipsychotic prescribing, such as medication reviews, need to be combined 
with evidence-based non-pharmacological interventions 212. A systematic review of the 
effectiveness of interventions to reduce inappropriate prescribing of antipsychotic 
medications in people with dementia living in residential care settings identified that, for 
long-term reduction in antipsychotic prescribing, interventions needed to address cultural 
issues and the poor availability of non-drug alternatives to antipsychotics 201.  It is clear that 
if an intervention is to achieve a long-term reduction in psychotropic prescribing in 
dementia it must provide options for practical, implementable, non-resource intensive 
approaches to non-pharmacological strategies.  
 
Strengths & Limitations 
One of the strengths of this review is the rigorous approach employed. Each stage of the 
review process involved at least two authors working independently. The synthesis of 
qualitative and quantitative studies has led to a more substantive interpretation of the 
research phenomenon than is available from a single study. Adding to, rather than 





mechanistic. Indeed there is the risk with meta-ethnography that the richness or integrity of 
the original work will be lost 250, a concern that, by overly deconstructing the original 
qualitative work, the researcher attempts to “sum up a poem” 251. Efforts were made to 
retain the content and context of the original studies throughout the data extraction and 
analysis.  Three members of the review team are practising GPs (AJ, TF, CB), however, the 
multidisciplinary nature of the review team which included a pharmacist (KW), a public 
health researcher (JB) and a nurse (AC) helped to reduce the potential for professional 
biases. 
The review did not include a search of the grey literature. Since our search of the electronic 
databases was extensive we felt that the grey literature was unlikely to result in any 
additional insights. A number of the studies included in the review focused on a singular 
aspect of BPSD management; antipsychotic prescribing in a nursing home setting. Hence, 
issues relating to antipsychotics may be over-represented in this review. Although 
integrated reviews of qualitative and quantitative research is still a relatively novel approach 
it has been used effectively in previous mixed method systematic reviews of similar research 
questions 120,248. It has enabled the integration of the quantitative assessments of GPs’ 
knowledge of and attitudes towards BPSD with a more qualitative understanding of GPs’ 
experiences of BPSD, enhancing the review’s utility and impact.  
The focus of this review is on GPs who manage people with dementia living at home and 
who may also provide care to people with dementia in nursing homes. Other models of 
care, such as that in The Netherlands where specially trained elderly care physicians provide 





reassuring to find that many of the findings from studies conducted with physicians working 
in the Dutch model of nursing home care concurred with our review findings 154,299,300.  
To our knowledge this is the first time the CERQual tool has been used to assess the 
confidence of findings of a mixed methods systematic review of this kind. However, there 
are limitations to applying the CERQual tool in this instance. In particular, the inherent 
‘thinness’ of the data from the quantitative studies raised concerns when judging the 
adequacy of the data. Nonetheless, the novel application of the CERQual tool to our review 
findings does provide a useful indication of the confidence we have in the study findings. 
5.2.6 CONCLUSION 
This review offers new insights into GPs’ perspectives on the management of BPSD and 
highlights the limited research in this area.  Most of the research on dementia care in 
general practice appears to have focused on diagnosis rather than the long term 
management of the person with dementia. We need to explore the challenges of managing 
BPSD in general practice, not at the expense of research on diagnostic challenges, but at 
least with the same degree of depth. Targeted interventions that are supported by 
appropriate resourcing could make the provision of high-quality, personalised care to 
people with BPSD achievable in a primary care setting. This review will help to inform the 
design and development of interventions to support GPs managing BPSD which should 
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Background: General practitioners (GPs) have identified the management of behavioural 
and psychological symptoms of dementia (BPSD) as a particularly challenging aspect of 
dementia care. However, there is a paucity of research on why GPs find BPSD challenging 
and how this influences the care they offer to their patients with dementia. 
Objectives: To establish the challenges GPs experience when managing BPSD; to explore 
how these challenges influence GPs’ management decisions; and to identify strategies for 
overcoming these challenges. 
Design: Qualitative study of GPs’ experiences of the challenges of managing BPSD. 
Methods: Semi-structured interviews were conducted with 16 GPs in the Republic of 
Ireland. GPs were purposively recruited to include participants with differing levels of 
experience caring for people with BPSD in nursing homes and in community settings to 
provide maximum diversity of views. Interviews were analysed thematically.  
Results: Three main challenges of managing BPSD were identified; lack of clinical guidance, 
stretched resources and difficulties managing expectations. The difficulties of accessing 
clinical guidance negatively impacted on GPs’ confidence when managing BPSD. 
Additionally, in the absence of appropriate resources GPs felt reliant upon sedative 
medications. GPs believed their advocacy role was further compromised by the difficulties 
they experienced managing expectations of family caregivers and nursing home staff.  
Conclusions: This study helps to explain the apparent discrepancy between best practice 
recommendations in BPSD and real-life practice. It will be used to inform the design of an 






Behavioural and psychological symptoms of dementia (BPSD) is a term that encompasses a 
wide range of behaviours and symptoms that affect the majority of people with dementia at 
some point in their illness 92. BPSD includes behaviours and symptoms such as agitation, 
aggression, wandering, depression and sleep disturbance. The presence of BPSD results in 
an increased risk of admission to long term care facilities 128, longer in-patient hospital stays 
113 and is a major contributor to caregiver stress and depression, even more significant than 
cognitive decline 116.  
The management of BPSD is complex as there are many contributing factors including 
unmet care needs, underlying acute medical conditions and environmental triggers 108.  In 
addition to the complexities in assessment, effective treatments are limited. Best practice 
recommendations encourage the use of individualised non-pharmacological management 
strategies such as music therapy 241, however, these are often difficult to translate into 
implementable management strategies. Psychotropic medications continue to be used to 
manage BPSD in both residential and community settings 156,197, despite their well-known 
risk to people with dementia 159,160 and calls for action to reduce antipsychotic prescribing 
196. 
General Practitioners (GPs) play a pivotal role in managing BPSD, however, previous 
quantitative research has found they lack confidence in this area 80,152,301. In one survey 
most GPs acknowledged the importance of non-pharmacological approaches to managing 
BPSD, however, they found non-pharmacological difficult to implement in practice and 
reported using pharmacological management strategies instead 152. Furthermore, practice 





interdisciplinary teams can act as barriers to GPs caring for people with BPSD 243.  
Interventions are needed to support GPs in their management of BPSD. However, we are 
unaware of any such interventions. Recent research has identified education in BPSD as a 
priority for GPs 279 but we do not have a good understanding of how GPs currently manage 
BPSD and the root causes of their lack of confidence. An important first step in intervention 
design is to establish a thorough understanding of existing behaviour 239,242. However, GPs’ 
experiences of managing BPSD have not been previously researched. The aim of this study is 
to identify the challenges GPs experience when managing people with BPSD and to explore 
how these challenges influence their management decisions. Potential strategies that GPs 
use to overcome these challenges will also be identified. The findings of this study will be 




Semi-structured interviews were conducted with GPs to explore the challenges they 
experience managing BPSD. Ethical approval was granted by the Social Research Ethics 
Committee in University College Cork (2016-098).  
Sampling and recruitment 
Given the high prevalence of BPSD in residential care settings 302  initial sampling focused on 
GPs with a nursing home commitment. Twenty-three nursing homes in the southern region 
of the Republic of Ireland were contacted and the GP who attended the nursing home was 





differing practice locations (urban/rural), years in practice and dementia workload with the 
goal of achieving maximum variation. The recruitment process occurred concurrently with, 
and in response to, the data analysis. During the analysis process it was identified that GPs 
with no nursing home commitment may have different experiences of managing BPSD, 
consequently, these GPs were also invited to participate. Using the same criteria as above 
this sample of GPs was purposively recruited by identifying GPs in a national medical 
directory.  
GPs were contacted by letter and invited to participate. One week later the GPs were 
contacted by telephone. If they agreed to participate an information sheet was forwarded 
and an interview was scheduled. Criteria for reporting qualitative research as described in 
the COREQ guidance were followed 303. 
Semi-structured interview process 
The interviews were conducted in the GP’s surgery or in an office in University College Cork 
between October 2016 and April 2017. The lead author (AJ), a GP with an interest in 
dementia, conducted all of the interviews. There was one telephone interview. Written 
informed consent was obtained prior to each interview.  All of the interviews, bar one, were 
audio-recorded and transcribed verbatim. The one interview that was not recorded, at the 
request of the participating GP, was typed up from field notes. The lead author (AJ) de-
identified the transcripts and assigned the transcripts anonymised codes (e.g. GP01) to 
protect the identity of the participants. Furthermore, to ensure confidentiality identifiable 
information was removed from the quotes selected. NVivo 11 software was used to manage 
the data. The topic guide was informed by a literature review of GPs’ knowledge of and 





all of whom are practising GPs. The literature review identified issues such as self-
confidence which were used as prompts during the interview. The topic guide was 
iteratively developed through a process of consensus with the multidisciplinary research 
team which included expertise in general practice (AJ, TF, CB), dementia in primary care (TF, 
AJ), public health and health services research (JB, SMcH). The topic guide was then piloted 
with a convenience sample of two GPs. Minor amendments were made to the script sheet 
and use of probes as a result of this piloting. (The topic guide is available in appendix 2, 
supplementary material 10). Throughout the interviews participants were encouraged to 
discuss their own clinical cases. 
Analysis 
Data analysis followed the principles of thematic analysis as outlined by Braun & Clarke 101. 
Data analysis was performed concurrently with data collection, allowing emerging themes 
to be further explored in subsequent interviews. An extensive familiarisation process was 
conducted by two researchers (AJ, TF) who read and re-read all transcripts. The lead author 
(AJ) open-coded all the transcripts. The second researcher (TF) independently open coded a 
subset of the interviews (>50% of the transcripts) that were purposively selected to ensure a 
wide range of years of experience and dementia workload. Regular meetings were held 
throughout the interview process to discuss emerging themes and to examine convergence 
and divergence of the researchers’ findings. Any uncertainties were discussed with a third 
researcher (SMcH) who also independently coded two interviews that were purposively 








Twenty-four GPs were invited to participate in a semi-structured interview, sixteen of whom 
agreed to participate. The reason for non-participation was documented where possible; 
the main reason given for non-participation was lack of time. The characteristics of 
participants are shown in Table 9. Overall, conceptual data saturation was reached after 
thirteen interviews. After this three more interviews were conducted during which no new 
data emerged, confirming data saturation 304. Interviews were, on average, 37 minutes in 
duration (range 20 to 63 minutes).  
Table 9. Characteristics of GPs who participated in the interviews  
 Participants, n (%) 
Length Qualified  
<10 years   4 (25) 
10-19 years   7 (44) 
>20 years   5 (31) 
Nursing Home Commitment  
Attends Weekly   8 (50) 
Attends Monthly   3 (19) 
No formal Nursing Home commitment   5 (31) 
Practice Location  
Urban   6 (37) 
Rural   3 (19) 
Mixed   7 (44) 
Type of Practice  
Small (1 – 3 GPs)   7 (44) 
Large (>3 GPs)   9  (56) 
Sex  
Male   8  (50) 







GPs’ experiences of managing dementia 
The complexity of dementia care was highlighted by many of the participants. Overall their 
attitude to dementia care, and in particular, BPSD, was pessimistic. It was perceived by 
many to be an ‘an unsolvable problem’. 
 “I think, what is the answer to really challenging behaviour associated with dementia 
in the community? That’s not just something that I am missing, it is something that 
we are all missing in this society” GP_02 
Nearly all the participants struggled at a professional, and sometimes at a personal level, 
with what they saw as the limited treatment options available. Rather than deciding on the 
‘best’ treatment option, they felt they were merely making a decision on whether or not to 
sedate. 
“It is awful to watch somebody who has dementia and it seems to be awful to 
experience dementia so the temptation is to just sedate people through that process 
and it is hard to decide. When you step back and think about that it seems awful that 
you just sedate them through this end part of their lives.” GP_05 
In the context of this experience three main challenges of managing BPSD were identified.  
1. Lack of clinical guidance  
2. Stretched resources  
3. Conflicting expectations 
The impact of each challenge on the GP’s management decision was identified. Factors 
identified by GPs as helpful in overcoming the challenges of managing BPSD were also 





Table 10. The challenges of BPSD, how they impact on the GP’s decision making and what factors 
help GPs to overcome these challenges 
        
          Challenge  
 
Impact of Challenge on 
Management of BPSD 
  
Factors that helped overcome 
this challenge 
 
Lack of Clinical Guidance 
- Guidelines 






Experience of managing BPSD 
Ability to utilise personal 









Relationships with community 






- Nursing Staff 
 




Having family on-board 
Continuity of care leading to 







Challenges of managing BPSD 
Lack of clinical guidance 
Assessment and management of BPSD was seen as a clinically complex area. The lack of 
clinical guidance, both in terms of GP-specific guidelines and access to clinical advice, was 
identified as a challenge. Thus, the management of behavioural and psychological 
symptoms was seen as a ‘grey area’.  
In the absence of what the GPs considered to be implementable guidelines for the 
management of BPSD they felt they were often making decisions in a vacuum. While 
accepting that the evidence for the various pharmacological options was limited, 
participants wanted clarity on what medications were appropriate or not. 
 “I think there is probably no magic solution to this but I think a clear algorithm of 
medications that are appropriate [is needed]. I think [it] would be the most practical 
thing… maybe they do not have a massive amounts of evidence but GPs, they would 
feel they need something in their armoury. ” GP_05 
The lack of available guidelines, in particular pharmacological guidelines, meant that 
prescribing decisions were primarily informed by the GPs own personal beliefs about the 
drug. These beliefs were shaped by their previous experience of prescribing the drug. 
Experience was often viewed as being superior to knowledge acquired through formal 
learning.  
“In my experience I have learned on the job, it’s not that I do extensive reading, it’s 
not that I go to a lot of meetings… It’s very easy for me because it’s intuitive – I do it 






In addition to professional experience, personal experience of having a family member with 
dementia was identified by several GPs as being a very valuable source of knowledge.  
While many participants found the lack of guidelines challenging, others seemed quite 
content to base their decisions on their own experience rather than evidence and felt this 
was an inevitable part of general practice. 
“A lot of what we do on a day-to-day basis isn’t written in any journal, you know, 
while you try to be evidence based, a lot of it is from experience.” GP_10 
 
Although most participants wanted guidelines in BPSD, some participants argued that 
having a guideline in this area may not be appropriate. As they saw it, there was no ‘one-
size fits all’ solution to the problem. 
 
 “I just think that it is such a variable - like hypertension is hypertension and 
hypertension it isn’t really, you know. I think the problem with dementia is that it 
affects everybody completely differently.” GP_15 
As well as prescribing dilemmas participants frequently spoke about the difficulties 
associated with assessing for potentially reversible causes of BPSD, such as pain. Several 
participants wanted clinical guidance on how to better assess for alternative causes of these 
behaviours. 
In addition to lack of guidelines many participants also experienced difficulty accessing 
clinical advice from secondary care. Some participants were uncertain about what service to 





 “[If] you need to talk to someone about a chest pain well you clearly know who to go 
to whereas it is not as clear here I think.” GP_01 
There were some suggestions that the lack of a GP expert in the area of dementia meant 
that they lacked the support of a colleague with a special interest in the area. As a result, 
although colleagues were mentioned as important sources of emotional support, other GPs 
were not usually considered as sources of clinical support.  
Some participants described how they relied on personal contacts to access advice and 
reassurance from secondary care colleagues.  
“You know, when you just want to ask a simple straight forward question but it isn’t 
easy to access people, you know... I probably call in favours…” GP_10 [GP with no 
nursing home commitment] 
This view was usually expressed by GPs who had no nursing home commitment. In contrast, 
where the participating GP had a nursing home commitment there was often an established 
relationship with either a geriatrician, or old age psychiatrist who attended that nursing 
home. This relationship gave GPs what they sought most from consultant colleagues- 
reassurance. 
 “Neither of them mind me calling them directly on their mobiles, they are very very 
accessible… just the reassurance that you are probably doing things okay, you know.” 
GP_09 [GP who attends several nursing homes] 
 





The participants who had significant experience of managing dementia and who were 
supported by access to consultant advice appeared to have more confidence in managing 
BPSD.  This confidence influenced their management, making them more willing to engage 
in trial prescribing, more cognisant of avoiding crisis presentations and more aware of their 
own limits. 
“What I’ve learnt, that lingo from the psychogeriatricians, is that you ‘give it as a 
trial’ and sometimes it’s absolutely bingo and sometimes it bounces off and you 
move off it pretty quickly and try the next one.“ GP_04 [GP with large nursing home 
commitment] 
However, this confidence did not seem to extend to non-pharmacological management 
strategies. Even the GPs with extensive professional dementia experience often lacked 
confidence in recommending non-pharmacological strategies to family carers. Some 
participants either underestimated, or were unaware of, advice that they could provide to 
families of people living with dementia in the community. Other GPs did not think it was 
their role to give advice on non-pharmacological strategies. They felt they lacked the time 
and the skills to do this. However, the majority felt that it was their role to refer a patient to 
the relevant person who could provide this advice. 
 
“I mightn’t have the skills myself but I would be able to refer them to people who 
would have the skills.” GP_15 
In general, GPs who had personal experience of dementia strongly advocated for non-





They had little faith in the role of medications for BPSD beyond its role to sedate. They 
actively sought to identify and manage carer burden. 
“Putting signs up everywhere and all these small things that actually to people who 
are living it day to day probably make a big difference…. I don't personally think this 
is a problem that is going to be solved by medication.  This patient has dementia. This 
is part of the illness. Unless you just sedate them all to the point where they are 
sitting asleep all day – which with having a Dad with dementia you would sometimes 
have to wonder would that just be easier.” GP_05 
 











Stretched Resources  
Participants found it difficult to recommend non-pharmacological strategies when the 
appropriate resources were not in place to support these strategies.  
“You would like to be able to say ‘I think this patient will benefit from art or music 
therapy’. You can suggest those but it might be easier to see those happen if there 
was a primary care element that was providing them.” GP_05 
In particular, the absence of sufficient community-based resources, such as adequate home-
help hours, were frequently mentioned as a barrier to providing optimal care in the 
community.  
 “There isn’t enough home help anyway … If he had more support at home he could 
stay at home and he would love to stay at home but he can't.” GP_14  
Resources available depended upon whether the GP was supported by a fully-functioning 
primary care team and on the extent of voluntary support agencies in the area. Availability 
of resources was not related to the size or setting of the GP practice. Participants felt the 
challenge presented by the inadequacy of resources was outside of their control, describing 
how this challenge stemmed from government policy or from nursing home management 
decisions. Good working relationships with allied health care professionals helped 
participants to overcome this challenge. However, several participants reiterated that, 






Resource limitations in nursing homes also impacted on GPs’ decision making as it reduced 
their management choices. For example, several participants reported that low staffing 
levels acted as a barrier to recommending labour-intensive non-pharmacological strategies. 
 “To be honest it is kind of awkward because I am not going to be the one doing the 
work and I am asking people who are working very hard and are very stretched.” 
GP_03 
Many participants described being unable to access resource-intensive management 
strategies, such as one-to-one nursing care, when needed. This, in turn, resulted in 
increased prescribing of sedative medication. 
 “The only thing that would work is if somebody stayed talking to her continuously. 
Which wasn’t practical so we tried every pharmacological intervention that was 
possible. Eventually she got the ultimate cure, a PE [pulmonary embolism] which 
was, unfortunately, I think the only thing that gave her relief.”  GP_13 
 
Conflicting expectations 
Tension arose when the family had expectations, deemed unreasonable by the GP, of what 
the GP could do to improve these behaviours.  
 “It's their children that are very difficult, you know, very demanding, expecting us to 
provide a lot of stuff that we just can’t.” GP_14 
The expectations of the family at times influenced the GP’s decision to prescribe. 
 “I feel you are just prescribing things to keep the family happy because they are at 





Having the family ‘on-board’ with the management plan helped GPs overcome this 
challenge. While different strategies were employed to engage families, most focused on 
improving communication with family members. 
 “So I don’t interact with them on the phone now anymore. I need to see them in front 
of me because I need to get a better feel for what they understand that I am trying to 
do, or not trying to do.” GP_15 
Managing the expectations of nursing home staff was also identified by many participants as 
a challenge. Some participants described how they struggled to maintain their advocacy role 
for their patients in a nursing home setting.  
 
 “From a nursing home point of view patients that sleep through the night are the 
easiest patients to manage… and I think that if patients want to be night owls and 
stay up late and sleep in that they should be allowed to do that, if that is their own 
natural way.” GP_03 
As a result of these conflicting priorities many GPs described feeling pressurised to prescribe 
sedative medication. Poor pathways of communication between the general practitioner 
and the nursing staff further exacerbated the conflict caused by these competing priorities. 
“… but the Matron is standing over you saying chart it down PRN [as required] and 
you are saying ‘well are they constipated’? ‘I don’t know, well we have to have to go 
and ask Mary. Jane will you go and find Mary to ask her.’ And then she would say ‘oh 
I wasn't looking after her last night’ and twenty minutes later you’re like ‘oh God 





In situations where there was a long-standing relationship of trust between the nursing 
home staff and the GP their priorities were more aligned and there was consequently less 
pressure.  Consistency of care was considered an important factor to building this 
relationship of trust. Structured visits were seen to facilitate the provision of continuity of 
care and led to good communication channels between the GP and nurses.  
 “I listen to them because I trust them. I trust the nursing staff.” GP_11 
In addition to the expectation of family members and staff in nursing homes, two 
participants commented on how they felt an expectation from consultant colleagues to 
follow advice given. They described feeling “compelled” to follow advice even if it conflicted 
with their own views on what was best for the patient.  
 “If you ask for a review and you are given a review and someone has prescribed 
something. You feel compelled to go with that then. You know… it is very hard to call 
them back a second time if you don’t take their opinion on the first occasion.” GP_12 
However, this view was not held by the majority of participants who felt that consultant 
colleagues valued their opinion.  
 
6.5 DISCUSSION 
The lack of optimism towards the management of BPSD was pervasive. The challenges 
associated with BPSD were viewed by some participants as insurmountable and outside of 
the GP’s control. Many participating GPs struggled at an ethical level with the decision to 
prescribe potentially harmful sedative medication but felt they had little else to offer. 





patient was often compromised. What was best for the person with dementia was 
complicated by competing expectations of family caregivers and the conflicting priorities of 
nursing home staff.  In the absence of appropriate resources for non-pharmacological 
strategies and in the face of such pressure, GPs felt they had no viable alternatives to 
sedative medications. In addition to prescribing pressures and resource constraints, GPs 
were further challenged by the lack of appropriate clinical guidance in the area.  
The GP’s own experience with a drug emerged as the critical factor that influenced their 
prescribing decisions. In general practice the practitioner’s previous experience with the 
drug plays an important role in prescribing decisions 305. It is possible that the lone-working 
nature of general practice means that GPs are more likely to rely on and trust their own 
experiences. However, previous qualitative research that explored old age psychiatrists’ 
prescribing decisions in BPSD also found that in most cases choice of medication was based 
on familiarity and past experience with a drug 273.  This suggests that, in BPSD, the 
importance of previous experience with a drug when making prescribing decisions might be 
a reflection of the lack of robust evidence for prescribing in this area rather than particular 
professional characteristics. In our study GPs’ experience of managing BPSD increased their 
knowledge which subsequently led to greater confidence (see Figure 11). This study builds 
on existing literature that demonstrated that GPs lack confidence in managing BPSD 80,152,301 
and extends our understanding by explaining the factors that affect GPs confidence - namely 
experience and access to clinical guidance. This study goes further by exploring the impact 
that this confidence has on their management of BPSD. Confidence allowed GPs to engage 
in trial prescribing, gave them an awareness of their own limits and enhanced their ability to 





confidence in dementia care has the potential to positively influence practitioner behaviour 
306.  
GPs reported that the paucity of resources made the implementation of non-
pharmacological strategies unfeasible and increased the prescribing of sedative medication. 
This is supported by previous research that has identified the challenge resource constraints 
creates for GPs managing BPSD 243 and research that has recognised the influence of 
resource inadequacies on GPs’ prescribing of antipsychotics in dementia 153. Resource 
constraints clearly act as a barrier to non-pharmacological strategies.  However, in our study 
there was also evidence of a lack of ownership of non-pharmacological strategies by GPs. 
Whether this role should fall to GPs or is more appropriately led by community based 
occupational therapists or psychologists who have been trained in this field is debatable, but 
in the absence of these resources it does inevitably fall to the GP.  
Many participants highlighted the important role of the family caregiver and found 
managing expectations of family, to be very challenging. However, the GPs expectations of 
family involvement could be, in itself, an unreasonable expectation. In the context of 
inadequate resources, it is possible that a reasonable request for support from a family 
member was seen by the resource-poor GP as being an unrealistic expectation. From a 
nursing home perspective the existence of a good working relationship with nursing home 
staff helped GPs to manage conflicting priorities. This finding supports research which has 
shown the importance of good relationships between staff when managing people with 
dementia in a nursing home 307. Our study further identified that continuity of care, which 






The common thread throughout was the challenge posed by insufficient resources. Difficulty 
accessing advice from secondary care colleagues probably stems from an inadequately 
resourced service. Inability to meet expectations of family caregivers is influenced by the 
lack of community based services and supports. The pressure from nursing home staff is 
related, at least in part, to understaffing and what is often an unsuitable environment.  
 
Strengths and Limitations 
The systematic sampling process and the discussion of clinical cases in the interviews, 
allowed in-depth access to information-rich, real-life cases of BPSD and its management.  
Concepts emerging in the analysis were brought forward to subsequent interviews and the 
extent to which emerging themes resonated with the experience of participants was 
assessed, improving the credibility of the research. The use of analyst triangulation helped 
to increase the confirmability of the findings. The interviewer was a GP. We believe that 
having a GP interviewer facilitated recruitment and encouraged GPs to participate in the 
study.  Clinician researchers interviewing other clinicians has the potential to introduce bias 
as the interviewee might see the clinician researcher as an expert who will judge both their 
clinical and moral decision making 308. However, it is also acknowledged that when 
participants in interviews recognise the researcher as a clinician the interviews tend to 
provide richer and more personal accounts of attitudes and behaviour in clinical practice 308. 
Indeed in this study, having a clinician researcher facilitated the in-depth discussion of 
clinical cases as part of the interview. We found that having a GP interviewer allowed 
participating GPs to discuss their experiences in a safe non-judgemental, collegial 





Attempts were made to reduce the risk of professional bias by involving a non-clinician in 
the analysis process.   
Implications for research and practice 
This study provides a better understanding of GPs’ behaviours when managing BPSD which 
will facilitate the design of a more targeted intervention to support GPs in their delivery of 
care to these patients 239. There is a role for educational interventions for GPs in BPSD, in 
particular interventions that focus on assessment of BPSD and non-pharmacological 
strategies. However, the complexities of the challenges identified in this study highlight the 
need for additional interventions to support any educational initiatives. Shared decision 
making tools may help overcome the challenges presented by managing conflicting 
expectations from both family care givers and nursing home staff. However, in order for a 
shared decision making tool to be effective, the GPs need to have the confidence, 
knowledge and skill to discuss and give advice on the various treatment options 309. Another 
challenge in the development of an effective shared prescribing decision tool is the 
insufficient evidence on the benefits of pharmacological options in BPSD. Furthermore, 
although there is a need for clinical guidance for GPs in BPSD, formal guidelines may not be 
appropriate given the heterogeneity of these behaviours and symptoms. However, a flexible 
management algorithm may be helpful. Clinical pathways or algorithms can help bridge the 
gap between best practice recommendations and the practical implementation of these 
recommendations at the coal-face 310, an approach which would be particularly pertinent in 
BPSD.  It is important that future research and practice focuses on appropriate assessment 
of BPSD in order to identify potentially reversible causes of BPSD rather than choosing 





requires a culture shift in how BPSD is managed. Such a culture shift will require appropriate 
resources, education and clinical guidance.  
6.6 CONCLUSION 
In the context of rising dementia prevalence the demand for community-based dementia 
care will increase. This is the first study to investigate the challenges GPs encounter when 
managing BPSD. This study helps to explain the apparent discrepancy between best practice 
recommendations in BPSD and real-life practice. The findings will be used to inform the 



















CHAPTER 7. THE KNOWLEDGE AND ATTITUDES OF GENERAL 
PRACTITIONERS TO THE ASSESSMENT AND MANAGEMENT OF PAIN 
IN PEOPLE WITH DEMENTIA  
 
 



















Pain in people with dementia is underdiagnosed and undertreated. General practitioners 
(GPs) play a pivotal role in dementia care but their perspective on pain in people with 
dementia remains largely under-researched. The aim of this study was to explore GPs’ 
knowledge and attitudes towards pain assessment and management in people with 
dementia. 
Methods 
This was a descriptive cross-sectional study. A questionnaire was adapted from a previous 
study and piloted with GPs. The questionnaire was posted to a census sample of all GPs in 
Cork city and county in the southern region of Ireland. The questionnaire collected 
demographic information, responses to a series of Likert statements assessing GPs 
knowledge and attitudes, and provided an opportunity for the GP to give qualitative 
feedback on their experiences of managing pain in dementia. SPSS v25 was used for 
statistical analysis. Qualitative responses were thematically analysed. 
Results 
Of the 320 questionnaires posted, 157 completed questionnaires were returned (response 
rate of 49%). The sample was representative of GPs nationally in terms of years in GP 
practice and practice location. Over two-thirds (108/157) of respondents had a nursing 
home commitment. Only 10% of respondents (16/157) were aware of any dementia-specific 
pain assessment tools. The larger the nursing home commitment of the GP the more likely 





believed people with dementia could not self-report pain. Respondents were uncertain 
about the safety of using opioid medications to treat pain in people with dementia with only 
51.6% agreeing that they were safe. The qualitative comments highlighted the importance 
the GPs placed on surrogate reports of pain, GPs’ uncertainty regarding the value of formal 
pain assessment tools and the challenges caused by under-resourcing in general practice. 
Conclusion 
This study has highlighted aspects of pain assessment and management in dementia that 
GPs find challenging. Guidance on pain assessment and management in people with 
dementia do not appear to be translating into clinical practice. The findings will inform 
educational interventions being developed by our research team as part of the 













The global prevalence of dementia is increasing. In 2013 it was estimated that 44 million 
people worldwide were living with dementia and this figure is expected to reach 75 million in 
2030 and 135 million by 2050 311. Although these estimates may be reduced by improvements 
in population health, such as reductions in smoking and hypertension, current evidence 
suggest that only 10% of the expected rise in incidence will be avoided by improvements in 
these disease control measures 312. A second major health issue facing the older population 
is that of chronic pain. The prevalence of pain is strongly correlated with increasing age 313,314. 
People with dementia appear to have a significantly increased risk of pain 137, with up to half 
of people with dementia estimated to be living with chronic pain 138-140. In one study of nursing 
home residents the prevalence of chronic pain in residents with dementia was almost double 
that of residents without dementia 315. Similarly, in the community setting, pain is more 
prevalent in people with dementia than in people without dementia 137,139,316. This increased 
prevalence is related, at least in part, to the significantly higher burden of co-morbid physical 
disease in people with dementia 317,318 which contributes to increased musculoskeletal pain 
319,320, orofacial pain 321 and neuropathic pain 322. However, pain in people with dementia is 
often underdiagnosed, underestimated and undertreated 315,323,324.   
The negative impact of undiagnosed, untreated pain in dementia is substantial. In a person 
with dementia untreated pain can worsen cognitive function, lead to depressive symptoms, 
reduce quality of life and trigger or exacerbate behavioural and psychological symptoms of 
dementia (BPSD) 138,315,325,326. The aetiology of BPSD is often multifactorial 108, however, pain 
is one of the most important causal factors for BPSD 138. Indeed interventions targeting pain 





not either understand or be able to effectively communicate pain and so pain may be 
expressed through behaviours such as agitation or aggression 328. In addition to the distress 
and discomfort untreated pain can cause, not correctly identifying pain as a trigger for these 
behaviours can lead to the inappropriate prescribing of potentially harmful psychoactive 
medications to people with dementia. In one study the presence of pain in nursing home 
residents was found to be significantly associated with the use of antipsychotic medication 
191. In addition to the harmful side effects of psychotropic medication in people with dementia 
159,160 these drugs often have a sedative effect which can mask behaviours that are indicative 
of pain 329, further contributing to under-diagnosis.  
The vast majority of people living with dementia either live at home in the community or in a 
residential care setting such as a nursing home 21. The general practitioner (GP) is the key 
healthcare professional for a person with dementia as they provide care in both the 
community and in nursing home settings. GPs play a pivotal role in assessing and managing 
pain in people with dementia, however, they are challenged by many aspects of dementia 
care including the management of BPSD 87,198,293,330 and providing end of life care 331. Both the 
management of BPSD and the provision of end of life care in dementia require GPs to assess 
for and manage any underlying pain. In a recent qualitative study conducted by the authors, 
GPs reported difficulty identifying pain as a potential trigger for BPSD 332. However, to the 
best of our knowledge no research to date has explored GPs’ perspectives on pain 
management in dementia. The aim of this study was to explore the knowledge and attitudes 








An anonymous postal questionnaire was sent to a census sample of all GPs in Cork city and 
county in the southern region of Ireland in May 2017. Ethical approval was granted by the 
Social Research and Ethics Committee in University College Cork (Log2016-050). 
 
Questionnaire 
There was no previously validated questionnaire available to address this research question. 
However, we did identify an appropriate questionnaire that was used in a previous study that 
explored nurses’ knowledge of and attitudes to pain management in dementia 333. With the 
original authors’ permission we adapted this questionnaire for use with GPs. We (AJ, ML, TF), 
all practicing GPs with an academic interest in dementia care, reviewed the questionnaire to 
ensure its appropriateness and relevance to a general practice setting. Furthermore, the 
questionnaire was piloted with five GPs, all of whom have experience managing people with 
dementia in community and nursing home settings. Subsequently, minor amendments were 
made to enhance the clarity of the questionnaire. The final questionnaire developed for use 
in this study contained three sections. The aim of the first section was to capture demographic 
information from the GPs. The second section consisted of a series of five-point Likert-type 
statements exploring GPs’ knowledge and attitudes to pain in people with dementia. The final 
section provided GPs with the opportunity to give free-text responses. (The questionnaire is 








The questionnaire was posted with an information sheet to all 320 GPs practicing in the Cork 
region. With a large urban and rural population, a census sample of Cork GPs is largely 
representative of GPs nationally.  The sample size was calculated based on this census 
population of 320 with desired precision estimates of +/-5% around a prior estimate of 50%. 
Based on these calculations to adequately power the study the sample size required was 175 
respondents. All GPs were identified from the Irish Medical Directory 334. A stamped 




The data from the responses were coded and SPSS version 25 was used for statistical analysis. 
Chi-square tests and Mann-Whitney test were used to explore associations between 
demographic data and responses, with differences at a level of 95% probability and above 
regarded as statistically significant. The following demographic associations were explored; 
years in practice, presence of a nursing home commitment and the extent of the GPs nursing 
home commitment (as indicated by the number of residents the GP cared for). Free-text 
responses were entered into MS Word and were thematically analysed 101 by two of the 










Of 320 questionnaires sent, a total of 157 completed questionnaires were received, 
representing a response rate of 49% (157/320).  The respondents had a broad mix of practice 
locations and years of experience. The demographic characteristics of respondents is 
displayed in Table 11.  




Practice Location  
    City 45 (28.6) 
    Town                 42 (26.7) 
    Rural                 23 (14.6) 
    Mixed                 47 (29.9) 
  
Years of GP Experience  
    0-5 yrs 20 (12.7) 
    6-15 yrs 48 (30.6) 
    16-25 yrs 41 (26.1) 
   >= 26 yrs 48 (30.6) 
  
Nursing Home Commitment  
   No commitment 49 (31.2) 
   Attends 1 nursing home 42 (26.5) 
   Attends 2 nursing homes 39 (24.8) 






Provision of care  
Over two-thirds (108/157) of respondents had a nursing home commitment (mean number 
of nursing homes +/- SD = 1.35 +/- 1.19; range (0-5)). These GPs provided care to a total of 
2,393 people in nursing homes (mean number of patients = 15; range (1-112)). The 
respondents reported that just over half of these nursing home patients (1,242/2,393) had 
dementia. Of the GPs who provided care to nursing home residents, the majority (60.2%) did 
a regular round in the nursing home. Over half of the GPs with a nursing home commitment 
did 1 or more nursing home round per week (mean number of rounds per week = 1, range (0-
5)). Rural GPs were significantly more likely to have a nursing home commitment (P–value = 
0.042).  There was no association found between the numbers of years a GP was in practice 
and having a nursing home commitment. 
 
Pain assessment in dementia 
The overwhelming majority of GPs (98%) agreed that the presence of dementia can make pain 
difficult to assess (Table 12). A smaller majority of respondents (68.7%) felt that pain was 
under-recognised in patients with dementia. The majority of GPs surveyed agreed that 
observing behavioural and physiological indicators of pain and obtaining surrogate reports 
are important when assessing pain in a person with dementia. However, most GPs were 
unfamiliar with dementia-specific pain assessment tools with only 10% reporting any 
knowledge of their existence. The larger the nursing home commitment of the GP, as 
indicated by the number of nursing home residents they cared for, the more likely they were 
to be familiar with pain assessment tools for people with dementia (P-value = 0.048). 





guidelines/policies on pain management in the nursing homes they attended. The numbers 
of years the GP was in practice was not associated with an increased familiarity with pain 
assessment tools. Despite the lack of awareness of pain assessment tools, the majority 
(73.2%) of respondents believed that a pain assessment tool would be useful to increase 
recognition of pain in patients with dementia in nursing home settings.   
 
Table 12. Responses to Likert statements on assessment of pain in people with dementia 







N, (%)  
Disagree* 
N, (%) 
The presence of dementia can make pain 
assessment difficult. 
154 (98.0) 3(1.9) 0 
A person with dementia is not able to 
accurately provide a self-report of their pain. 
113 (72.0) 20(14.0) 24 (15.2) 
Pain assessment tools used for cognitively 
intact people are not appropriate for people 
with dementia. 
103 (65.6) 33 (21.0) 21 (13.3) 
I am familiar with pain assessment tools 
specifically available for use with a person 
with dementia. 
16 (10.1) 20 (12.7) 121 (77.0) 
When assessing pain in a resident with 
dementia, it is important to observe 
behavioural indicators of pain (e.g. facial 
expressions, body movements, posture). 
154 (98.0) 2 (1.2) 1 (0.6) 
When assessing pain in a resident with 
dementia, it is important to consider 
physiological indicators of pain (e.g. heart 
rate, blood pressure, temperature). 
144 (91.7) 12 (7.6) 1 (0.6) 
When assessing pain in a resident with 
dementia, it is important to consider a 
family/care givers report 
150 (95.5) 7 (5.5) 0 
*Note: The original Likert scale options “strongly agree” and “agree” were combined 






Management of pain in dementia 
The responding GPs appeared less certain about aspects of the management of pain in 
dementia (Table 13). The overwhelming majority (95%) agreed that the treatment of pain 
should follow a step-wise approach. However, 26% either disagreed or neither agreed nor 
disagreed that optimal treatment of pain is achieved when analgesics are given on a regular 
basis. The respondents were particularly uncertain about the safety of using opioid 
medications in people with dementia. Just over half of GPs surveyed (51.6%) agreed with the 
statement that opioid analgesics are safe to use when treating pain in dementia, while 34.4% 
neither agreed nor disagreed with the statement and 14% believed opioids were unsafe in 
this patient group. There was no statistically significant association found between the GP’s 
knowledge of the management of pain in dementia and their number of years in practice or 














Table 13. Responses to Likert-type statements on management of pain in people with dementia 
 







 N, (%)  
Disagree* 
N, (%) 
Residents with dementia who are experiencing 
pain should be managed differently to cognitively 
intact residents. 
52 (33.0) 34 (21.6) 71 (45.2) 
The drug treatment of pain in a resident with 
dementia should follow a step-wise approach. 
149 (94.9) 5 (3.1) 3 (1.9) 
Optimal treatment of pain is achieved when 
analgesics are given on a regular basis. 
116 (73.8) 31 (19.7) 10 (6.3) 
Paracetamol is the best analgesic to use for 
residents with dementia who are experiencing 
chronic pain. 
98 (62.4) 43 (27.3) 16 (10.2) 
It is safe to use opioid analgesia to treat pain in 
residents with dementia. 
81 (51.6) 54 (34.4) 22 (14.0) 
Residents with dementia are less likely to 
become addicted to opioid analgesics than 
cognitively intact patients. 
21 (13.3) 65 (41.4) 71 (45.2) 
There is a greater risk of side effects from opioid 
analgesics (e.g. respiratory depression, 
confusion) when used in residents with 
dementia. 
101 (64.3) 36 (22.9) 20 (12.7) 
Non-drug based methods of pain control (e.g. 
TENs, Heat/Cold, massage, complimentary 
therapy) are useful in the management of pain in 
residents with dementia. 
129 (82.1) 20 (12.7) 8 (5.09) 
*Note: The original Likert scale options “strongly agree” and “agree” were combined to 











Of the 157 respondents, 49 GPs (31% of respondents) provided additional qualitative 
feedback in the free text section of the questionnaire. There were a number of themes 
identified from the free-text responses. The three main themes identified were; (i) the role of 
pain assessment tools, (ii) the importance of input from carergivers and (iii) challenges of 
resource limitations. Verbatim quotations are presented here to illustrate the themes. 335 
These particular quotations were selected as they were considered to be typical of the 
responses that underpinned the development of each theme. 
 
Theme 1: Role of pain assessment tools 
Several of the responding GPs expressed a desire for guidance in the area of pain assessment 
and management in dementia: 
“Would love guidance on pain management in these patients” (Respondent_79, 
experienced GP, urban practice, no nursing home commitment) 
 
Some respondents expressed apprehension about introducing pain assessment tools. 
“I feel a lot of ‘tools’ can lead to unnecessary work if arbitrarily based on BP readings, 
heart rates etc e.g. MEWS score in hospital which is why I’d be wary of their use. 
Would need to be used judiciously”  
(Respondent_84, recently qualified GP, rural practice, with nursing home 
commitment) 
 
Many GPs perceived pain assessment tools as yet another tool that would add to GPs’ 





“A pain assessment tool wouldn’t be helpful in nursing homes as it would add more 
workload to already onerous paperwork” 
(Respondent_128, recently qualified GP, urban practice, with nursing home 
commitment) 
 
Theme 2: The importance of input from caregivers 
A second theme identified was the value GPs placed on the input of relevant caregivers, who 
knew the person with dementia well, when assessing pain:  
“Key component to good assessment depends on good collateral history - family/close 
friends, nursing staff/carers.” 
(Respondent_46, experienced GP, rural practice, with a nursing home commitment) 
 
In particular many GPs highlighted the important role of nurses in pain assessment: 
 “Feedback from nurses helps to make appropriate prudent descriptions.” 
(Respondent_75, experienced GP, mixed practice setting, with a nursing home 
commitment) 
 
The GPs described how they relied on the nursing staff and trusted their opinion when 
assessing a person with dementia: 
“An experienced nurse is the best person to rely on, they know as do the carers – 
listen to them and you’ll get it right.” 










Theme 3: The challenges of under-resourcing 
 
A third theme identified was the challenges GPs experienced providing care to people with 
dementia given the current underfunding of Irish general practice. 
“Dementia [is] not currently a paid ‘chronic disease’ in GP, poor remuneration.” 
(Respondent_114, mid-career GP, mixed practice setting, no nursing home 
commitment) 
 
The GPs reported extensively about the impact of recent austerity cuts in Ireland which 
dramatically cut funding to GPs who provide care to nursing home residents: 
“Usual gripe – fee for attending nursing home residents in now 1/3 of what it was in 
2008! Hhhmmmm…..” 
(Respondent_70, mid-career GP, rural practice, with a nursing home commitment) 
 
Several GPs also stated that they no longer provided care to nursing home patients as a result 
of these reductions in remunerations: 
“I have given up nursing home care. Funding poor. Bureaucracy a problem.” 
(Respondent_26, experienced GP, urban practice, no nursing home commitment) 
 
7.5 DISCUSSION 
This is the first study that has explored GPs’ assessment and management of pain in people 
with dementia. Our findings suggest that GPs are confident in many aspects of assessing pain 
in people with dementia such as the value of observing behavioural and physiological 





aspects of assessing and managing pain in dementia. The majority of GPs surveyed believed 
that a person with dementia cannot self-report pain and the vast majority of GPs were 
unfamiliar with dementia-specific pain assessment tools. In the absence of either a self-report 
or a standardized observational tool to assess pain, the responding GPs appeared to rely 
significantly on surrogate reports from family members and nursing home staff when 
assessing pain in dementia. Although the majority of responding GPs welcomed the idea of 
guidance in the area of pain assessment and management in dementia, in the free-text 
comments many questioned the value of a standardized, observational pain tool. 
Furthermore, when managing pain in people with dementia the GPs were particularly 
uncertain about the role of opioid medication and the consequences of the use of opioids in 
people with dementia. While the majority of GPs agreed that in order to achieve optimum 
pain relief analgesia should be prescribed regularly, over a quarter of GPs surveyed did not 
agree with this statement. The inference being that these GPs are favouring ‘as required’ 
analgesic medication, a sub-optimal method of pain control. Although we did find that GPs 
with a larger nursing home commitment were more likely to be familiar with dementia-
specific pain assessment tools, in general, the experience level of the GP was not associated 
with increased levels of knowledge or a more positive attitude towards pain assessment and 
management in dementia. 
 
Comparison with existing literature 
Our findings indicate that GPs’ value good communication with family members and nursing 
home staff when managing pain in people with dementia. This finding is similar to previous 





educational needs in dementia 87 both GPs and family caregivers emphasized the importance 
of good channels of communication in dementia care. In our study, the GP respondents also 
emphasized the importance of a report from nursing staff or family carer when assessing pain 
in the qualitative free-text responses. In our study nursing staff were seen by the GPs to 
facilitate pain assessment. This is in contrast to findings from a previous study that examined 
nurses knowledge and attitudes to pain management in dementia where nurses identified a 
lack of GP support as a barrier to successful pain management 333.  Previous research with 
GPs found that consistency of care was an important factor in improving relationships 
between GPs and nursing staff 332. In that study structured visits by the GP to the nursing 
home were seen to facilitate the provision of continuity of care and led to good 
communication channels between the GP and nurses 332. Effective communication between 
nursing staff and GPs is an essential component of any optimisation of pain assessment and 
management in nursing home settings. 
The majority of respondents in our study believed that people with dementia could not 
accurately provide a self-report of pain. However, self-reporting of pain is considered the gold 
standard method of pain assessment 336 and can be a reliable way of assessing pain in people 
with dementia 336-338. Best practice recommendations advise that where possible attempts 
should always be made to elicit self-reports of pain from the person with dementia 336. 
Although in the very advanced stages of dementia many individuals may be unable to self-
report pain 320, people with mild-moderate 191,339 and in some cases severe dementia 340 have 
been found to provide valid self-reports of pain. Our finding echoes previous research with 
nursing home managers which found that only 8.3% of respondents felt that people with 
dementia could self-report pain 341. The large majority of GP respondents agreed with the 





finding could mean that an attempt is not being made to elicit a self-report from a person 
with dementia. However, this needs to be explored further, ideally with qualitative research, 
to establish the impact this attitude has on how GPs assess pain in people with dementia. 
Nearly all GP respondents agreed that patient observation was a critical part of pain 
assessment in dementia. Despite this belief the vast majority of respondents were not using 
any validated, standardised, observational approach. Observational methods are central to 
clinical assessment, especially when a person lacks the ability to self-report, however, there 
is a risk of observer bias if there is no standardized approach to the observation 337. A large 
array of pain assessment tools exist for use in people with dementia - a recent systematic 
review of pain assessment tools included twenty-eight such tools 342. However, the vast 
majority of GP respondents were unaware of these tools. Similar to previous findings from a 
study with community pharmacists 316, the more experience the GP had with dementia the 
more likely he or she was to be aware of these tools. The lack of awareness of dementia-
specific pain assessment tools is a particularly noteworthy finding since the majority of 
respondents thought that having such a pain assessment tool would be helpful. This highlights 
an incongruity between research in this area and real-life clinical practice. These tools appear 
to be rarely used in general practice.  
The responding GPs lack of familiarity with pain assessment tools may be surprising to 
researchers in the area but may be unsurprising to front-line GPs. GPs do not readily embrace 
assessment tools 343,344. They are inductively trained to rely on their clinical skills. This is in 
contrast to nursing staff who are specifically trained to use and rely on assessment tools. In 
the free-text responses some GPs feared the additional workload such tools could bring and 





GPs’, hospital physicians’ and nurses’ perspectives on the use of observational pain tools in 
people with dementia identified a number of barriers to using observational pain tools, one 
being the perceived lack of value in using them 345. Furthermore, participants in that 
qualitative study described using the pain tools to comply with local recommendations but 
not actually using the results to inform treatment decisions 345.  This echoes some of the 
concerns raised by participants in our study that a pain tool would become another source of 
paper-work rather than a tool to aid clinical decision making. GPs are not usually the 
healthcare professional tasked with completing a pain assessment tool; in a nursing home 
setting that role would typically fall to the nursing staff. GPs do still need to be aware of these 
tools in order to interpret the findings and generate appropriate management plans in 
discussions with nursing staff. However, clinicians and nurses can find the results of pain 
assessment tools difficult to interpret 346.  Implementing these observational pain assessment 
tools in isolation, without adequate guidance on how to interpret the results, will not lead to 
improved treatment of pain 320.  The tools in themselves will not result in improved care unless 
they are combined with guidance that will help clinicians to translate a pain score into an 
appropriate treatment plan.  
Respondents appeared unsure about the safety of opioid analgesics in people with dementia. 
This is similar to previous research conducted with nurses 333, nurse managers 341 and 
community pharmacists 316 all of whom had similar concerns regarding the safety of 
prescribing opioids to people with dementia. Guidelines on pain management in the older 
adult do recommend considering opioid analgesics for patients with moderate to severe pain, 
particularly if the pain is causing functional impairment or reducing quality of life 313. The 
uncertainty the GP respondents felt regarding the safety of opioid medication in dementia is 





Age is a significant predictor of opioid related harm 347,348. Adverse effects of opioids can 
include respiratory depression, sedation, constipation, nausea and dizziness 349. Many of 
these adverse effects increase with age 350 and frailty 348 both of which are associated with 
dementia. Furthermore, these adverse effects can be particularly problematic to identify in a 
person with advanced dementia because of their reduced ability to communicate. However, 
when managing pain in people with dementia the adverse effects of opioids needs to be 
weighed up against the harmful effects of undertreating pain. Although a narrow majority 
agreed with the statement that opioids were ‘safe in people with dementia’, a larger majority 
of respondents agreed with the statement that there is ‘a greater risk of side effects from 
opioid analgesics when used in people with dementia’. Many respondents appeared to feel 
that, despite the increased risks, the use of opioids in people with dementia was still “safe”. 
How this belief influences the GP’s prescribing is unclear. Previous research suggested that 
people with dementia may receive less opioids 351.  A qualitative study which examined GPs’ 
perspectives on prescribing opioids for chronic pain found that fear of causing harm was a 
barrier to prescribing opioids to the older adult 352. Despite this a recent systematic review 
identified that, internationally, prescribing of opioids to nursing home residents has increased 
over time 353. Similarly, a large Danish study found that buprenorphine and fentanyl patches 
were more commonly prescribed to people with dementia 354. It is possible that these opioid 
patches are perceived as having less side effects than oral opioids or as being more tolerated 
by people with dementia. However, these transdermal opioid patches typically contain a 
stronger opioid dose than oral opioids, and since the adverse effects of opioids are dose 
related these patches are likely to result in more, not less, side effects. Prescribers’ 
perspectives of the role of different opioid medications in the management of pain in 





Although optimal treatment of pain is achieved when analgesics are given on a regular basis 
355, over a quarter of respondents in our study did not agree with this statement. A similar 
finding was reported in previous research with nurses 341 where 20% of respondents either 
agreed, or neither agreed nor disagreed, with a statement that ‘optimal pain treatment of 
pain relief is achieved when analgesics are given in a PRN (or as required) way’.  If the value 
of regular administration of analgesia is not recognized this could result in the prescribing of 
analgesics in the less-effective ‘as required’ way. Research conducted in nursing homes in 
Northern Ireland in 2015 found that in the majority of residents with dementia, analgesic 
medication was prescribed 'as required’ and not regularly 191.  Likewise, research from the 
U.S. found that cognitively impaired nursing home residents were less likely than their 
cognitively intact peers to be prescribed regular, scheduled analgesia and were more likely to 
be prescribed analgesic medication in an ‘as required’ way 324. To receive this ‘as required’ 
medication a person would either need to ask the nurse for pain relief or the nurse would 
need to identify that the person was in pain and give them pain relief 324. In the case of a 
person with advanced dementia neither of these situations are very likely to occur. In view of 
their cognitive and communication difficulties a person with advanced dementia is unlikely to 
self-request analgesia and we know from existing evidence that there are a number of 
barriers to nurses identifying and initiating pain relief in a person with dementia 333,341.  
 
Areas for future research & implications for policy & practice 
This study highlights several areas of GPs assessment and management of pain in dementia 
that could be explored with future research. There were some findings that warrant further 





people with dementia cannot self-report pain. Future qualitative research with GPs in this 
area would help gain a deeper understanding of the context and nuances that are involved in 
this complex area. It would be important to ascertain how GPs’ knowledge of and attitudes 
towards pain in people with dementia impacts on their actual prescribing of analgesia to 
people with dementia. A quantitative study of current prescribing of analgesia to people with 
dementia both in nursing homes and in the community would be an important 
complementary study. These studies would lead to a more extensive understanding of the 
problem and would help to inform the development of effective interventions to improve the 
management of pain in dementia in primary care settings.  
There is a role for educational interventions for GPs that focus on pain assessment and 
management in dementia. The results of this current study will inform the ongoing, national 
roll-out of educational interventions for GPs in dementia care that have been developed by 
our research team 133,356 as part of the implementation of the Irish National Dementia strategy 
29. Previous educational interventions for GPs in the area of pain management in dementia 
have used teleconferencing technology based on the Project ECHO© model and have been 
found to improve healthcare professionals’ knowledge and self-efficacy of pain assessment 
and management in advanced dementia 357. Such educational interventions would be 
particularly acceptable to general practitioners as they eliminate the need for travel and don’t 
require any prolonged periods away from practice. Another important finding was in relation 
to educational initiatives was that GPs see nurses as facilitators to optimum pain 
management, whereas in previous studies 333,341 nurses identified GPs as barriers to optimum 
pain management. This highlights a communication gap between these two professional 
groups, both of whom play a pivotal and complementary role in the assessment and 





educational initiatives in this area. Palliative care is another professional group that have a 
significant role to play in the management of pain in dementia, particularly in complex cases, 
yet we know that many people with dementia are not routinely assessed to determine their 
palliative care needs 358. An inter-professional educational approach including all the relevant 
professional groups could help improve communication and bridge professional divides 359, 
which would play an important role in improving the care provided to people with dementia 
who are living with chronic pain. 
Although relevant and important, we know that educational interventions alone have limited 
effect in changing GPs’ behaviour in dementia care 286,287. To effectively improve GPs’ 
performance in dementia care, education needs to be combined with adequate 
reimbursement and organisational incentives 360. A previous systematic review highlighted 
how time constraints and inadequate remuneration act as barriers to optimum diagnosis and 
management of dementia in primary care 72. In Ireland general practice receives only 4.5% of 
the overall health budget, significantly lower than other European countries 54. Additionally, 
recent government-led austerity cuts in Ireland have dramatically cut funding to general 
practice, these cuts have particularly affected general practitioners providing care to nursing 
home residents. In our study the dissatisfaction of GPs with the current under-resourcing of 
dementia care was evident in the free-text responses. Many GPs discussed the challenges of 
providing optimum care to people with dementia in the context of current resource 
limitations, reporting that they can no longer provide care to nursing home residents. Like 
many other European countries 361-363, Irish general practice is currently facing a recruitment 
crisis 67. This recruitment crisis is particularly affecting rural general practice, therefore, it was 
notable that rural based GPs were significantly more likely to provide care to nursing home 





inadequate reimbursement, the future of GP led nursing home care is uncertain.  Future 
policy needs to focus on adequate resourcing of dementia care in both community and 
nursing home settings. 
The study results have several immediate practical implications for GPs caring for people 
with dementia. The implications for GPs assessing pain in people with dementia include; 
being more aware of the increased risk of pain in people with dementia, considering pain as 
a potentially reversible trigger for BPSD, providing people with dementia an opportunity to 
self-report pain and familiarising themselves with the pain assessment tools that may 
already be in place in the nursing homes they attend in order to facilitate more effective 
communication with the nursing home staff. From a pain management perspective one 
practical implication for GPs is that if pain is identified, or suspected, then it is important 
that the person’s pain is not under-treated. Inappropriate prescribing in people with 
dementia does not just mean over-prescribing. It also pertains to under-prescribing of 
appropriate medications that can improve comfort and overall quality of life.  
 
Strengths and Limitations 
Although a 49% response rate is modest, it is typical of postal  surveys with this professional 
group 364. Our response rate is similar to the response rate in a previous national study on GPs 
attitudes to diagnosis in dementia 301 and significantly higher than a recent online survey of 
GPs referral patterns in dementia care in Ireland 365. To adequately power this study a sample 
size of 175 respondents was required. Therefore, with 157 respondents the study was 
marginally underpowered. Furthermore, this study was a census study of a specific 





generalisability of the study, however, the respondents’ demographic characteristics, in terms 
of years of experience and practice location, are representative of GPs nationally 45. A large 
proportion of respondents had a nursing home commitment. There is currently no Irish data 
available on the number of GPs who attend nursing homes, therefore, it is difficult to 
ascertain whether this represents a respondent bias. It is possible that GPs with a nursing 
home commitment were more likely to respond to the survey as they may have been more 
interested in the research topic. Finally, this was a cross-sectional survey of self-reported 
knowledge and there is evidence to suggest that when self-reporting physicians may 
underestimate their knowledge in an area 366. The nuances of clinically complex areas such as 
this are difficulty to fully address with a single study that rely primarily on self-reporting 
measures. However, since there is very little research exploring GPs experiences of managing 
pain in people with dementia our chosen methodological approach is a necessary and 
reasonable place to start. 
 
7.6 CONCLUSIONS  
Despite the pivotal role GPs play in dementia care their experience of managing pain in 
dementia is greatly under-researched. Prior to this study very little was known about GPs’ 
knowledge of and attitudes towards the assessment and management of pain in dementia. 
This study enriches existing literature in the area of pain management in dementia care and 
also raises some important issues that should be explored in future research.  Pain 
management in a person with dementia touches on some of the most fundamental aspects 
of a GP’s role as a patient advocate. It is, therefore, challenging to identify aspects of care that 





design effective interventions to appropriately address them. The results of this study will be 
used to inform the development of interventions to improve the management of dementia 






























CHAPTER 8. GENERAL PRACTITIONERS’ KNOWLEDGE OF AND 
ATTITUDES TOWARDS PRESCRIBING ANTIPSYCHOTICS IN 
DEMENTIA: A DESCRIPTIVE CROSS-SECTIONAL STUDY  
 
 



















The studies conducted to date in this thesis highlighted the key challenge that antipsychotic 
prescribing presented to GPs when managing BPSD. One of the main findings from the 
systematic review, reported in Chapter 5, was that antipsychotics were sometimes used to 
enable family members and nursing home staff to cope with the behaviours and symptoms. 
Findings from the qualitative study, reported in Chapter 6, also emphasised the challenges 
GPs experience when prescribing antipsychotics in BPSD. In the qualitative study some GPs 
appeared to be unaware of the adverse effects of antipsychotic and over-estimated their 
benefits in managing BPSD. These studies had established that GPs’ prescribing of 
antipsychotic medication was an aspect of GPs’ behaviour when managing BPSD that needed 
to be explored further. To date no study had explored GPs’ prescribing of antipsychotic 
medications in Ireland. It was not known what psychotropic agents GPs prescribe in BPSD, or 
in what situations GPs prescribe medications to people with BPSD. It was not known whether 
GPs monitor their antipsychotic prescribing in BPSD or whether they feel confident to 
discontinue these medications in BPSD. To further explore the findings of the systematic 
review and the qualitative study a descriptive cross-sectional study was designed to enhance 
my understanding of GPs’ antipsychotic prescribing in BPSD in Ireland. The aim of this study 
was to establish GPs’ knowledge of and attitudes towards antipsychotic prescribing to inform 







A survey was posted to a census sample of all GPs working in counties Cork and Kerry in the 
southern region of Ireland. This census sample was identified through the Irish Medical 
Directory. The sample size was calculated based on this census population of 468 with a 
margin of error of +/− 5% and a response distribution of 50%. To adequately power the study 
the sample size required was 212 respondents. All GPs received a leaflet with information 
about the purpose of the study and a personally addressed letter inviting them to complete 
and return the questionnaire with the free post envelope provided. Participation was 
voluntary and consent was assumed through completing the questionnaire. All GPs who 
returned a completed questionnaire were included in the study.  
An anonymous 21-question questionnaire was used to collect data. The questionnaire used 
was adapted, with permission, from a previous study with Australian GPs. 155 The 
questionnaire was modified to explore the findings of the systematic review and the 
qualitative study. The questionnaire was piloted with 3 GPs with an interest in dementia care 
and refined based on their feedback. The finalised questionnaire had three parts. The first 
part gathered participant’s demographic information. The second part consisted of several 
five-point Likert-type statements, a series of ranking questions and multiple choice questions 
that collected information about GPs’ prescribing habits. Finally, the last part asked GPs to 
share any comments they had in the free text area provided. The questionnaire is available in 
Appendix 4, supplementary material 12. 
Ethical approval was received by the Clinical Research Ethics Committee of the Cork teaching 





Excel and SPSS version 24 were used to conduct the statistical analysis. Chi-square tests and 
Fisher’s tests were used to evaluate associations between demographic variables and GP’s 
responses, with a P-value of <0.05 considered significant. The qualitative comments provided 
by GPs in the free text responses were entered into Microsoft Word where they were 
thematically analysed. Responses to Likert-type questions were collapsed into 3 categories as 
given in Table 15 and Table 16. The original Likert scale options “rarely benefit” and “some 
patients” were combined to “rarely/some patients”, whereas the options “50% of patients” 
and “most patients” were combined to “more than 50% of patients”. 
 
8.3 Results 
Of the 468 questionnaires posted, 168 completed questionnaires were returned. 12 
uncompleted questionnaires were returned with a note from the GP explaining they had 
recently retired. Consequently, the corrected sample size of eligible GPs who received the 
questionnaire was 456, representing a response rate of 36.8%. The sample was 
representative of GPs nationally in terms of years of practice (p<0.001). Participants 










Table 14. Demographic characteristics of GP respondents to questionnaire on attitudes to 
antipsychotic prescribing in BPSD 


































62.5 % (105/168) of respondents had a nursing home commitment. Of these GPs who had a 
nursing home commitment, 62.9% (66/105) paid regular visits to the nursing home (at least 
weekly rounds). The mean number of nursing home attended was 2.05 (SD +/− 1.38; range 1-
9). GPs provided care to 2703 nursing home patients in total (mean number of patients in a 





years of experience the GP had in primary care and having a nursing home commitment 
(p=0.24) or between the location of the practice and having a nursing home commitment 
(p=0.70).  
Responses to selected questions regarding prescribing habits are given in Table 15 and Table 
16 below. All GPs (100%, 168/168) believed that antipsychotics, benzodiazepines and 
antidepressants did not benefit all patients with BPSD. A little over half of GPs (56%, 94/168) 
said they would prescribe an antipsychotic in more than 50% of cases where their patients 
with dementia were physically aggressive. A small majority (52.4%, 84/168) said they did not 
have a repeat prescribing policy for patients with dementia on antipsychotics. 70.6% 
(115/163) of respondents reviewed people with dementia living in the community and on 
antipsychotics at least three monthly. 79.2% (80/101) of GPs reviewed people with dementia 
living in a nursing home and on antipsychotics at least three monthly. 
Table 15.  Responses to question on the benefit of different psychotropic agents in BPSD 
 Rarely /benefit some 
patients 
Benefit more than 
50% of patients 
Benefit all patients 
First generation 
antipsychotics - such 
as haloperidol 
143/168 (85.1%) 25/168 (14.9%) 0/168 (0%) 
Second generation 
antipsychotics - such 
as risperidone  
107/168 (63.7%) 61/168 (36.3%) 0/168 (0%) 
Benzodiazepines 158/168 (94%) 10/168 (6%) 0/168 (0%) 







Table 16.  Responses to question on situations that GPs would prescribe an antipsychotic in BPSD 
 Rarely / some 
patients 
More than 50% of 
patients 
All patients 
Physical aggression 66/168 (39.2%) 94/168 (56%) 8/168 (4.8%) 
Verbal aggression 109/168 (64.9%) 56/168 (33.3%) 3/168 (1.8%) 
Wandering 145/168 (86.3%) 21/168 (12.5%) 2/168 (1.2%) 
Calling out 146/168 (86.9%) 20/168 (11.9%) 2/168 (1.2%) 
Agitation and 
unsettled 
85/168 (50.6%) 77/168 (45.8%) 6/168 (3.6%) 
 
58.4% (98/168) of GPs agreed they found it relatively easy to consult and refer to geriatricians 
and old age psychiatry if required. There was no significant association found between the 
practice setting (urban, rural or mixed) and the ease to refer to specialists (p=0.25). 69% 
(116/168) of respondents agreed that they routinely recommended non-pharmacological 
interventions for behaviours that are challenging in dementia before considering medication. 
Nursing staff were ranked as the group of people who most influenced GPs’ prescribing of 
antipsychotics (80%, 133/166).  
GPs were asked what they believed to be the barriers to recommending non-pharmacological 
management strategies for people with BPSD living at home and those living in nursing 
homes. In the community, the most significant barriers were reported to be: a lack of 
resources in the primary care team, pressure to prescribe from the relatives and a lack of 
confidence in advising on non-pharmacological strategies. In the nursing home setting the 





be: pressure to prescribe medication from nursing home staff, a lack of nursing home staff 
and resources and a lack of nursing home staff skills. 
63.1% (106/168) of GPs were concerned that withdrawing medication would impact 
negatively on the quality of life of the resident leading to a return of challenging behaviours 
or disturbing psychological symptoms. However 54.1% (91/168) of GPs said they felt 
‘reasonably to totally confident’ to reduce or stop psychotropic medication in a stable patient 
with dementia where the medication was initiated by secondary care or a dementia specialist. 
No association was found between years of experience as a GP and confidence to withdraw 
medication (p=0.25).  60.7% (102/168) of GPs said they required more training and experience 
to improve how they manage BPSD. GPs were asked what would help reduce the usage of 
psychotropic agents in BPSD. The most influential methods reported were: increasing staff 
levels at nursing home to implement non-pharmacological strategies, increasing access to 
geriatricians and old age psychiatrists, and increased funding to GPs for providing elderly care 
to people with dementia.  
35 of the 168 respondents (20.8%) left qualitative comments at the end of the questionnaire. 
Three major themes emerged from the free-text responses: pressure to prescribe from 
nursing home staff, inadequate resources and the potential benefit of antipsychotics in some 
situations. To illustrate the major themes, verbatim quotations considered to be 
representative of the typical comments that lead to the development of each theme are 
presented below. 
Theme 1: Pressure to prescribe from nursing home staff 





"Have had enormous pressure to 'sedate' patients in nursing homes from nurses." 
(Respondant_145, experienced GP, mixed practice setting, nursing home commitment) 
Some GPs described a lack of understanding from the nursing home staff about the dangers 
of antipsychotics in dementia.  
"Feel there is a poor understanding of the negative impact of these medications on patients 
with dementia among relatives and nursing home staff. Often intense pressure to prescribe. 
Chemical restraints that have taken the place of physical restraints and are no less 
dangerous." (Respondant_8, experienced GP, mixed practice setting, no nursing home 
commitment) 
Some GPs suggested that the demand for antipsychotics from nursing home staff is due to a 
lack of staff and resources in the nursing home.  
"People in nursing homes often have challenging behaviors with dementia. Due to lacked 
ability to manage in nursing homes, often staff look for something to manage the problem 
patient. Often due to too many patients per nurse in nursing homes […]" (Respondant_101, 
mid-career GP, rural practice, nursing home commitment) 
 
Theme 2: Lack of resources 
GPs mentioned a lack of resources for non-pharmacological strategies. 
"I think better resourcing of day centres for patients with dementia is vital - music, 
aromatherapy, exercises all vital. Also better division of the above within nursing home setting 





pain in dementia." (Respondant_148, recently qualified GP, mixed practice setting, nursing 
home commitment)  
They highlighted a need for increased staffing levels in nursing homes and staff education in 
the area of BPSD.   
"Resources/staffing biggest issues [...] Better staffing/training/education as well as increase 
community care packages to keep patient comfortable in a familiar environment for as long 
as possible would be most effective in the long term." (Respondant_6, recently qualified GP, 
mixed practice setting, nursing home commitment)  
 
Theme 3: Perceived benefit 
GPs highlighted that the management of BPSD can be frustrating for clinicians. 
"Dementia is very challenging to deal with, needs huge amount of time and the reality is that 
we just don't have it - patients suffer as a result." (Respondant_84, mid-career GP, mixed 
practice setting, no nursing home commitment) 
GPs reported that in some cases, the use of antipsychotics was found to be beneficial. 
" … He was on all appropriate medication but got very agitated in the afternoons. A tiny 
amount of antipsychotic helped hugely. In a life changing way - he could cope again. I don't 
know what else we could have done. I cannot stress enough how hard living with dementia is. 
It is still important to help and I feel antipsychotics still have a small role. " (Respondant_ 51, 





GPs described the complexities of balancing risk to other residents and staff when managing 
BPSD. 
"The dynamic is between managing challenging behaviors especially when staff and other 
residents are actually being injured and minimizing the use of antipsychotics in the elderly. " 
(Respondant_30, experienced GP, rural practice, nursing home commitment)  
 
8.4 Discussion 
This study enhances our knowledge on how GPs in Ireland manage the prescribing of 
antipsychotic medications in BPSD. There were a number of positive findings in this study. 
The majority of GPs believed most people with BPSD did not benefit from psychotropic 
medications. The majority of GPs routinely recommended non-pharmacological 
interventions for behaviours that are challenging in dementia before considering 
medication. The majority of GPs reviewed people with dementia who were on 
antipsychotics within the timeframe recommended in guidelines. The majority, albeit a 
small majority, of GPs reported that they found it relatively easy to access support from 
secondary care colleagues when managing BPSD. The majority of GPs felt confident to 
reduce or stop psychotropic medication in a stable patient with dementia even when the 
medication was initiated by secondary care.  
The findings demonstrate that GPs are aware of the limited benefit of psychotropic 
medications in BPSD, that GPs routinely recommend non-pharmacological strategies first 
line, that GPs are monitoring their prescribing of antipsychotics and that they seem willing 





encouraging findings. However, there were some conflicting results. Despite the belief that 
psychotropic medications rarely benefited, or only benefited some people with BPSD, the 
majority of GPs reported that they would prescribe antipsychotics to most people with 
dementia who were physically aggressive. Likewise, nearly half of GP respondents reported 
they would prescribe antipsychotic medication to people with dementia who were agitated 
or unsettled. There is a discrepancy between the GPs’ knowledge on the limited efficacy of 
antipsychotic medications and their clinical practice. The findings on the barriers to 
recommending non-pharmacological approaches to BPSD go some way to explaining this 
discrepancy. Lack of appropriate resources and pressure to prescribe acted as barriers to 
the GP when attempting to recommend non-pharmacological alternatives. Nursing home 
staff were identified as the group of people which most influenced GPs’ prescribing of 
antipsychotic medication.  Likewise, ‘increased staffing levels in nursing homes’ was 
identified as the single change that would most help GPs to reduce the usage of 
psychotropic medications in BPSD. 
 
Comparison with existing literature 
This study highlighted the essential role played by nursing home staff when GPs are making 
a decision to initiate, reduce or stop an antipsychotics in a person with BPSD. That a nurse 
would be a key influence on a GPs decision to prescribe an antipsychotic is not, in itself, 
surprising. In a nursing home setting, the nurse is providing daily one to one care for the 
person with BPSD. The nurse is, therefore, best placed to report on the person with 
dementia mood and behaviour. The GP relies on this account from the nurse and it rightly 





influence, the GPs reported feeling pressurised by nursing home staff to prescribe 
antipsychotics. Previous studies have identified how pressure from nursing home staff 
influenced GPs’ management decisions in BPSD 153,155,283. In these studies, nursing staff were 
often seen as a barrier to a GP recommending non-pharmacological strategies. Similarly, in 
the qualitative study conducted for this thesis, GPs reported that they found it challenging 
to manage the expectations of nursing home staff, especially in the context of poor 
communication pathways between the GP and nursing staff 332.  
At what point does the nurse’s influence move from an informative aid in a GP’s decision 
making process on whether to prescribe an antipsychotic to a source of pressure? It could 
depend on GP factors. A previous Australian study found that the more experienced a GP 
was, in terms of years in practice, the less likely they were to rate ‘pressure to prescribe’ as 
a barrier to recommending non-pharmacological treatments in BPSD 155.  In our previous 
qualitative study we did find that GPs who had experience caring for people with dementia 
had more confidence in their management of BPSD 332. However, in this present study 
neither years in practice nor the extent of the GP’s nursing home commitment influenced 
whether they rated ‘pressure to prescribe’ as a barrier.  The experience of being under 
pressure to prescribe also could depend on the relationship that exists between the GP and 
the nursing staff. As identified in the qualitative study reported in Chapter 6, the influence 
of nursing staff can be helpful and appropriate in the context of a long-standing relationship 
of trust between the GP and the nurse 332.  A recent systematic review of the qualitative 
evidence surrounding antipsychotic prescribing in BPSD highlighted the importance of 
effective communication between healthcare professionals and identified a collaborative 
approach as the key component of any attempts to reduce inappropriate prescribing of 





antipsychotic medication could depend on wider resourcing issues in the nursing home. In 
this study ‘increased staffing levels’ was the number one recommendation of participating 
GPs when asked what would help to reduce the prescribing of psychotropic medications in 
dementia. Previous studies have identified that chronic understaffing in nursing home can 
hinder the nursing staff’s ability to implement non-pharmacological strategies 367 and, thus, 
increase pressure on GPs to prescribe sedative psychotropic medications 155,283.  It is likely 
that the prescribing pressure the GP feels from the nursing staff are a combination of all 
these factors; the experience level of the GP, the relationship between the nurse and the 
GP, and the resource constraints of the nursing home. 367 
 
Strengths and limitations 
GPs’ demographic characteristics are representative of GPs nationally in terms of years of 
practice but is not representative in terms of practice location or type. This may, therefore, 
affect the generalisability of our findings. Due to resource constraints, it was not possible to 
follow non-responders with reminder letters. A sample size of 212 respondents was required 
to adequately power this study, which means that with only 168 participants, our study was 
underpowered. This study is also limited by the circumscribed geographical area of its sample 
size, which only represents the southern region of the Republic of Ireland. Finally, this study 
relied on participant recall of what they would do in specific situations. This might have biased 
responses towards what GPs perceive as best practice but the study does give us an idea of 







This study has provided me with essential data on how GPs approach the initiation, 
monitoring and reduction of antipsychotic medication in BPSD. This study has added 
breadth to the depth of information acquired in the qualitative study. The findings of this 























CHAPTER 9. DEVELOPMENT OF A TOOL FOR MONITORING THE 
PRESCRIBING OF ANTIPSYCHOTIC MEDICATIONS TO PEOPLE WITH 
DEMENTIA IN GENERAL PRACTICE: A MODIFIED EDELPHI 
CONSENSUS STUDY 
 




















Despite their adverse effects antipsychotics are frequently used to manage behavioural and 
psychological symptoms of dementia. Regular monitoring of antipsychotic prescribing has 
been shown to improve the appropriateness of prescribing. However, there is currently no 
consensus on what the components of such a monitoring tool would be. 
Aim 
The aim of this study was to use an expert consensus process to identify the key 
components of an antipsychotic repeat prescribing tool for use with people with dementia 
in a general practice setting. 
Methods 
A modified eDelphi technique was employed. We invited multidisciplinary experts in 
antipsychotic prescribing to people with dementia to participate. These experts included 
general practitioners (GPs), geriatricians and old age psychiatrists. The list of statements for 
round 1 was developed through a review of existing monitoring tools and international best 
practice guidelines. In the second round of the Delphi any statements which had not 
reached consensus in the first round were presented for re-rating, with personalised 
feedback on the group and the individual’s response to the specific statement. The final 








A total of 23 items were rated over two eDelphi rounds and one face-to-face consensus 
meeting to yield a total of 18 endorsed items and 5 rejected items. The endorsed 
statements informed the development of a structured, repeat prescribing tool for 
monitoring antipsychotics in people with dementia in primary care. 
Conclusions 
The repeat prescribing tool developed provides GP with practical advice that is lacking in 
current guidelines and will help to support GPs by providing a structured format to use 
when reviewing antipsychotic prescriptions for people with dementia, ultimately improving 
















Most people living with dementia will experience behavioural and psychological symptoms 
of dementia (BPSD) at some stage in the illness 103 with some studies estimating that 
between 80 to 90% of people with dementia will experience at least one symptom of BPSD. 
105 BPSD encompasses a wide range of non-cognitive symptoms that affect people living 
with dementia and includes behaviours such as agitation or aggression and psychological 
symptoms such as anxiety or hallucinations. BPSD is associated with increased rates of 
admission to nursing homes, 114longer in-patient hospital stays 113 and is a major contributor 
to caregiver stress and depression. 116 General practitioners (GPs) play a pivotal role in the 
care of people with dementia, 5,6 providing for the day-to-day medical care of people with 
dementia living in their own homes and in nursing homes. However, similar to their 
secondary care colleagues, 273 GPs can find the management of BPSD a particularly 
challenging aspect of dementia care. 87,332 Non-pharmacological strategies are 
recommended first line in BPSD. 187 Personalised non-pharmacological interventions such as 
personalised music therapy 144,148 and formal caregiver training to enhance communication 
skills 148 may have a role in the management of BPSD, however, uptake of non-
pharmacological strategies is low. 151 Psychotropic medication, in particular antipsychotics, 
are frequently employed to manage BPSD, 151 however, antipsychotics are not 
recommended unless there is a serious risk of harm to the person with dementia or others. 
187 Antipsychotics have particular adverse effects in people with dementia including an 
increased risk of stroke and increased mortality. 159,160 Furthermore, evidence suggests 
antipsychotics are, at best, only minimally effective at improving BPSD. 160,368 Despite their 





dementia experiencing BPSD. 156,157 The rates of antipsychotic prescribing in people with 
dementia vary from country to country with rates as high as 29% in a 2013 audit conducted 
in Ireland 194 and lower rates of 17.7%  in a comparable 2012 audit in the UK. 195 Nursing 
home residents, who typically have more advanced dementia, are significantly more likely 
to be on an antipsychotic medication than people with dementia living in their own homes, 
194 up to five times as likely in one study. 156 
The reasons for continued prescribing of these potentially harmful medications is complex. 3 
In the context of stretched resources non-pharmacological alternatives to antipsychotic 
prescribing can be viewed as being impractical and not implementable. 276 The benefit of 
antipsychotic medication can be over-estimated. 330 Furthermore, both GPs and consultant 
psychiatrists report that they sometimes feel under pressure from nursing home staff, and 
occasionally family caregivers, to prescribe medications. 273,332 As a result, antipsychotics are 
sometimes employed to enable the person with dementia, their caregiver, and the nursing 
home staff to cope with these behaviours and symptoms. 3  
When prescribed for BPSD, antipsychotics should only be used on a short-term basis and 
should be reviewed for side-effects and for effectiveness as many of the harmful side-
effects of antipsychotics are dose and duration dependent. However, there is evidence that 
antipsychotics are often inappropriately prescribed to people with dementia for prolonged 
periods of time, 157 sometimes without a documented indication 369 and with sub-optimal 
review processes. 370 A systematic review in 2014 examined interventions to reduce 
inappropriate prescribing of antipsychotic medications in care homes and identified a wide 
variety of interventions from educational interventions to organisational changes. 201 





prescribing with some promising results. 201 Since that 2014 review other studies have 
shown that regular monitoring of antipsychotic prescribing can reduce the overall 
prescribing of antipsychotics in dementia 210 and improve the appropriateness of 
prescribing. 298 The WHELD study identified the value of antipsychotic review, 
demonstrating that it can lead to a 50% reduction in antipsychotic use in nursing homes. 210 
However, it also highlighted that to positively benefit the person with dementia any 
intervention to reduce antipsychotic medication needs to be supported by non-
pharmacological interventions such as social interaction. 210 
A qualitative study explored the challenges GPs experienced with BPSD. 332  In that study the 
participating GPs called for GP-specific guidance on the pharmacological management of 
BPSD. 332 Guidance for GPs in the form of a repeat prescribing tool to monitor the 
prescribing of antipsychotics in dementia would facilitate the conduct of antipsychotic 
reviews in general practice. However, there is currently no consensus on what the 
components of such a tool would be.  
The aim of this study was to use an expert consensus process to identify the key 
components of an antipsychotic repeat prescribing tool for use with people with dementia 




A Delphi method was used to establish expert consensus that would inform the 





dementia on antipsychotic medications. The Delphi is a “group facilitation technique that 
seeks to obtain consensus on the opinions of experts through a series of structured 
questionnaires” (known as rounds). 371 The key features of the Delphi method include; 
recruiting relevant experts to the study, compiling a questionnaires with a list of statements 
that the experts rate for agreement, calculating the results, giving anonymised feedback to 
participants about how their responses compare to the rest of the group and giving 
participants the opportunity to revise their responses to the questionnaire in light of this 
feedback. 372 This iterative process continues over multiple rounds of questionnaires until 
consensus is reached, with some statistical criterion being used to define consensus.  A 
modified Delphi was employed here, which combines the questionnaire with a physical 
meeting of experts to discuss the results. 373 This face-to-face meeting is recommended at 
the end of the last round to exchange views and resolve uncertainties and is, therefore, 
often considered to function as a final ‘round’. 373 We utilised a web-based platform to 
organise and facilitate communication. This eDelphi approach has practical advantages over 
the traditional paper-based Delphi model facilitating the participation of experts from 
different geographical locations and enabling faster response times. 374 
Research steering group: 
The research team formed a research steering group. This consisted of the research 
facilitator (NG) and two general practitioners (TF, AJ) both of whom have clinical and 
research expertise in the management of BPSD. The function of this working group was to 
review the literature to inform the development of the first round of the questionnaire and 





uncertainties. The members of the research steering group did not complete the eDelphi 
questionnaires. 
Selection and recruitment to the expert panel: 
Participants in the Delphi were purposively selected by the research team based on their 
known expertise in the area. 371 To ensure diversity, a panel of medical experts was 
recruited from different medical specialities to participate in the Delphi consensus. Medical 
professionals participating in the eDelphi included GPs, old age psychiatrists and 
geriatricians. 
GPs were eligible to participate if they met the following inclusion criteria; minimum of 10 
years as a practicing GP, regularly engaged in the management of patients with BPSD and 
provide care to people with dementia in a nursing home setting. GPs meeting these 
inclusion criteria were identified nationally. From this population, a sample of GPs was 
purposively selected to include GPs of different ages and with different practice locations 
(rural/ urban) with the goal of achieving maximum variation. Consultant psychiatrists and 
consultant geriatricians were eligible to participate in the study if they provided care to 
people with BPSD in a nursing home setting and if they had a research interest in this area 
with relevant peer-reviewed publications. Once eligible participants were identified they 
were individually emailed, provided with information on the study and invited to participate 
in the eDelphi.  
Questionnaire development: 
The questionnaire was iteratively developed by the research steering group. The content of 





templates from the UK and Canada 375-377  and by a review of international guidance 
documents on antipsychotic prescribing in dementia. 142,378-381 
Analysis of rounds & consensus criteria: 
We asked the participants to state the extent to which they agreed with a list of statements 
using a 5 point Likert scale. The option to provide free-text comments was provided 
throughout the questionnaire. The level of percentage agreement necessary to reach 
consensus for this particular study was informed by the literature on consensus criterion in 
Delphi processes 382 and by Delphi studies exploring similar research areas. 383-385 In cases 
where a statement received greater than or equal to 80% agreement it was agreed that 
consensus had been reached. These statements were omitted from further rounds and 
were automatically included in the monitoring template. Any statement receiving <40% was 
rejected and, therefore, excluded from the monitoring template. All statements that fell 
between 40%- 79% agreement were deemed undecided, i.e. had not reached consensus 
and so these statements were carried forward into the next round to be re-rated.  
In the second round of the eDelphi any statements which had not reached consensus in the 
first round were presented for re-rating using the same 5 point Likert scale. In this round 
each participant was provided with individualised feedback which included the mean 
answer of the group response to each statement in round one. Additionally, the 
participant’s own response to the statements in round 1 were provided to illustrate their 
position in the group. This offered Delphi members an opportunity to revise and refine 
initial answers based on the group opinion. Free text comments provided by participants in 
round one were also included as statements in round two if the same suggestion was made 





>70% agreement was consensus to include the statement and <50% agreement was 
consensus to exclude the statement.  
Study Ethics: 
Ethical approval was granted by Clinical Research Ethics Committee of the Cork Teaching 
Hospitals. Participants were advised in an information sheet and in the initial email they 
received, that completion of the first round of the eDelphi was considered to be their 




A total of 17 medical professionals with expertise in dementia care were invited to 
participate and 14 agreed to participate in the study. This group of 14 experts included; 8 
general practitioners, 4 old age psychiatrists and 2 geriatricians (see table 17 for the 
breakdown of the retention rate for each professional group).   
 
Table 17. eDelphi participants by professional group 






8 8 7 
Psychiatrists 4 4 2 








A total of 23 items were rated over two rounds to yield a total of 18 endorsed items and 5 
rejected items. Table 18 details the number of items rated, endorsed and rejected over the 
two eDelphi rounds. 
Table 18.  eDelphi statements accepted, rejected and re-rated at each stage  













Round 1 21 11 1 9 2 
Round 2 11 9 2 2* 0 
*2 statements brought to research steering group for discussion were ultimately rejected 
 
Round 1 questionnaire results: 
The first-round questionnaire consisted of 21 statements and participants were asked to 
rate the statements using a 5 point Likert scale (see table 19). Surveys were open for 
completion for 2 weeks. Nine of the statements reached consensus and were endorsed in 
round one. These statements were, therefore, included in the monitoring template and 
were excluded from the second-round survey. One statement received only 28.5% 
agreement, which was below the cut off of 40%, so this statement was automatically 
excluded from the monitoring template and from any further rounds of questionnaire. 11 
statements did not reach consensus, rating between 40% and 79%, therefore, all these 
statements were included in round two for re-rating. All statements that were endorsed, 










A repeat prescribing monitoring template for AP use in 
patients with dementia should include personal details 






A repeat prescribing monitoring template for AP use in 
patients with dementia should include clearly stated medical 
diagnosis 
92.8% Endorsed 
A repeat prescribing monitoring template for AP use in 
patients with dementia should include the name, dose and 
duration of AP drug prescribed 
92.8% Endorsed 
A repeat prescribing monitoring template for AP use in 
patients with dementia should include whether or not 
additional PRN APs were used during period of AP 
prescription  
100% Endorsed 
Medical review prior to initiation of APs for patients with 
dementia should include documented consent from patient 
with dementia/patient's next of kin prior to initiation of drug 
therapy 
28.5% Rejected 
Medical review prior to initiation of APs for patients with 
dementia should include trial of non-pharmacological 
treatment options prior to initiation of AP drug therapy 
92.8% Endorsed 
Prior to initiation of AP drug therpay by GPs, in patients with 
dementia, the following should be checked and documented  
 
  
1. Baseline FBC 78.5% No 
consensus 
2. Baseline LFTs 64.2% No 
consensus 
3. Baseline TFTs 78.5% No 
consensus 
4. Baseline U&Es 78.5% No 
consensus 
       5.   Baseline BMI  64.2% No 
consensus 
       6.  Baseline ECG  78.5% No 
consensus 
Adverse drug reactions – GPs should document 
improvements/disimprovements in BPSD following a period 
of AP use 
100% Endorsed 
The presence/absence of the following medication side 
effects should be documented prior to repeat prescribing of 






1. Increase in BMI 71.4% No 
consensus 
2. Cardiovascular disease/worsening of condition in 
patients with pre-existing cardiovascular disease 
78.5% No 
consensus 
3. Sedation  100% Endorsed 
4. Extra-pyramidal symptoms/impaired mobility 100% Endorsed 
5. Confusion 92.8% Endorsed 
Regarding review of AP prescription for patients with 
dementia: 
  
1. Patients with dementia who are prescribed AP 
drugs in the community for the first time should have 





2. Following initial 6 week review patients with 
dementia on AP therapy should have documented 
review by their GP at least 3 monthly thereafter 
85.7% Endorsed 
3. Medical reasons for continuation/discontinuation 




Qualitative feedback provided by participants in the free-text comment boxes of round one 
was thematically analysed. Where a suggestion was made by two or more participants it 
was included in the questionnaire for round 2. One suggestion made by 2 participants was 
that urinalysis or mid-stream urine (MSU) should be done as a baseline test prior to 
initiation of antipsychotic medication.  
‘…urinalysis should be standard baseline test +/- MSU…’ (Old Age Psychiatrist 1) 
‘I would also do an MSU’ (GP 1) 
As a result of these comments a statement on performing mid-stream urine analysis was 
included in the second round questionnaire.  
Another item that received several qualitative comments was the statement that 





was commenced. Three participants suggested that medical review should occur earlier 
than this: 
‘Earlier initial review may be more appropriate e.g 2 to 4 weeks’ (Old Age Psychiatrist 
1) 
‘Should be reviewed within a month’ (Geriatrician 2) 
‘Review should be earlier than 6 weeks’ (Old Age Psychiatrist 2) 
As result of these comments an additional statement was included in the questionnaire for 
round two stating that review should occur at 4 weeks. Even though the original statement 
that a review should occur at 6 weeks did achieve consensus in round one, in light of the 
qualitative feedback, the research steering group decided to include the original statement 
again in the questionnaire for round 2.  
The wording of one of the statements was modified based on the qualitative feedback 
provided by participants. The modified item related to conducting a body mass index (BMI) 
measurement. Initially the question was ‘The presence/absence of the following medication 
side-effects should be documented prior to repeat prescribing of antipsychotics in patients 
with dementia…increase in BMI’. This rating did not reach consensus in round one and 
concerns were raised about the practicality of measuring the BMI: 
‘BMI risk would not be high up my decision-making process given the typical patient 
profile…’ (Geriatrician 1) 
‘It would not be easy to weigh and measure a patient in a family home setting’ (GP 2) 
As a result, this question was modified to include the stem “where feasible” and was 





Finally, concern was raised as to the feasibility of performing an electrocardiograph (ECG) 
prior to commencing an antipsychotic:  
‘…Re ECG, this is very relevant, but not always possible – again, I don’t do this 
routinely myself. And would you hold down a psychotic patient to do an ECG??’ 
(Geriatrician 1) 
‘…A baseline ECG could be difficult in a home setting’ (GP 1) 
This statement had not achieved consensus in round one (78.5% agreement) so it was 
included in the second round questionnaire. Additionally, these qualitative comments 
regarding the feasibility of conducting an ECG were included in the individualised feedback 
to participants in round two. 
 
Round 2 questionnaire results: 
The second-round questionnaire consisted of 13 statements; 11 statements that did not 
reach consensus in round one and 2 additional statements that were included in response 
to the qualitative comments provided by participants in round one. Consensus was reached 
on 12 of the 13 statements in round two. Details on each statement included in round 2 and 
the consensus outcome are given in table 20. Nine statements achieved ≥70% agreement 
and these statements were included in the monitoring template. Two statements were 
rejected as they achieved ≤50% agreement. Two statements did not reach consensus in 
round 2 but both statements reached a low percentage agreement of 54%. In the context of 
the low percentage agreement for these two statements and in view of the fact that a third 





steering group for discussion. In a modified eDelphi such a face-to-face consensus meeting 
is often considered to be an additional round. 373 
The first statement discussed by the research steering group was the statement on the 
documentation of an increase in BMI prior to repeating a prescription for an antipsychotic. 
After discussion with the steering group this statement was rejected. The decision to 
exclude the statement was informed by the qualitative feedback in the Delphi rounds, a low 
percentage agreement of 54% in round two and a 17.4% reduction in percentage agreement 
from the first round to the second round.  The second statement discussed at the meeting 
was the statement that after initiation of an antipsychotic a patient should have a 
documented review by their GP within 4 weeks. This statement was added to round 2 after 
consideration of the qualitative feedback from round one, however, it received only a 54% 
agreement rating in round 2. The conflicting statement, recommending review at 6 weeks, 
was endorsed in both round one and round two of the eDelphi. In this context, it was 
decided to reject this statement that review should occur within 4 weeks in favour of the 
statement that review should occur at 6 weeks. 
The combined consensus from round one and round two resulted in 18 statements that 
were endorsed by the expert panel. These 18 statements informed the content of an 
antipsychotic repeat prescribing tool for GPs to use when monitoring people with dementia 
on antipsychotics. The final tool was developed by the Delphi steering group and is available 











Prior to initiation of AP therapy by GPs in patients 
with dementia, the following should be checked; 
 
  
1. FBC 90.9% Endorsed 
2. LFTs 90.9% Endorsed 
3. TFTs 90.9% Endorsed 
4. U&Es 81.8% Endorsed 
5. BMI 50% Rejected 




Where feasible, the presence/absence of the 
following medication side effects should be 
documented prior to repeat prescribing of APs in 
patients with dementia; 
 
  
1. Increase in BMI 54% Brought for discussion 
in the research steering 
group 
2. Cardiovascular disease/worsening of 
condition in patients with pre-existing 
cardiovascular disease  
 
72.7% Endorsed 
In a monitoring template for repeat prescribing of 
APs in patients with dementia;  
 
  
1. Patients with dementia who are 
prescribed AP drugs for the first time 
should have a documented review by 
their GP within 6 weeks 
72.7% Endorsed 
2. Following initial review, patients with 
dementia on repeat prescribed AP therapy 
should have documented review by their 
GP at least 3 monthly thereafter 
72.7% Endorsed 
3. Medical reasons for 
continuation/discontinuation of the drug 
should be documented by the GP at each 
review 
81.8% Endorsed 
4. Patients with dementia who are 
prescribed AP drugs for the first time 
should have a documented review by 
their GP within 4 weeks 
54.5% Brought for discussion 







This study utilised a modified eDelphi expert consensus process to inform the development 
of an antipsychotic repeat prescribing tool in people with dementia in a general practice 
setting. This repeat prescribing tool will provide GPs with a practical, relevant and 
implementable resource that will support them in monitoring their patients with dementia 
on antipsychotic medications.  
A number of key issues regarding the challenges of monitoring antipsychotic prescribing in 
dementia were identified including use of ECG, measurement of BMI and the scheduled 
time for review of prescribing. The practical difficulties of obtaining an ECG prior to initiation 
of antipsychotic medication was highlighted by several participants in the qualitative 
feedback, however, it did ultimately achieve consensus in round 2 and was, therefore, 
included in the final tool. International guidelines do not specifically recommend performing 
an ECG, 142,378,381 however, given the propensity of nearly all antipsychotic medication to 
cause QT prolongation it is a reasonable consideration, where practical, in advance of 
initiating these medications. Likewise, although BMI measurement is not recommended in 
the existing guidelines, 142,378,381 it was included as a statement for review in the eDelphi as 
antipsychotics are known to result in weight gain. 386 However, the difficulties of measuring 
BMI prior to initiation of an antipsychotic was highlighted by several participants and this 
statement was eventually rejected in round 2.  
One particularly contentious issue was the recommended time interval after an initial 
prescription for an antipsychotic during which a GP review of the effect of the medication 
should be undertaken, with some participants advocating for a review within 4 weeks 





the statement that was ultimately endorsed. The existing guidelines do vary on this issue of 
when a review should occur after initiation of an antipsychotic medication in a person with 
dementia. For instance, the most recent 2018 NICE guidelines on dementia care recommend 
that initial treatment with an antipsychotic should use the lowest effective dose for the 
shortest time with a reassessment of the person at least every 6 weeks. 141 This is echoed in 
the American Psychiatric Association (APA) 2016 guidelines on antipsychotic medications in 
dementia which recommends a review of symptoms 4-6 weeks after initiation of an 
antipsychotic. 142 Guidance from Australia recommend that if there is no treatment efficacy 
within a relatively short timeframe, (e.g. one to two weeks), treatment should be 
discontinued. 381 Overall, in the different guidance documents the recommended time 
between medication initiation and GP review of the effect of the medication ranges from 2 
to 6 weeks. The different guidance documents do not distinguish between a person with 
dementia living at home from a person with dementia living in a nursing home setting. 
However, in a nursing home setting residents are being observed by the nursing home staff, 
therefore, a GP review at 6 weeks may be acceptable. It is likely, however, that a person 
with dementia living at home would benefit from an earlier review.  
One finding that was overwhelmingly rejected in round one was the statement that ‘medical 
review prior to initiation of antipsychotics for patients with dementia should include 
documented consent from patient with dementia/patient's next of kin prior to initiation of 
drug therapy’. This statement was included in the original questionnaire for round one as 
both the NICE guidance and the APA guidance both recommend discussing the benefits and 
potential harms with the person and their family member or carer prior to commencing an 
antipsychotic. The practical challenges of obtaining ‘documented consent’ may have 





participants to discuss the risks and benefits with the person with dementia or their 
caregiver. Antipsychotics should only be prescribed if the person with dementia is a danger 
to either themselves or to others. 187 In these situations it may not always be possible to 
obtain documented consent from either the person with dementia, who may not be able to 
give informed consent, or their family member, who may not be available.  
 
Comparison with existing literature 
The Delphi consensus approach has been used successfully to develop criteria for potentially 
inappropriate medication in people nearing the end of life. 179 More specifically Delphi 
studies have been used previously to address the issue of potentially inappropriate 
prescribing of medication to people with dementia. 387-392 However, we are unaware of any 
existing literature that used a consensus development method to inform the development 
of an antipsychotic repeat prescribing tool for use in people with dementia.  Previously a 
modified eDelphi consensus procedure was used to develop practice guidelines on the 
prescription of antipsychotics to people with dementia living in care homes. 393 The majority 
of clinicians participating in that expert panel were Old Age Psychiatrists, however, the 
views of geriatricians and GPs were incorporated. Although the study did not develop a 
repeat prescribing tool it did address certain issues surrounding antipsychotic initiation and 
review and the results largely echoed our results, however, there were some notable 
differences. These differences centred on the consensus reached on the consultation that 
should take place with family caregivers and on conducting ECGs prior to initiating 
antipsychotic medication. Firstly, the study recommended that EGG was only necessary in 





that can prolong the QT-interval.  Secondly, the study affirmed that the patient (if 
appropriate) and the primary family caregiver should be consulted in the critical phases of 
treatment, specifying that they should be consulted pre-treatment with an antipsychotic. 
The study did not discuss what the time interval should be between antipsychotic initiation 
and review, however, it does state that if there is a lack of improvement, the dose should be 
increased until side effects appear, and continued for a period of 4 weeks.   
 
Strengths & Limitations 
A Delphi method was chosen here as it is particularly appropriate when developing a 
consensus when existing evidence is insufficient. Other methods of consensus development, 
such as nominal group technique was not feasible as the experts participating in the 
consensus development worked in different geographical regions. Another strength of 
choosing the Delphi technique is that of quasi-anonymity 382 although the participants are 
known to the researcher, the participants remain anonymous to each other, preserving 
independent opinion. The multidisciplinary nature of the Delphi participants offered the 
opportunity to consider the different views of clinicians involved in the care of people with 
BPSD and enriched the results. 
A limitation of this study is the small number of Delphi participants, with only 14 members. 
However, as little as 10 members have been reported to yield strong evidence in Delphi 
studies. 394 Another limitation is the relatively high dropout rate of 21.4% after 3 members 
dropped out of the study in round 2. However, despite this drop out, the response rate 
remained above 70% for each round, which is the recommended response level in order to 





methodology prevented in-depth discussion amongst the expert participants, however, the 
ability to provide in-depth qualitative feedback allowed for the sharing of idea. Additionally, 
the existence of the research steering group facilitated in-depth discussion on selected 
topics as required. As the content for this eDelphi was quite clinical in nature the decision 
was made to not include people living with dementia or their caregivers in the initial eDelphi 
process. However, an important next step would be to get the input of people living with 
dementia, their caregivers and nursing home staff prior to implementation of the 
monitoring tool in a clinical setting. 
Implications for future research 
The existence of a repeat prescribing tool for monitoring antipsychotic prescribing in general 
practice will not in itself guarantee that monitoring will occur. The feasibility and 
acceptability of the tool needs to be evaluated in clinical practice. This phase will involve all 
relevant stakeholders including people with dementia, their caregivers, nursing home staff 
and community pharmacists. 
This tool needs to be evaluated to identify whether implementation of the tool leads to 
more frequent reviews and more appropriate prescribing and de-prescribing of 
antipsychotics in people living with dementia. Future research then needs to focus on 
incorporating this antipsychotic repeat prescribing tool into a wider intervention that 
addresses all the barriers to conducting antipsychotic reviews in people with dementia in a 
general practice setting. These challenges can include a lack of knowledge on the part of 
some GPs of the adverse effects of antipsychotics in dementia and an overestimation of 
their benefits in BPSD. 155,278 This can lead to a lack of motivation to monitor prescribing on 





highlighting the value of monitoring antipsychotics, GPs need to be further supported by 
practical advice on how to conduct an antipsychotic review and how to gradually taper 
antipsychotic medications. This repeat monitoring tool provides general prescribing 
guidance to GPs monitoring patients with dementia on an antipsychotic. However, patients 
will need to be assessed and managed at an individual level in accordance with their co-
morbidities and risk factors. The tool developed here is intended as an educational device as 
well as a practical tool. Further GP relevant guidelines on antipsychotic prescribing would 
support GPs in conducting this task. 332  
 
9.6 Conclusion 
Through an expert consensus process we developed a repeat prescribing tool for use by GPs 
when initiating and monitoring antipsychotic medications prescribed to people living with 
dementia in the community or in a nursing home setting. This tool provides GP with 
practical advice that can be lacking in current guidelines and provides an additional level of 
detail to GPs to aid clinical decision making. This tool will help to support GPs by providing a 
structured format to use when reviewing antipsychotic prescriptions in people with 









CHAPTER 10. DESIGNING AN INTERVENTION TO IMPROVE THE 
MANAGEMENT OF BEHVIOURAL AND PSYCHOLOGICAL SYMPTOMS 
OF DEMENTIA IN GENERAL PRACTICE USING THE BEHAVIOUR 
CHANGE WHEEL 
 


















It has been suggested that one of the reasons for the limited success of healthcare 
behavioural change interventions in the past has been a lack of an explicit rationale for the 
intervention chosen and the use of inappropriate methods to design interventions. 236 
Previously, many interventions have been designed based on researcher intuition or, to use 
a term coined by Martin Eccles, the principle of ‘it seemed like a good idea at the time’. 396 
Furthermore, healthcare interventions are notoriously poorly described, 397 making 
replication arduous or even impossible. 398 In the context of poor intervention design, 
inadequate intervention description and difficulty replicating healthcare interventions the 
value of theory based approaches to intervention design is increasingly recognised. The UK 
Medical Research Council (MRC) guidance on developing complex interventions in 
healthcare, outlined in Chapter 4 of this thesis, endorses the idea of identifying and 
developing theory in order to explain the rationale for a complex intervention, identify the 
changes that are expected from the intervention and to investigate how this change might 
be achieved. 242 However, the MRC guidance does not advocate for any particular theory 
and there is a vast array of potential theories to choose from. The Behaviour Change Wheel 
(BCW) developed by Michie et al offers a potential solution by  describing a structured, 
reproducible approach to applying behavioural theory to intervention development, 239 as 
previously outlined in Chapter 4 of this thesis. Each step of the structured approach of the 
BCW can be mapped to the MRC framework for developing complex interventions in 







Table 21. How the BCW steps map to the three stages of intervention development outlined in the 
MRC framework (adapted from Sinnott et al) 399 
MRC Development Stage BCW Stages BCW Steps 
1. Identify the 
evidence base 
1. Understand the 
behaviour 
1. Define the problem in 
behavioural terms 
2. Select the target 
behaviour 
3. Specify the target 
behaviour 





4. Identify what needs to 
change 
5. Identify appropriate 
intervention functions 
6. Identify policy categories 
3. Model process and 
outcomes 




7. Identify behaviour change 
techniques (BCTs) 
8. Determine mode of 
delivery 
 
At the centre of the BCW is the COM-B model. The COM-B model identifies three core 
components of behaviour change; capability (the physical or psychological capability to 
enact the behaviour), opportunity (physical or social environment to enable the behaviour) 
and motivation (reflective and autonomic mechanisms that activate or inhibit the behaviour 
(see Figure 12). When considering the reasons why an individual is, or is not, engaging in a 










Figure 12. The COM-B model of the BCW (source: Howarth et al, 2017 400) 
 
 
The Theoretical Domain Framework (TDF) is an elaboration of the COM-B model. The TDF is 
a tool for selecting which behavioural change techniques (BCTs) to include in behavioural 
change interventions. 401 Originally developed to understand health professional behaviour, 
402 the TDF has been used primarily in the context of health to understand behaviour at the 
individual level. 239 Each of the 12 domains of the TDF can be mapped to a COM-B 
component (see Figure 13). 402 In this chapter we describe how the steps outlined in the 
BCW approach guided the development of our intervention to improve the management of 
















The BCW outlines three phases in the intervention design process; understanding the 
behaviour, identifying possible interventions and identifying content and implementation 
options.  
Phase 1: Understand the behaviour 
The BCW begins with a behavioural analysis of the problem. The first step in designing an 
effective intervention is having a clear understanding of the problem you are attempting to 
address in behavioural terms. There are four steps outlined in phase 1 of the BCW (as 
outlined in Table 14). 
Step 1: Define the problem in behavioural terms 
This step aims to clearly define the problem you are trying to address. We searched for 
relevant literature in the area of the management of BPSD in general practice. There was no 
qualitative synthesis or systematic review of the literature conducted to date, therefore, we 
conducted a mixed methods systematic review and meta-ethnography of GPs’ knowledge, 
attitudes and experiences of managing BPSD [as described in Chapter 5]. 330 The over-
arching perspective identified from the meta-ethnography was that in the context of 
resource limitations a therapeutic void was created in BPSD. This resulted in GPs being over 
reliant on antipsychotics and family caregivers when managing BPSD. We also conducted a 
qualitative exploration of GPs’ experiences of the challenges of managing BPSD in general 
practice [as described in Chapter 6]. 332 Many participating GPs struggled at an ethical level 
with the decision to prescribe potentially harmful sedative medication but felt they had little 





expectations and the lack of implementable clinical guidelines. In the qualitative study, GPs 
reported difficulty assessing for potential causes of BPSD, in particular pain. This led to a 
descriptive cross-sectional study exploring GPs’ knowledge and attitudes to the assessment 
and management of pain in dementia. This study is described in full in Chapter 7. 403 In the 
study the importance of good communication with family carers and nursing home staff was 
highlighted, drawing attention to the potential value of an inter-professional approach to 
educational initiatives in this area. The study also highlighted the challenges of providing 
optimum care to people with dementia with the current climate of under-resourcing in both 
nursing home and community settings in Ireland. To further investigate the findings of the 
qualitative study a descriptive cross-sectional study was conducted that aimed to explore 
the knowledge and attitudes of GPs to the prescribing of antipsychotics in people with 
dementia in Ireland. In this study, reported in Chapter 8, the majority of GPs reported 
recommending non-pharmacological strategies first line when managing BPSD. The GPs 
reported that the main influencers of prescribing antipsychotics in BPSD were nursing staff 
and family.  Of note the majority of respondents did not routinely monitor antipsychotic 
prescribing in people with dementia 
Step 2: Select the target behaviour 
The aggregated data from the meta-ethnography, 330 the interviews with GPs 332 and the 
quantitative survey of GPs knowledge of and attitudes to the assessment and management 
of pain in dementia, 403  and the quantitative survey of GPs knowledge of an attitudes 
towards the prescribing of antipsychotic medications in dementia were thematically 





We (AJ, TF) then assessed and prioritised the potential behaviours by applying the following 
criteria outlined by the BCW; 404 the likely impact of changing the behaviour, how easy it is 
likely to be to change the behaviour, the positive ‘spillover effect’ that change this 
behaviour may have on other behaviours, the ease with which one could measure the 
extent to which the intervention has changed the behaviour.  These criteria are outline in 
Table 22. The list of potential target behaviours were evaluated on these four criteria. For 
each of the four criteria the potential behaviour was given a score from ‘very promising’ 
(score of 3) to ‘unpromising’ (score of -1), leaving each potential behaviour with a ‘total 
score’. This process led to the identification and prioritisation of the most promising 
behaviours to target. Through discussions with the wider research team, which included 
three practising GPs (AJ, TF, CB), a public health researcher (JB) and a health psychologist 
with expertise in the BCW (JMcS), the target behaviour was selected. The sources of data 
that informed the decisions made in steps 2-4 are outlined in the schematic below (Figure 
13). 








Factors to consider when selecting the target behaviour: 
• The likely impact of changing the behaviour 
• How easy it is likely to be to change the behaviour 
• The positive ‘spillover effect’ that change this behaviour may have on 
other behaviours  
• The ease with which one could measure the extent to which the 






Step 3: Specify the target behaviour 
The aim of step 3 of the BCW is to specify the behaviour in appropriate detail and in its 
context. We specified who needed to perform the behaviour, what needed to be done and 
when, where and how often they need to do it. This step required input from two GPs with 
a special interest in dementia care (AJ, TF) and a third author (JMcS) who has expertise in 
intervention design using the BCW. This step also required specific clinical detail to specify 
the target behaviour. This clinical detail was lacking from existing guidelines. Therefore, the 
the eDelphi study, reported in Chapter 9, provided consensus on aspects of the clinical 





Figure 14. BCW Phase 1: Understand the Behaviours 
            
            Data sources      BCW Steps     Phase 1 outcomes
   













Step 3: Specify the target behaviour 
Mixed Methods Systematic Review 
& Meta-ethnography           
(Chapter 5) 
 
 Qualitative Study with GPs 
(Chapter 6) 
 
Online Discussion Forum       
(appendix 6, supplementary 
material 14) 
 
Cross-sectional descriptive study 
of GPs’ knowledge of & attitudes 
towards the prescribing of 
antipsychotics (Chapter 8) 
 
Step 2/3: Select & Specify the 
Target Behaviour 
• Using criteria outline in 
table 15 




Step 4: Identify what needs 
to change 
• Code data sources to the 
COM-B model 




• Target behaviour 
selected 
• The reasons why GPs not 
engaged in this target 
behaviour identified 
(using the COM-B model) 
• Domains that should be 




Cross-sectional descriptive study 
of GPs’ knowledge of & attitudes 







Step 4: Identify what needs to change 
The aim of this step is to identify what it will take to bring about the desired behaviour 
change. This step involves using the COM-B (capability opportunity motivation – behaviour) 
model to understand the target behaviour in the context in which it occurs. As shown in 
Figure 14, we used four sources of data to understand why the target behaviour was not 
being carried out; the primary interview data from the qualitative study,332 the meta-
ethnographic synthesis from the systematic review, 330 the results of the descriptive cross 
sectional study on the knowledge and attitudes of GPs to the management of BPSD and, 
finally, data from an online GP dementia module.  
The data from the GPs participating in the online dementia module was collected from an 
online discussion forum for 19 GPs who were engaged in a 12 week blended learning 
course. Two of the authors (AJ & TF) designed and developed this online module. One unit 
of the dementia module related to the management of BPSD and ran over two-weeks. Case-
based scenarios were used to facilitate an online discussion where GPs shared their 
knowledge and experiences of managing BPSD. AJ acted as an online tutor for these two 
weeks. A summary of the methods and results of this analysis of the online discussion forum 
is available in Appendix 6, supplementary material 14. 
We (AJ, TF) coded the original interview data, the original meta-ethnography data, the 
quantitative results on GPs knowledge and attitudes towards BPSD and the online 
discussion forum data relevant to the GPs’ physical and psychological capabilities, social and 
physical opportunities and automatic and reflective motivations. The aim of this process was 
to highlight why GPs were not engaged in the target behaviour and what needed to occur 





using a more detailed tool to understand behaviour, the TDF. The results of this behavioural 
analysis was then presented to the expert panel for discussion and was refined accordingly.  
 
Phase 2: Identify intervention options 
In phase 1 we selected the target behaviour and identified the COM-B components and TDF 
domains that could be targeted as potential levers of change. The next phase involved 
considering what types of interventions were likely to bring about this desired behaviour 
change. This phase consists of two steps. 
Step 5: Identify intervention functions 
The BCW describes nine intervention functions that were identified following a synthesis of 
19 frameworks of behaviour change interventions. 239The nine intervention functions are; 
education, incentivisation, environmental restructuring, training, enablement, modelling, 
persuasion, coercion and restriction. For each of the barriers to achieving the target 
behaviour (identified in step 4), the intervention function that would best address that 
barrier was selected from the nine intervention functions. The selection of intervention 
function was aided by the matrix outlined in the BCW process which links each COM-B 
component, or TDF domain, with the intervention function which is likely to be effective in 
bringing about that change. 239 The intervention functions were then graded into first and 
second line options using the APEASE criteria. The APEASE criteria is an approach outlined in 
the BCW process. 404 APEASE criteria considers the affordability, practicability, effectiveness, 





In addition, previously unreported data from the qualitative interviews with GPs 332 and the 
meta-ethnography 330 were analysed and the results informed the selection of appropriate 
intervention functions. During the interviews conducted with GPs, they were asked about 
strategies they believed would improve the management of BPSD in general practice (see 
part 3 of the topic guide in appendix 2, supplementary file 10). We (AJ,TF) coded and 
analysed the data to identify potential intervention features that GPs believed to be 
important and we identified particular interventions suggested by GPs. Previously 
unreported data from the studies included in the meta-ethnography were also analysed and 
coded to identify intervention features suggested by the original authors of the included 
studies. NVivo 11 was used for data management. We (AJ, TF) used the data from the 
qualitative interviews, the meta-ethnography and our experience as GPs to rank the 
intervention functions using the APEASE criteria. A third author with expertise in using the 
BCW (JMcS) was consulted regularly.  
 
Step 6: Identify policy categories 
The BCW suggests which policy categories are likely to be appropriate and effective in 
supporting each intervention function. For each intervention function identified in step 5 we 
identified the policy categories that could potentially support the delivery of the 
intervention functions. We then identified the policy categories that were common across 
all the identified intervention functions. From this list we selected the most appropriate 






Phase 3: Identify content and implementation options 
In the third phase we detailed the content of the intervention and identified the most 
appropriate method of implementing the intervention. 
Step 7: Identify behaviour change techniques 
The BCW approach links intervention functions, as identified in step 5, to behavioural 
change techniques (BCTs). These BCTs are the “active component of an intervention 
designed to change behaviour”. 239 For each intervention function, the BCTs that are 
outlined in the BCW guidance as being the ‘most appropriate’ for that function were 
considered. 239 This resulted in the creation of a ‘long list’ of potentially relevant BCTs for 
each intervention function. We (AJ, TF) then narrowed down this list by consulting the BCW 
book, where there is a table linking intervention functions to the most frequently used BCTs, 
and by applying the APEASE criteria to the potential BCTs. This resulted in a shortened list of 
30 potentially relevant techniques. Each of these BCTs were considered in the context of 
BPSD management in nursing homes and the most appropriate BCTs were shortlisted by AJ 
& TF (both of whom have practical experience of providing GP care to nursing homes and, 
therefore, had a good understanding of the environmental context).  The final BCTs to be 
included in the intervention were agreed through discussion with the wider multidisciplinary 
research team, which involves expertise in general practice (AJ, TF, CB), dementia in primary 
care (AJ, TF), prescribing in general practice (CB) and intervention design (JMcS, JB). In a 
multi-disciplinary research team meeting we collectively assessed the suitability of each of 
the BCTs. When making a decision to eliminate or retain a BCT the panel was influenced by 





GPs’ knowledge and attitudes to BPSD management and the findings from the online 
discussion forum. 
Step 8: Identify mode of delivery 
To inform the selection of the preferred mode(s) of delivery we sought the input of relevant 
stakeholders. As noted by Jones et al., when studies are concerned with defining criteria for 
clinical interventions the most appropriate experts will be clinicians practising in the field; 
406 which in this case is GPs. However, the nursing home staff are also a key stakeholder 
group, as are the community pharmacists attending the nursing home. To identify 
community pharmacists we contacted two large nursing homes in the Cork area and asked 
them for the details of the providing pharmacy. We then contacted the pharmacies and 
asked them to participate in a meeting. Two pharmacists agreed to participate in the 
meeting where the plans for the intervention were outlined and the pharmacists were 
asked for their feedback on the intervention. Specifically we enquired about the proposed 
role of the pharmacist in providing feedback to GPs on their antipsychotic prescribing in a 
nursing home. Nursing staff that were known to the researchers through their involvement 
in national guideline development committees were contacted and asked to participate in 
an interview. Two nurses agreed to review the intervention components and provide 
feedback in an interview with AJ. To further engage with GPs we discussed the proposed 
intervention with 16 GPs enrolled in the 2018/9 blended learning dementia module. The 
intervention was described in a thread of the online discussion forum and participants were 
invited to give their feedback on the intervention and the supporting material (i.e. the 
monitoring tool and the audit template). The intervention was also discussed in a face-to-





feedback was obtained from these stakeholders is available in Appendix 6, supplementary 
material 19).  In deciding on the most appropriate mode of delivery, in addition to this work 
with relevant stakeholders, the APEASE criteria and issues related to future evaluation of 
the intervention were considered by the research team.  
In developing the clinical content of the intervention it was noted that there was a lack of 
consensus on some of the recommendations in existing clinical guidelines on BPSD. To 
address this lack of consensus a modified eDelphi technique was employed to clarify aspects 
of the clinical content of the intervention. 405 This eDelphi study is reported in Chapter 9 of 
this thesis. 
We used the TIDieR (Template for Intervention Description and Replication) checklist to 
describe our final intervention in detail, thus allowing for future replication. 407 
 
10.3 RESULTS 
Phase 1: Understand the behaviour 
 
Step 1: Define the problem in behavioural terms 
The healthcare problem was identified as being the mismatch between GPs current 
approach to the management of BPSD, as identified in the studies conducted as part of the 
research 330,332,403 and best practice recommendations.  
International best practice recommends that non-pharmacological interventions be used 
first line in BPSD and that pharmacological interventions should only be used where there is 





interviews, the challenges GPs experienced when attempting to implement these best 
practice recommendations at the coal-face was evident. In the context of resource 
constraints, a lack of clinical guidelines and prescribing pressures, it was challenging for GPs 
to not prescribe psychotropic medication. The decision to prescribe was often viewed in a 
finite way with little consideration given to the possibility of stopping or withdrawing the 
medication in the future. Similarly, in the meta-ethnographic synthesis, a review finding in 
which we had a high level of confidence was that antipsychotics were used to facilitate 
coping; their use enabled nursing home staff, family carers, the person with dementia and, 
at times, the GPs to cope with the behaviours and symptoms.  
Step 2: Select the target behaviour 
The aggregated synthesis of the four different data sources, 330,332,403 as outlined in Figure 
14, enabled the research team to generate a list of potentially modifiable GP behaviours to 
address the problem (Table 23). 
Monitoring of antipsychotic prescribing was considered to have a high likelihood of 
implementation. Unlike some of the other potential target behaviours monitoring 
antipsychotic prescribing would not require a significant investment in healthcare funding, 
although it was recognised that it would require an investment of GPs’ time. Addressing the 
monitoring of antipsychotic prescribing was considered to have very promising effects on 
‘spill-over behaviours’ such as providing an evidence base for prescribing decisions, 
decreasing reluctance to discontinue or reduce antipsychotics and creating more realistic 
expectations on the benefits of antipsychotic prescribing. However, it was noted that one 
potentially negative spill-over effect of monitoring antipsychotic medications in BPSD is that 





such as benzodiazepines and z-drugs. 7,104  These drugs have an inferior evidence base and 
their sedative effects can result in significant adverse events in this patient population. 
Although this substitution is more likely to occur if the intervention targeted initiation of 
antipsychotics rather than monitoring, it is still important that an intervention focusing on 
the monitoring of antipsychotic medications addresses this potential negative spill-over 
effect. Finally, it was considered that the extent to which an intervention in this area would 
change the target behaviour was very measurable. 
The other modifiable behaviours were judged to be less promising overall when all the 
criteria outlined in Table 22 were considered. Some behaviours such as ‘maintaining good 
relationships with primary care team members’ were considered to have a low likelihood of 
implementation given the regional variation of functioning primary care teams. 2 Other 
behaviours such as ‘not relying on family caregivers’ were considered to be impractical 
given that the behaviour was influenced by inadequate community based services and 
supports. All four data sources highlighted the challenges that GPs face attempting to 
provide optimum care in a sub-optimum environment with understaffing in nursing homes 
and inadequate supports in the community.  The decision to focus on the monitoring of 
antipsychotics, rather than the initiation of antipsychotics, was deliberate and was informed 
by all four data sources. By focusing on the monitoring of antipsychotics we are addressing a 
specific behaviour where antipsychotics are commenced with no plan for monitoring or 
discontinuing. Targeting the monitoring of antipsychotics in BPSD was considered to have a 
high chance of resulting in behaviour change. A review of systematic reviews of effective 
interventions in primary care found that interventions related to prescribing showed a 
particularly good effect on quality improvement. 408 Interventions that aim to reduce 





prescribing have been shown to be successful. 201,298 In a recent cluster randomised 
controlled trial conducted in the UK the introduction of antipsychotic reviews was shown to 
significantly reduce antipsychotic use by up to 50%. 210 
Finally, existing evidence and new evidence conducted for this research suggested that the 
monitoring of antipsychotic prescribing is currently sub-optimal. In the UK, a national audit 
of antipsychotic prescribing conducted in 2012 found 1001 (62%) of patients with dementia 
were prescribed an antipsychotic for more than 6 months and only three-quarters had a 
documented review of response in the previous 6 months. 370 The national audit identified 
that medication review of long term prescribing of antipsychotic prescribing as a priority 
area to improve the care provided to people with BPSD. Findings from our qualitative study, 
332 the cross-sectional descriptive study on GPs management of BPSD and the online 
dementia module all suggested that most GPs in Ireland did not have a formal, systematic, 






Table 23.  BCW Step 2/3.  
Prioritising modifiable GP behaviours that could improve the management of BPSD in general practice identified from the four data sources 
Behaviour Impact of changing 
behaviour 
Likelihood  of 
Implementation 
Spill-over effect on 
other behaviours 
Ease of measurement Total 
Score* 
 
Failure to engage in a proactive 








-May improve referrals 






       7 
 
Focusing on medication management of 





-barriers to detailed 








   
     10 
 
Not maintaining good relationships with 







-PCT often only virtual 












       6 
 
Making decisions on the management of 







-if guidelines are GP 




-decrease AP rx, 
increase dose reduction 






    
       9 
Consulting GP colleagues for emotional 






-reason for not 
consulting other GPs is 
Very Promising 




-may be difficult to 
measure the impact 
 





complex & relates in 




of a group of GPswSI 
dementia 
encourage use of an 
evidence-base 
Relying on pharmacological interventions 
when managing BPSD instead of non-
pharmacological management strategies 
(SR, QS) 










    10 
Using antipsychotics to enable family 
caregivers and nursing home staff to 
cope with the behaviours and symptoms 












      7 
 
Basing prescribing decisions on their own 
personal experience with drug rather 






-some GPs prefer to 
make decisions this 
way (QS) 







      8 
 
Incorrectly estimating the risk versus the 






-but if there are no 
practical alternatives 
provided given then 








        
    10 
Failure to discontinue psychotropic 
medication as concerned this will lead to 





-but resourcing may 
still provide a barrier 
 
Promising 
-could impact on over-
estimation of benefits of 










Not monitoring the prescribing of 















-impact on reluctance to 
d/c, over-estimating 
benefits, basing 
prescribing decisions on 




over-emphasis on APs 
could lead to prescribers 
switching to less 
effective, sedative 






     12 
 
Not effectively managing expectations of 







-poor diagnostic & 
disclosure practices 








       6 
 
Not relying on family caregivers to 
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Step 3: Specify the target behaviour 
The BCW provides guidance on questions that need to be answered in order to specify the 
target behaviour as precisely as possible. 239   
What is the behaviour that will be targeted for change? 
The monitoring of antipsychotic prescribing in people with dementia. 
Where is the behaviour performed? 
Antipsychotics are prescribed to people with dementia living at home in the community and 
those living in nursing homes. 194 These two settings, a person living in a nursing home and a 
person living at home in the community, differ significantly in terms of systems, 
stakeholders and environmental context. For example, in our systematic review we found 
that in the community the family plays a pivotal role, however, in the nursing home setting 
it is the nursing home staff who are the predominant influence on prescribing. 330 Other 
practical differences exist such as how the medications are prescribed; prescribing in the 
community setting occurs in a GP practice which, in Ireland, is almost universally computer 
based; 45  however, prescribing in the nursing home setting is typically paper based. 
Consequently, it is unlikely that the same intervention could be designed for and effectively 
implemented in these two diverse settings.  
In deciding on which setting to focus on, the research team considered the evidence for the 
prescribing of antipsychotics in the two settings and consulted with GPs working clinically in 
both areas. People with dementia living in nursing homes are significantly more likely to be 
prescribed an antipsychotic than those living in the community. 194 A 2016 Irish study found 





an existing prescription for an antipsychotic, whereas 19% (78/409) of people with 
dementia admitted from their own homes had a pre-existing prescription for an 
antipsychotic. 194 Furthermore, a UK study in 2012 197 looking at the prevalence of anti-
psychotic prescribing in dementia in 59 GP practices found that 15.3% (161/1051) of people 
on the register were receiving low-dose anti-psychotics. This UK study examined whether 
the prescription originated in primary or secondary care and found that only 43% (70/161) 
of these prescriptions for anti-psychotics were initiated by the GP. Therefore, of the 1051 
people with dementia living at home who attended these 59 GP practices 70 people (6.6%) 
were commenced on an antipsychotic by a GP – an average of only 1 person per GP 
practice. A further issue raised through discussion with our expert panel was that GPs don’t 
tend to monitor their prescribing of any one particular class of drug in the community. 
Therefore, the acceptability of asking GPs to monitor one specific drug in one specific 
disease entity was discussed. In contrast, in the nursing home setting, medications are more 
likely to be monitored and reviewed. In view of the much higher prevalence of antipsychotic 
prescribing in nursing homes, and considering that medication monitoring is more 
acceptable in nursing home environment, the research team selected the nursing home 
setting as the more appropriate setting to target with our intervention. 
 
Who needs to perform the behaviour and with whom do they perform it? 
GPs need to monitor their prescribing of antipsychotics to people with dementia. However, 
they need to be supported by nursing staff. Other relevant stakeholders include; the person 
with dementia who is prescribed the antipsychotic and their family; the community 





When is the behaviour performed? 
In Ireland the independent nursing home regulator, HIQA, currently requires that nursing 
homes conduct a general medication review of each resident’s medication every three 
months. There is no specific requirement for reporting on antipsychotic monitoring. 
However, it was considered that this would be an opportune time to specifically introduce a 
review of antipsychotic prescribing.  
Existing guidelines differ in their recommendations on when reviews of antipsychotic 
prescribing should occur. For example, the American Psychiatric Association (APA) published 
practice guidelines on the use of antipsychotics in dementia in 2016. 142 This guideline 
recommended that if there is no clinically significant response after a 4-week trial of an 
adequate dose of an antipsychotic drug then the medication should be tapered and 
withdrawn. However, UK based guidance documents such as the recently updated NICE 
guidance recommend assessing response at “regular intervals” and reviewing antipsychotic 
prescribing every 3 months or according to need. 141  
To address some of the inconsistencies in the recommendations around antipsychotic 
monitoring in people with dementia, the results of the eDelphi consensus on the monitoring 
of antipsychotic prescribing in dementia were used to inform the specification of the target 
behaviour. 405 In consideration of the results of the eDelphi study we agreed that the review 
of antipsychotic prescribing in people with dementia should occur 6 weeks after a new 
prescription and every 3 months thereafter or more frequently if clinically indicated. 
The target behaviour was, therefore, specified as GPs to systematically monitor their 
prescribing of antipsychotic medication to people with dementia in nursing home settings 





Table 24. Specifying the target behaviour 
BCW Question Decision Reason for decision 
 
What behaviour? Systematically monitoring 
the prescribing of 
antipsychotic medication 
to people with dementia 
Identified as an aspect of BPSD that is 
sub-optimally management.  
Considered to have a high likelihood of 
implementation. 
 
Where is the 
behaviour 
performed? 
Nursing homes Antipsychotic prescribing for BPSD is 
significantly more common in nursing 
homes than the community. 
Nursing home regulations mean that 
monitoring of prescribing is more 
acceptable. 
 




GP needs to perform the 
behaviour, with nursing 
staff 
GPs provide the vast majority of care 
to nursing home residents and are 
responsible for prescribing and repeat 
prescribing.  
 
When and how 
often? 
After 6 weeks if a new 
prescription is initiated 
and 3 monthly thereafter 
(as part of the 3 monthly 
medication review) 
 
Informed by clinical guidelines and 
eDelphi consensus study  
 
Step 4: Identify what needs to change 
We (AJ, TF) analysed the primary data set from the interview study, the meta-ethnography, 
the quantitative survey of GPs knowledge and attitudes to the management of BPSD and 
the online discussion forum from the dementia model using the COM-B model (see Figure 
12) to identify GPs’ capabilities (C), opportunities (O) and motivations (M) for monitoring, or 
not monitoring the prescribing of antipsychotic medications in people with dementia. The 





available on Table 25.  We identified psychological capability, physical opportunity, social 
opportunity and reflective motivation as potentially important COM-B components to 
target. 
Psychological capability 
Some GPs are unaware of the adverse effects of antipsychotics in dementia and over-
estimate their benefits in managing BPSD. They, therefore, may not see the benefit of 
monitoring their prescribing of antipsychotics. Some are also unsure of how to formally 
monitor their prescribing of antipsychotics. 
Physical Opportunity 
All data sources confirmed that there is a lack of GP relevant guidelines on antipsychotic 
prescribing and monitoring in dementia. The four data sources also highlighted that 
monitoring requires resources. However, nursing home and GP resources are already 
stretched. A further barrier was the lack of clear pathways of care and difficulties accessing 
advice from secondary care colleagues regarding antipsychotic prescribing. In the 
quantitative survey of GPs’ knowledge of and attitudes towards BPSD management, 
increased access to specialist advice was the area ranked second highest that, if improved, 
would help GPs to reduce their prescribing of psychotropic medications (the first ranked 
being increased staffing levels in nursing homes). This ability to access advice is particularly 
salient in the situation where the antipsychotic was originally commenced by secondary 






Monitoring of antipsychotics in a nursing home setting requires collaboration and a good 
working relationship with nursing home staff. However, conflicting priorities and poor 
continuity of care can negatively impact on this collaborative relationship. In this context 
many GPs, especially less experienced GPs, felt under pressure from nursing home staff to 
prescribe. This pressure from nursing home staff was evident in all four data sources. 
Reflective Motivation  
GPs are reluctant to discontinue antipsychotics as antipsychotics fill a therapeutic void. GPs 
feel they have no implementable alternatives to prescribing antipsychotics. Therefore, the 
risks associated with antipsychotics are tolerated. A further barrier that impacts on GPs’ 
motivation to monitor prescribing is the concern some GPs have that, if the antipsychotic is 
removed, the behaviours that triggered the initial prescription may return. This creates a 
certain amount of clinical inertia when it comes to monitoring antipsychotics. If the 
antipsychotic improves the behaviour the GP may not intend to discontinue it. If there is no 








Table 25. BCW Step 4: Identify what needs to change  
Behavioural Analysis using COM-B & further expanded to TDF:  
 
 
What are the GP barriers to monitoring their prescribing of antipsychotics in BPSD in a 











Translation of the 
behaviour change 
techniques within the 
intervention 
 
Barrier with evidence from supporting data TDF 
Domain(s) 
COM-B    
 
Lack of awareness of the adverse effects of antipsychotics 




“I have gone off Olanzapine a bit with the weight gain thing, I 
think there is a general trend away from Olanzapine because 
of that.  I used to use a bit of Haloperidol I suppose before, 
again that's kind of gone out of fashion a bit, its Serenace isn’t 
it?  Quetiapine not so much, I tend to use that in younger 
people.” (GP14) 
I: “And would you have any reservations about using 
antipsychotics in people with dementia?” 
GP: “No, I am happy enough. If the situation needs it I would 
be happy enough.” (GP10) 
 
Systematic Review 
“GPs over- estimated the benefit in symptom relief of second-
generation antipsychotics with 63% of GPs expecting benefit 





























Provide information on 
the evidence for the use 
of antipsychotics in BPSD. 
Provide information on 
the adverse effects of 
antipsychotic 
medications. 
Discuss recent best 
practice national 
guidelines developed by 
experts recommending 
monitoring of 
antipsychotic prescribing.  
 
This information would be 
best provided in a small 
group face-to-face setting 
as proven to suit GPs 
educational needs in 
dementia care. 87,133  





“The main barrier GPs identified was that discontinuation 
would potentially negatively affect the quality of life of the 
resident,”(Azermai et al, SR) 
 
Online Module Discussion Forum 
“I was surprised by lack of evidence for Seroquel [in the 
reading material].” (GP Participant) 
 
“…while I was aware of risks associated with antipsychotics I 
certainly underestimated the risks and over-estimated the 
benefits. I don’t have a protocol for reviewing/reducing 
antipsychotics.....YET! I hope I will be making some changes 
following what I am learning here.” (GP Participant) 
 
Quantitative study of GPs’ knowledge of & attitudes towards 
BPSD management 
Over one-third (36.3%) of respondents felt that the majority 
of patients with BPSD benefited from second generation 
antipsychotics 
ongoing access to the 
information it could also 
be hosted in an online 
format that would be 
immediately accessible to 
GPs on their desktops. 409 
Unclear on how to formally monitor prescribing  
 
Qualitative Study 
“GP: I wouldn't have much confidence in is how high to go up 
with Seroquel… do you just keep it on 25mg at night, I 
wouldn't be 100%  confident with that and at what level you 
would say ‘oh god that is way too much’.” (GP6) 
“I would think that the challenge for me is spending time and 
familiarising what the treatment options are, okay, and then 
having the confidence then to try them and then to write in 
the chart or make a mental note myself as to how effective or 





















Provide a prompt (written 
or IT based) that functions 
as a checklist of items to 
consider when conducting 
a review of an 
antipsychotic prescription 
to a person with dementia 
and would be used at the 
time of performance of 
antipsychotic review to 
guide the GP. Given that 
the vast majority of 
nursing homes in Ireland 






“As things progress from moderate to more severe, the 
behavioural management with medication, I think we all just 
kind of make a stab here and there at what we feel might be 
appropriate, do you know?” (Foley et al, SR) 
 
“Only a third of [nursing] homes report[ed] consistent review 
of patients initiated on antipsychotics within the six week 
recommendation.” (Mavrodaris et al, SR) 
 
Online Module 
“How do you actually do your repeat prescribing [of 

















session from a credible 
peer where information is 
provided on best practice 
guidelines on when and 
how antipsychotic 
monitoring in people with 
dementia should be 
conducted.  
 
Lack of GP-relevant guidelines  
 
Qualitative Study 
“Bits and pieces that I would have looked at over the years but 
again a lot of that would not be appropriate in the community, 
so not a huge wealth of guidelines there to go with.” (GP3) 
“So we are all working, well I am, I am working away in that 
grey area at the moment.” (GP7) 
Systematic Review 
“When do you add in psychotropic medication, what type of 
medication, what dosages, for how long? We need guidelines 
on that” (Foley et al, SR) 
Online Module Discussion Forum 
“In the nursing home… its often the case ‘do you remember so 
and so she reminds me of her that’s what worked for 

















(BCT 12.5)  
 
Provide guidance on 
antipsychotic monitoring 
and initiation to GPs. This 
could take the form of 
tool that summarises the 
main points on best 
practice in antipsychotic 







Monitoring requires collaboration between nursing home 
staff and GPs, however, conflicting priorities and lack of 
continuity can impact on this collaboration. GPs can feel 
under pressure from nursing home staff to prescribe 
 
Qualitative Study 
“A lot of the medication can be pushed by the staff in the 
nursing homes.” (GP9) 
“…I can’t understand why you are asking me to prescribe an 
antipsychotic which has got all kinds of potential side effects, 
you know, because it doesn’t suit you that Mrs Murphy is 
starting to wander a bit, you know.” (GP15) 
Systematic Review 
“Often it is pressure from nursing homes or carers for 
medication to calm a patient down that is trigger for 
prescribing. ” (Mavrodaris et al, SR) 
 
“Our results suggest that nursing staff have the largest 
influence on prescribing psychotropic medication in this 
setting.” (Cousins et al, SR) 
 
Online Module Discussion Forum 
 “It can be really difficult not to prescribe something to 
frustrated, tired carers and nursing staff.” (GP Participant) 
 
“I think the pressure is definitely borne out of initial 
expectations by carers and nursing home staff that these 
patients should conform to their idea of appropriate 

























































GPs conducting a review 
with the input from 
multidisciplinary 
colleagues –nursing home 
staff with input from 
pharmacy where feasible. 
Having an 
interprofessional 
educational (IPE) session 
should help align the 
priorities of the different 
health care professionals 
and foster the 
development of practical 
social supports359,410 and 




Change the physical 
environment to overcome 
barriers to collaboration 
between nursing home 
staff and GPs. This could 
involve having the 
dispensing chart in with 
the drug kardex so that if 
a person is on an 
antipsychotic PRN then 
the frequency with which 






Quantitative study of GPs’ knowledge of and attitude to BPSD 
management 
When ranking the barriers to recommending non-
pharmacological interventions the majority of respondents 
ranked ‘pressure to prescribe medication from nursing home 
staff/ nurses’ as the number 1 barrier. 
The vast majority (80.1%) of respondents reported that 
nursing staff were the biggest influence on their prescribing. 
 
Free text comments: 
“Often intense pressure to prescribe.” (Respondent_8) 
“Have had enormous pressure to 'sedate' patients in NH from 
nurses.” (Respondent_145) 
 
The presence of a repeat 
prescribing tool could 
help to keep GPs and 
nurses ‘on the same page’ 
with regards to repeat 
prescribing. 
Concern that discontinuing medications will lead to a re-
emergence of symptoms 
 
Qualitative Study 
“I think everybody would be terrified to stop it in case her 
behaviours got a bit worse or they would say she slipped more 
and it was your fault she slipped more. So I think whatever 
about starting the meds I think it is almost impossible to stop 
the meds.”  (GP15) 
Systematic Review  
“Behavioral problems after antipsychotic discontinuation was 
a major concern, as well as hindrance to others and risk of 
harm to the resident.” (Azermai et al, SR) 
 
“Prescribing or maintaining the dose of an already prescribed 




















































In an educational session 
introduce the evidence 
that the majority of the 
time discontinuing APs 
does not lead to a re-




national guideline on 
when to attempt 
withdrawal of APs 
 
The qualitative study 
highlighted the value GPs 
put on their own 
experience, even above 
the evidence. Thus, it 





Online Module Discussion Forum 
 “Once behaviour has improved all involved are loathe to 
change any medication for fear of return to troublesome 
behaviour.” (GP Participant) 
 
“I need to actively consider weaning drugs when things settle 
gain and withdrawing if possible as I need to consider the 
longterm risk to the patient. I think I was more inclined to 
leave well enough alone previously.” (GP Participant) 
 
Quantitative study of GPs’ knowledge of and attitude to BPSD 
management 
When asked to rate their agreement with the following 
statement “I am concerned withdrawing medication will 
impact negatively on the quality of life of the resident leading 
to a return of challenging behaviours or disturbing 
psychological symptoms”. The majority of responding GPs 
agreed with this statement (63%). The rest were either neutral 





























GP to be able to monitor 
the outcome of any 
reductions/ withdrawal of 
AP prescribing. GPs could 
be facilitated in this task if 
the providing pharmacy 
could issue a 3 monthly 
list of residents in the 
nursing home who are on 
APs with the AP dose.  
 
Explicit detail should be 
provided in the 
educational session (and 
any supporting online 
material) on how to 
maximise success when 
monitoring or 
withdrawing APs. 
Reluctant to discontinue antipsychotics as they fill a 
therapeutic void. GPs feel they had no alternatives, thus, the 
adverse effects of antipsychotics are tolerated. 
 
Qualitative Study 
“There is nothing worse than watching a patient that is 
agitated. It is terrible. It is torturous. So if there is a possibility 
I suppose that you will give them something at night and they 
will get a few hours sleep well then…” (GP5) 
 “The only thing that would work is if somebody stayed talking 
to her continuously. Which wasn’t practical and we tried every 




























It will be necessary to 
provide some detail to 
GPs on alternatives to 
prescribing. Highlighting 
the importance of a 
thorough assessment for 
potential triggers of BPSD 
e.g. pain. If the 
monitoring tool also 
provided a summary of 
essential components of 







“According to many of the GPs an increased risk of stroke or 
other cardiovascular outcomes was considered a worthwhile 
trade-off, if prescription of the antipsychotic would improve 
the patient’s mental wellbeing.” (Mavrodaris, SR) 
 
“Alternatives are often inaccessible and unaffordable for 
many people with dementia or care homes.” (Azermai, SR) 
 
Online Module Discussion Forum 
 “I have to say I rarely recommend non pharmacological 
managements … I definitely am not confident recommending 
[them] and feel ill equipped to recommend” (GP Participant) 
 
Quantitative study of GPs’ knowledge of and attitude to BPSD 
management (Free text comments) 
“While I know the adverse effects + risks of AP are true, there 

















GPs will need support 
from the nursing staff in 
this regard as alternatives 
to prescribing rely heavily 
on input from nursing 
staff. An IPE session 





Monitoring is resource-intensive but resources, both GP and 
nursing home resources, are already stretched 
 
Qualitative Study 
“[Nursing home rounds can be] very time consuming and it is 
always stressful, definitely always stressful and the challenges 
are capacity as well because we [GPs]  run a very tight 
schedule during the day and are kept to a very tight schedule 
anyway.” (GP3) 




















































Provide resources that 
would facilitate 
monitoring of 
antipsychotics. A tool (IT 
or paper based) to 
support GPs conducting 
antipsychotic reviews. IT 
tools that identify people 
with dementia on 
antipsychotics in a patient 
database have been 
developed by the wider 






“GPs described inadequate nursing staff levels and resources 
as the main factors that limit the use of non-pharmacological 
interventions and their ability to reduce the usage of 
psychotropic agents in nursing homes.” (Cousins et al, SR) 
 
“Concern was again expressed regarding resource constraints 
(Mavrodaris et al, SR) 
 
Online Module Discussion Forum 
 “It all seems to come back to the big word and big deficit-
TIME!” (GP Participant) 
 
“Too few nursing homes have proper dementia units” (GP 
Participant) 
 
Quantitative study of GPs’ knowledge of and attitude to BPSD 
management 
When asked what would help them reduce their use of 
psychotropic agents in BPSD the factor ranked number one 
most frequently by respondents was ‘increased staff levels in 
nursing homes’.  
 
Free text comments 
“Resources/staffing biggest issues, low staffing means safety 
is big issue for patient and staff & at some time safer to 
medicate a patient with BPSD” (Respondent_6) 
 
“Dementia is very challenging to deal with, needs huge 
amount of time + the reality is that we just don't have it - 























could be a valuable part 




(CPD) points to GPs. 
1.Conducting an 
antipsychotic review 
would be eligible for 
internal CPD points.  
2. If the GP monitored the 
outcome of the 
monitoring process this 
could form the basis of an 
audit. An audit is an 
annual CPD requirement 
for GPs. If the 
intervention included an 
audit template this would 
further incentivise the GP 
to conduct the audit and, 
therefore, engage with 
the monitoring process. 
3. Finally, if there was an 
education component to 
the intervention and if we 
could get that education 
component accredited for 
external CPD points then 
this further incentivise 







Phase 2: Identify intervention options 
Step 5: Identify intervention functions 
We found that all nine intervention functions were potentially relevant. We used the 
APEASE criteria to determine the most relevant intervention functions in the context of the 
Irish healthcare system. Our assessment using the APEASE criteria was informed by the 
authors’ clinical experience as practising GPs (AJ, TF, CB) and by previously unreported data 
from the interview study and meta-ethnography where suggestions for appropriate 
intervention functions was analysed. This new analysis is presented with relevant supporting 
quotes in appendix 6, supplementary material 15 and 16. The assessment and grading of 
each of the nine intervention functions is presented in appendix 6, supplementary material 
17 with their relevant categorisation into first line, second line or inappropriate option. The 
intervention functions judged to be most relevant for our intervention were education, 
environmental restructuring, incentivisation and enablement. The relationship between the 
behavioural analysis, as presented in the components of the COM-B analysis and the 
domains of the TDF, and the different intervention functions considered are shown in Table 
25.  
Step 6: Identify policy categories 
Using the BCW guidance all seven policy categories were identified as potentially 
appropriate in supporting the four intervention functions identified in step 5. Three policy 
categories were common across the four selected intervention functions; guidelines, 
regulations and legislation. Regulation and legislative change was beyond the scope of this 
project, therefore, we identified guidelines as the most relevant policy category for this 





guidelines in the area of prescribing of psychotropic medications to people with BPSD. At 
the time of writing these guidelines have been approved and prioritised by the National 
Clinical Excellence Committee (NCEC); the national body who endorse national clinical 
guidelines in Ireland. Thus, these guidelines will be supported for implementation as a 
National Clinical Guideline. 
 
Phase 3: Identify content and implementation options 
Step 7: Identify behaviour change techniques (BCTs) 
Nine BCTs were ultimately selected as being the most relevant ingredients for our 
intervention.  
1) Information about health consequences (BCT code 5.1) 
2) Information about others approval (BCT code 6.3) 
3) Feedback on outcome of behaviour (BCT code 2.7) 
4) Add objects to the environment (BCT code 12.5) 
5) Prompts/ cues (BCT code 7.1) 
6) Action planning (BCT code 1.4) 
7) Restructuring the physical environment (BCT code 12.1) 
8) Social support (practical) (BCT code 3.2) 
9) Material incentive (BCT code 10.1) 
The translation of these BCT components into the final intervention components was an 
iterative process. AJ & TF met multiple times to discuss how these BCTs could feed into 





would be considered acceptable to GPs. The BCTs associated with each intervention 
function and an elaboration of how these BCTs could be used to encourage GPs to monitor 
their prescribing of antipsychotic medications to people with dementia in nursing homes is 
outlined in detail in Appendix 4, supplementary file 17. The intervention components were 
presented to the wider research team in a multidisciplinary research team meeting and 
agreed upon. 
Step 8: Identify mode of delivery  
A three-component intervention was developed and is graphically represented in Figure 15. 
One of the intervention components is a repeat prescribing tool to facilitate the monitoring 
of antipsychotic medications in BPSD. As there was no consensus in existing guidelines as to 
what the components of such a monitoring tool would be, the modified eDelphi consensus 
study reported in Chapter 9 was conducted to identify the key components of an 
antipsychotic repeat prescribing tool to monitor the prescribing of antipsychotic 
medications in BPSD in a general practice setting. 405  
To further refine all the components of the intervention, the proposed content and mode of 
delivery was discussed with the following stakeholders; directors of nursing in nursing 
homes (n=2), community pharmacists (n=2) and GPs (n=16). AJ conducted individual semi-
structured interviews with the directors of nursing and the community pharmacists. 
Feedback from GPs on the proposed intervention was obtained from discussion of the 
intervention in an online forum and during a GP dementia study day organised by AJ. 
Analysis of the feedback from these three stakeholder groups is available in appendix 6, 
supplementary material 19. Of note, the nurses interviewed anticipated that the main 





from the GPs. Likewise, the GPs were apprehensive about potential resistance from the 
nursing staff, particularly if the monitoring of the antipsychotics was to result in plans to 
reduce or withdraw the antipsychotic medications. In light of the stakeholder feedback, the 
design and layout of the monitoring tool was further refined. The final monitoring tool is 
available in appendix 4, supplementary material 19. Once the intervention had been 
finalised, the TIDieR checklist functioned as a guide and informed the specification of the 
planned delivery of the intervention content and is available in appendix 4, supplementary 
material 23. 
Description of the Intervention 
The final intervention contains three components. 
(i) The first component is an interprofessional educational (IPE) session on BPSD to be 
conducted in the nursing home with nursing staff and the visiting GP(s). This IPE session 
will last approximately one hour and will be co-facilitated by an upskilled GP and a 
nurse with an interest in dementia care. The content will focus on the learning needs 
identified in this research; 87,330,332 the assessment of BPSD, the risk/benefits of different 
psychotropic medications, monitoring and withdrawal of antipsychotic medications. 
The importance of a structured, systematic approach to antipsychotic monitoring in 
people with dementia will be highlighted. The educational session will be eligible for GP 
external continuous professional development (CPD) points. Obtaining CPD points is a 
professional development requirement for GPs and will, therefore, help to incentivise 
GPs to attend. (A proposed outline of the IPE session is available in Appendix 4, 






(ii) The second component of the intervention is a repeat prescribing tool to support GPs 
in the monitoring of their antipsychotic prescribing to people with dementia. The tool 
will help to facilitate reviews of antipsychotic prescribing to people with dementia as 
part of the three monthly medication review. This tool will be introduced to the health 
care professionals in the IPE session outlined above and will also be available for 
download, with instructions on how to use it, on a website www.dementipathways.ie. 
This website was developed by the lead author (AJ) as an online clinical dementia 
resource for GPs and other primary care team members. 409 
 
(iii) The third component of the intervention provides feedback to the GP on their 
prescribing practices and facilitates the completion of an internal audit of their 
prescribing of antipsychotic medication to people with the dementia. GPs in Ireland 
must conduct an audit of an aspect of their clinical practice on an annual basis in order 
to meet professional competency requirements. Three approaches were employed to 
facilitate the GP in their conduction of an internal audit in this area. Firstly, the 
pharmacy managing the dispensing for the nursing home will provide feedback on 
antipsychotic prescribing to the nursing home every three months. Secondly, a paper-
based audit tool was developed to provide GPs with a template of how to conduct the 
audit. (Available in appendix 4, supplementary material 21).  Finally, although the 
majority of nursing homes in Ireland are paper based, in a minority of nursing homes 
the GP practice software is remotely integrated with the nursing home. This integration 
allows residents’ clinical details and prescriptions to be recorded electronically in the 
nursing home and allows the GP to access these medical records from the GP practice’s 





place GPs can conduct the audit electronically. To enable these GPs to conduct an 
electronic audit, a software-finder tool was developed in collaboration with the Irish 
College of General Practitioners and the Irish Primary Care Research Network (IPCRN). 
411  The finder tool creates a list of all patients in the practice that are either coded for 
dementia or prescribed a dementia specific medication (an acetylcholinesterase 
inhibitor or memantine). This effectively creates a dementia register for the practice. 
The finder tool will then search through this dementia register to identify people who 
are on an antipsychotic medication. It will produce a report for the GP with a list of the 
people with dementia, what antipsychotic medication they are on and the dose.  
(Further details on this electronic audit tool is available in Appendix 4, supplementary 
material 22). It is envisaged that these three elements; feedback from the pharmacy, 
the audit template and the software finder tool will support and facilitate a GP in 






Figure 15. The intervention with the relevant supporting behaviour change techniques and the intervention function that each component 
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This paper describes a systematic, structured approach to the development of an 
intervention to improve the management of BPSD in general practice. The intervention 
development process was informed by a mixed methods systematic review,330 qualitative 
research with GPs,332 a quantitative survey of GPs knowledge and attitudes towards pain in 
dementia, 403 a survey of GPs management of BPSD and analysis of an online GP discussion 
forum on BPSD. By drawing on the findings of these studies, engagement with an expert 
panel and theoretical modelling with the BCW, we identified failure to monitor prescribing 
of antipsychotic medication to people with BPSD living in nursing homes in a systematic and 
structured way as the key behaviour to target with this intervention. By applying the BCW to 
our multiple data sources we identified the reasons why GPs were not engaged in this target 
behaviour and what needed to occur for the target behaviour to be achieved. We identified 
psychological capability, physical opportunity, social opportunity and reflective motivation 
as the important COM-B components to target with our intervention. Four intervention 
functions were identified as being particularly relevant for our intervention with nine 
associated BCTs. Developing the intervention content involved consultation with an expert 
panel, engagement with relevant stakeholders and an eDelphi consensus building process. 
The final intervention involves three key components; an interprofessional education 
session with GPs and nursing home staff, a tool to facilitate monitoring of antipsychotic 
prescribing in BPSD and facilitation of a self-audit of GPs’ prescribing of antipsychotic 
medication in BPSD.  
We found that the monitoring of antipsychotic medication in BPSD is influenced by many 





contextual factor. The importance of adequate resourcing of nursing homes was 
emphasised by participating GPs at all stages of this research. 330,332,403 Furthermore, in 
choosing this particular target behaviour we were aware of the three potential barriers; (i) 
that a focus on antipsychotic prescribing could increase the prescribing of other less 
effective sedating psychotropic medications to manage BPSD, (ii) that implementable 
alternatives to pharmacological approaches would need to be highlighted, (iii) to be 
effective the intervention would need to involve collaboration between the GPs and the 
nursing home staff. Through the first component of our intervention, the IPE session, we 
attempt to address these three potential barriers. The educational session will outline the 
limited evidence for alternative pharmacological options in BPSD and will also outline an 
approach to assessment of BPSD. These two features will address the issues of potential 
substitution of antipsychotics for another less effective psychotropic medication and the 
need to consider non-pharmacological approaches. In our preliminary work 87,330,332 we also 
identified a number of specific knowledge deficits such as the overestimation of the benefits 
of antipsychotic medication in BPSD and an under-estimation of their adverse effects. The 
educational session will address these identified knowledge gaps. If these knowledge gaps 
are not addressed then any intervention targeting improving the monitoring of 
antipsychotic medication in BPSD is likely to be unsuccessful.  
We recognise that the passive provision of information does not necessarily translate into 
improved knowledge. However, research conducted by two of the authors (TF, AJ) supports 
the value of small-group, peer-led educational sessions in improving dementia knowledge in 
primary care. 133 Furthermore, by making the education session interprofessional we aim to 
address the third potential barrier - the need for improved communication and 





intervention provided by GPs and nurses emphasised how each professional group feared 
resistance from the other and this was seen as the key barrier to successful implementation 
of the intervention. This finding further highlighting the importance of an interprofessional 
educational session. A previous systematic review of the effects of IPE has highlighted its 
role in improving professionals’ attitudes to one another and in increasing collaborative 
knowledge. 359 Specifically in the area of dementia care, IPE has been shown to have the 
potential to improve collaborative knowledge. 410 Two of the authors (AJ, TF) have 
previously developed and piloted an interprofessional dementia education workshop for 
community-based primary care healthcare professionals in Ireland 412 (published paper 
available in appendix 12). The vast majority of participants in the pilot phase of that 
interprofessional intervention reported that the workshop positively contributed to 
enhanced team work and collaboration. Furthermore, that study highlighted the benefits of 
having two facilitators for an IPE session. Echoing previous research that has found co-
facilitation to be an important method of strengthening collaboration and supporting 
interprofessional facilitators. 413 These findings informed the decision to have two 
facilitators, from each of the relevant professions (i.e. a GP and nurse), co-facilitate the 
educational session.  We recognise that co-ordinating an IPE session can be logistically 
difficult, 412 especially since GPs have very limited time available. The impact of time 
constraints will need to be investigated further in a future feasibility study. However, it is 
encouraging that the feedback received to date from nursing home staff and GPs on the 
concept of this IPE session has been positive.  
Educational interventions in BPSD have been found to be successful in the past but their 
beneficial effect has been largely only short-term. 208  The second component of the 





needed practical guidance on how to formally monitor antipsychotic prescribing in BPSD. 
Moreover, by providing the participants in the IPE session with a goal at the end of the 
session- improve monitoring of antipsychotic medication, and a tool that will facilitate this 
goal, we hope to achieve more long term change in practice. The tool itself will also be 
available for download on an existing website that was developed by the lead author (AJ) as 
an educational resource for primary care team members providing dementia care. 409 This 
website provides educational material in the area of assessment of BPSD and practical 
advice on withdrawing antipsychotic medication in people with dementia, further 
emphasising the learning from the IPE education session. Additionally, the repeat 
prescribing tool will enable the monitoring process by providing a forum for collaborative, 
structured review of antipsychotic prescribing. In a recent RCT a multidisciplinary approach 
to a structured review of antipsychotic prescribing has been shown to significantly improve 
the appropriateness of antipsychotic prescribing to people with dementia in a nursing home 
setting. 298 Furthermore, the repeat prescribing tool should facilitate the need for practical 
social support between the nursing staff and the GP, ensuring that the two professional 
groups remain ‘on the same page’ when monitoring antipsychotic medications in BPSD.  
The final component of the intervention, the facilitation of an internal audit, will provide 
GPs and nursing home staff with feedback on the outcome of the monitoring process. 
Feedback from pharmacies and the audit template will enable GPs to undertake a self-audit. 
Additionally, if the medical records in the nursing home are integrated electronically with 
the GPs’ practice software, then the IPCRN finder tool will provide further assistance to the 
GP conducting the audit. Similar IPCRN finder tools have been successfully implemented in 
Irish GP practices in the areas of mental health 414 antimicrobial prescribing 415 and 





of improving the quality of other aspect of dementia care in general practice, such as coding 
of dementia diagnosis. 417 The audit component of this intervention will also meet the GP’s 
mandatory annual CPD requirement for completion of a self-audit. 418 
 
Comparison with other work 
Two previous systematic reviews have evaluated interventions to improve the management 
of BPSD in the nursing home setting; one conducted by Thompson-Coon in 2014 201 and one 
conducted by Birkenhager-Gilesse in 2018. 208 The Thompson-Coon et al review evaluated 
the effectiveness of interventions to reduce inappropriate prescribing of antipsychotics to 
people with dementia living in residential care settings. 201 The Birkenhager-Gilesse et al 
systematic review was a meta-analysis of the effect of multidisciplinary psychosocial 
interventions for BPSD on the psychotropic drug prescription rate in nursing homes 208. Both 
of these systematic reviews found that interventions designed to improve BPSD are often 
poorly described making interpretation of the results and future replication of the studies 
difficult 208 201. It appears from these reviews that intervention studies in the area of BPSD 
often fail to clearly report why the particular intervention was chosen. Furthermore, the 
intervention development process is often inadequately reported. These reviews identified 
that in order to change prescribing behaviour the intervention needs to target the 
prescribing physician, 208 yet surprisingly GPs’ involvement in these intervention studies to 
date has been minimal. Despite the poor understanding of the challenges GPs experience 
managing BPSD, it appears that none of the interventions targeting GPs actively sought to 
understand or address this poor understanding. Furthermore, the studies included in these 





intervention. Our study addresses this gap in the literature. By using the BCW approach to 
our intervention development process we provide a transparent and reproducible guide to 
the development of an intervention to improve the management of BPSD in general 
practice. To ensure our intervention was practical and appropriate, GPs were actively 
involved at all stages of our intervention development process.  
Since its introduction in 2011, the BCW has been used as a theoretical model to inform the 
development of many, complex health-care interventions. These interventions have 
targeted a diverse range of health issues such as multimorbidity, 399 obesity in pregnancy, 419 
diabetes 420 and sexual counselling in cardiac rehabilitation. 421 In some studies the target 
behaviour was pre-determined based on existing international guidance. 421 In our study, 
the paucity of existing evidence of current practice in BPSD and the lack of international 
guidance meant that the target behaviour was not decided in advance. Therefore, similar to 
other studies which used the BCW to develop complex interventions for general 
practitioners in the areas of multimorbidity 399 and test ordering, 422 we used the BCW 
approach to identify what behaviour to target with our intervention. In some instances the 
BCW has been used to modify existing healthcare interventions. 423 In other studies the 
intervention content incorporated existing tools. 399  In our study, due to the paucity of 
interventions in this area that targeted GPs, it was necessary to develop an intervention de 









GPs’ behaviour appears to be strongly influenced by their ability to access appropriate 
supports for the person with dementia both in the community and in nursing homes. 
However, addressing these resource limitations was beyond the scope of our intervention. 
Likewise, GPs experienced difficulty accessing clinical support within the healthcare system 
when managing people with BPSD. One barrier to monitoring the prescribing of 
antipsychotics in BPSD, which is not addressed with this intervention is the lack of 
integrated care pathways between secondary care and primary care. The lack of clear 
pathways makes it difficult for some GPs to access advice and support when monitoring or 
attempting to withdraw antipsychotic medications in dementia. 332 A particular problem if 
the GP themselves did not initiate the medication. The impact of these resource and health 
system limitations will need to be evaluated in future feasibility and pilot phases.  The 
design of the intervention was further restricted by the real world complexities of accessing 
information on prescribing in Irish general practice. As discussed in Table 7, ideally, in the 
audit component of our intervention, GPs would receive external feedback that allowed 
them to benchmark their performance against their peers nationally. A Cochrane review 
demonstrated that external feedback and audit are effective methods of changing physician 
practice. 424 Furthermore, external feedback and audit has been demonstrated to be an 
effective intervention in primary care to reduce potentially inappropriate prescribing in 
older adults. 425 However, there is no national data set in Ireland that records disease-
specific prescribing of antipsychotic medications at general practice level. Therefore, it is not 
possible to provide GPs with anonymised feedback that would allow them to benchmark 





The concept of the “treatment culture” of a nursing home has been found to have a 
significant influence on antipsychotic prescribing in BPSD. 3 One study found that nursing 
homes with a “resident-focused” culture were associated with lower rates of antipsychotic 
prescribing. 307 Changing the culture of a nursing home can require a change in 
organisational structure, resourcing and even architectural structure. Factors such as under-
staffing and high staff turnover can lead to organisational instability and a lack of consistent, 
well-trained nursing staff which negatively impacts on treatment culture. 426 Thus, changing 
culture was beyond the scope of this intervention. However, a previous stakeholder 
consensus study identified some of the key characteristics of an “ideal” nursing home in 
terms of promoting culture change and our intervention does address a number of these 
key characteristics, namely; improving interprofessional relationships, collaborative decision 
making and quality improvement processes. 427 Through our IPE session we will attempt to 
improve relationships between GPs and nursing home staff. A recent systematic review on 
the influences on decision-making regarding antipsychotic prescribing in nursing home 
residents with dementia identified that nursing home managers can play a significant role in 
dictating the culture of the nursing home. 3 Therefore, the nurse home managers will be 
invited to this IPE session. The repeat prescribing tool will involve GPs and nurses in a 
collaborative decision making process. Furthermore, the intervention aims to introduce a 
systematic quality improvement initiative into the nursing home, ultimately improving the 
care provided to individual residents. Thus, although culture change within the nursing 
home is beyond the specific remit of the intervention, we hope its various components will 
collectively have a positive impact on the nursing home culture. 
We have drawn on a specific systematic approach to intervention development in this study 





However, there may be alternative theories that might be applicable to explain GPs’ 
behaviour in the management of BPSD. We believe that the use of a systematic and 
transparent theoretical approach enabled us to develop an intervention that is evidence-
based, reproducible and implementable. That being said, the use of the BCW to guide 
intervention is not a panacea for all the challenges that accompany an intervention 
development process. As the authors of the BCW approach themselves attest, the BCW is 
not a “magic bullet” for intervention design. 404 It provides a guide for the researcher to 
follow but allows for, and at times demands, the researcher to make a series of subjective 
decisions. Three of the authors’ (AJ, TF, CB) work clinically as GPs. Their clinical experience 
ultimately influenced some of these subjective decisions. However, the involvement of 
three practising GPs in this intervention development process; two with academic and 
clinical interest in dementia (AJ, TF) and one with an academic interest in prescribing (CB) 
was counter-balanced by the involvement of a BCW expert (JMcS) and an experienced 
public health researcher (JB). Furthermore, in this instance, we feel that the research teams’ 
knowledge of the clinical context and their professional experience working in nursing home 
settings was a distinct advantage when making the subjective, pragmatic decisions that the 
BCW requires. Indeed, we believe that making these decisions without our professional and 
clinical experience would have been extremely difficult. Additionally, we had a wide range 
of data sources to inform our decisions ranging from our systematic review, the qualitative 
study with GPs, two surveys of GPs’ knowledge and attitudes to aspects of BPSD 
management and data from on online GP discussion forum on BPSD. These data sources, 
combined with the extensive professional experience of the research team, added to the 





choosing, or not choosing, a particular option is documented in the supporting 
supplementary files, adding to the transparency of our methods. 
This study focused on developing an intervention to change the behaviour of one health 
care professional involved in the management of BPSD- the GP. We could have taken a 
more complex, multi-faceted approach to our intervention development process that 
incorporated all the potential relevant stakeholders. However, we wanted to focus on one 
healthcare professional, whose views on BPSD are often under-represented in the 
development of interventions that are largely designed to change their practice; the GP. The 
GP is not the sole health care professional involved in the care of people with dementia. In 
the nursing home setting the nursing staff play a pivotal role as do the health care assistants 
and family carers. Allied health care professionals such as occupational therapists and 
community pharmacists also have a role in the care provided to people experiencing BPSD. 
However, these stakeholders have different functions and responsibilities in the care of a 
person with BPSD. Attempting to address the myriad of different behaviours and challenges 
that face all these different stakeholders when managing BPSD with a single intervention 
would have led to a very complex and, potentially, unworkable intervention. In our 
intervention, by focusing on one professional group, we aim to target a specific problem. 
We strove to reduce the complexity of the intervention whilst addressing the complexities 
of the behaviours at play. The underlying premise being that a smaller, targeted change is 
more achievable and more sustainable and is, therefore, more likely to result in significant 
behavioural change that can be built on in future interventions. 404 Rome wasn’t built in a 





The final intervention targets GPs’ behaviour but it also includes two relevant stakeholders; 
nurses and, more peripherally, community pharmacists. The qualitative study, the 
systematic review, the two descriptive cross-sectional studies and the analysis of the online 
discussion forum all highlighted the influence nursing staff have on GPs’ management of 
BPSD in nursing home settings. Additionally, we considered recent research conducted in 
Ireland with nursing home staff, which explored their perspectives on antipsychotic 
prescribing in BPSD 367. That research echoed much of our findings on the barriers to 
implementing evidence-based prescribing practices for BPSD in nursing home settings and 
highlighted the importance of the relationship between GP and nursing home staff, 367 
giving further support to our chosen intervention. Interventions that aim to make changes 
to medications do benefit from patient buy-in. 428 In this clinical context achieving patient 
buy-in is complicated.  We are addressing prescribing in a patient cohort who, by the nature 
of their illness and its probable advanced state (given the presence of significant BPSD and 
the person’s residence in a nursing home), are unlikely to be able to effectively engage in a 
shared-decision making process. When managing advanced dementia in a nursing home 
setting that patient buy-in does, in many ways, become nursing buy-in, further emphasising 
the importance of involving nursing home staff in this intervention. Although the family 
caregiver typically plays a more significant role in the care of a person with dementia in the 
community than in the nursing home, it would be import to ascertain the views of family 
carergivers in any future feasibility study of this intervention.  
Community pharmacists were identified as another health care professional that have a role 
to play in supporting GPs in their monitoring of antipsychotic prescribing in BPSD. A recent 
RCT conducted in Canada demonstrated that pharmacists can effectively stop the 





influence GPs’ prescribing in BPSD to the same extent as nurses do, their role in supporting 
medication reviews in BPSD is acknowledged by GPs. 155 A recent feasibility study conducted 
in the UK demonstrated the potential impact of pharmacist-led medication reviews in 
improving the management of BPSD in care homes. 430 However, in an Irish context 
significant involvement from the providing pharmacist in the review of antipsychotic 
prescribing is not currently feasible. The pharmacies providing care to Irish nursing homes 
typically go through a competitive tendering process to win the contract to provide 
pharmacy services to a nursing home. Consequently, the providing pharmacist can often be 
located hundreds of miles away, making direct involvement of the providing pharmacy in a 
medication review logistically challenging. Furthermore, evidence suggests that community 
pharmacists generally do not feel suitably trained to advise medication changes in the area 
of BPSD, an area that is viewed by community pharmacists as a ‘specialist’ area. 431 
However, in recognition of the role of pharmacists, we have involved them in the process by 
requesting they provide feedback on antipsychotic prescribing rates to the nursing homes, 
thereby facilitating the GPs in conducting a self-audit and enabling GPs to monitor the 
outcome of their initiative. 
Implications for future research 
Following the MRC framework recommendations for the development of complex 
interventions, 242 the next step will involve exploring the feasibility of the intervention. It is 
important that before any evaluation of effectiveness is undertaken we need to assess if the 
intervention is feasible, acceptable and leads to behaviour change. To ensure the 
intervention is implemented as intended, to understand how the intervention produces 





implementation of the intervention, an initial process evaluation stage will need to be 
conducted. 432 Process evaluation has an important role in understanding the feasibility of 
an intervention and also for optimising its design and implementation. If the intervention is 
found to be feasible then further research could focus on evaluating its effectiveness in a 
randomised controlled trial with accompanying economic evaluation. Evidence of 
effectiveness and economic benefits will help to address the policy categories identified that 
need to be addressed to support a nationwide implementation of this intervention. 
10.5 CONCLUSION 
To our knowledge, this is the first intervention to have focused specifically on GPs 
management of BPSD and has directly involved GPs in the intervention development 
process. Each decision made has been clearly described and is available for review, either 
within the text or in the supplementary material provided. Therefore, whether this 
intervention ultimately proves to be effective or not, we believe this paper is valuable as it 
provides researchers in intervention development with a worked example of the application 
of the BCW to this complex clinical problem. Furthermore, this paper provides important 
information on the clinical context in which these behaviours are performed. In particular, 
we provide insights into GPs’ perspectives on the factors influencing their management of 
BPSD. Given the limited role GPs have played to date in the development of interventions in 
BPSD, this paper addresses a specific gap in the research and gives a voice to a pivotal, but 







CHAPTER 11: DISCUSSION 
 
11.1 INTRODUCTION 
This chapter will present an overview of the issues raised in this thesis. The main findings of 
this thesis will be outlined to demonstrate how the different studies included in this thesis 
converged to address the overall research aim. The strengths and limitations of this thesis 
will be discussed in detail. Finally, the implications of this thesis in terms of policy, practice 
and future research will be explored.  
 
11.2 MAIN FINDINGS 
This thesis outlines how, in consultation with GPs and in response to the specific challenges 
GPs encounter when managing BPSD, an intervention was developed to improve the 
management of BPSD in general practice. 
Before we attempt to change healthcare professionals practice, we need to understand 
what their current practice is and what their perspectives are on the challenges of 
implementing best practice. In this thesis, the systematic approach adopted for developing 
the intervention incorporated a number of consecutive phases. These phases aimed to 
identify current practice in BPSD and the challenges of implementing best practice in 
general practice. Each phase built upon and informed the next. First, the qualitative and 
quantitative literature on GPs’ knowledge of, attitudes towards and experiences with BPSD 
was synthesised using a mixed methods integrated approach. By adopting a meta-





developed. This line of argument described the therapeutic void that GPs face when 
managing BPSD and identified that to fill this therapeutic void there is an over-reliance on 
antipsychotic medication and on family carers. The review highlighted the paucity of 
qualitative literature conducted with GPs that specifically examined GPs’ perspectives on 
the management of BPSD. This gap in the literature was particularly striking when the large 
number of qualitative studies that have been conducted with GPs in the area of dementia 
diagnosis are considered. 73,292,433-436 Therefore, to further increase our understanding of the 
problem, a qualitative study was conducted to explore GPs’ experiences of the challenges of 
managing BPSD. The qualitative study emphasised that BPSD is an area that GPs struggle 
with professionally and, at times, personally. Participating GPs believed they had no viable 
alternatives to sedative medications, yet they felt that their decision to prescribe was 
sometimes in conflict with their primary role as an advocate for their patients.  In the 
qualitative study, the difficulties GPs encountered assessing a person with BPSD for 
potentially reversible triggers, such as pain, was apparent. This finding was explored further 
in a descriptive cross-sectional study on GPs’ knowledge of and attitudes towards the 
management of pain in dementia. In addition to identifying aspects of GPs’ management of 
pain in dementia that appear to be sub-optimal, some of the challenges GPs experience 
providing nursing home care in Ireland were identified. In Chapter 8, these three studies 
were further integrated with two other data sources; an analysis of an online GP discussion 
forum on BPSD and a questionnaire based study on GPs’ knowledge of and attitudes 
towards BPSD. The intervention development process was informed by a detailed analysis of 
these five data sources and, in consultation with an expert panel, followed the systematic 
approach outlined in the BCW. The final intervention addresses a specific aspect of the 





promote the targeted and systematic monitoring of antipsychotic medication prescribed to 
people with BPSD residing in nursing homes. There was a lack of consensus in the literature 
on some of the clinical aspects of monitoring antipsychotics in BPSD. Therefore, a modified 
eDelphi consensus process was employed to identify the key components of an 
antipsychotic monitoring tool. 405 
11.3 STRENGTHS AND LIMITATIONS 
This research provides an in-depth analysis of the challenges that GPs encounter when 
managing BPSD. The research phenomenon was studied in its natural setting and significant 
consideration was given to the context in which the management of BPSD occurs. This 
analysis was then used to inform the development of an intervention which aims to improve 
GPs’ behaviour in the management of BPSD using behaviour change theory. I will now 
explore the strengths and limitations of this research. 
A strength of this thesis is that GPs, who are the target population of the intervention, were 
involved at every stage of the development process. The research question emerged from a 
learning needs assessment with GPs, people with dementia and family caregivers. 87 The 
systematic review, qualitative study, cross-sectional study and eDelphi consensus study 
allowed the selection and tailoring of a contextually appropriate intervention. Subsequent 
feedback from GPs on the proposed intervention provided further understanding of the 
cultural and contextual factors at play and enabled refinement of intervention. The high 
level of engagement with the key stakeholder in the intervention should improve GPs’ 
ownership of the final intervention. Improving ownership of the intervention is considered 





care. 437 McHugh et al conducted qualitative research with GPs in Ireland in 2010 exploring 
their attitudes and openness to engaging in quality improvement in general practice. 438 The 
study identified that GPs’ had a sense of inertia towards quality improvements. This inertia 
stemmed from the competing demands of providing chronic disease management in a 
health service with inadequate resources. The authors suggested that this inertia could be 
addressed by involving GPs at an early stage in the intervention development process, an 
approach adopted in this research. Furthermore, in this thesis the continuous GP 
involvement ensured the development of a clinically-relevant intervention that attempts to 
address the real-life complexities of managing BPSD. Using a systematic approach to the 
intervention development process ensured that this ‘real world’ intervention was still 
grounded in evidence. The significant involvement of GPs in the intervention development 
process also meant that, rather than imposing an intervention on disempowered GPs, the 
intervention attempts to provide GPs with an opportunity to improve their practice with 
due consideration of the real-world contextual challenges they face.   
A potential limitation is that, despite the exhaustive consultation with and input from GPs, it 
is possible that this research selectively reached those GPs who were most positive about 
change and most willing to engage in improvement initiatives. There is a danger, therefore, 
that the views of the GPs who are most disillusioned with current practices and most 
resistant to change were not ascertained. Although GP participants in the qualitative study 
and in the online module may represent a subset of GPs who are more amenable to change 
and more interested in dementia care than GPs who did not participate in the module, the 
inclusion of the results of the two cross-sectional descriptive studies in the intervention 





open to change and less involved with dementia care. For example, in the cross sectional 
study the dissatisfaction of participating GPs with the current remuneration structure for 
GPs engaged in dementia care was evident. In the qualitative study, although participating 
GPs spoke about the challenges of managing BPSD in the context of stretched resources, the 
resources they sought were primarily improved services and supports, rather than increased 
remuneration for the GP. It is possible that the GPs who were disillusioned with current 
provision of dementia care were less likely to engage in the qualitative study. However, this 
demonstrates the benefit of using multiple sources of data to inform the intervention 
development process. In this research, the use of a combination of different data sources, 
from GPs engaged in dementia care at multiple levels, enhanced the authenticity of the 
overall research findings. 
Another potential limitation is that the GPs that participated in the qualitative interviews 
and the cross-sectional descriptive study were all from one geographical area in the south of 
Ireland. However, to overcome this limitation participants in the qualitative study were 
purposively sampled to represent the spectrum of Irish general practice. In the cross-
sectional descriptive study the respondents were identified as being representative of GPs 
nationally. Additionally, the intervention development was informed by GP participants in 
the dementia module and GPs who participated in the eDelphi consensus study; these GPs 
were recruited at a national level, thereby improving the transferability of the findings 
within Ireland. Furthermore, the intervention addresses a number of the challenges 
identified in the systematic review, which represented the views of GPs internationally, 





The under resourcing of community and nursing home services was identified as being a key 
influence on GP decision-making processes in BPSD.330,332 However, it was beyond the scope 
of this thesis to address these wider contextual issues of under-resourcing in primary care in 
Ireland. It could be suggested, that by introducing this intervention to improve the 
management of BPSD in general practice, GPs are being asked to change an aspect of their 
practice without providing them with any increased financial resources to do this. On the 
other hand, evidence suggests that GPs engage in quality improvement for many reasons 
including; a desire to improve care, to maintain professional autonomy and for reasons of 
professional pride. 439 Financial remuneration is just one reason. 439 A 2011 Cochrane review 
evaluated the impact of financial incentives on healthcare professional behaviour and found 
that financial incentives may be effective in changing healthcare professional practice. 440 
Yet, a recent review of reviews by Chauhan et al evaluated the effectiveness of behaviour 
change interventions that were specifically directed at primary care health care 
professionals and found that the use of financial incentives alone did not significantly 
influence practice in the long term. 441  The review did find that combining financial 
incentives with educational interventions and audit/feedback can be effective in changing 
GP’s behaviour. 441 This combination of incentivisation and education has been shown to be 
a promising method of changing GP behaviour in the area of generic prescribing. 442 
Similarly, Perry et al in their review of the effects of GP educational interventions in 
dementia care, highlighted that to effectively change GP practice in dementia care, 
education needs to be combined with adequate reimbursement and organisational 
incentives. 360 In the current Irish context of financial austerity and low morale amongst GPs, 
45 the success of an intervention, any intervention, which asks GPs to change their practice 





Engaging health care professionals in change will always be a challenge when the system in 
which they work is under-resourced. 443 This holds true regardless of the individual merits of 
the intervention being introduced. The intervention developed here aims to specifically 
address how care is provided by GPs to people with BPSD in nursing home settings. In this 
research, the dissatisfaction GPs felt with their roles and responsibilities in the nursing 
homes they attended was clear. Several GPs in the qualitative study intimated that the only 
reason they attended nursing homes was out of a sense of civic responsibility. This was 
particularly true of rural GPs, who were often the only GP in the area. It has been observed 
that, in healthcare, attempts to change behaviour ultimately depends on human will.444 In 
this intervention, significant efforts were made to ensure the GPs would be incentivised to 
engage with the intervention; through provision of continuous professional development 
points and by the development of tools to facilitate engagement in the intervention. 
However, a certain reliance on the GP’s goodwill remains. Therefore, it is possible that the 
GPs who will readily engage with this intervention will be those GPs that, heretofore, are 
already providing optimal care. 
This research targeted the behaviour of GPs. Targeting behaviour is an important 
component of quality improvement. However, it could be argued that improving the care 
that healthcare professionals provide requires more than just changing individual behaviour. 
The systems in which health care professionals work need to change too. The Chronic Care 
Model provides a framework for the improvement of chronic disease management in 
primary care. 445 The model outlines the components required for high quality chronic 
disease management and emphasises that chronic disease management takes place in three 





practice or behaviour, is embedded in a health system, which is embedded within the wider 
community of policies and resources. Improvements in system-level factors, for example, 
the provision of community based dementia advisors,446 have the potential to improve the 
quality of care a person with BPSD receives. Indeed, there are many factors outside of an 
individual GP’s control that could be targeted to improve the care provided to people with 
BPSD. However, this intervention aims to specifically target GPs’ behaviour and, therefore, 
focuses on one aspect of GP’s management of BPSD that is known to be sub-optimal and is, 
importantly, within a GP’s control.  
The systematic approach taken to the intervention development process is a strength of this 
research. At a high-level, there is some debate on the value of theory in intervention 
development, 447 with researchers arguing that a better approach may be to use logic and 
common sense instead of theories. 448 However, proponents of theory-based approaches 
maintain that theory helps to develop more evidence-based, transparent and ultimately 
more successful interventions. 236,449,450  Indeed, the poor success of healthcare 
improvement interventions in the past has been attributed to the failure to adopt a theory-
based approach to intervention development.237 Although, the success of theory based 
interventions have yet to be directly compared to atheoretical interventions, Davidoff et al 
argue that theory is always at work in improvement interventions; the issue is not whether 
researchers use theory but whether they are explicit about the formal or informal theory 
they are using. 449  Overall, current opinion supports the use of an explicit theory when 
developing healthcare interventions believing that it produces more sustainable, 
reproducible interventions and enables researchers to effectively evaluate and learn from 





did not mean that professional intuition was abandoned or ignored. The use of an explicit 
theory simply allowed intuition and experience to be incorporated into the design of the 
intervention in a transparent, systematic way. 
The explicit theory that informed this research was the BCW. While advocating for the use 
of a theory-driven approach to intervention development, some commentators have 
criticised the BCW. Ogden, one such commentator, contends that the BCW attempts to 
“reduce variability” and “systematise behaviour” in way that is both unfeasible and 
undesirable. 451 Yet, others argue that the advantage of the BCW is that it allows the design 
of “real world interventions, especially by those less familiar with the area [of behaviour 
change]”, 452 a point conceded by Ogden. 453  Personally, as a clinician with no background in 
health psychology, using the BCW helped to demystify behaviour change theory. The 
relative accessibility of the BCW, when compared to other potential theories for 
incorporated behaviour change in intervention development such as Intervention Mapping, 
454 increased its appeal and influenced the decision to engage with the BCW approach. 
However, it is worth considering whether the wide remit and accessibility of the BCW 
results in a generic ‘Theory of Everything’ that has the potential to “create a false sense of 
security”, 455 making something appear simple when it is not. 453 A potential limitation of the 
BCW is that all intervention functions and BCTs are presented as being equally effective in 
any context. The researcher can choose any BCT as long as it represents that intervention 
function, without consideration of whether or not that BCT has been shown to be effective. 
Another limitation is the tendency of the BCW to compartmentalise behaviours, creating an 
illusion of separateness, when in reality the behaviours are typically inter-connected and 





approach it models. In practice, however, it meant that the same behaviour could be coded 
multiple times under different domains and could be represented in multiple behaviour 
change techniques. This ensures that the approach taken to the intervention development 
process is comprehensive and exhaustive. Such a meticulous approach does have 
consequences. The BCW, although thorough, is not necessarily efficient. That been said, for 
this thesis, using the BCW provided a language and a framework with which to explicitly and 
transparently develop the intervention. No theory is perfect but the BCW proved to be a 
particularly useful approach here.    
 
11.4 IMPLICATIONS FOR POLICY  
The publication of the Irish National Dementia Strategy brought a welcome focus to the 
provision of dementia care in Ireland and recommended a community-led approach to 
dementia care. Such a community-focus requires a primary care led approach to the 
management of dementia. This thesis has outlined a number of challenges of providing a 
primary care approach to the management of BPSD. These challenges need to be addressed 
at a policy level if the vision of community-led dementia care is to become a reality. I will 
now outline the policy implications of this research. I will first focus on the community 
setting, then on the nursing home setting and finally I will consider the need for guideline 
development. 
Supporting people with dementia to live at home for as long as possible is the over-arching 
aim of nearly all government policies and national dementia strategies internationally.28-30 
There are economic, societal and healthcare benefits associated with supporting people 





BPSD is a significant trigger for admission to nursing homes. 114 It would seem logical, 
therefore, that improving how BPSD is managed in the community could effectively 
postpone a person’s admission to a nursing home. This research has identified a number of 
areas, which if addressed with appropriate policy, would improve the management of BPSD 
in the community. The systematic review and the qualitative study both highlighted the 
inadequate resourcing of primary care teams and community supports. This insufficient 
resourcing of primary care teams was identified as the main barrier to recommending non-
pharmacological strategies to manage BPSD in the descriptive cross sectional study of GPs’ 
management of BPSD. GPs need access to community-based multidisciplinary supports to 
successfully implement non-pharmacological strategies in BPSD. This is not currently the 
case in Ireland. 2  Several participants highlighted how government led reductions in ‘home 
help’ hours can result in an otherwise unnecessary, and significantly more costly, admission 
to long term care. Furthermore, the lack of effective care pathways between GPs and 
secondary care colleagues when managing BPSD was apparent in both the systematic 
review and the qualitative study. Even identifying which specialist to access for advice on 
the management of BPSD was a challenge for GPs; some felt it was the remit of old age 
psychiatry, others geriatricians and others still were unsure; relying on ‘personal favours’ to 
access advice from secondary care colleagues.332 Policy that provides for integrated and 
resourced care pathways would help to facilitate effective communication between primary 
and secondary care.  
This research has also identified a number of policy implications for the management of 
BPSD in nursing home settings. The lack of nursing home staff and under-resourcing were 
seen as significant barriers to the provision of optimal care of BPSD in nursing home 





nursing home staff to cope with inadequate resourcing. 330,332 If one reflects upon this, it is 
concerning that both public and privately run organisations are relying on pharmacological 
prescriptions for residents to enable staff to cope with insufficient resources. The GPs who 
participated in this research also frequently referred to the pressure from nursing home 
staff to prescribe psychotropic medications in BPSD.332 Policy requirements that encourage 
and support educational training in BPSD assessment and management for nursing home 
staff could facilitate more consistent engagement with educational initiatives. 
Throughout this thesis the need for implementable guidelines was highlighted by GPs. The 
need for guidelines was also identified and prioritised in the policy category of the BCW 
intervention development process. As part of the implementation of the Irish National 
Dementia Strategy a guideline has been developed on the use of psychotropic medications 
for the management of BPSD. The process of developing this guideline began in October 
2017. As a GP, with a clinical and research interest in the area of BPSD, I was invited to be 
the ICGP representative on this guideline development group. I was also nominated as one 
of the five individuals to sit on the writing group. In this way I was able to introduce my 
thesis findings into the guideline development process. This guideline has recently being 
prioritised by the NCEC (National Clinical Excellence Committee), the national body who 
endorse clinical guidelines in Ireland. Thus, this guideline will be supported for 
implementation as a National Clinical Guideline. This means that going forward the 
prescribing of psychotropic medications to people with dementia will be audited and 
educational tools and training in the area of BPSD will be implemented. The details of what 
areas will be targeted for audit have yet to be determined, however, I will be part of the 





11.5 IMPLICATIONS FOR PRACTICE 
This research attempts to close the gap between evidence on best practice approaches to 
the management of BPSD and the context in which these management decisions are made. 
Peters et al have highlighted the importance of considering the dynamics of behaviour 
change when developing an intervention. 456 Specifically, Peters has outlined how the 
behaviour change methods selected should be carefully matched with the determinants of 
the behaviour in question; to ensure that the behaviour can, in fact, be changed. 457 GPs 
participating in the qualitative study considered the challenges associated with managing 
BPSD to be insurmountable and outside of their control. This intervention demonstrates to 
GPs that, although they are constrained by the health system in which they work, not all of 
the challenges associated with managing BPSD are insuperable. Monitoring the prescribing 
of antipsychotic medication is a manageable task that has the potential to improve the care 
they provide to people with dementia in nursing homes.  
The decision to target the monitoring of antipsychotic medications in BPSD, rather than 
targeting the initiation of antipsychotic medication in BPSD, reflects an attempt to reconcile 
the apparent incongruity that exists between best practice recommendations and real-
world contextual challenges in BPSD management. In the context of current resource 
restrictions, the extent to which the initiation of antipsychotic prescribing could truly be 
changed was questionable. In choosing to target the monitoring of antipsychotic 
medication, rather than targeting the initiation of these medications, I am not proposing 
that inappropriate prescribing be tolerated. However, I am accepting that it is not currently 
possible to completely eliminate the use of antipsychotic medication in BPSD. Nor is it clear 





level of antipsychotic prescribing, nor is there a clear “unsafe” level. However, as the 
harmful effects of antipsychotics are dose and duration dependent, it is clear that 
prescribing antipsychotics, without an adequate and effective review process in place, is 
potentially harmful to the person with BPSD. The intervention addresses a specific area of 
sub-optimal practice in BPSD – the failure to monitor ongoing prescribing of potentially 
harmful antipsychotic medication to people with dementia. 370 Effectively addressing the 
inadequate monitoring of antipsychotics in dementia will improve the management of BPSD 
by ensuring people with dementia are not inappropriately prescribed antipsychotic 
medication for prolonged periods of time, without a documented indication and without a 
scheduled review process in place. Importantly, based on my provisional work, targeting this 
behaviour appears to be acceptable to GPs, whereas, targeting their clinical decision to 
initiate antipsychotic medication in the first place is likely to be less acceptable and fraught 
with contextual limitations. That being said, as outlined in Chapter 8, by selecting 
monitoring of antipsychotics as the target behaviour for this intervention, a certain ‘spill-
over’ effect on appropriate initiation of antipsychotics is expected.  
The intervention developed here is particularly suited to GPs with a large nursing home 
commitment, where one GP provides regular, structured nursing home care to the majority 
of the residents. Although this is the model of care provided by many GPs in Ireland, it is not 
the model for all.  But should it be? The descriptive cross-sectional study highlighted that 
many GPs in Ireland do not provide structured visits to the nursing home they attend. 403 In 
these instances, nursing home attendance is an ‘add-on’ to the GP’s daily workload, often 
occurring before the working day begins or during a rushed lunchtime visit. Consequently, 
the care provided is often reactive, in response to crisis situations or acute problems. 





This nursing home may be a significant distance away from the GP’s surgery. For those GPs, 
structured visits are unfeasible from a resource perspective and it is envisaged that these 
GPs may be less likely to engage with the proposed intervention. There may be some 
concerns that having just one GP providing all the medical care in a nursing home could 
affect patient choice and autonomy. However, the qualitative study conducted as part of 
this research highlighted many of the benefits of one GP providing all, or the majority of 
care, in a nursing home. These benefits included increased consistency of care, an upskilled 
GP and better relationships with nursing home staff. In BPSD management, the importance 
of good communication pathways between GPs and nursing home staff was emphasised in 
the systematic review and the qualitative study. 330,332 Additionally, having a large nursing 
home commitment provides economies of scale for the GP and can enable and encourage a 
GP to provide more proactive care. 100 Consequently, one consideration for future practice 
that emerges from this research is whether medical care in nursing homes should be 
provided by one, upskilled GP. A practice model to consider is the system in place in The 
Netherlands where a distinct speciality of nursing home medicine exists. 277 A recent 
systematic review examined how the health outcomes of residents in long term care 
facilities varied according to which professional group provided the first-line medical care. 
458 It found that having a specialist (versus a generalist) doctor providing the first line care 
was associated with improved prescribing outcomes but the impact on unplanned hospital 
transfer was less clear and there was no impact on mortality. 458  The findings of this thesis 
would suggest that where a GP has a large nursing home commitment, they benefit from 
increased experience of managing BPSD, experience that can improve their confidence and 






11.6 IMPLICATIONS FOR FUTURE RESEARCH 
The next step for this research should be the conduct of a feasibility study. Conducting a 
feasibility study is important in order to assess the extent to which the limitations identified 
in section 9.3 impact on the acceptability of the intervention from the perspective of all the 
relevant stakeholders. The concept for this research emerged from the initial educational 
needs analysis which was conducted with GPs, people with dementia and their carers. 87 
That educational needs analysis was effectively used to inform the development educational 
material for health care professionals developed as part of the wider PREPARED project. 
133,409,412 Carers and people with dementia may also have a role in informing the educational 
content of the interprofessional education component of this intervention. Furthermore, in 
order to have outcome measures that are meaningful, it is imperative that the perspectives 
of people with dementia and their carers are included in any future feasibility study. 
There are also more general implications for conducting intervention development research 
in this area and, in particular, conducting intervention development research with GPs. GPs 
are frequently the subject of research, particularly healthcare research that focuses on 
quality improvement initiatives and behaviour change interventions. However, GPs are 
rarely effective partners in the development of these interventions. Research is often 
conducted on the decisions GPs make, without an adequate attempt to understand and 
appreciate the contextual constraints in which they make these decisions. In my own 
discussions with healthcare researchers they sometimes consider GPs as a ‘hard to reach’ 
group who are reluctant to engage with the research process. This can also be seen in the 
literature. For example, a recent feasibility study that introduced a pharmacist-led 





difficult to engage with GPs, experienced high GP drop-out rates and found that GPs who 
did participate were very slow to implement the medication changes suggested. 430 The 
authors postulated the reasons for this lack of GP engagement; considering things like the 
time required for the GP to engage in the intervention and the GPs relationship with the 
care home and with the pharmacist. The authors suggested that improved engagement with 
GPs at the beginning of the intervention with the option of continuous professional 
development points for the GP might improve future roll-outs. 430 Consequently, the 
question arises; are GPs truly hard to reach or are attempts made by researchers to include 
GPs in the research process inadequate, or more importantly, inappropriate? If the aim is to 
change behaviour then it is critical that we first understand the behaviour and the context in 
which the behaviour occurs. If the barriers to GPs performing a behaviour are not identified 
then it is unlikely the intervention developed will effectively target GPs’ behaviour. 
Therefore, research that aims to change GPs behaviour needs to first understand what their 
current practice is and what their perspectives are on the challenges of implementing best 
practice. Future research about GPs needs to more proactively and effectively engage with 
GPs. Involving GPs as equal partners in the research process will also improve their ultimate 
ownership of the behaviour change intervention. Attempting to change the behaviour of 
any health care professional group, without attempting to get their ‘buy in’ may be an 
exercise in futility. 437  
The attention given to research in the area of BPSD in the past is not reflective of the 
significant impact BPSD has on healthcare professionals, people with dementia and their 
caregivers. The management of BPSD in general practice has not received the same level of 
research focus as other aspects of dementia care. One could postulate that the reason for 





sometimes, conflicting evidence base. Thus, it does not lend itself to easily measurable 
outcomes. Research in the area of BPSD may be seen as less quantifiable and inherently 
more complex. The intervention developed in this thesis focused on one specific, target 
behaviour. However, this research has systematically identified a number of other 
behaviours in BPSD that contribute to the sup-optimal management of BPSD in general 
practice. These behaviours and some potential interventions that could address them have 
been transparently detailed in this thesis. Thus, this information could provide a starting 
point for other researchers interested in developing interventions for GPs managing BPSD.  
11.7 CONCLUSION 
This thesis presents a series of research that advances our knowledge of GPs’ perspectives 
on the management of BPSD. Prior to conducting this research it was known that BPSD was 
a challenging area for GPs. This research provides a new depth of understanding as to why 
this is a challenging area for GPs. By using this new understanding to inform the 
development of an intervention to improve the management of BPSD in general practice, 
this thesis has addressed a specific gap in the literature. A systematically developed and 
clinically implementable intervention has been developed to address a sub-optimal aspect 
of BPSD management in general practice. The novel intervention was developed through 
detailed application of existing and new evidence to models of behaviour change. Thus, this 
research has made a meaningful contribution to the body of knowledge on BPSD 
management in general practice and also to the literature on the development of 
interventions for GPs in areas of clinical complexity. It is anticipated that the outputs of this 
thesis will contribute to the ultimate goal of improving the quality of care delivered to 
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Appendix 1. Supplementary Material for Chapter 5 - Systematic 
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Supplementary Material 1. PRISMA-P Checklist. 




Identification 1a Identify the report as a protocol 
of a systematic review 
101 
Update 1b If the protocol is for an update 
of a previous systematic review, 
identify as such 
Not an update 
Registration 2 If registered, provide the name 
of the register (such as 




Contact 3a Provide name, institutional 
affiliation, email address of all 
protocol authors; provide 
physical mailing address of 
corresponding author 





Contributions 3b Describe contributions of 
protocol authors and identify 
the guarantor of the review 





Amendments 4 If the protocol represents an 
amendment of a previously 
completed or published 





Sources 5a Indicate sources of financial or 
other support for the review 





Sponsor 5b Provide name for the review 
funder and/or sponsor 









Role of sponsor or 
funder 
5c Describe role of funder(s), 
sponsor(s), and/or 
institution(s), if any, in 
developing the protocol 






Rationale 6 Describe the rationale for the 
review in the context of what is 
already known 
103-104 
Objectives 7 Provide an explicit statement of 
the question(s) the review will 
address with reference to 
participants, interventions, 




Eligibility criteria 8 Specify the study characteristics 
(such as PICO, study design, 
setting, time frame) and report 
characteristics (such as years 
considered, language, 
publication status) to be used 
as criteria for eligibility for the 
review 
109 (Table 2) 
Information sources 9 Describe all intended 
information sources (such as 
electronic databases, contact 
with study authors, trials 
registers or other grey 
literature sources) with planned 
dates of coverage 
110 
Search strategy 10 Present draft of search strategy 
to be used for at least one 
electronic database, including 
planned limits, such that it 
could be repeated.  






Data management 11a Describe the mechanism(s) that 
will be used to manage records 
and data throughout the review 
111 
Selection process 11b State the process that will be 
used for selecting studies (such 
as two independent  reviewers) 
through each phase of the 
review (that is, screening, 







Data collection process 11c Describe planned method of 
extracting data from reports 
(such as piloting forms, done 
independently, in duplicate), 
any processes for obtaining and 
confirming data from 
investigators 
112 
Data items 12 List and define all variables for 
which data will be sought (such 
as PICO items, funding source), 
any pre-planned data 
assumptions and simplifications 
113 (Table 4) 
Outcomes and 
prioritization 
13 List and define all outcomes for 
which data will be sought, 
including prioritization of main 
and additional outcomes, with 
rationale 
116 
Risk of bias in 
individual studies 
14 Describe anticipated methods 
for assessing risk of bias of 
individual studies, including 
whether this will be done at the 
outcome or study level., or 
both; state how this 
information will be used in data 
synthesis 
117-118 
Data synthesis 15a Describe criteria under which 
study data will be quantitatively 
synthesised 
N/A 
 15b If data are appropriate for 
quantitative synthesis, describe 
planned summary measures, 
methods of handling data and 
methods of combining data 
from studies, including any 
planned exploration of 
consistency (such as I2, 
Kendall’s ) 
N/A 
 15c Describe any proposed 
additional analyses (such as 
sensitivity or subgroup 
analyses, meta-regression) 
N/A 
 15d If quantitative synthesis is not 
appropriate, describe the type 
of summary planned 
113-115 
Met-bias(es) 16 Specify any planned assessment 
of meta-bias(es) (such as 
publication bias across studies, 









17 Describe how the strength of 
the body of evidence will be 




Supplementary Material 2. Search terms for the systematic review 
How the search terms were combined with Boolean logic for the Medline, Ovid search 
1. Exp Primary Health Care/  
2. Exp General Practice 
3. Family Practice/  
4. Exp General Practitioners/ 
5. Exp Physicians, Family/ 
6. Exp Physicians, Primary Care/  
7. family medicine.ti,ab 
8. 1 OR 2 OR 3 OR 4 OR 5 OR 6 OR 7 
9. Exp Dementia/ 
10. Exp Alzheimer Disease/  
11. dementia.ti,ab. alzheimer*.ti,ab. 
12. (cognitive adj (impairment or decline)).ti,ab 
13. 9 OR 10 OR 11 OR 12 
14. Exp Antipsychotic Agents/  
15. Exp Anxiety/ 
16. Exp Aggression/  
17. Exp Wandering behavior/ 
18. Exp Sleep Disorders/ 
19. Exp Apathy/ 
20. Exp Irritable Mood/ 
21. Exp Psychotic Disorders/ 
22. Exp Depression/ 
23. Behavio?ral and psychological symptom*ti,ab 
24. BPSD.ti,ab 
25. Challenging behavio?r*ti,ab 
26. Responsive behavio?r*.ti,ab 
27. Neuropsychiatric symptom*.ti,ab 
28. Non-cognitive symptom*.ti,ab 
29. Noncognitive symptom*.ti,ab 
30. Psychological symptom*.ti,ab 
31. Psychiatric symptom*.ti,ab 
32. Difficult behav*.ti,ab 
33. Disruptive behav*.ti,ab 
34. Behavio?ral symptom*.ti,ab 
35. (agitated or agitation).ti,ab 





37. (anxiety or anxious).ti,ab (aggressive* behav*).ti,ab 
38. 14 OR 15 OR 16 OR 17 OR 18 OR 19 OR 20 OR 21 OR 22 OR 23 OR 24 OR 25 OR 26 OR 27 OR 
28 OR 29 OR 30 OR 31 OR 32 OR 33 OR 34 OR 35 OR 36 OR 37 
39. 8 AND 13 AND 38 
 
Supplementary Material 3. Excluded Studies 
Reasons for excluding studies after full text review 
# Authors, Study Reason for excluding 
1 Bowers J, Jorm AF, Henderson S, Harris P. 
General practitioners' reported knowledge 
about depression and dementia in elderly 
patients. Australian and New Zealand 
Journal of Psychiatry. 1992;26(2):168-74. 
Does not describe the 
knowledge, attitudes or 
experiences of GPs in relation to 
BPSD. Focus was on GPs 
knowledge in relation to 
dementia diagnosis.  
2.  McIntosh IB, Swanson V, Power KG, Rae 
CAL. General practitioners' and nurses' 
perceived roles, attitudes and stressors in 
the management of people with dementia. 
Health Bulletin. 1999;57(1):35-40. 
Focus is on GP & nurse stress in 
managing dementia. Mentions 
BPSD only as a source of stress 
but does not investigate GPs 
knowledge, attitude or 
experiences of managing BPSD. 
3. O'Connor DW, Pollitt PA, Hyde JB, Brook 
CPB, Reiss BB, Roth M. Do general 
practitioners miss dementia in elderly 
patients? British Medical Journal. 
1988;297(6656):1107-10. 
Focus on GP's ability to detect 
dementia with no reference to 
BPSD. 
4.  Parmar J, Dobbs B, McKay R, Kirwan C, 
Cooper T, Marin A. Diagnosis and 
management of dementia in primary care: 
exploratory study. Canadian family 
physician Medecin de famille canadien. 
2014;60. 
Does not describe the 
knowledge, attitudes or 
experiences of GPs in relation to 
BPSD. Did find that BPSD was 
under-documented in the notes 
but did not explore GPs 
knowledge, attitudes or 
experiences of BPSD. 
5. Parsons C, McCorry N, Murphy K, Byrne S, 
O'Sullivan D, O'Mahony D, et al. Assessment 
of factors that influence physician decision 
making regarding medication use in 
patients with dementia at the end of life. 
Focus on discontinuation of 
medications in end of life 
advanced dementia. Does 
mention discontinuation of 





International journal of geriatric psychiatry. 
2014;29(3):281-90. 
explore this in the context of 
BPSD. 
6.  Patterson SM, Hughes CM, Lapane KL. 
Assessment of a United States 
pharmaceutical care model for nursing 
homes in the United Kingdom. Pharmacy 
world & science : PWS. 2007;29(5):517-25. 
 
Not specific to dementia or BPSD 
but focus on prescribing and 
medication use in NHs. 
[Conflicting votes, agreed by 
arbitration that should be 
excluded on the grounds that it is 
not dementia or BPSD specific. 
7.  Payne M, Gething M, Moore AA, Reid MC. 
Primary care providers' perspectives on 
psychoactive medication disorders in older 
adults. American Journal Geriatric 
Pharmacotherapy. 2011;9(3):164-72. 
Explores PCPs experiences of 
psychoactive medication misuse 
in older adults but does not 
specifically look at  dementia or 
BPSD 
 
8. Pentzek M, Wollny A, Wiese B, Jessen F, 
Haller F, Maier W, et al. Apart from nihilism 
and stigma: what influences general 
practitioners' accuracy in identifying 
incident dementia? American Journal of 
Geriatric Psychiatry.17(11):965-75. 
Knowledge and attitude survey 
of GPs re dementia but does not 
explore BPSD 
9. Petrazzuoli F, Vinker S, Koskela TH, Frese T, 
Buono N, Soler JK, et al. Exploring dementia 
management attitudes in primary care: a 
key informant survey to primary care 
physicians in 25 European countries. 
International Psychogeriatrics. 2017:1-11. 
Focus is on dementia diagnosis 
and initial treatment, not BPSD.  
10. Pond CD, Brodaty H, Stocks NP, Gunn J, 
Marley J, Disler P, et al. Ageing in general 
practice (AGP) trial: a cluster randomised 
trial to examine the effectiveness of peer 
education on GP diagnostic assessment and 
management of dementia. BMC family 
practice. 2012;13:12. 
Protocol of a study that focuses 
on evaluating impact of GP 
educational intervention on 
dementia diagnosis. Does not 
describe the knowledge, 
attitudes or experiences of GPs 
in relation to BPSD. 
11.  Qazi A, Spector A, Orrell M. User, carer and 
staff perspectives on anxiety in dementia: a 
qualitative study. Journal of Affective 
Disorders.125(1-3):295-300. 
No general practitioners included 
in the focus groups for the study. 
12. Rockwood K, Black SE, Robillard A, Lussier I. 
Potential treatment effects of donepezil not 
detected in Alzheimer's disease clinical 
Focus is on GPs experiences of 
the potential treatment effects 





trials: a physician survey. International 
journal of geriatric psychiatry.19(10):954-
60. 
explore the GPs knowledge & 
attitudes or experiences of BPSD. 
13.  Sawan MJ, Jeon YH, Fois RJ, Chen TF. A 
qualitative study exploring visible 
components of organizational culture: what 
influences the use of psychotropic 
medicines in nursing homes? International 
psychogeriatrics / IPA. 2016:1-11. 
 
Semi-structured interviews with 
health care professionals 
(including 8 GPs) on what 
influences the use of 
antipsychotic prescribing in 
nursing homes. Minimal 
identifiable data on GPs. There is 
no explicit reference to dementia 
or BPSD. Went to 3rd reviewer for 
consensus as conflicting votes. 
Excluded on the basis that study 
results cannot be presumed to 
be reflective of GPs experiences 
to BPSD as not the only reason a 
nursing home resident could be 
on an antipsychotic. 
14.  Stewart TV, Loskutova N, Galliher JM, 
Warshaw GA, Coombs LJ, Staton EW, et al. 
Practice patterns, beliefs, and perceived 
barriers to care regarding dementia: A 
report from the American Academy of 
Family Physicians (AAFP) National Research 
Network. Journal of the American Board of 
Family Medicine. 2014;27(2):275-83. 
BPSD mentioned as being the 
most challenging aspect of 
dementia care but no reflection 
on GPs knowledge of, attitude 
towards or experiences of BPSD. 
15.  Shaw C, McCormack B, Hughes CM. 
Prescribing of Psychoactive Drugs for Older 
People in Nursing Homes: An Analysis of 
Treatment Culture. Drugs - real world 
outcomes. 2016;3:121-30. 
Not dementia specific, focus is on 
prescribing of psychoactive drugs 
which does not necessarily 
equate to BPSD. Only 1 quote 
from GP in the paper. Went to 
third reviewer for arbitration. 
Decision to exclude on basis that 
does not explicitly related to 
BPSD. 
16.  Tang EYH, Birdi R, Robinson L. Attitudes to 
diagnosis and management in dementia 
care: Views of future general practitioners. 
International Psychogeriatrics. 2016. 
 
BPSD mentioned as being one of 
the most challenging aspect of 
dementia care but no exploration 
of GP registrars’ knowledge of 





17.  Tinsley JA, Shadid GE, Li H, Offord KP, 
Agerter DC. A survey of family physicians 
and psychiatrists. Psychotropic prescribing 
practices and educational needs. General 
Hospital Psychiatry.20(6):360-7. 
Does not describe the 
knowledge, attitudes or 
experiences of GPs in relation to 
BPSD 
18. Turner S, Iliffe S, Downs M, Wilcock J, 
Bryans M, Levin E. General practitioners’ 
knowledge, confidence and attitudes in the 
diagnosis and management of dementia. 
Age and ageing. 2004;33. 
 
Examines some of the barriers to 
good practice. Ranks BPSD as the 
most difficult aspect of dementia 
care. However, no specific 
attitudinal question related to 
BPSD. Only 1 knowledge 
question related to depression. 
Initial conflict between reviewers 
but through discussion agreed to 
exclude on the basis that no 
significant data related to 
knowledge and attitude towards 
BPSD. 
19.  van Hout HP, Vernooij-Dassen MJ, Stalman 
WA. Diagnosing dementia with confidence 
by GPs. Fam Pract. 2007;24(6):616-21. 
 




Veneziani F, Panza F, Solfrizzi V, Capozzo R, 
Barulli MR, Leo A, et al. Examination of level 
of knowledge in Italian general practitioners 
attending an education session on diagnosis 
and management of the early stage of 
Alzheimer's disease: Pass or fail? 
International Psychogeriatrics. 
2016;28(7):1111-24. 
Focus on impact of an 
educational intervention on 
knowledge and attitudes to 
dementia but limited primarily to 
issues around diagnosis, no 
exploration of knowledge or 
attitudes towards BPSD 
21.  Werner P, Gafni A, Kitai E. Examining 
physician-patient-caregiver encounters: the 
case of Alzheimer's disease patients and 
family physicians in Israel. Aging & mental 
health.8(6):498-504. 
 
Looks at how the presence of 
agitation affected how the GP 
communicated the diagnosis of 
dementia and other dementia 
related information. Went to 
third reviewer for arbitration 
decision to exclude on the basis 
that it does not describe the 
knowledge, attitudes or 






22.  Wijeratne C, Harris P. Late life depression 
and dementia: A mental health literacy 
survey of Australian general practitioners. 
International Psychogeriatrics. 
2009;21(2):330-7. 
Focus of survey was on diagnosis 
not BPSD. 
23.  Alexander C, Fraser J. General practitioners' 
management of patients with mental health 
conditions: The views of general 
practitioners working in rural north-western 
New South Wales. Australian Journal of 
Rural Health. 2008;16(6):363-9. 
 
Small survey of ~38 GPs looking 
at their attitudes and confidence 
to mental health conditions in 
general but does not specifically 
explore their attitudes or 
confidences with BPSD. 
24.  Azermai M, Kane J, Liperoti R, Tsolaki M, 
Landi F, Passmore AP, et al. Management of 
behavioural and psychological symptoms of 
dementia: Belgium, Greece, Italy, United 
Kingdom. European Geriatric Medicine. 
2013;4(1):50-8. 
 
Not an original research study. 
Examines how the same patient 
with dementia would be 
managed in different European 
countries. 
25.  Boustani M, Sachs G, Callahan CM. Can 
primary care meet the biopsychosocial 
needs of older adults with dementia? 
Journal of general internal medicine. 
2007;22(11):1625-7. 
 
A review article. 
26.  Bridges-Webb C, Giles B, Speechly C, 
Zurynski Y, Hiramanek N. Patients with 
dementia and their carers in general 
practice. Australian family physician. 
2006;35(11):923-4. 
 
Does not describe the 
knowledge, attitudes or 
experiences of GPs in relation to 
BPSD 
27.  Cantegreil-Kallen I, Turbelin C, Olaya E, 
Blanchon T, Moulin F, Rigaud AS, et al. 
Disclosure of diagnosis of Alzheimer's 
disease in French general practice. 
American journal of Alzheimer's disease and 
other dementias. 2005;20(4):228-32. 
 
Focus on diagnosis disclosure not 
on BPSD. 
28. Chang E, Daly J, Johnson A, Harrison K, 
Easterbrook S, Bidewell J, et al. Challenges 
for professional care of advanced dementia. 






International journal of nursing practice. 
2009;15(1):41-7. 
 
29.  Davies N, Mathew R, Wilcock J, Manthorpe 
J, Sampson EL, Lamahewa K, et al. A co-
design process developing heuristics for 
practitioners providing end of life care for 
people with dementia. BMC palliative care. 
2016;15(1):68. 
 
Describes a co-design process of 
designing an intervention for end 
of life care in dementia but does 
not explore GP’s perspective on 
BPSD. 
30.  Donyai P, Ibrahim K, Almutairi S. Stopping 
medication and decision-making biases. 




31.  Gonzalez-Moneo MJ, Simó M, Pie M, Rivero 
D. Preferences of general practitioners and 
carers of Alzheimer patients regarding the 
use of neuroleptics for behavioural 
disorders in Alzheimer's disease. 
International journal of geriatric psychiatry. 
2008;23(10):1095-7. 
Does not describe the 
knowledge, attitudes or 
experiences of GPs in relation to 
BPSD. Unclear if GPs were even 
involved. "Physicians" 
interviewed but no breakdown of 
background of these physicians. 
32. Gove D, Downs M, Vernooij-Dassen M, 
Small N. Stigma and GPs’ perceptions of 
dementia. Aging & mental health. 
2016;20(4):391-400. 
 
Focus on stigma and factors that 
influence diagnosis, not BPSD. 
33.  Harris DP, Chodosh J, Vassar SD, Vickrey BG, 
Shapiro MF. Primary care providers' views 
of challenges and rewards of dementia care 
relative to other conditions. Journal of the 
American Geriatrics Society. 
2009;57(12):2209-16. 
 
Reports the GP’s perspective on  
another aspect of dementia with 
no reference to BPSD 
34.  Iliffe S, Wilcock J, Haworth D. Obstacles to 
shared care for patients with dementia: a 
qualitative study. Fam Pract. 
2006;23(3):353-62. 
 
Focus on shared care and issues 
around diagnosis not BPSD 
35. Kor Pui-Kin P, Lai Kam-Yuk C, Liu Yat-Wa J, 
Dai Lok-Kwan D, Ting Shuk-Man S, Choi K. A 
Does not describe the 





survey of physician practices in managing 
people with dementia in Hong Kong. 
European Journal of Psychiatry. 
2015;29(3):183-98. 
 
experiences of GPs in relation to 
BPSD only discussed in relation 
to being a reason for referral. 
36.  Krolak-Salmon P, Roubaud C, Finne-Soveri 
H, Riolacci-Dhoyen N, Richard G, Rouch I, et 
al. Evaluation of a mobile team dedicated to 
behavioural disorders as recommended by 
the Alzheimer Cooperative Valuation in 
Europe joint action: Observational cohort 
study. European Journal of Neurology. 
2016;23(5):979-88. 
 
Does not describe the 
knowledge, attitudes or 
experiences of GPs in relation to 
BPSD. 
37.  Manu E, Marks A, Berkman CS, Mullan P, 
Montagnini M, Vitale CA. Self-perceived 
competence among medical residents in 
skills needed to care for patients with 
advanced dementia versus metastatic 
cancer. Journal of Cancer Education. 
2012;27(3):515-20. 
 
Survey of medical residents, a 
small number of whom were 
family medicine residents. 
However, the number of family 
medicine residents surveyed was 
not clear and the views of family 
medicine residents was not 
analysed separately. 
 
38.  Midlov P, Bondesson A, Eriksson T, 
Nerbrand C, Hoglund P. Effects of 
educational outreach visits on prescribing of 
benzodiazepines and antipsychotic drugs to 
elderly patients in primary health care in 
southern Sweden. Fam Pract. 
2006;23(1):60-4. 
 
Does not describe the 
knowledge, attitudes or 
experiences of GPs in relation to 
BPSD 
39.  Murphy K, O'Connor DA, Browning CJ, 
French SD, Michie S, Francis JJ, et al. 
Understanding diagnosis and management 
of dementia and guideline implementation 
in general practice: a qualitative study using 
the theoretical domains framework. 
Implement Sci. 2014;9:31. 
Focus on dementia diagnosis and 
identification of co-morbid 
depression. Note did identify 
study from references 
(Teele_2004) 
40.  Ólafsdóttir M, Foldevi M, Marcusson J. 
Dementia in primary care: Why the low 





detection rate? Scandinavian journal of 
primary health care. 2001;19(3):194-8 
41. Downs M, Cook A, Rae C, Collins KE. Caring 
for patients with dementia: The GP 
perspective. Aging & mental health. 
2000;4(4):301-4. 
Does not describe the 
knowledge, attitudes or 
experiences of GPs in relation to 
BPSD. 
42.  Gurka P, Bacher R, Kemmler G, Hinterhuber 
H, Lingg A, Marksteiner J. Pharmacological 
treatment strategies of residential primary 
care providers in dementia diseases--results 
of a representative survey in western 
Austria. Pharmacopsychiatry.35(4):144-9. 
Does not describe the 
knowledge, attitudes or 
experiences of GPs in relation to 
BPSD 
43. Shah S, Harris M. A survey of general 
practitioner's confidence in their 
management of elderly patients. Australian 
family physician.26 Suppl 1:S12-7. 
 
This survey does not focus 
specifically on dementia or BPSD 
but looks more generally at GPs 
confidence in managing an older 
adult. 
44.  Stoppe G, Sandholzer H, Staedt J, Winter S. 
Sleep disturbances in the demented elderly: 
Treatment in ambulatory care. Sleep: 
Journal of Sleep Research & Sleep Medicine. 
1995;18(10):844-8. 
 
This survey is quite old. It looks 
at GPs responses to a vignette of 
a patient with dementia who has 
sleep disturbance. The focus of 
the survey is on the medication 
chosen to treat the sleep 
disturbance. The decision made 
to exclude as it is specifically 
focused only on sleep 
disturbance.  
45.  Stoppe G, Sandholzer H, Winter S, Kiefer J, 
Staedt J. Treatment of the memory-
disturbed elderly in primary care. Primary 
Care Psychiatry. 1998;4(4):205-9. 
Focus is not on BPSD. 
46.  Wilcock J, Iliffe S, Turner S, Bryans M, 
O'Carroll R, Keady J, et al. Concordance with 
clinical practice guidelines for dementia in 
general practice. Aging & mental 
health.13(2):155-61. 
 
Focus is on GP's adherence to 
guidelines regarding diagnosis. 
BPSD mentioned but only 
whether symptoms enquired 
about. Does not explore GPs 
knowledge, attitudes or 
experiences re BPSD. 
47. Wilcock J, Jain P, Griffin M, Thuné-Boyle I, 
Lefford F, Rapp D, et al. Diagnosis and 
management of dementia in family 
Only assesses if BPSD was 
recorded/ asked about/ 





practice. Aging & mental health. 
2016;20(4):362-9. 
assess K&A or experiences of GPs 
managing BPSD.  
48. Zwijsen SA, Gerritsen DL, Eefsting JA, 
Smalbrugge M, Hertogh CMPM, Pot AM. 
Coming to grips with challenging behaviour: 
A cluster randomised controlled trial on the 
effects of a new care programme for 
challenging behaviour on burnout, job 
satisfaction and job demands of care staff 
on dementia special care units. 
International journal of nursing studies. 
2015;52(1):68-74. 
No GPs involved- questionnaire 
to care staff. 
49. Peri K, Kerse N, Moyes S, Scahill S, Chen C, 
Hong JB, et al. Is psychotropic medication 
use related to organisational and treatment 
culture in residential care. Journal of Health 
Organization & Management. 
2015;29(7):1065-79. 
Survey questionnaire. Focus is on 
antipsychotic prescribing and NH 
treatment culture not on GPs 
knowledge, attitudes or 
experiences with BPSD. 
 
50.  Martin RM, Rink E, Wilkinson DG, Mann RD. 
Did knowledge, opinions, background, and 
health authority advice influence early 
prescribing of the novel Alzheimer's disease 
drug donepezil in general practice? - 
National postal survey. 
Pharmacoepidemiology and drug safety. 
1999;8(6):413-22. 
Reports the GP’s perspective on 
prescribing of Donepezil with no 
reference to BPSD. 
51.  Riancho J, Jiménez-López Y, Sánchez- de la 
Torre JR, Pardina-Vilella L, Sánchez-Juan P. 
How much do Spanish clinicians know about 
dementia? Journal of the Neurological 
Sciences. 2017;372:468-70 
Letter to the Editor. Quant 




A further 14 records were excluded from the Full-Text screen without being read in full for the 
following reasons:  
1. Records where no English version was available were excluded from FT reading (n=10).  
2. Where only a conference abstract was available the original authors were contacted where 
possible to see if a full-text version was available. Where no full text was available these 
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problem. There 
aren’t enough 




bottom line is 
it’s hard. The 
feedback is 
  Clinicians may 
rely more on 
medications if 











































Most of the 
time when they 
come in to see 
me there may 
Since I’m not a 
licensed 
clinical social 
worker and I 
don’t know 
what’s 
available in the 
community, 
and I don’t 
know how to, 
nor do I have 
time to call up 
and make 
arrangements 
for meals on 
wheels, or call 
up and find out 
what they 
need for a 
choreworker, 
or call up and 
find out how to 
access 
daycare. All I 






with the family 
in the 15 
minutes.” 
As a result of 
having 
insufficient 



















I think we’re 
all drowning, I 
do. It’s, you 
know, we are 
all truly trying 
to keep our 
heads above 
 




just get to the 
point there 
where, I don’t 
know how to 







want a second 
opinion too in 
making sure 
my diagnosis 










back and they 
are usually, 
they don’t have 






I just feel, I 
don’t have the 
network we 
need, so, 
because for the 
dementia care 







feel I don’t 
have this. I 
don’t think 
anybody has 


















wetting the bed 

























there’s a green 
booklet that 
the County put 
out a couple of 
years ago. (pg. 
1490) 
 
I mean, there 
are books that 
tell you who, 
but there’s so 
many listings 
in those books 
it’s hard to 
work your way 
through those 
to figure out, 
okay, for this 
person in this 
circumstance 
who are the 
two or three 
people that I 
need to get 
involved, and 
it’s confusing 













doing all the 
other stuff 
that we’re 
doing with all 
the other 
patients that, 
to be honest, 
sometimes it’s 
like, you know, 
you just don’t 
want these 
people in your 
practice cause 
a 15-minute 





Lack of time 





the gist of care 




access to a 
social worker, 













often felt they 
had little 
choice but to 
try and 
manage care as 
best they could 
despite a 
perceived lack 
of   
time and 
training.  Some 
physicians 
expressed 
see when, and 




















and so they 





the majority of 
the visit is 
hand-holding 
and listening, 
that sort of 
thing. It takes 












placed in a 
situation in 
which they felt 
compelled to 
provide care 
that they felt 
was beyond 
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  Pivotal Role of 
Family 
Sub-themes Time-intensive Knowledge & 
self-efficacy 
Care Pathways To facilitate 
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is the GPs’ 




















of BPSD. (pg 
231) 
GPs may feel 
they are left to 
deal  






al strategies to 
be easy. (pg. 
230) 
 






































































yet they have 






base. (pg. 232) 
with the crisis 












































 GPs consider 
antipsychotic 
discontinuatio
n to induce 
more suffering 


















effects has not 
yet reached 




















others and risk 































GPs alluded to 
uncertainty of 















 ‘‘Often it is 
pressure from 
nursing homes 
or carers for 
medication to 
calm a patient 
down that is 
trigger for 































GPs and care 
home staff at 














































































roles in the 
management 
of patients 





were not clear 
or clinically 
useful. (pg 35) 
 





















such as a trial 
reduction of 










man that I saw 
last week … he 
was weeping 
for his wife 
who has been 
dead for many 
years, and 
they put him 
on quetiapine. 





what I know 
of them, I 
think we have 
to be careful 
not to go to 
the other 
extreme 
where we just 











“ I think 
doctors are 





before so I 
would do a 
prescription 
for risperidone 
if I get told, 
right, increase 
the dose or 
can we titrate 
the dose? 











And I mean he 
gets tearful if 
you talk about 

































justified but I 
think it’s still 





do, we just 
prescribe a 
medicine.  











  Justification of 
antipsychotics 
  Pivotal Role of 
Family 
Sub-themes Time-intensive Knowledge & 
self-efficacy 
Care Pathways To facilitate 
coping (in 
PwD, their 







































for how long? 
We need 
guidelines on 











or of how to 
access services.  
I would 
probably 





   ‘One of the big 
learnings I’ve 
had is the carer 
support and 
how important 
carer support is 
in the 
management of 




the need for 
respite & 
home-help  
‘I think you live 
on this lifeline 
of getting this 
respite and 
that helps you 
to cope as a 
carer’ (pg. 5) 
 
 ‘I know that 
there is some 
support 
available … we 
have a very 
vague idea of 
that … but I 
myself 
wouldn’t be 
able to provide 

















































the quality of 
life, leading to 


























less likely to 
rate pressure 
to prescribe 































as significant a 

















benefit in half 














• Managing BPSD was complex, 
resource intensive and sometimes 
unrewarding for the GP.  
• GPs lacked confidence when 
managing BPSD and wanted input 
from either secondary care or relevant 
members of the primary care team. 
However, the lack of clearly defined 
care pathways meant that GPs 







• GPs were more comfortable 
prescribing medication than advising 
on non-pharmacological 
management strategies. 
• GPs found that antipsychotics 
enabled the patient with dementia, 
the family caregiver, the nursing 
home staff and the GPs themselves 
to cope with BPSD.  
• GPs had a tendency to over-estimate 
the benefits of antipsychotic 
prescribing. Consequently, in the 
context of the challenges of 
implementing non-pharmacological 
alternatives, the risks associated 
with antipsychotics were tolerated.   
• The family of the person with 
dementia plays a crucial role in the 
management of BPSD. However, the 
needs of the carer could be intensive 
and challenging for the GP, 
particularly in the context of limited 
community supports for family 
caregivers.  
 
 Line of argument synthesis:  GPs experience difficulties accessing supports for family caregivers and for themselves when managing BPSD. 
Under-resourcing, poorly defined roles and a lack of integrated care pathways may contribute to GPs’ 
feelings of isolation and low self-efficacy when managing BPSD. Low self-efficacy is further exacerbated 
by the lack of practical, implementable treatment strategies which can lead to an over-reliance on both 
family care-givers and psychotropic medications to fill the therapeutic void created. It appears that these 
conditions can culminate in a reactive response to the care of people with BPSD where behaviours and 






Supplementary Material 5. Quality assessment tool for descriptive cross-
sectional studies 
 
Reviewer Initials _____________ 
 
Study Name  ____________________________________________ 
Author   ___________________________ 
Year   ___________  
 
 Yes No Unclear Not 
applicable 
1. Was the research question or objective in this paper 
clearly stated? □ □ □ □ 
2. Was the study population clearly specified and defined? □ □ □ □ 
3. Was the sample likely to be representative of the study 
population? □ □ □ □ 
4. Was the target population involved in the instrument 
development? □ □ □ □ 
5. Was the questionnaire piloted? □ □ □ □ 
6. Was a response rate mentioned within the study? □ □ □ □ 
7. Was a sample size justification, power description, or 
variance and effect estimates provided? □ □ □ □ 
 
 






Supplementary Material 6. ENTREQ Statement  
 
Item Guide and Description 
  
  
1.Aim To develop a synthesis of qualitative and quantitative studies on GPs’ 
knowledge, attitudes and experiences of managing BPSD in order to 
develop a conceptual understanding of the perspective of GPs on the 
management of BPSD. The results will be used to inform the 





Meta-ethnography as described by Noblit & Hare will be used to 
synthesis the results of this mixed method review 
3. Approach to 
searching 
 
Pre-planned comprehensive search to seek all available studies 
4. Inclusion criteria Phenomenon of interest: The knowledge, attitude or experiences of GPs 
towards the management of BPSD in community and/or nursing home 
setting. 
Population: General Practitioners 
Language: English language only 
Year Limits: None 
Types of studies: Primary studies using qualitative or quantitative 
research methods 
Article must be published in full in a peer-reviewed journal 
 
5. Data sources Electronic databases searched: MEDLINE (Ovid), EMBASE (Elsevier), 
CINAHL, PsychINFO, Academic Search Complete, SocIndex, Social Science 
Full Text 
Initial search was in June 2017 
Search was last updated on 25th of October 2017 
 
6. Electronic search 
strategy 
 
Literature search terms are described in Appendix 1 Supplementary 
Material 2 
7. Study screening 
methods 
 
At the first stage of study screening duplicates and clearly irrelevant 
studies (for example pre-clinical studies) were removed by AJ.  
Abstracts were then screened by teams of two independent reviewers - 
AJ with either TF, AC or CB. 
All eligible studies included in full-text screening were also screened by 
AJ and a second independent reviewer (TF/AC/CB). 
Any conflicts regarding the eligibility of a study were resolved through 
discussion between the paired teams. Where consensus was not 









Details of the study characteristics are provided in Table 6 
9. Study selection 
results 
Figure 9 outlines the study selection process in a PRISMA flow diagram. 
Supplementary Material 3 and 7 provides details on the excluded studies 
and the reasons for exclusion. 
 
10. Rational for 
appraisal 
 
The rational for quality appraisal was to assess the quality of study 
conduct.  
11. Appraisal items Joanna Briggs Institute Critical Appraisal Checklist for Qualitative 
Research was used to assess the qualitative studies 
 
Since there is no agreed quality assessment tool for assessing the quality 
of descriptive cross-sectional studies a new original tool was developed 
by two of the reviewers (AJ, JB) that was based on other original tools 
developed for a similar purpose. Available in supplementary file 3. 
 
12. Appraisal process All included papers were independently assessed by two reviewers.  
AJ & JB independently assessed 10 out of the 11 included studies. 
As AJ was a co-author on one of the included studies CB & JB 
independently assessed the quality of that study. 
 
13. Appraisal results Study quality assessments are available in the supplementary file 6. 
Studies were not excluded on the basis of quality as we believe that all 
studies may contribute to some valuable insights to our research 
question. 
Additionally, two independent reviewers (AJ, KW) applied the CERQual 
tool to the review findings. This tool helped to identify potential 
weaknesses in the included study and was used to evaluate our 
confidence in our review findings. 
 
14. Data Extraction All text from the result, discussion and conclusion sections of the 
included studies were extracted verbatim and imported into a software 
package for analysis.  
The following study characteristics were extracted; author, year of 
publication, country of conduct, study objectives main findings, study 
design & methods of analysis, participants and setting. These 
characteristics are displayed in Table 6. 
 
15. Software NVivo 11 
 
16. Number of 
reviewers  
Four reviewers (AJ, KW, CB, TF) were involved in reading all included 
studies in detail and constructing the initial key concepts. All six 
reviewers were involved in the translation and synthesis steps. 
 
17. Coding Comprehensive, line-by-line, open-coding to search for concepts 
 
18. Study Comparison 
 
To examine the contribution of each study to a key concept the review 





 the synthesis of these two papers with paper 3 and so on. This process 
was conducted in chronological order starting with the earliest study. 
Within the key concepts attention was paid to deviant cases. Two 
authors (AJ, KW) performed reciprocal and refutational analyses to 
summarise shared themes across the studies. To facilitate this step a 
table was developed to display the identified concepts and themes 
across all the studies (available in supplementary material 4). 
Relationships between the conceptual groups and themes were 
organised and illustrated by the use of conceptual maps which were 
shared with the wider review team. 
 
19. Derivation of 
themes 
 
The approach taken to developing the key concepts, themes and sub-
themes was inductive and iterative. 
20. Quotations 
 
Direct quotes from the primary studies are presented in italics and 
indented in the results section of this manuscript. The interpretations of 
the authors of these primary studies are also presented in the result 
section of this manuscript indented but not in italics. 
These quotes are also presented in more detail in supplementary 
material 4. 
 
21. Synthesis output 
 
The synthesis team (all authors) linked the third-order interpretations 
into a ‘line of argument’ which represents the overarching perspective of 




















Supplementary Material 7. Reasons for the exclusion of records at the abstract 
screening stages 
AJ conducted a preliminary screen of titles and abstracts to exclude any studies that were 
clearly irrelevant. 435 studies were excluded at this point. Reasons for exclusion are listed 
below. 
1,203 studies were included the second stage of the title and abstract screening. At these 
stage all titles and abstracts were independently screened against inclusion criteria by at 
least two reviewers (AJ, AC, TF, CB). 1,123 studies were excluded in this title and abstract 
stage.  
Reasons for exclusion from stage 1 title and abstract screening (n= 435) 
• Study is a book review, book chapter, thesis or dissertation, editorial / opinion 
piece or conference abstract (n= 75) 
• Not on dementia (n= 261)  
o The studies that were excluded were on heart failure, COPD, epilepsy, 
childhood behavioural disorders. Where there was any potential link to 
dementia, however tenuous, the study was included. 
• Focus was exclusively on cognitive screening tools (n=32) 
• Not in primary care setting/ does not involve general practitioners (n= 67)  
o These studies were also not relevant to BPSD. Any studies that were 
potential relevant to the management of BPSD were included at this 
initial screen, even if they didn’t involve GPs. 
 
 
            
              
      
       
            
          
       
         
              
             
           
        
 
 
            
              
      
       
            
          
Reasons for exclusion from stage 2 title and abstract screening (n = 1,123) 
• Not on dementia  (n = 313) 
 
• Study is a case study, book review, book chapter, thesis, editorial, opinion piece, 
conference abstract, letter or protocol with no data (n=294) 
 
• Does not include GPs (n = 263) 
 
• On dementia prevention/screening/ diagnosis not management ( n = 105) 
 
• Not a primary care setting (n = 75) 
 
• Not knowledge or attitude based (n = 48) 
 
• Duplicate (n = 25) 
 
        
             






Supplementary Material 8. Quality Appraisal of all Included Studies 
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Table 2 Quality Appraisal of Descriptive Cross-Sectional Studies 
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Supplementary Material 9. 
CERQual Assessment of 




       











Unmet Primary Care Needs        
1. Managing BPSD was 
complex, resource 
intensive and sometimes 
unrewarding for the GP.  
 
 
   243,284              Minor concerns 
 
 
One of the 
studies was 
judged to be of 
high quality. The 
other was of 
moderate quality, 










to the context 
specified in our 
review question. 






the relevance of 
the setting as 
both studies were 









finding was well 
grounded in the 










to support this 
review finding 





























2. GPs lacked confidence 
when managing BPSD and 
wanted input from either 
secondary care or relevant 
members of the primary 
care team. However, the 
lack of clearly defined care 
pathways meant that GPs 
experienced difficulty 
accessing advice.  
152,153,243,27
9,284 
Minor concerns  
 
 
Three of the 
studies were 
judged to be of 
high quality while 
the other two 













No, or very minor 
concerns 
 
Four of the 
studies were 
considered highly 
relevant. One of 
the studies was 
assessed to be 
moderately 
relevant due to 
minor concerns 
with regards to 
the population & 
phenomenon of 
interest.  













Two of the 
studies 
offered highly 
rich data to 
support this 




rich data. The 





















Justification of Antipsychotics        
1. GPs were more 
comfortable prescribing 









Two of the 
studies here were 
judged to be of 
high quality. One 
study was judged 
to be of 
moderate quality. 




Two of the 
studies were 
considered to be 
highly relevant.  
Two of the 
studies were 
conducted >20 
yrs ago and 



































adequacy of the data 
and methodological 
limitations. Minor 
concerns about the 








judged to be of 
moderate to low 




s of the sample 







this still provided 
interesting 
context for the 
review question. 
There was minor 
concerns re the 
relevance of one 
of the studies as 
it included only 









very thin.  
2. GPs found that 
antipsychotics enabled the 
patient with dementia, 
their carer, the nursing 
home staff and the GPs 







Two of the 
studies were 
considered to be 
of high quality. 
Two of the 
studies were 
considered to be 
of moderate to 










Although this is 
relevant to our 
research question 
there are minor 
concerns that this 
may have over-




the use of 
antipsychotics 



















did not offer 
the same level 



























relevance of this 
finding to our 
overall review 
question which 





3. GPs had a tendency to 
over-estimate the benefits 
of antipsychotic 
prescribing. Consequently, 














moderate to high 
quality. Concerns 












Although this is 
relevant to our 
research question 
there are minor 
concerns that this 
may have over-
estimated the 















of the studies 
was assessed as 
being 
moderately 









































Pivotal role of family        
1. The family of the person 
with dementia play a 
crucial role in the 
management of BPSD. 
However, the needs of the 
carer could be intensive 
and challenging for the GP, 
particularly in the context 
of limited community 
supports for family 
caregivers.  
 
243,279,284 Minor concerns 
 
 
Two of the 
studies were of 
high quality and 










One of the 
studies was 
considered to be 
highly relevant to 
the research 
question. Two of 
the studies did 
not have BPSD as 
their primary 
focus; one of 
these studies was 
still deemed to be 
highly relevant, 
whereas, the 
other study which 




considered to be 
moderately 
relevant. 








finding was well 
grounded in the 
















































APPENDIX 2. Supplementary data for Chapter 6. Qualitative Study 
 




Firstly I wanted to say thank you for taking the time to meet with me, it is much 
appreciated. 
 
2) Background Information  
 
Perhaps it would be helpful for me to give you an overview of the research that will 
be informed by today’s interview and also an overview of the interview itself before 
we start. 
 
As part of the wider dementia project we have identified some areas of dementia 
care that GPs tend to find particularly challenging. The management of behavioural 
and psychological symptoms of dementia has emerged as a particularly difficult area 
for GPs (these refer to symptoms such as agitation, anxiety, aggression). 
 
3) Expectations/ Interview Format 
These can often be incredibly challenging clinical situations to manage, either in 
Primary Care or in Secondary Care. There’s no right or wrong answers to these 
questions. All I want to hear is your own perspective and your own experiences. The 
results of these interviews will be used to inform the design of an intervention to 
support GPs managing these patients in Primary Care. 
 
So with regards to the interview today we will start by discussing how often you 
encounter dementia in practice. We will chat a little about your experience 
managing patients with dementia who have challenging behaviours. Hopefully then, 
we will talk about potential strategies that you feel would better support you 
managing people with BPSD. 
 













 Can I ask how long you are in GP Practice? 
 
“There are many ways to describe these behaviours and symptoms that people with 
dementia experience. Sometimes the acronym BPSD is used to refer to behavioural and 
psychological symptoms of dementia. Examples of typical behaviours and symptoms that 
this term covers would include agitation, aggression, wandering, anxiety etc” 
 Do you encounter these symptoms much in practice?  
o Have you much experience looking after patients in a nursing home setting? 
 Do you have a regular time allocated to visiting the nursing home or 
do you attend sporadically as needed? [introduced in response to the data 
analysis] 
o Do you have a community hospital commitment? 
o Do you have many patients with BPSD living at home in the community with 
family carers? 
 







 Some GPs find BPSD to be a challenging area to manage. Would this be your experience 
of BPSD?  
if the GP does not elaborate on the specific challenges of managing BPSD probe further. 
 What aspect(s) of managing BPSD do you find particularly challenging? 
 
Aim: Establish GP’s experience of managing BPSD 
 
Aim: 





If answer doesn’t address the following points or if the following points then specifically 
probe for their attitude towards: 
 
1. Assessing a patient with BPSD 
“These patients can be difficult to assess …. “ 
If not elaborated on probe for how the GP rules out medical, psychological and 
environmental causes. 
 What are the potential causes that you would consider first and how do you go 
about out-ruling them? 
 “These patients can be difficult to assess” Do you feel confident that you can 
generally out-rule a medical, environmental or psychological cause? 
 What would help you with the assessment of these patients? 
 
2. The use of medications in BPSD.  
 
“Some GPs have discussed the difficulty they experience prescribing medications in this 
patient group.” 
 How do you feel about prescribing medications in BPSD?  
If not mentioned probe specifically for knowledge of and attitude towards 
prescribing antipsychotics in BPSD.  
o What are your thoughts on using antipsychotics such as 
risperidone or quetiapine with these patients? 
 
 What reservations (if any) do you have about prescribing to these 
patients? 
If not mentioned probe for… 
o Some GPs have mentioned their concern about the sedative 
nature of a lot of these drugs do you have any thoughts on that? 
[introduced in response to the data analysis] 
 
 How do you decide on which medication to use? 
o Would you feel confident in your choices? 
 Do you ever feel under pressure to prescribe? 
o If yes; how do you feel about that?  
 
3. Their attitude towards non-pharmacological management strategies. 
 Do you feel confident advising carers on non-pharmacological management 
strategies for these behaviours at home?  





o Do you see giving this type of advice as part of your role as a GP? 
[introduced in response to the data analysis] 
 
 
4. Resourcing issues  
 
 Any aspect of managing BPSD in a community setting that are challenging?  
o Potential Probes 
 How has your experience of managing the carer been? 
 Sometimes in the community setting a certain amount of risk may 
need to be tolerated in order to ensure patient autonomy- would 
this be your experience? 
 Are there any resources or multidisciplinary supports in the 





“These are clearly complex cases to manage. Are there any resources or supports you might 
access to help you make management decisions in BPSD?” 
If not mentioned probe re the following resources. 
Clinical Supports 
1. GP Colleagues 
 Would you engage in discussions with colleagues?  
 
2. OAP/ Geriatricians 
 Do you find Geriatricians or OAPs to be helpful resources? 
 Would you ever phone a consultant about cases of BPSD?  
 When would you refer to a consultant? 
 Do you utilise personal relationships to access supports and 
advice? [introduced in response to the data analysis] 
 Are there any barriers to referring to consultants? 
 Are they accessible? 
 Do you find referring these patients beneficial?   
o Under what circumstance is it beneficial or not? 
o What do they typically recommend that you might not have done 
yourself? 
3. Guidelines/ Online Resources 








At a personal level what do you feel facilitates you managing these patients? 
Prompts; 
o Confidence in managing these patients? 
o Role of experience? 
o Knowledge level? 
o Job Satisfaction? 
o Knowing your own limits? 
o Avoiding crisis presentations where possible? [introduced in response to the data 
analysis] 
o Personal experience with dementia? [introduced in response to the data analysis] 
 







 How could you as a GP be better supported in the area of managing people with 
BPSD? 
o What resources would be helpful? At a nursing home and at a community 
level? 
 Would you be keen to participate in further education? 
• If yes, what form would you like that education to take? 
• What specific aspect would you like education on? 
 Have you any suggestions on what might be practically helpful to you when you are 
deciding on an appropriate management plan for a patient with BPSD? 
o If not mentioned probe for the following strategies: 
 Are there any guidelines you follow currently? 
• If appropriate probe for GPs opinion on relevance of a 
management algorithm even though evidence supporting the 
data presented may be low. [introduced in response to the data 
analysis] 
 If GP suggests strategies/strategy for behavior change probe for the perceived 
feasibility of the strategies/ strategy. 




Probe for potential strategies that may support effective approaches 






Final Question: Is there anything other aspect of managing patients with BPSD that you 




Finishing the Interview 
Many thanks for your time today. It is very important that we understand the personal 
accounts of GPs. This will ensure that the project is informed by the day-to-day experiences 























APPENDIX 3. Supplementary data for Chapter 7. Cross-sectional 
study on pain management in dementia 
 
Supplementary material 11. The Questionnaire 
Section A: General Information 
 
This section is concerned with gathering information about you and where you work. 
1. Where is your practice based?    City ☐   Town ☐   Rural ☐   Mixed ☐ 
2. How many years are you practicing as a GP?   
0-5 ☐ 6-15☐   16 -25☐ 26+ ☐ 
3. Do you provide regular care to residents of nursing homes?  Yes ☐    No☐  
(if answer to Q3 is “no” then please skip to Q8) 
4. How many nursing homes do you regularly attend?      __________ 
 
5. How many nursing home residents do you look after? __________ 
 
a. Approx. how many of these residents suffer from dementia? ________ 
 
6. Do you do regular visits (e.g. weekly round) to nursing homes?   
Yes☐           No☐ 
6.1  How many rounds do you do per week?   _________________ 
 
7. Are there guidelines/policies on pain management in the nursing    home?      
  Yes ☐          No☐        Don’t know☐ 
 
8. Do you think that pain is under-recognised in patients with dementia?          






9.  Do you think that a pain assessment tool, for the recognition of pain in patients with 
dementia, would be helpful in Nursing Homes?         
Yes☐        No☐         Don’t know☐ 
 
Section B: Assessment and Management of Pain in Dementia 
This section of the questionnaire is divided in to two parts, each of which is concerned with a different aspect of 
pain in residents with dementia.  For each statement please indicate with a tick how strongly you agree or 




ASSESSMENT OF PAIN IN RESIDENTS WITH DEMENTIA 
 
 








10. The presence of dementia in a 
person can make pain assessment 
difficult. 
     
11. A person with dementia is not able 
to accurately provide a self-report 
of their pain. 
     
12. Pain assessment tools used for 
cognitively intact residents are not 
appropriate for people with 
dementia. 
 
     
13. I am familiar with pain assessment 
tools specifically available for use 
with a person with dementia. 
     
14. When assessing pain in a resident 
with dementia, it is important to 
observe behavioural indicators of 
pain (e.g. facial expressions, body 
movements, posture). 
 














15. When assessing pain in a resident 
with dementia, it is important to 
consider physiological indicators of 
pain (e.g. heart rate, blood 
pressure, temperature). 
 
     
16.  When assessing pain in a resident 
with dementia, it is important to 
consider a family/care givers 
report. 
 
     
 
 
MANAGEMENT AND TREATMENT OF PAIN IN RESIDENTS WITH DEMENTIA 
 
 
17.  People with dementia who are 
experiencing pain should be 
managed differently to people 
who are cognitively intact. 
 
     
18. The drug treatment of pain in a 
person with dementia should 
follow a step-wise approach. 
     
19. Optimal treatment of pain is 
achieved when analgesics are 
given on a regular basis. 
     
20.  Paracetamol is the best analgesic 
to use for people with dementia 
who are experiencing chronic pain. 
     
21.  It is safe to use opioid analgesia to 
treat pain in people with 
dementia. 
     
22. People with dementia are less 
likely to become addicted to 




















23. There is a greater risk of side 
effects from opioid analgesics (e.g. 
respiratory depression, confusion) 
when used in people with 
dementia. 
 
     
24. Non-drug based methods of pain 
control (e.g. TENs, Heat/Cold, 
massage, complimentary therapy) 
are useful in the management of 
pain in people with dementia. 
 





Have you any further comments or remarks to make in relation to this questionnaire or the 














APPENDIX 4. Supplementary data for Chapter 8. Cross-sectional 
study on antipsychotic prescribing 























APPENDIX 5. Supplementary data for Chapter 9. eDelphi Study 
Supplementary Material 13. Monitoring Tool for Antipsychotic Drugs in BPSD  
Resident’s Name:       Date of Birth:          
 Initiation of Antipsychotic 
Drug Name: _____________________   Dose: ________________ Frequency: ____________________ 
Date of initial prescription: _______________ prescribed by: GP  OAP   Geriatrician     Unknown 
What is/was the reason for initial prescription (specify behaviour/ symptom you are attempting to treat): 
 
PRN antipsychotic medication also prescribed: YES   NO      
If yes, specify: medication ________________ dose ____________ frequency _________________  
 
 
Trial of non-pharmacological treatment options prior to initiation of antipsychotic: YES  NO   
Details of non-pharm strategies:  
 
The following were checked and documented (tick where appropriate) 
FBC     LFT     TFT    U&E      ECG   
Initial medical review at 6 weeks (i.e. 6 weeks after initiation) 
Resident’s behaviour/symptom has; improved  worsened  stayed the same     
Details__________________________________________________________________________________ 
Have any of the following been experienced by the resident since initiation of antipsychotic drug: 
1. Sedation   2. Extra-pyramidal symptoms     3. Increased confusion      4. Increased falls   
Outcome of initial review (6 weeks after initiation) 
Antipsychotic drug treatment will be: continued      discontinued     altered  (specify) ___________ 
Reasons for continuation of antipsychotic drug (where applicable):  
 
 
This resident will be reviewed at 3 monthly (see overleaf)  





Ongoing monitoring of antipsychotics for resident (available on the back of the initial 



































 No change – 








         
         
























         






APPENDIX 6. Supplementary data for Chapter 8. Intervention 
Development  
 
Supplementary Material 14. Analysis of online GP discussion forum on the 
management of BPSD 
Candidate’s role in this study: The candidate (AJ) came up with the concept for this study, 
applied for ethical approval, collected the data and led the data analysis. Dr Tony Foley 
assisted with the data analysis.  
Background 
GPs who were participating in an online dementia module were presented with two mock 
clinical cases in the area of BPSD and were asked to outline how they would approach the 
case in clinical practice. They discussed their approaches in an online discussion forum. Their 
responses were then be analysed and common themes were identified with the aim of 
identifying factors that influence decision making processes. 
This study was solely designed to inform this PhD research and will not be published as a 
separate study. Ethical Approval granted by SREC (Social Research Ethics Committee) in UCC 
in September 2017; Log number 2017-106. 
The aim of the study was to inform the design of an intervention to support the 
management of BPSD in general practice by specifically looking at what factors that GPs 
consider when managing BPSD and how these factors influence GPs decisions. 
Methods 
The participating GPs were all students on a 12 week online postgraduate dementia module 
that was developed by the PhD candidate and Tony Foley. The PhD candidate is the module 
co-ordinator. The online module runs annually from September to December. Two weeks of 
the online module were devoted to the management of BPSD (first two weeks in 
November). A clinical case related to the topic was posted to the online discussion forum at 
the beginning of each week and the participating students then contribute to the discussion 
board with their thoughts on how they would approach the clinical case. The PhD candidate 
was also the tutor for the two weeks in question. 
In the module that ran in 2017 19 of the 20 participating GPs consented to being part of this 
research study. AJ extracted the qualitative data from the discussion forum, anonymised the 
data and put it in a text file. The files were then uploaded to NVivo and thematically 







A number of themes emerged namely; feeling resource poor, not having the confidence or 
knowledge to recommend non-pharmacological treatments and the important role of the 
GP in the community. I will outline examples of some verbatim quotes that support these 
themes. 
I) Feeling resource poor 
The participating GPs felt frustrated by the time-constraints that inadequate resourcing put 
them under, many spoke in particular about time-constraints; 
“At times like that I wish that we were not so time poor.” 
 “I do feel that as GPs our time with patients is so short that it can be very hard to go into too 
much detail with non pharmacological suggestions apart from encouraging them to seek out 
day centres which are generally wonderful” 
Others felt though, although they were resource poor having upskilled in the assessment of 
BPSD over the first week of the unit they felt “empowered to look for other causes for the 
patients symptoms and not take the easy route and prescribe” 
2) Lacking confidence to recommend non-pharmacological strategies 
Some GPs reported lacking the confidence to recommend non-pharmacological strategies.  
“I have to say I rarely recommend non pharmacological managements to patients and I will 
need to change my practice from this module. For some reason I find that I do mention it in a 
nursing home setting but have not broached it with carers in the same capacity. I definitely 
am not confident recommending these strategies and feel ill equipped to recommend.” 
“Now that I am confronted not sure how much I pass on to patients at the surgery as  all the 
non- pharmacological methods are initiated by staff at the nursing home.” 
However, others were more comfortable recommending these strategies; 
“I have found most NH/Community Hospitals and family very receptive to music therapy, 
especially now when you can easily download older tracks from the Internet, but most 
nurses and carers are so busy in these places that it's hard.”   
Others, spoke about how a ‘risk-averse’ mentality can frequently act as barriers to the 
implementation of non-pharmacological strategies; 
“We have had a baking session "cancelled" by environmental health on the grounds of 






3) The important role of the GP in the community setting 
“I think we have an important role here to support and give information to families.” 
 
Supplementary Material 15. Additional analysis of the GP interviews  
1. Data from the qualitative study on potentially relevant intervention features 
The important features of an intervention in the area of BPSD as identified by GPs 
participating in the qualitative study. The GPs highlighted the need for the intervention to 
come from a credible source, to be GP relevant, succinct and accessible. The importance of 
involving relevant stakeholders such as nursing home staff in the intervention was also 









“ [the intervention] would have to provide information that would 
be useful for GP's and would give them something new, do you 
know, like I think something that talks maybe about dementia 
and prescribing in dementia without coming up with some clear 
solutions and guidance wouldn’t be that useful, you know” (GP1) 
Led by a GP expert/ 
credible peer 
 
“I mean in an ideal world I suppose you would have a colleague 
who had a special interest in dementia” (GP5) 
“.. from someone that I would trust” (GP7) 
 
Involve nurses and 
the nursing home 
sector 
 
“We need nursing homes to buy in to that too, the staff in nursing 
homes, people that run them need to say actually we have a 
responsibility here making sure that the tablets that ye use are 
checked to be safe on a regular basis, how can we help you kind 
of thing.  So in terms of nursing home care maybe it could be 
something that could be put to the nursing home sector as well 
as the doctors and the nurses as well.”  (GP7) 
 
Informed by general 
practice 
“The idea would be if they could say that most of this information 
is derived from primary healthcare that would be great. I think 
that would carry more cogency than something hospital based … 
that the context is realistic” (GP7) 
 
Needs to be succinct 
and accessible 
 
“something simple with a few points that you could quickly 
reference” (GP1) 
“It is always just nice to have you know very clear succinct 





That very digestible information that you feel is very credible and 
that you can definitely justify and it gives you your options very 
clearly.” (GP2) 
 
Accessible/ Online “The days of paper are gone. I can’t tell you where anything that I 
have taken from any meeting in paper form is now because no 
one want a messy consultation room, everything is much easier 
to access on your hard drive or on the Internet.” (GP1) 
… something that you could draw on when somebody is sitting in  
front of you that would be significant.” (GP1) 




“Talking to colleagues, you know and comparing notes and you 
know compare specifics even antidotes, you learn. I find I learn a 
lot from those situations… You do need a forum where you can 
talk about these things, you know, on a regular basis.” (GP8) 
 
 
   
When GPs were asked to suggest an intervention that would support them in caring for 
people experiencing BPSD interventions that centred around guidance on prescribing were 
the overwhelming the most common interventions suggested. These format of these 
prescribing guidance varied from prescribing aids, prescribing guidelines, management 
algorithms to online educational prescribing resources. Other interventions suggested 
included; guidance on non-pharmacological supports, increased access to community 
supports for carers, online modules and community based dementia nurse. (Table 2) 
 







Supporting quote from qualitative study 
Prescribing protocol/ 
aid/ guideline / 
algorithm 
 
“What would be very useful I think like from my perspective 
would be clarity on you know, I suppose the best of what’s there, 
you know, no medication is ideal but what are the really red flag 
side effects that you need to think about with a particular class of 
medication. And what’s your most appropriate first line 
medication. I think there is probably no magic solution to this but 
I think a clear algorithm of medications that are appropriate. I 
think would be the most practical thing.” (GP1) 
“I think a clear prescribing guideline would be helpful but there 





challenges and a lot of the evidence from the big studies is 
different from anecdotal evidence which can be difficult … it 
could exist but not be used, whereas you need something that 
will be used.” (GP3) 
 
“I think you need to make sure that you have the appropriate list 
of possible medications and try such and such, and if such and 
such doesn't work try something else.  Algorithms are always 
handy I suppose for GP's where you are not trying to flick through 
a BNF and see what you are supposed to be doing, so maybe 
those are things that could be up in a Nursing Home you know 
that you don't necessarily have them with you and it would be 
part of the nursing home. Maybe do not have a massive amounts 
of evidence because I think if you were to go round and speak to 
GP's they would feel they need something in their armoury when 
they are faced with family members or nursing staff” (GP5) 
 
“If you had a protocol that would go through things in a step wise 
fashion okay… then this is what you would recommend … if there 
is behavioural issues to think down this pathway this and this 
might be of benefit.” (GP10) 
 
 
“If there was a straight forward protocol. BPSD it’s definitely a bit 
hap hazard like, yeah the treatment of it. If there was some kind 
of a semi protocol as to look this is step one, step two, step three, 
this is what we say we shouldn’t use. And this is what we say we 
would advise. No one is saying that it should be like the 
guidelines for diabetes or GOLD guidelines or something like - it is 
not going to be as straight forward as that but maybe they would 
be such an idea as well we avoid this and here is a group of three 
that we would prefer to use and these one the less preferable 
ones. Something along those lines.” (GP12) 
“I think clear guidelines would be useful.” (GP13) 
“… even guidelines, you know, I don’t know whether there are 
guidelines. Simple guidelines maybe non pharmalogical and then 
pharmacological then but I certainly haven’t seen anything like 




“A public health nurse that is Dementia specific, because I can 
imagine that public health nurses have a lot on their plate and 
there should be something like that, and that they liaise 
specifically with GPs” (GP3) 
“I think in an ideal world it would be individual care packages 










“I think it would be useful to have a list of ideas for non- 
pharmacological interventions.” (GP13) 
“Simple guidelines maybe non pharmalogical and then 
pharmacological.” (GP14) 
Assessment checklist “You know and make sure the bowels are okay and you know 
they are hydrated and you know it all seems obvious but when 
you are faced with a demented or a delirious patient it kind of 
goes out the window a bit. If there was a check list, you know 
even, I know now we are always get check lists and things but 
that would be helpful. A kind of a delirium check list you know.” 
(GP14) 
Online Module “I think a certain amount of educational support would be good 
there, maybe through online modules.” (GP7) 
 
Community based 
services and supports 
“I still think it is going to be more community resources, I still 
think that’s the way to go.” (GP15) 
“would probably benefit from saying look this is a clear 
description of what local services are available, they are limited 







Supplementary Material 16. Additional analysis of the studies included in the 
Systematic Review 
Interventions suggested by authors of the studies included in the systematic review that 












Guidelines that are 




“Evidence-based clinical practice guidelines targeted specifically 
at the management of BPSD in primary care could, therefore, be 
beneficial.” (Buhagiar) 
 
“Practical guidance on pharmacological and nonpharmacological 
alternatives.” (Azermai) 
 
“Understandable guidelines for all healthcare workers.” 
(Mavrodaris) 
 
“Better dissemination of practice guidelines cautioning about the 
limited benefit of antipsychotic medication in BPSD may prompt 
practitioners to more rationally prescribe these medications.” 
(Cousins) 
 




“Priority needs to be given to developing clear local pathways of 
dementia care in the community, readily accessible by GPs.” 
(Foley) 
 
“The development of structured shared-care frameworks 
between primary care and specialist services….. Collaboration 
with specialist services may also facilitate GPs to translate their 
wealth of clinical knowledge into clinical practice.” (Buhagiar) 
 
Education for GPs – 








“GPs need to be supported by educational programmes that 
bolster their confidence in the care of people with dementia at 
large. In turn, this can provide them with further confidence in 
the management of the more specific and challenging aspects of 
the illness, like BPSD.” (Buhagiar) 
 
“Physicians learn by experience; therefore, one way to broaden 
their exposure to nonpharmacological interventions is to include 
curricula on multidisciplinary dementia care programming into 
continuing medical education programs.” (Colenda, 1996) 
“Quality of care might be improved by physician education 
around management of behavioral problems.” (Hinton) 
Involve nurses “Antipsychotic discontinuation is only likely to succeed with 
involvement and cooperation of nurses.” (Azermai) 
 
“The importance of integrated approaches involving regular 
prescription review, targeted joint educational programs (for 
care home staff, pharmacists and physicians) and relationship 








GPs for care provide 
 
“Reimbursement for treating patients with substantial behavioral 
complexity and developing incentives for health care 
organizations to deliver more comprehensive (and costly) care 
upfront to postpone as long as possible more costly 
























Supplementary Material 17.  BCW Step 5: Identify intervention functions using APEASE criteria 
We used the APEASE criteria to judge the merit of each intervention function individually. The acronym stands for affordability, practicability, effectiveness 
and cost effectiveness, acceptability, side effects/ safety and equity. Using this process we categorised the intervention functions into first line and second 
line or inappropriate.  















































































Education       The need to increase knowledge on aspects of AP prescribing and 
monitoring emerged as a significant area that needs to be addressed in 
step 4. Educational interventions should aim to increase GPs’ 
awareness of the limited benefits and significant adverse effects of APs 
in PLWD. 
 
To date, a number of educational interventions have been developed 
and implemented as part of the wider research project. Two of the 
authors (AJ, TF) have developed and implemented a peer-led, 1 hour 
workshop on BPSD assessment and management 133. More than 80 
workshops have been run nationwide and these workshops have been 
attended by over 500 GPs. However, this workshop was not designed 
to specifically address our target behaviour of improving the 






Small group workshops that are practice-based are resource intensive. 
Several GPs interviewed in the qualitative study advocated for 
educational interventions to be online (See BCW Step 5 outlined in 
supplementary material 17). Online educational interventions can be 
provided with less costs, are more practical, equitable and acceptable 
to GPs. As part of the wider PREPARED project we have developed a 
dementia elearning module with the ICGP (Irish College of General 
Practitioners). The lead author (AJ) developed the content for a one 
hour BPSD elearning unit as part of a suite of dementia elearning 
modules. 
 
 It is important that any educational interventions on AP monitoring 
provides practical information on non-pharmacological alternatives.  
The target behaviour is the monitoring of AP prescribing not the 
reduction of AP prescribing, however, a potential unintended 
consequence of an over-emphasis on the dangers of AP prescribing 
could be an increase in prescribing of other psychotropic medications 
such a benzodiazepines that are equally undesirable medications for 
the management of BPSD.  
 
However, we know that educational interventions alone have limited 
effect when attempting to change GP practice in dementia care 286,287. 
Therefore an educational intervention needs to be supported by 
service innovation service innovations 287 and appropriate resources 297 
.  
Incentivisation       In the context of stretched resources and the limited time available to 
GPs it is essential that they are incentivised to perform antipsychotic 
prescribing reviews/ monitoring of antipsychotic prescribing. GPs in 
Ireland providing care to the nursing home residents are not 
adequately reimbursed and many GPs currently provide care out of a 
sense of duty and goodwill. Asking GPs to take on an additional task 
(i.e. monitoring prescribing of APs) may be met with resistance unless 






shown to effectively improve GP rates of dementia diagnosis in the UK. 
76 
 
The incentive chosen needs to be affordable and equitable (available to 
all). It is important that the incentive is linked to monitoring of 
prescribing rather than reductions in prescribing in order to avoid 
unwanted consequences such as a reduction of AP prescribing but an 
increase in other psychotropic medications that are equally harmful. 
Certain types of financial incentivisation may not be practical or 
affordable given the current climate of under-resourcing of Irish 
primary care.  
 
An incentive in the form of provision of continuous professional 
development points might be a poor feasible incentivisation structure. 
GPs in Ireland need to submit CPD annual. The required CPD points are; 
20 external points, 20 internal points (for practice improvement 
initiatives) and 1 annual audit. This intervention could address all 
components of the GP’s CPD requirements; an educational session 
could be approved for external CPD points, conducting an antipsychotic 
review would be eligible for internal CPD points and conducting an 
audit of the outcome of the review process would provide a GP with 




      Changing the current physical and social context is essential in order to 
successfully change GPs’ behaviour regarding the monitoring of APs in 
PLWD. Any change must be accessible to all (equitable). 
 
Interventions such as the improved integration of care pathways 
between primary & secondary care could improve the monitoring of 
APs in PLWD. Similarly, the resourcing of designated time to conduct a 
multi-disciplinary AP review in a nursing home would be effective 298. 
However, although these interventions would be effective, they are not 






government level. Likewise, they may not be equitable, as the ability of 
nursing homes to resource multi-disciplinary AP reviews may vary.  
 
The provision of continuity of care by a single GP might not be realistic 
or acceptable by GPs, many of whom work part-time or having 
competing clinical duties. There is also the argument that forcing a one 
GP per nursing home policy goes against the fundamental right of a 
patient to choose their care provider. 100 However, other examples of 
environmental restructuring such as the implementation of a GP 
relevant AP prescribing guideline would be acceptable by many GPs as 
was evident in our qualitative study and in the systematic review (see 
supplementary material 15 and 16) and would also be affordable.  
 
 
Training      /- In addition to education GPs may require training in monitoring 
antipsychotic medications. If a monitoring tool or guideline is 
introduced GPs would require training in the use of that tool or 
guideline. Training in the tool/guideline is likely to increase the 
effectiveness and the acceptability of the tool/guideline. However, 
face-to-face training of GPs may not be affordable and, given the busy 
work day of a GP, it may also not be practical. Consequently it may not 
be considered acceptable by GPs. Face-to-face training may also not be 
equitable if the training is not available in all regions. However, if the 
training in how to use the monitoring tool was introduced as part of the 
proposed IPE educational session in the nursing home this may be 
feasible and acceptable. 
 
Additionally, although the target behaviour is on monitoring APs rather 
than using non-pharmacological strategies evidence shows that any 
attempt to monitor AP prescribing should be supported by access to 
non-pharmacological strategies 212. Therefore, training to GPs on how 
to advise on non-pharmacological strategies may be beneficial. 






acceptable to GPs who may not consider advising on non-
pharmacological strategies within their professional remit, this was 
evident in data in both the online dementia module and the qualitative 
study. 
 
Enablement       This intervention function refers to reducing barriers to increase 
capability (beyond education and training) or opportunity (beyond 
environmental restructuring). When considering our target behaviour 
this could refer to providing GPs with support from pharmacy 
colleagues or access to advice from secondary care colleagues. It could 
also refer to better communication between nursing staff and GPs 
enabling a more collaborative shared ownership of antipsychotic 
monitoring.  This intervention function is considered affordable, 
effective, equitable and should have limited unwanted consequences. 
Practically speaking an IPE session with nursing colleagues may 
increase this interprofessional support. 
 
First Line 
Modelling   ?    Modelling involves providing an example, in this case an example of 
successful implementation of an antipsychotic monitoring process, for 
people to aspire to. This could be effective as it would address the lack 
of optimism GPs showed towards the management of BPSD, which was 
particularly apparent in the qualitative interviews. It would be 
affordable and should not have any unwanted side-effects. However, it 
may not be equitable. Different nursing homes have different resources 
available in terms of staffing ratios and access to specialist advice. In 
Ireland the majority of nursing homes are private as opposed to state 
funded. Presenting a model that does not match the GPs own current 





















































































Persuasion       GPs are made aware of the adverse effects and limited benefits of 
antipsychotics in the management of BPSD and are supported through 
environmental restructuring and supports then further persuasion to 
complete monitoring is unlikely to be effect change. Using persuasion 
may also be unacceptable to GPs. 
 
Second Line 
Coercion            Creating an expectation of punishment or cost for not monitor. 
Punishment in the absence of reward/incentivisation for monitoring of 
antipsychotic prescribing would be particularly unacceptable to GPs. It 
would also be practically difficult to enforce. Additionally, forcing 
monitoring upon GPs in such a manner may result in unintended 
consequences such as monitoring occurring in name only as a ‘tick the 
box’ exercise, something that would also affect the effectiveness of the 
intervention. It may also be inequitable as it fails to recognise the 
different resources available to GPs in different regions and in different 




Restriction         Restriction in this instance would mean using rules to increase the 
target behaviour (monitoring of antipsychotic prescribing) by reducing 
the opportunity to engage in competing behaviours. This is impractical 
as there is no direct competing behaviour here. 












useful for our 
intervention  
Potential behavioural change 
techniques associated with the 
intervention function 
Elaboration on how the behavioural change technique could be used to encourage GPs to 
monitor their prescribing of antipsychotic medication to people with dementia in nursing 
homes, based on the definition of that behavioural change technique404.  
Education Information about health 
consequences 
Provide information to GPs about the consequences of performing the behaviour. In the 
systematic review it was found that GPs tended to over-estimate the benefits of antipsychotic 
medications. The risks of antipsychotics to people with dementia was seen to relate to longevity 
of life rather than quality of life. GPs also felt that if they reduced antipsychotic medications this 
could lead to a return of the BPSD. These beliefs contributed to GPs reluctance to de-prescribe 
antipsychotic medications, which in turn contributes to not monitoring antipsychotics. If 
information provided specifically addressed these concerns this could improve the likelihood of 
GPs engaging with the target behaviour. 
Information about other’s approval Provide information about what other people think of monitoring antipsychotic medications. In 
this instance it might be useful to provide information on best practice guidance exists in this 
area and what these guidance documents recommend when monitoring antipsychotics in 
dementia. Many GPs in the qualitative study reported the lack of available clinical guidance to be 
a challenge when managing BPSD. The lead author of the study is part of a multi-disciplinary 
team developing national guidelines on the use of antipsychotics in dementia care. Sharing the 
results of the guideline with GPs which will recommend monitoring of antipsychotic medications 
would help address the challenge posed by the lack of national guidelines in this area. This could 
be delivered as part of the educational component of the education. 
Feedback on behaviour Monitor and provide information or evaluative feedback to GPs on performance of the 
behaviour. In this instance this would involve providing feedback to the GP on their engagement 
with the monitoring of antipsychotic medications in PLWD (what form it takes, frequency, 





feedback to GPs on their behaviour has been shown to be an effective method of changing GPs’ 
prescribing behaviour in other areas of clinical care. 459However, the more relevant measure for 
GPs might instead be receiving feedback on the outcome of the behaviour. 
Feedback on outcome(s) of the 
behaviour 
Monitor and provide feedback to the GP on the outcome of performance of the behaviour. The 
outcome here could be the number of antipsychotic reviews conducted or the % of people with 
dementia in the nursing homes on an antipsychotic medication. However, the % of people with 
dementia in the nursing homes on an antipsychotic medication is dependent on a number of 
other factors such as the staffing levels of the nursing home and the physical environment of the 
nursing home. 
It would be difficult to provide this feedback at a national level as there is no central database 
that records the prescribing. In Ireland the PCRS (Primary Care Reimbursement Service) process 
the payments to GPs and pharmacists. Therefore, it would be possible to identify the number of 
people with medical cards who were prescribed an antipsychotic. However, there are two 
limitations. Firstly, this only provides data on patients who have medical cards and excluded 
private patients. Secondly, there is no way of identifying the reason for the prescription or, 
indeed, the medical conditions of the patient – so there is no way of knowing if the prescription 
was for managing BPSD. 
However, external feedback could be presented to the GP at a nursing home level. Each nursing 
home has a pharmacy that manages all the prescriptions for the nursing home. That providing 
pharmacy could provide a list of the nursing home residents who are on an antipsychotic and 
their associated dosages. This could be provided on a three-monthly basis to facilitate the review 
process. However, the nursing home would have to identify from this list the residents who had 
dementia. Still this method of providing external feedback on the outcome of the monitoring 
process would be feasible and acceptable. 
Self- monitoring of behaviour Establish a method for GPs to monitor and record their own behaviour as part of the behaviour 
change strategy. This may be viewed by GPs as an additional task to do. The limited time 
available to GPs when caring for people with dementia was highlighted in both the interview 





than facilitating engagement with the target behaviour it may act as a barrier. However, if the 
self-monitoring was linked to an incentivisation for the GP, for example CPD points or to facilitate 
an audit, then it may have a role. 
Environmental 
re-structuring 
Adding objects to the environment  
 
Add objects to the nursing home environment in order to facilitate monitoring of antipsychotic 
medications, involving more than verbal, visual, or written information. Where there is an IT 
software system in place this may involve decision support software as this has been shown to 
be an effective intervention in dementia management in primary care.296 Additionally if there are 
patient software systems in place in the nursing homes then online audit tools could be used to 
monitor prescribing. The wider project has developed audit tools that will interact with the main 
patient software systems in Ireland and will identify people with dementia on antipsychotic 
medication. Audit tools and decision support tools have a particularly useful role in the 
community setting as the majority of GPs have patient software tools. However, the majority of 
nursing homes records are still paper based. The addition of a tool that would guide GPs on how 
to conduct an antipsychotic review would be helpful. In the qualitative study GPs identified that 
the management of BPSD was often seen as a ‘grey area’ by GPs who called for support in the 
form of GP relevant guidance documents. A tool to aid GPs in conducting antipsychotic reviews 




Introduce or define environmental or social stimulus with the purpose of prompting the desired 
behaviour. This could be a prompt to highlight the need for a review of antipsychotic prescribing 
in a person with dementia. [also Action Planning]. This prompt (written or IT based) could take 
the form of a checklist of items to consider when conducting a review of an antipsychotic 
prescription to a person with dementia and would be used at the time of performance of 
antipsychotic review,  
Restructuring the physical 
environment 
Change, or advise to change, the physical environment in order to facilitate the GP to monitor 
their antipsychotic prescribing in people with dementia. This could involve having the dispensing 
chart in with the drug kardex so if a person is on an antipsychotic PRN then the frequency with 
which this is given is identifiable. (In the qualitative study the fact that these two important 
sources of information are not available together was identified as an issue). Having a patient 





would be beneficial but perhaps cost-prohibitive to many. Creation of a designated time and 
place to conduct the review would help aid the process of antipsychotic review but again needs 
to be resourced.  
Restructuring the social 
environment 
A change in the social environment in the nursing home that would either facilitate antipsychotic 
reviews or create barriers to not conducting antipsychotic reviews. The influence of the 
relationship between the nursing home staff and the GP was highlighted in both the qualitative 
study and in the systematic review. Poor pathways of communication between the GP and the 
nursing home staff exacerbated the competing priorities that existed between GPs and nursing 
home staff. The creation of a relationship of collegiality and trust is an important aspect of 
successful behaviour change here. However, this may be more easily addressed where the 
nursing home has one main GP that provides the majority of the care. If there are multiple GPs 
attending the nursing home with only a few residents under the care of each it may be difficult 
to restructure the social environment. If the education provided was interprofessional and 
involved both GPs and nursing home staff this may help to improve the relationship between the 
two professional groups and help to get both groups ‘on the same page’. 
Enablement 
 
Social support (practical) 
 
 
Advise or provide social support that provide practical help for GP in the performance of 
antipsychotic monitoring. In both the qualitative study and in the systematic review the difficulty 
accessing practical advice from secondary care colleagues was highlighted. GPs were looking for 
reassurance from secondary care but found it difficult to access secondary care. If the GP was 
part of a multidisciplinary team who was collectively conducting this review (including CNM, 
pharmacist +/- old a psychiatrist or geriatrician) this might further improve the social support 
that would enable GPs to conduct antipsychotic monitoring. The support of the nursing home 
staff is key to the practical implementation of this behaviour change strategy. Having an 
interprofessional forum where the concept of the monitoring of antipsychotics is introduced may 
help to improve relations and ensure buy in from all professional groups. 
Social support (emotional) In our qualitative study many GPs described GP colleagues as being important social supports, 
although they often did not consider them experts in dementia care. However, this emotional 





Goal setting: behaviour  Set or agree on a goal for conducting of antipsychotic monitoring/ reviews. If a GP does not 
intend to monitor their antipsychotic prescribing in people with dementia it is more likely to be 
related to a lack of knowledge rather than a lack of intent. For the majority the intent is already 
there but the practical application is difficult due to the competing demands on their time. The 
challenge of the intervention will be how to make the target behaviour easier to conduct, rather 
than simply increasing GPs resolve to do it. 
Goal setting: outcome Set or agree on a goal defined in terms of a positive outcome of the conduct of antipsychotic 
monitoring review. The obvious goal here would be reduced antipsychotic prescriptions, 
however, this outcome in many ways addresses a different target behaviour – that of reducing 
antipsychotic prescribing. In the current environment of understaffing in nursing homes, 
insufficient resourcing for key workers such as dementia advisors and activities co-ordinators in 
nursing homes and in the context of environmental and structural inadequacies that make 
nursing homes often completely unsuitable for people with dementia an outcome of reduced 
antipsychotic prescriptions may be very difficult to achieve. In this context, if the outcome of 
reduced antipsychotic prescribing is not achieved then this could be de-motivating for GPs. The 
outcome should be the conducting of antipsychotic monitoring, not reducing antipsychotic 
prescribing. Although it is very likely that reduction in antipsychotic prescribing would be a ‘spill-
over’ impact of the antipsychotic monitoring, it is not the primary outcome. 
Action planning  Detailed planning of how GPs are expected to perform the behaviour. The details of how the 
monitoring of antipsychotics will occur needs to be explicit. This should include how frequently 
these medications should be reviewed. In the qualitative study and in the systematic review 
there was evidence that GPs were uncertain about how to formally conduct an antipsychotic 
review or monitor antipsychotics so in this context this is considered to be an important element 
of any behavioural change strategy. 
Review behavioural goals 
 
Review behaviour goal jointly with the GP and consider modifying behaviour change strategy in 
light of the strategy. This may not be practical to implement as jointly reviewing behaviour goals 





Review outcome goals Review outcome goals jointly with the GP and consider modifying goals in light of the 
achievement. Here this could relate to examining how many patients with dementia on 
antipsychotics are being monitored. Not feasible that the GPs goals could be jointly reviewed as 
it likely be too resource intensive.  
Reduce negative emotions Advise GPs on ways of reducing negative emotions to facilitate performance of the behaviour. In 
the qualitative study the lack of optimism GPs felt when managing people with dementia was 
apparent. Identifying and addressing these negative emotions may facilitate behaviour change. 
However, the negative emotions felt by GPs was a consequence of the lack of resources available 
and their feelings of frustration and, at times, their inability to act as advocates for their patients. 
The focus of the behaviour change strategy should be around practically facilitating the GPs to 
engage with the process of antipsychotic monitoring rather than addressing their justifiable 
emotions that stem from resource inadequacies. 
Conserve mental resources  In order to minimise demands on GPs mental resources they could be encouraged to consult 
guidelines on antipsychotic monitoring and alternatives to antipsychotic prescribing. In the 
qualitative study many GPs highlighted what they saw as the lack of GP-relevant, implementable 
guidelines so such guidelines would have to be developed in order to support GPs and conserve 
mental resources. 
Discrepancy between current 
behaviour and goal 
Draw attention to discrepancies between a GP’s current behaviour (in terms of the form, 
frequency, and duration of antipsychotic monitoring) and the GP’s previously set outcome goals 
or action plans. If this provided feedback to the GPs and allowed them to improve their 
behaviour based on this feedback this would function in a similar way to an audit. (Feedback on 
behaviour) Audit has been identified as an effective way of improving coding of dementia 
diagnosis in primary care. 417 
Pros and cons  The GP is advised to identify and compare the reasons for wanting (pros) and not wanting (cons) 
to change their behaviour regarding monitoring of antipsychotic medications. This would be 
resource intensive for the GP and is more likely to frustrate the GP than enable them. 
Focus on past success Advise GPs to think about or list previous successes in monitoring antipsychotic prescribing. The 





features that are not necessarily replicable. The monitoring may have also occurred in an 
unplanned manner. Therefore, if we highlight these success it may actually detract from the 
need for the behavioural change strategy we’re trying to implement.  
Anticipated regret Induce or raise awareness of expectations of a GP’s future regret about not monitoring 
prescribing of antipsychotics. This could be achieved by asking the GP to assess the degree of 
regret they will feel if they do not monitor their prescribing and the person with dementia has an 
adverse effect as a consequence of the antipsychotic prescribed. This may be perceived as being 
manipulative or emotionally coersive by GPs. The focus of the behaviour change should be on 
building on GPs good intentions in this area and facilitating the behaviour change rather than 
using any kind of coercion. 
Incentivisation Feedback on behaviour Discussed under ‘Education’ 
 Feedback on outcome of behaviour  Discussed under ‘Education’ 
 Monitoring of behaviour by others 
without evidence of feedback 
This is unlikely to be acceptable to GPs. To monitor the GPs behaviour without feedback would 
be seen as a negative threat rather than a positive incentive. 
 Monitoring outcome of behaviour 
by others with evidence of 
feedback 
Feedback to GPs on their benzodiazepine prescribing is an established and accepted method of 
monitoring GP’s prescribing of benzodiazepine prescribing. Therefore, introducing a similar 
method of monitoring antipsychotic prescribing may be successful. However, we are specifically 
looking at antipsychotic prescribing in a cohort of patients with dementia. There are many 
psychiatric conditions that would merit a prescription for an antipsychotic. Implementing an 
external monitoring system with feedback on antipsychotic prescribing in dementia specifically 
would be difficult to operationalise as data on the prescribing of antipsychotics could not be 
linked to a specific clinical condition. This is discussed in more depth under ‘Feedback on 
outcome(s) of the behaviour’. 
 Self-monitoring of behaviour Establish a method for the GP to monitor and record their own prescribing of antipsychotics. GPs 
do not tend to self- monitor their prescribing of any one particular drug class. Given existing 
resource constraints it is unrealistic and unviable to expect GPs to monitor their own prescribing 





However, if the self-monitoring was further incentivised by a “reward” of continuous 
professional development (CPD) points then this may be successful. 
 Material incentive Inform GPs that money will be delivered if, and only if, there has been effort and/or progress in 
performing the behaviour. For example, inform GPs that a financial payment will be made every 
three months if evidence provided that an antipsychotic review has taken place. This is very likely 
to be successful. Evidence from the UK has shown the impact of the financial incentive on rates 
of dementia diagnoses. 76 Payment for performance of quality indicators of care are very likely to 
work as an incentive for GPs to engage with the target behaviour. However, providing such a 
financial incentive is beyond the scope of this study. Another type of material incentive for GPs 
may be the accruement of continuous professional development (CPD) points. In Ireland, as in 
many countries, GPs have to submit evidence of completion of annual CPD in the form of 
external education, internal practice quality improvements and an audit. Conducting an 
antipsychotic review would be eligible for internal CPD points. If the GP monitored the outcome 
of the review process with could take the form of an audit. Finally, if there was an education 
component to the intervention and if we could get that education component accredited by the 
Irish College of General Practitioners for external CPD points then this further incentivise GPs to 










Supplementary Material 19. Stakeholder feedback on intervention concept 
Ethical approval was granted by the Social Research Ethics Committee of University College 
Cork, Log 2017-031 for obtaining input from the pharmacists and nurses. Ethical approval 
for feedback from GPs via the online dementia module was also granted by Social Research 
Ethics Committee of University College Cork in a separate application; Log number 2017-
106. 
 
1. Feedback from community pharmacists 
 
Aim 
To discuss the acceptability of the intervention from pharmacists’ perspective and to use 
these perspectives to refine the intervention developed. 
Methods 
Identified 2 community-based pharmacists who provide care to two large nursing homes in 
county Cork. Met with the two pharmacists on 10/10/18. Described the proposed 
intervention and asked for their feedback on the acceptability of the pharmacists’ role in 
providing feedback to GPs on their prescribing of antipsychotics.  
Results 
The participating pharmacists reported that it was possible to provide data on the nursing 
home residents who were on antipsychotic medication. However, it is a resource intensive 
exercise as it involves the pharmacist going through each residents drug chart manually and 
identifying a list of residents on an antipsychotic. The software packages used by 
pharmacies in Ireland would not be able to easily identify this list of patients. It would 
involve running a search for each individual antipsychotic drug. The search results would list 
all customers who receive an antipsychotic medication – so would include individuals living 
in the community and residents of other nursing homes. There is no way to filter the list 
based on residence. Therefore, this would have to be done manually by the pharmacists. 
However, once this list was created it could then be used as a template that the pharmacist 
could edit every 3 months to ensure it was up to date. 
Ideally, the pharmacist would be able to provide detail on the current dose and any changes 
to the dose of the antipsychotic medication. The pharmacists reported that this would be 
very difficult for them to do as it would involve keeping a weekly record of any changes 
made to each individual’s antipsychotic prescription. The pharmacists felt that the best they 
could do was to give a snap-shot of the current prescribing dose.  
When asked what the incentive was for the pharmacists to do this they replied that there 





the nursing home the contract stipulates that they will help with audits. Therefore, they do 
see facilitating audits as part of their nursing home workload. However, they highlighted 
that they already do a significant amount of audits in other areas of prescribing. They 
showed me two ‘audits’ that they are currently facilitating for two different nursing homes; 
one was a summary of all antibiotic prescriptions in a nursing home and the other was a list 
of all residents on blood pressure medication for another nursing home. It was highlighted 
that there was a limit to what resources could be allocated to facilitating these time-
intensive audits.  
Overall, the pharmacists felt that they could provide a list of residents in a nursing home on 
an antipsychotic medication. However, including recent variations in doses would be quite 
resource intensive. They felt it was possible to provide this list on a three monthly basis but 
acknowledge it would be resource intensive for the pharmacy in the context of other 
requests for prescribing data. Overall, the intervention was acceptable to the pharmacists. 
One of the pharmacists agreed to collect this data for one of the nursing homes to ascertain 
the workload and time that it would involve. Given that the pharmacy was not located close 
to the nursing homes they provided care to the concept of the pharmacist attending the 
multidisciplinary review meeting to discuss the prescribing was not considered acceptable.  
 
 
2. Feedback from GPs 
 
Aim 
To discuss the acceptability of the intervention from a GP perspective and to use these 
insights to refine the intervention developed. 
Methods 
As outlined, the candidate runs a 12 week blended learning dementia course for GPs 
annually. A previous cohort of GPs who completed this course in 2017-2018 influenced the 
intervention development process as outlined in Appendix 2. With the concept of the 
intervention finalised the 2018-2019 cohort of GPs enrolled in the online dementia course 
were asked to provide feedback on the intervention. The candidate is module co-ordinator 
for this course and also tutors the weeks of the online discussion forum that is devoted to 
the management of BPSD. To obtain the GPs’ insight into the chosen intervention a thread 
was opened on the online discussion forum. In this thread the candidate described the 
proposed intervention and asked for feedback from the GPs on what they saw as the 
barriers to the intervention. The participants were asked if they would engage with the 
intervention and the reasons why they would, or would not. The repeat prescribing tool was 
uploaded to the discussion forum. Participants were encouraged to download the tool and 
give their feedback on its usability/ practicality. The intervention was also discussed during 






Twelve GPs actively engaged in an online discussion on the intervention concept over a five 
day period.  
The GPs were positive about the intervention. Although all the twelve GPs had a nursing 
home commitment and a commitment to providing quality care, as evidenced by their 
participation in the dementia course, only one of the twelve GPs had a formal repeat 
prescribing process in place to monitor the prescribing of antipsychotics in BPSD in the 
nursing home. They appeared to feel empowered to tackle this aspect of the care they 
provided.  
“I don't have a policy for repeat prescribing of antipsychotics or for monitoring them, 
however, it is something I will try. The tool is very useful. “(GP_Participant 1) 
“I don’t have a formal prescribing or review policy in place but it’s something I do 
informally when doing general chart reviews in the nursing homes or doing repeat 
prescriptions. I'm currently actively trying to reduce the use of antipsychotics in the 
nursing homes [I attend] and will give the template a whirl and let you know how I 
get on.” (GP_Participant2) 
“I think this prescribing tool is a good start Aisling and I intend to discuss its use with 
the director of nursing at our local community hospital.  I like the educational aspect 
to the tool in that reference is made to non-medication treatment as the first line of 
management of BPSD and also that the adverse drug reactions are included which 
helps to focus the minds of staff -that these medications have potentially serious 
consequences.” (GP_Participant3) 
The particular aspect of the intervention that they felt most positive about or felt had the 
most promise with the repeat prescribing tool.  
“I have printed off the repeat prescribing template for anti -psychotic drugs -- I do 
intend to use.” (GP_Participant7) 
They felt that having this tool would provide them with a starting point for a conversation 
with the nursing staff and that it would help everyone be “on the same page” 
(GP_Participant2). The monitoring tool was seen to functions beyond simply monitoring of 
antipsychotics it was viewed as having potential as an educational tool that might unite GPs 
and nursing staff so that they would share the same goals.   
“The template is very helpful and the checklist is a useful aid for remembering what 
needs to be monitored. I have found that most nursing home patients are often new 
to us and have been long established on anti-psychotic medication and so 
deciphering adverse effects can sometimes be difficult, as is the process of 
introducing a weaning regime.  However, I think that having a written guideline can 






“Re the Anti-psychotic prescribing tool, or what I might start calling it, the "Pre-
Prescribing" tool, I think it's a great idea as it might change the "culture and 
expectation" of BPSD … it will question the appropriateness of medical intervention 
with drugs. Because it forces the team requesting this intervention to actually define 
the target behaviour; the emphasis on non-pharmacological management is clear, 
and defining what's been tried already here; the date of the initiation of the drug is 
clear; drug risks cardiovascularly and sedation-wise are highlighted for comment; 
and the drug review date is clear. The whole team's responsibility is shared - carers 
(lay or professional) and medical. I really like the review date being clarified so that 
the risk of long-term indefinite prescribing is controlled for, and de-prescribing can 
commence from then. Thus the expectation of the drug prescription being intended 
indefinitely without justification is challenged from the start. So big "likes" from me 
for this tool! (GP_Participant8) 
The focus on the non-pharmacological management first line was welcomed.  
“The antipsychotic monitoring tool looks excellent. I like the way that non-
pharmacological management strategies tried is up at the top, as first line 
management, as per current expert guidelines. It should focus the minds of nursing 
staff too on this point… I think I will be using this tool from now on, and the nursing 
homes we look after I think would be positive about it too. Like others, I have been 
overestimating the benefits of antipsychotic meds for BPSD. Thank you for this tool. 
(GP_Participant6) 
 
The participants did highlight some potential challenges of implementing a formal repeat 
prescribing policy for monitoring antipsychotic prescribing in BPSD. These challenges 
pertained largely to difficulties managing the expectations of the nursing staff. 
“I insist on having a copy of the kardex beside me, so I can keep the computer 
prescribing data accurate. I am not good at deprescribing and I find the nurses very 
resistant to lowering doses. But I will try harder.” (GP_Participant9) 
“It’s easier to deprescribe if the nursing home encourages it.” (GP_Participant10) 
“I think re lowering does, a lot depends on the nurse you're dealing with.  In both 
NHs we deal with I find the Matrons very amenable to reducing doses, and quite 
often if nurses on the wards have asked to increase doses the matron will say lets 
hold tough for a while and see if things will settle.  Makes a big difference when 
you're both on the same page!” (GP_Participant2) 
This challenge was exacerbated when there was frequent turnover of staff. 
“… [speaking about the director of nursing] her replacement just started -- she is very 
helpful -- but dealing with a different person who is not that familiar with the 





Not knowing the residents prior to their entry into the nursing home was also flagged as a 
challenge when attempting to deprescribe or reduce antipsychotic medications. 
“I find it extremely difficult when a new patient arrives and despite extensive notes it 
is very difficult to become familiar with all the issues -- medically, socially and 
psychologically.” 
Another challenge identified was that some nursing homes did not have the appropriate 
environment or infrastructure to manage BPSD. 
Unfortunately, our very expensive newly revamped community hospital is not 
dementia friendly and they actively discourage patients with BPSD. There is a long 
way to go before the HSE puts its house in order by providing leadership to ensure 
that care for our dementia patients is patient and family-centered and safe. 
(GP_Participant3) 
 
The audit tool was positively also positively received. 
“I had decided to do the audit on the use of anti-psychotics. This will be most useful.” 
(GP_Participant5) 
However, there was less comments on the audit tool when compared to the repeat 
prescribing tool. Therefore, during a face-to-face study run as part of the dementia module I 
outlined the audit tool in more detail with the module participants (n=16). Overall, the 
participating GPs were unsure whether pharmacists would provide the necessary 
information. They were also unsure whether nurses would be resistant to potential 
withdrawal of antipsychotic medications that could result from the monitoring process. 
 
 
3. Feedback from Nursing Staff 
 
Aim 
To discuss the acceptability of the intervention from the perspective of the director of 
nursing in a nursing home and to use these insights to refine the intervention developed. 
Methods 
I approached two directors of nursing that I identified as being part of a national guideline 
development group for prescribing in dementia. They both agreed to review the 





One interview was conducted in a face to face meeting. The other interview was a 
telephone interview. Both interviews were approximately 30 minutes in duration. 
 
Results 
The main barrier the nurses saw to the successful implementation of the intervention was 
lack of engagement from the GP.  
“If I went to [the visiting GP] with that form, I think he would throw his toys out of the 
pram.” 
The nurses themselves felt there wouldn’t be any significant barriers from the perspective 
of the nursing home, once the GPs were on board. In order to maximise the likelihood that 
the GPs would engage with the intervention both nurses felt that the majority of the 
paperwork should be completed by the nursing staff: 
“You know, if we’ve the work done for them and it’s in an accessible format… if it’s 
complicated and they’ve to do the work then it won’t happen. I think from a nursing 
perspective if we can educate the nurses and we can have it [the data for the monitoring] 
ready for the GPs then there won’t be a problem.” 
A number of suggestions were made on how the repeat prescribing tool could be improved 
upon and the following refinements were made to the repeat prescribing tool based on 
suggestions from the nurses. 
• A space was added to document who initially prescribed the medication (if known) i.e. 
GP or old age psychiatrist or geriatrician 
• An option was included in the initial review to indicate if the antipsychotic medication 
was altered (not just continued or discontinued). 
A significant refinement that was made as a result of the interviews with the two nurses was 
that an additional table was added to the back of the monitoring tool. This table included 
information that the GP would need to conduct the audit. Another benefit of this table was 
that it effectively dealt with the situation where a resident was on multiple antipsychotics. 
The nurse who made this suggestion highlighted the benefit in terms of “reducing 
paperwork” and “keeping all the information on the one sheet”, in order to decrease any 
negative reaction from the GP. 
Apart from a certain level of apprehensiveness that the GP would not engage with the 
intervention the nurses were positive about it. Specifically, they felt that the regulatory 













Supplementary Material 20. Outline of Interprofessional Education Session 
Proposed duration: 50 minutes 
Location: Nursing home where intervention being delivered 
Attendees: Visiting GP(s), Nursing home staff (all staff should be encouraged to attend, in 
particular director of nursing, nurses, care assistants) 
Facilitated by: GP and nurse that have attended relevant ‘train the trainer’ session 
Supporting documents: A full facilitator’s guide will be provided to facilitators with    
supporting PowerPoint slides. 
 
Brief outline of Interprofessional Education Session* 
*Allow for discussion and encourage group interaction throughout. 
1. A typical case of a nursing home resident with dementia presenting with symptoms of 
dementia will be presented. (5 mins) 
2. Explain concept of BPSD as means of communicating an ‘unmet need’. Provide an 
approach to assessing this man for potential triggers / unmet needs.  This will be detailed in 
the facilitators guide but example of approach to assessment provided here. (10 mins) 
 
3. Outline some potential non-pharmacological strategies that could be employed in the 
case presented (5 mins) 
4. Discuss risk/ benefit of psychotropic medications (5 mins) 
5. Role for monitoring and attempting withdrawal of antipsychotics (20 mins) 
 - introduce monitoring tool, demonstrate use & distribute amongst participants 
 -introduce audit tool, demonstrate use & distribute amongst participants 
 - allow for questions/ discussion 





Supplementary Material 21. Audit Template 
Audit Standard 
Antipsychotic medication in people with dementia should be regularly reviewed, and the 
outcome of the review should be documented in the clinical records. The review should take 
account of a) therapeutic response and b) possible adverse effects. (NICE Guideline on 
supporting people with dementia and their carers in health and social care)  
Specifically this audit aims to introduce structured monitoring for nursing home residents on 
antipsychotic medication for the management of behavioural and psychological symptoms 
of dementia (BPSD). The audit aims to ensure that these residents have a review of the 
effectiveness and continued need of the medication prescribed: 
- 6 weeks after initial prescription 
- 3 monthly thereafter 
 
Audit Cycle 1 (initial data to be collected) 
Step 1. Ask providing pharmacist to provide a list of all residents in the nursing home on an 
antipsychotic medication, including the antipsychotic name, dose and duration. 
Step 2. From this list identify residents who have been prescribed an antipsychotic for the 
management of behavioural and psychological symptoms of dementia (BPSD) 
- Exclude residents who have been prescribed an antipsychotic medication for a 
pre-morbid mental health illness 
Step 3*. From this list of residents with BPSD who are on an antipsychotic identify from the 
notes whether the antipsychotic was reviewed with the outcome of the review 
documented.  
(i) 6 weeks after initial prescription (if prescription was initiated in the nursing 
home) 
(ii) Every 3 months thereafter 
*Table 1 in this document provides example of how this data can be recorded. This 
table, once completed would provide the results for cycle 1 of the audit. 
 
Description of change to be implemented 
Introduce the repeat prescribing monitoring tool.  
- For each resident identified in Step 2 ask the nursing staff to add the repeat 





- Introduce a schedule for how each of these residents will have their monitoring 
tool completed over the next few months; e.g. agree that at the end of each 
structured visit to the nursing home the nurse in charge and the doctor will 
collaboratively review the antipsychotic prescribing to 3 residents, using the 
monitoring tool as a guide and for documentation purposes.  
- Once all residents on the list have had their antipsychotic medication reviewed 
by this process, schedule an ongoing 3 monthly review date with the nurse in 
charge for all the residents with dementia on antipsychotic medication. 
o In advance of this scheduled 3 monthly review the nursing staff will send 
the providing pharmacy the current list of residents with dementia on an 
antipsychotic and the pharmacy will update this list as necessary. 
o If a decision is made to reduce or withdraw the antipsychotic medication 
advice on doing this is available in the BPSD section of the clinical 
resource menu on this website: www.dementiapathways.ie 
 
Audit Cycle 2 (results of data collection post change) 
For audit cycle 2** 
Repeat steps 1 – 3 as outlined in audit cycle 1 
Step 4.  Add an additional columns to your data collection table (as shown in table 2 of this 
document) indicating whether or not the residents antipsychotic medication is now being 
reviewed within the recommended time frames, whether the residents remains on the 
antipsychotic and at what dose 
**Ideally there would be a significant time interval from conducting audit cycle 1 to conducting audit 
cycle 2 to allow for the intervention to be implemented and any potential impact assessed. We 
would recommend a 6 month interval if possible. 
 









Table 1. Example of table for data collection for audit cycle 1 
Resident’s name Name of 
antipsychotic 
prescribed 
Date commenced Current dose Documented 
evidence of 











B.H Risperidone Unknown – prior 
to NH admission  
1mg OD No N/A No 
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T.O.R Quetiapine 21st Oct 
2017 
50mg  Yes – 
mentioned in 
notes 






of cycle 2 did 











Supplementary Material 22. IPCRN Software Finder Tool 
If the nursing home’s medical records are integrated with the electronic monitoring record 
system of the providing GP then the GP can avail of the following software finder tool to 
facilitate the conduction of the audit.  The GP must be using one of the following GP 
practice systems to avail of this software finder tool; Socrates, Helix Practice Manager or 
HealthOne. These account for 3 of the 4 approved accredited software systems and cover 
the majority of Irish GP practices. >90% of Irish GP practices are computerised and approx. 
95% of computerised practices use of the 4 accredited software packages. 45 
 
1. If not already signed up to IPCRN the providing GP needs to sign up to the IPCRN (Irish 
Primary Care Research Network) via their website www.ipcrn.ie 
2. Once signed up the GP can go to the iPCRN tab on their practice software.  
3. They will be asked if they wish to create a list of all the patients in the practice with 
dementia. The software finder tool built will then search through all patients who are either 
(i) Coded with dementia (either coded with ICPC code or with any of the possible 
ICD10 codes*) 
OR 
(ii)Any patient on any of the three cholinesterase inhibitors (donepezil, galantamine, 
rivastigmine) or on mematine. (Since these medications are only indicated in 
dementia).  
This will generate a list of patients in the practice with a diagnosis of dementia, however, 
it is possible that some patients who have not had their diagnosis coded or that are not 
on a cholinesterase inhibitor/ memantine may be missed. 
4. Once this list has been created the GP will be able to generate an internal report that 
lists all these patients and any antipsychotic medication they are currently prescribed 
and the dose. ** 
 
5. They will then be asked if they wish to upload anonymised data to the IPCRN server. This 
is an optional step. No patient identifying data is included in this upload. This upload will 
enable the IPCRN to generate a report which will be emailed back to the practice in the 
form of an EXCEL spreadsheet. 
 
*The list of potential ICPC or ICD10 codes searched for 
ICPC (international classification of primary care): only one possible code for dementia in 





ICD10  (international classification of diseases – version 2010): multiple potential codes for 
dementia -  F00, F05.1, F00.0, F05.9, F00.1, F06.0, F00.2, F06.7, F00.9, F10.7, F01, G30, 
G30.8, G30.9, F01.1, G30.0, F01.2, G30.1, F01.3, G31.0, F01.8, G31.1, F01.9, G31.8, F02, 
F020, F02.1, F02.2 , F02.3, F02.4, F02.8, F03 
 
** The list of antipsychotic medication that is searched for 
ATC              Generic name 
N05AH04       Quetiapine 
N05AD01       Haloperidol 
N05AB06       Trifluoperazine 
N05AX08       Risperidone 
N05AH03       Olanzapine 
N05AB02       Fluphenazine 
N05AH02      Clozapine 
N05AA01      Chlorpromazine 
N05ALO5      Amisulpride 
N05AX12      Aripiprazole 
N05ALO1     Sulpiride 
N05AF05      Zuclopenthixol 
N05AD07     Benperidol 







Supplementary Material 23. The TIDieR Checklist 
          Information to include when describing an intervention and the location of the information 
Item 
number 
Item   




1. Provide the name or a phrase that describes 
the intervention. 
 Intervention to improve the monitoring of antipsychotic medication in people with dementi  
 WHY   
2. Describe any rationale, theory, or goal of the 
elements essential to the intervention. 
 This intervention was developed using the Behaviour Change Wheel (BCW) and aims to 
improve general practitioners (GPs) management of behavioural and psychological 
symptoms of dementia (BPSD) by improving the monitoring of antipsychotic medication 
prescribed for BPSD in nursing homes.  
 WHAT   
3. Materials: Describe any physical or 
informational materials used in the 
intervention, including those provided to 
participants or used in intervention delivery or 
in training of intervention providers. Provide 
information on where the materials can be 
accessed (e.g. online appendix, URL). 
 
 
The intervention includes: 
(1) An interprofessional educational session with GPs and nursing home staff. 
(2) A repeat prescribing tool to monitor the prescribing of antipsychotic medication in 
general practice. 
(3) A audit template to enable GPs to conduct an audit of their antipsychotic prescribing 
(4) If medical records in the nursing home are electronic and remotely integrated with the 





dementia and to identify if they are on an antipsychotic and the dose prescribed, further 
facilitating completion of an audit. 
 
The above materials are available to view as appendices to this PhD chapter and the final 
published paper. They will also be made available on the following website; 
www.dementiapathways.ie 
 
4. Procedures: Describe each of the procedures, 
activities, and/or processes used in the 
intervention, including any enabling or support 
activities. 
 The interprofessional educational session will be provided by two upskilled facilitators; a 
GP and a nurse. The GP and nurse will have previously participated in a ‘train the trainer’ 
session prior to delivering the interprofessional educational session. The education 
session will cover key aspects of BPSD management that were identified as being barriers 
to monitoring antipsychotic prescribing in BPSD; the assessment of BPSD, the 
risk/benefits of psychotropic medications, monitoring and withdrawal of antipsychotic 
medications. The GPs will be incentivised to attend the meeting by receiving external CPD 
points.  
 
The repeat prescribing tool and the audit template will be introduced in the educational 
session allowing a format to answer any questions on how to use them. Each resident 
with dementia currently on an antipsychotic medication or initiated on an antipsychotic 
medication in the future will have a copy of the repeat prescribing tool in their chart. In 
the three monthly medication review this chart will be consulted and updated jointly by 





The providing pharmacist will provide feedback on the antipsychotic medication in the 
nursing home every three months. This feedback will support GPs in conducting an 
annual audit of their antipsychotic. GPs will be further supported in this task by the audit 
template which will function as a ‘how to guide’. The GPs will be incentivised in this task 
as the audit will meet the GPs annual continuous professional development (CPD) 
requirement that they must conduct an annual audit. 
 
 WHO PROVIDED   
5. For each category of intervention provider 
(e.g. psychologist, nursing assistant), describe 
their expertise, background and any specific 
training given. 
 Criteria for the GP and nurse facilitating the IPE session 
1. Have experience of managing BPSD in a nursing home setting. 
2. Be available to attend the ‘train the trainer’ sessions 
3. Be available to provide feedback to the research team on acceptability or 
feasibility issues with the intervention 
The facilitators will be trained by the research team in a ‘train the trainer’ session. They 
will provided with a facilitator guide and with slides for presentation to staff. 
 
 HOW   
6. Describe the modes of delivery (e.g. face-to-
face or by some other mechanism, such as 
internet or telephone) of the intervention and 
whether it was provided individually or in a 
group. 
 All nursing staff, care assistants and GPs in the nursing home will be invited to attend the 
face-to-face interprofessional education session. The facilitators will work from a pre-
developed facilitators guide. In that session the other two components of the 
intervention – the repeat prescribing tool and the audit template will be introduced by 





 WHERE   
7. Describe the type(s) of location(s) where the 
intervention occurred, including any necessary 
infrastructure or relevant features. 
 The intervention will take place in nursing homes.   
 
WHEN and HOW MUCH 
  
8. Describe the number of times the intervention 
was delivered and over what period of time 
including the number of sessions, their 
schedule, and their duration, intensity or dose. 
 The educational interprofessional session will be delivered once and last approx. one 
hour. The antipsychotic monitoring tool will be introduced for each patient with dementia 
who is on an antipsychotic and will reviewed every 3 months as part of the resident’s 
medication review.  The audit will be conducted on an annual basis. 
 TAILORING  N/A (intervention not yet delivered). 
9. If the intervention was planned to be 
personalised, titrated or adapted, then 
describe what, why, when, and how. 
  
 MODIFICATIONS  N/A (intervention not yet delivered). 
10.ǂ If the intervention was modified during the 
course of the study, describe the changes 
(what, why, when, and how). 
  
 HOW WELL  N/A (intervention not yet delivered). 
11. Planned: If intervention adherence or fidelity 






if any strategies were used to maintain or 
improve fidelity, describe them. 
12.ǂ 
 
Actual: If intervention adherence or fidelity 
was assessed, describe the extent to which the 














Appendix 7.  Research training 
February 2016  PG 6008 Qualitative data analysis, UCC 
April 2016   PG7016 Systematic Reviews for the Health Sciences (5 Credits), UCC  
March 2017   PG6024 Qualitative Research Inquiry (5 Credits), UCC  
October 2017  Designing Effective Interventions for Behaviour Change I, School of 
Psychology, National University of Ireland Galway (NUIG) 
February 2018  Designing Effective Interventions for Behaviour Change II, School of 
Psychology, NUIG 
May 2018   Certificate in Teaching & Learning (30 Credits), UCC 
April -July 2018 Introduction to Statistics for Health Care Research, Oxford University 













Appendix 8. Prizes and awards relating to doctoral research 
Awarded the Irish College of General Practitioners Career Research Award - €45,000 over 3 
years. This was a peer-reviewed, competitive grant awarded in September 2017. I was the 
sole recipient of this grant. 
James McCormick Prize for Best Research Project at Association of University Departments 
of General Practice (AUDGPI) and Irish College of General Practitioners (ICGP) Joint Scientific 
Meeting, March 2018 for research on “General practitioners knowledge of, attitudes 
towards and experiences with behavioural and psychological symptoms of dementia: a 
mixed methods systematic review” 
AUDGPI Bursary for Best Presentation at AUDGPI & ICGP Joint Scientific Meeting March 
2018 for presentation on “General practitioners knowledge of, attitudes towards and 
experiences with behavioural and psychological symptoms of dementia: a mixed methods 
systematic review” 
Awarded ICGP research paper of the year at the 2018 ICGP AGM, Dublin for the paper 
“Working away in that grey area…” A qualitative exploration of the challenges general 
practitioners experience when managing behavioural and psychological symptoms of 
dementia. Published in Age & Ageing. 
Awarded Junior Researcher prize at Society for Academic Primary Care ASM in London in 
2018 receiving a bursary to attend North American Primary Care Research Group (NAPCRG) 
conference. Prize was awarded for my presentation on “General practitioners knowledge of 






Appendix 9.  Dissemination of doctoral research 
Peer-reviewed publications  
Jennings AA, Foley T, Walsh KA, Coffey A, Browne JP, Bradley CP. General practitioners’ 
knowledge, attitudes and experiences of managing behavioural and psychological symptoms 
of dementia: protocol of a mixed methods systematic review and meta-ethnography. 
Systematic Reviews. 2018;7:62. 
 
Jennings AA, Foley T, Walsh KA, Coffey A, Browne JP, Bradley CP. General practitioners' 
knowledge, attitudes, and experiences of managing behavioural and psychological 
symptoms of dementia: A mixed-methods systematic review. Int J Geriatr Psychiatry. 
2018;33(9):1163-1176. 
 
Jennings AA, Foley T, McHugh S, Browne JP, Bradley CP. 'Working away in that Grey Area...' 
A qualitative exploration of the challenges general practitioners experience when managing 
behavioural and psychological symptoms of dementia. Age Ageing. 2018;47(2). 
 
Jennings AA, Linehan M, Foley T. The knowledge and attitudes of general practitioners to 
the assessment and management of pain in people with dementia. BMC Fam Pract. 
2018;19(1):166. 
 
Jennings AA, Guerin N, Foley T. Development of a tool for monitoring the prescribing of 
antipsychotic medications to people with dementia in general practice: a modified eDelphi 
consensus study. Clinical Interventions In Aging. 2018;13:2107-2117. 
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Aisling A. Jennings.  What are GPs’ views on BPSD management? Faculty of Old Age 
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Aisling A. Jennings. What are GPs’ views on BPSD management? British Gerontology Society 





Peer-reviewed abstract publications 
Aisling A Jennings, Maura Linehan, Tony Foley. General Practitioners’ Knowledge of and 
Attitude Towards the Assessment and Management of Pain in People with Dementia, Age 
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Management of Behavioural and Psychological Symptoms of Dementia. Alzheimer’s & 
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Conference proceedings: oral presentations 
May 2017  9th International Dementia Conference, Dublin. The management of BPSD in 
general practice. 
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UK GPs’ perspectives on the management of BPSD. 
Oct 2017  European General Practice Research Network (EGPRN) conference, Dublin, 
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attitudes towards and experiences with managing BPSD: a mixed methods 
systematic review and meta-ethnography. 
Sept 2018 Irish Gerontology Society ASM, Cavan, Ireland. GPs knowledge of and 
attitudes towards pain management in dementia: a descriptive cross-
sectional study 
 
Conference proceedings: poster presentation 
March 2017  14th Annual Psychology, Health and Medicine Conference, RCSI, Dublin, 
Ireland. GPs’ perspectives on the management of behavioural and 
psychological symptoms of dementia.  
July 2017  Alzheimer Association International Conference (AAIC), London. General 
Practitioners Perspectives on the Management of Behavioural and 
Psychological Symptoms of Dementia. 
Sept 2018 Irish Gerontology Society ASM, Cavan, Ireland. Development of a tool for 
monitoring the prescribing of antipsychotic medications to people with 
dementia in general practice: a modified eDelphi consensus study. 
Oct 2018  Alzheimer’s Europe annual conference, Barcelona, Spain. Development of a 
tool for monitoring the prescribing of antipsychotic medications to people 
with dementia in general practice: a modified eDelphi consensus study. 
Oct 2018 Alzheimer’s Europe annual conference, Barcelona, Spain. GPs’ knowledge of, 
attitudes towards and experiences with managing BPSD: a mixed methods 








May 2018 Irish College of General Practitioners (ICGP) AGM & Summer School, Dublin 
Managing Agitation in Dementia: The Evidence and The Reality; is there a 
middle ground? 
Oct 2018 Association of University Departments of General Practice in Ireland 
(AUDGPI) Early Career Research Day, University of Limerick 
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Development and evaluation of a primary care interprofessional education intervention to 
support people with dementia. Journal of Interprofessional Care. [In press] 
 
Jennings AA, Boyle S, Foley T. The development and evaluation of an online dementia 
resource for primary care based health professionals. Internet Interventions. 2018;11:47-52. 
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facilitated dementia workshops in general practice. Education for Primary Care. 
2018;29(1):27-34. 
Foley T, Boyle S., Jennings A., Smithson W. H. "We're certainly not in our comfort zone": a 
qualitative study of GPs' dementia-care educational needs. BMC Fam Pract. 2017;18(1):66. 
McLoughlin K, Pope L, Walsh E, Jennings A, Foley T. The MRCGP Clinical Skills Assessment: 
an integrative review of evidence. Education for Primary Care. 2018:1-7. 
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Peer-reviewed abstract publications 
Aisling A. Jennings, Siobhán Boyle, Tony Foley. The development and evaluation of an 
online dementia supports directory for primary care. International Journal for Integrated 
Care. 2017; 17(5), A201, pp1-8 
 
Siobhan Boyle, Anne Quinn, Katherine Thackeray, Kathleen McLoughlin, Aisling Jennings, 
Tony Foley. Development and Evaluation of a Dementia Education Workshop for Primary 
Care Teams in Ireland, Age and Ageing, 2017; Volume 46, Issue Suppl_3, Pages iii13–iii59, 
Tony Foley, Cormac Sheehan, Trish O’ Sullivan, Aisling A. Jennings  What do 
Physiotherapists Need to Know about Dementia Care? A Focus Group Study. Age and 
Ageing. 2018; 47 (suppl_5) 
Ruby Chang, Aisling A. Jennings, Tony Foley.  Developing Curricular Priorities for a Dementia 




McLoughlin, K., Thackeray, K., Jennings, A., Boyle, S. and Foley, T. (2017). A guide to clinical 
audit of dementia care in General Practice: A Guide Developed for the ICGP. 
https://www.icgp.ie/go/pcs/scheme_framework/clinical_audit 
Tony Foley, Aisling Jennings, W Henry Smithson, Kathleen Mc Loughlin. Educational 
interventions to improve the diagnosis and management of dementia in general practice: a 
protocol for a systematic review of empirical literature. PROSPERO 2017:CRD42017073142  
 
Foley T, Jennings A. Dementia Care in General Practice: Facilitator’s Guide for GP workshop. 
Primary Care Education, Pathways and Research of Dementia (PREPARED). 2016 
http://dementiapathways.ie/_filecache/d43/336/634-gp-facilitator-workshop-guide.pdf 
Foley T, Jennings A. Dementia Care in Primary Care - an Interprofessional Approach: 





(PREPARED). 2017  http://dementiapathways.ie/_filecache/d74/b0c/627-pct-guide-for-
workshop-faciliatators.pdf 
Conference proceedings: oral presentations 
May 2017  9th International Dementia Conference, Dublin. The development and 
evaluation of www.dementiapathways.ie an online dementia resource for 
primary care based health professionals.     
Feb 2017   INMED (Irish Network of Medical Educators) Annual conference, UCC, Cork. 
Development and Evaluation of an Interprofessional Dementia Education 
Workshop for Primary Care Teams  
 
Conference proceedings: poster presentations 
May 2017  International Conference on Integrated Care (17th IFIC), Dublin, Ireland. The 
development and evaluation of an online dementia supports directory for 
primary care. 
Sept 2018 Irish Gerontology Society ASM, Wexford, Ireland. Development and 
Evaluation of a Dementia Education Workshop for Primary Care Teams in 
Ireland 
Sept 2018 Irish Gerontology Society ASM, Cavan, Ireland. What do Physiotherapists 
Need to Know about Dementia Care? A Focus Group Study. 
Sept 2018 Irish Gerontology Society ASM, Cavan, Ireland. Developing Curricular 
Priorities for a Dementia Module for General Practitioners Using an eDelphi 
Consensus. 
Oct 2018  Alzheimer’s Europe annual conference, Barcelona, Spain. Development and 








May 2018  Irish Gerontology Society - Interdisciplinary Education Symposium, Dublin 
Enhancing interdisciplinary dementia care by learning and working together - 
our experience in PREPARED. 
 
Research funding awards 
Oct 2018 Co-applicant on grant awarded by the Alzheimer’s Society of Ireland for a 
























Appendix 11.  Other professional activities 
During the three years of my PhD, in addition to working GP work and my work on the 
PREPARED project, which is outlined in Chapter 1, I was also was involved in a number of 
other professional activities. Here is a brief outline of some of the additional professional 
activities in which I was engaged over the past three years. 
 
1. The Irish College of General Practitioners (ICGP), Quality in Practice (QIP) Dementia 
Guide. 
I contributed to the update and revision of the ICGP QIP Dementia Guide. This document 
has been approved by the QIP committee of the ICGP and will shortly be available to all GPs 
via the ICGP website.  
 
2. The ICGP Nursing Home Group 
I was involved in the establishment of a nursing home group within the ICGP. It is a national 
network of GPs who are involved in the provision of nursing home care. The group meets 
twice yearly for educational sessions and has an active online discussion forum. I am on the 
education sub-committee of this group.  
 
3. Cork GPs with a Special Interest in Dementia Care 
I was a founding member of this group of Cork GPs who have an interest in dementia care. I 
am currently the elected secretary for this group. The group, which is still establishing, 
meets every three months and discusses cases and reviews latest evidence in dementia 








4. Organised GP Dementia Study Days in UCC 2017 & 2018 
As part of my role as module co-ordinator of an online blended learning GP dementia 
module I have arranged four successful dementia study days for GPs in UCC in 2017/18. 
 
5. Member of the website reference group for the HSE Understand Together website 
Invited to be the GP representative on the website reference group for the HSE public 
awareness campaign entitled Understand Together. http://www.understandtogether.ie/       
 
6. National Dementia Office guideline development group – the development of evidence 
based guidelines on the appropriate prescribing of psychotropic medications in BPSD 
As outlined in the thesis, I was invited to be the GP representative on this guideline 
development group. I was also one of five people on the writing group of this guideline.  
 
7. ICGP Research Committee 
Member of the ICGP research committee from March 2018 to present. This committee 
meets every three months and its aim is to develop and support research in general practice 
in Ireland.  
 
8. Undergraduate & postgraduate teaching, University College Cork 
I lectured on the following undergraduate modules; HC1002, HC2002, CP3105, GP4000 and 
on the postgraduate Masters in Dementia care.  I also supervised the research projects of 
three undergraduate final year medical students. 
 
9. Peer-reviewing  
I regularly peer-review for the following journals; BMJ Open, BMC Family Practice, 
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